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SUMMARY 
Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second in 
women. CRC is curable by surgical resection if it is diagnosed in early stage but requires more 
complex therapeutic approaches including chemotherapy at more advanced stages. Although overall 
patient survival is improving, survival rates for advanced CRC are poor and adverse events (AEs) 
associated with multi-drug combination chemotherapy can severely compromise quality of life in CRC 
sufferers. 
In China, integrative treatments which combine herbal medicines (HM) and chemotherapy are applied 
in hospital settings with the aim of enhancing the benefits of conventional treatments and alleviating 
the side effects of chemotherapy. Outside China, there is widespread use of HMs by cancer patients. 
However, the number of different HMs in use is large, they are often used in combination, and the 
evidence for their effects (if any) is limited.  
Hence, the primary objectives of this study were to:  
• Evaluate the efficacy and safety of HMs in the clinical management of CRC;  
• Identify potentially effective HMs and combinations of HMs that warrant further research;  
• Investigate the actions and mechanisms of action of promising HMs in experimental models 
of CRC; and  
• Determine directions for future research. 
The first stage of the project involved a comprehensive systematic review of randomised controlled 
trials (RCTs) that evaluated HMs in patients with CRC. Eighty-eight (88) RCTs were included 
(Chapter 4). The majority of studies were of integrative treatments for CRC. Meta-analyses found the 
addition of HM interventions to conventional chemotherapy provided benefits for tumour response, 
survival, alleviation of chemotherapy-related AEs and improved quality of life. This suggested that at 
least some of the included HMs improved clinical outcomes and warranted further study. However, 
the variety of HMs and chemotherapy regimens tested in the studies was considerable, participants 
were at different stages of the disease and there was potential for bias in the published studies 
(publication 1 Chen et al 2018).  
To further explore the effects of HMs, more focussed meta-analyses were conducted of RCTs that 
only enrolled people with advanced CRC and all employed FOLFOX4, which is the most commonly 
used regimen (Chapter 5, publication 5 Chen et al 2014). The result showed that even in advanced 
CRC patients, the addition of HMs to FOLFOX4 enhanced the tumour response rate by 9% based on 
data from 12 RCTs (880 participants) without statistical heterogeneity, and improved Quality of Life 
based on Karnofsky Performance Status. Importantly, there were significant reductions in severe 
 xxxv 
 
(grade 3/4) chemotherapy-induced AEs for nausea & vomiting (9.5% reduction, 9 RCTs) and 
neutropenia (8.7% reduction, 10 RCTs) without heterogeneity. Both AEs are clinically important since 
they can lead to cessation of treatment which shortens overall survival.  
The HMs were composed of multiple ingredients, so the question was which of these ingredients made 
greater contributions to the overall effects detected in the pooled data in the meta-analyses? To 
approach this question, a larger meta-analysis pool was identified and a novel approach to sensitivity 
analyses was developed. The inclusion criteria for studies were broadened to encompass other 
oxaliplatin-based chemotherapies besides FOLFOX4, since these are known to have similar effects on 
tumour response and similar AE profiles. The resultant studies were all of Chinese HMs, most of 
which used orally administered formulae. Meta-analyses of the oral HM studies were conducted for 
tumour response rate (31 studies, 2,145 participants), nausea and vomiting (21 studies, 1,322 
participants) and neutropenia (24 studies, 1,319 participants) (Chapter 6). In each case, there were 
significant improvements in the oral HM plus chemotherapy groups compared to the chemotherapy 
alone groups for all grades of the AE without important heterogeneity, based on large sample sizes. 
This lack of statistical heterogeneity combined with large sample sizes provided the opportunity for a 
series of sensitivity analyses aimed at determining which (if any) specific herbs, or combinations of 
herbs, improved the meta-analysis results of the pool of studies in which the herb was an ingredient. If 
a herb consistently improved the outcome, whenever it was included in a formula along with a variety 
of other herbs, it was considered a candidate for further research.  
The above meta-analyses and sensitivity analyses identified promising herbs for reducing 
chemotherapy-induced nausea and vomiting (publication 3 Chen et al 2016b) and chemotherapy-
induced neutropenia (publication 2 Chen et al 2016c); and improving tumour response rate 
(publication 4 Chen et al 2016a). Of these outcomes, tumour response was selected as particularly 
relevant for further research. Of the three herbs identified as most likely to have contributed to 
improved tumour response (ku shen, chi shao and e zhu), one was selected for further research. This 
herb (ku shen) is always derived from the root of the plant Sophora flavescens, is well characterised, 
and some of its constituent compounds have been identified. Of these, the alkaloid matrine has been 
reported to have antitumour effects, so this was selected for a series of experiments. 
Matrine was tested in four human CRC cell lines: LS 174T, Caco-2, SW1116 and RKO (Chapter 7). 
Cell viability, measured using CCK-8 assays, showed that matrine inhibited proliferation of these cell-
lines, time- and dose-dependently. Optical microscopy of cell morphology indicated cells underwent 
apoptosis rather than necrosis. Matrine was much less cytotoxic than oxaliplatin. Flow cytometry was 
used to measure DNA content for cell cycle analysis, and Annexin V-FITC/PI double staining was 
used to measure cellular apoptosis. The results showed that matrine induced cell cycle arrest at the G1 
phase, and induced apoptosis in each cell-line in a time- and dose-dependent manner.  
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To explore the likely molecular mechanisms of action of S. flavescens and its various constituent 
compounds, including matrine, a detailed review was conducted of published in vitro and in vivo 
studies in models of CRC (Chapter 8). This identified a number of intracellular signalling pathways, 
including WNT signalling, MAPK signalling, TGF-β signalling, and p53 signalling, as likely to be 
central to the anti-proliferative actions of this HM. In conclusion, matrine and other S. flavescens 
compounds show important bioactivities in CRC. Future studies in CRC cell-lines and in vivo models 
of CRC could investigate the effects of Sophora alkaloids and flavonoids on the protein components 
of the above pathways (Chapter 9).  
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Chapter 1. Introduction 
1.1 Background to the disease 
Colorectal cancer (CRC) refers to malignant tumours that develop in the colon or rectum. The majority 
of CRCs are carcinomas that mutate from the epithelial cells (Stewart et al., 2006). The International 
Statistical Classification of Diseases (ICD 10) specifies colorectal cancer under: malignant neoplasms 
of the colon (code C18), rectosigmoid junction (code C19) and rectum (code C20) (World Health 
Organisation, 2016). 
According to the World Health Organization (WHO) Cancer Report 2012, CRC is the third most 
common cancer in men and the second in women. Worldwide, it is estimated that there were over 1.4 
million new CRC cases and more than 694,000 deaths from CRC in 2012 (Ferlay et al., 2014). In 
Australia, CRC was estimated to be the second most commonly diagnosed cancer in both sexes in 
2017 and was the cancer with the third highest mortality (Australian Institute of Health and Welfare, 
2017). In China in 2011, CRC was ranked fifth in men and third in women and was the fifth leading 
cause of cancer death in both men and women (Chen et al., 2015). 
Epidemiological studies have identified factors that may increase the risk of CRC including hereditary 
factors (in a small proportion of cases), increased age, chronic inflammatory bowel diseases, and 
lifestyle-related factors such as excessive consumption of red meat, preserved meat and animal fat, 
lack of exercise, obesity, alcohol consumption and smoking. Conversely, the risk of CRC is reduced 
by higher consumption of vegetables and fruit, exercise, vitamin D, calcium, folic acid, non-steroidal 
anti-inflammatory drugs (NSAIDs) and hormone replacement therapy (HRT) for postmenopausal 
women (American Cancer Society, 2008).  
CRC can be curable when diagnosed at a sufficiently early stage to enable complete surgical resection 
of the pre-carcinoma polyp or early stage carcinoma. Bowel cancer screening programs can detect 
possible CRC and an endoscope can be used to diagnose the disease and remove early stage polyps 
(Hayat, 2009; Winawer et al., 1993; Faivre et al., 2004). However, CRC is asymptomatic at the early 
stage and may have progressed to invade the intestinal wall and have spread to lymph nodes by the 
time clinical symptoms are evident. Although survival rates are high (90%) at the early stages of the 
disease, in advanced colorectal cancer (ACRC) the median survival time, even with the best available 
treatment, may only be 12 months (Sargent et al., 2005; Stewart et al., 2006; Ries et al., 2008). 
Therefore, it is imperative that new methods for the prevention and management of CRC be 
developed. 
   
2 
1.2 Conventional treatment for colorectal cancer 
In conventional medicine, where possible, surgical resection is the primary treatment for CRC. 
Following resection, cytotoxic chemotherapy is often used to prevent the recurrence of cancer. This is 
known as adjuvant chemotherapy. In ACRC, when the tumour is not resectable, chemotherapy and/or 
radiotherapy may be used to downstage the tumour and potentially allow complete surgical resection. 
This is known as neoadjavant therapy. In advanced and progressive disease combinations of surgery, 
chemotherapy and/or radiotherapy may be used to maintain or improve quality of life and prolong 
survival. In late stage disease, palliative therapies are used to manage symptoms (American Cancer 
Society, 2008; Braun & Seymour, 2011). In recent years bio-targeted monoclonal antibodies have 
been developed into drugs that can be used in the more advanced stages of CRC (Braun & Seymour, 
2011; Hirsch & Zafar, 2011). 
Due to the cytotoxic actions of chemotherapy on fast-dividing cells, these drugs also have adverse 
effects on normal cells in the body, especially on normal fast-dividing cells such as the cells in hair, 
skin, the gastrointestinal tract and the bone marrow. As a result, a number of chemotherapy-related 
adverse events (AEs) may occur during and/or after chemotherapy, including nausea and vomiting, 
diarrhoea, bone marrow suppression, and neuropathy which impair quality of life and may lead to the 
cessation of the chemotherapy earlier than is optimal (DeHaven, 2007). A number of therapies are in 
current use to manage these adverse events but new therapies are still needed. 
1.3 Herbal medicine and colorectal cancer 
There is increasing international interest in complementary and alternative medicine (CAM) therapies, 
including herbal medicines (HMs) for CRC. Up to 75% of CRC patients in Western countries were 
reported to have used a form of CAM and nearly half of them claimed benefits (Sewitch & Rajput, 
2010). A survey of European countries found nearly half of CRC patients (48.7%) used HM 
(Molassiotis et al., 2005). HMs have been used to treat many ailments including tumours for centuries 
in China and in other Asian countries, and Asian HMs are increasingly being used in Western 
countries (Dobos et al., 2005; Qi et al., 2010). 
Chinese herbal medicine (CHM) is a major arm of Traditional Chinese Medicine (TCM) which is 
commonly combined with conventional therapy in hospitals in China for the management of a wide 
range of cancers (Dobos et al., 2005; Parekh et al., 2009; Saif et al., 2010). CHM typically involves 
the oral administration of multi-herb formulas as decoctions, tablets or capsules; and sometimes as 
enemas or intravenously (Gu et al., 2009; Wang et al., 1999). 
HMs have been reported to: alleviate AEs induced by conventional cancer therapies and improve a 
patient’s quality of life (Molassiotis et al., 2009); enhance cellular immunity of cancer patients 
   
3 
receiving chemotherapy or radiotherapy (Zhuang et al., 2009); reduce cancer pain (Xu et al., 2007); 
relieve cancer related fatigue (Jeong et al., 2010); and improve anorexia and cachexia (Lee & Lee, 
2010). 
Experimental studies have demonstrated that bio-active components in HMs possess anti-cancer 
activities including: inducing tumour cell apoptosis; inducing tumour cell differentiation; cellular 
transduction pathway regulation; suppression of tumour angiogenesis; inhibition of telomerase 
activity; regulation of immune function; and reversal of multiple drug resistance (Han & Li, 2009). 
However, numerous issues remain unresolved. These include the complexity of the chemical 
components of HMs; limited understanding of their pharmacological mechanisms; variability in the 
quality of the HMs; potential for herb-drug interactions; the incidence of herbal toxicity, especially 
when used at high doses and with long term use; and the quality of existing randomised controlled 
clinical trials (RCTs). These issues are of concern to medical practitioners and patients (Fong, 2002).  
1.4 Objectives of this research project 
The primary objectives of this research project were to:  
• evaluate the efficacy and safety of HMs in the clinical management of CRC;  
• identify potentially effective HMs and combinations of HMs that warrant further 
experimental and clinical research;  
• investigate the actions and mechanisms of action of promising HMs in experimental models 
of CRC, and  
• determine directions for future experimental and/or clinical research. 
This project involved a sequence of stages, each of which was designed to answer one or more of the 
following research questions.  
1.5 Research questions 
The following research questions were targeted in this study: 
1. Can HM interventions, used either singly or in combination with conventional therapies, 
elevate tumour response rate and/or prolong the survival of CRC patients? (Chapters 4 and 5) 
2. Can HM interventions alleviate the adverse events associated with conventional anti-cancer 
treatments for CRC? (Chapters 4 and 5)  
3. Can HM interventions improve the quality of life of CRC patients? (Chapters 4 and 5) 
4. How safe are HM interventions for CRC? (Chapters 4 and 5) 
5. Which herbs and herbal combinations appear effective for CRC treatment and/or alleviation of 
adverse events associated with conventional CRC treatments? (Chapter 6) 
   
4 
6. What are the effects of specific herb-derived compounds in CRC cell lines? (Chapter 7) 
7. What are the likely mechanisms of action of potentially effective HMs and their constituent 
compounds? (Chapter 8) 
8. What questions could be addressed in future studies and how would a future study be 
implemented? (Chapter 9) 
1.6 Thesis outline 
The thesis includes nine chapters, including the present introductory chapter. The chapters are outlined 
below. 
Chapter 1: General introduction 
This chapter introduces the topic and and the general needs for this reseach. It summarises the features 
of CRC including epidemiology, incidence rates and mortality worldwide; the risk factors and 
prevention; the staging of CRC and survival rate. It introduces the conventional treatment and the HM 
management of CRC. The research questions are also presented in this chapter.  
Chapter 2: Literature review: physiology, aetiology, diagnosis and treatment of colorectal 
cancer 
This chapter reviews: the large intestine anatomical location and physiological functions; details CRC 
epidemiology, risk factors, prevalence and burden; outlines bowel cancer screening programs; explains 
the etiology and tumour immunology of CRC; outlines CRC diagnosis and staging systems; 
summarises the current management of CRC using conventional treatments; details the use of CHM in 
cancer treatments, especially for CRC; explains the integrative management of CRC; and introduces 
the literature on laboratory studies of CHM for CRC. 
Chapter 3: Research methodology 
This chapter details the research methods and procedures used in each stage of the project. This 
includes: 1. the procedures for systematic reviews and meta-analyses based on the Cochrane 
Handbook 5.1.0 (Higgins & Green, 2011); 2. the approach used for the selection of short-lists of 
potentially effective HMs based on sensitivity analysis of the clinical literature; 3. the methods for the 
experimental investigation of selected herb(s)/compounds using CRC cell-lines to determine 
cytotoxicity; 4. the approach to the literature on in vitro and in vivo studies that investigates the 
molecular mechanisms of action of selected herb(s)/compounds in the management of CRC.  
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Chapter 4: Systematic review of herbal medicines in the management of colorectal cancer 
This chapter reports the results of a systematic review and a series of meta-analyses of the results of 
RCTs of HMs in the management of CRC. Meta-analysis was carried out into two major groups 
according to the intervention in the test arm: 1. HM alone versus chemotherapy, or placebo, or no 
treatment; and 2. HM combined with chemotherapy versus chemotherapy.  
Chapter 5: FOLFOX4 combined with herbal medicine for advanced colorectal cancer 
FOLFOX4 is a well-established and commonly used regimen for advanced CRC (ACRC). This 
chapter reports the results of a focussed series meta-analyses of RCTs of FOLFOX4 combined with 
HMs for advanced CRC in a palliative setting.  
Chapter 6: Contributions of specific plants to tumour response, neutropenia, nausea and 
vomiting 
This chapter provides results of a series of meta-analyses of oxaliplatin-based chemotherapies 
combined with HM for: 1. tumour response rate (tRR) (42 included studies); 2. neutropenia (29 
included studies); and 3. nausea and vomiting (27 included studies). Each meta-analysis includes a 
sensitivity analysis aimed at selecting short-lists of HMs that are potentially effective for each of these 
outcomes. It also reviews the experimental literature on the short-listed herbs for tumour response rate, 
neutropenia and nausea and vomiting. 
Chapter 7: Colorectal cancer cell-line study of matrine from ku shen (Sophora flavescens root) 
The herb ku shen, which is from the root of the plant Sophora flavescens, was identified as having 
potential effects on tumour response in the meta-analysis of clinical trials in Chapter 6. This effect was 
supported by a review of the experimental literature. Chapter 7 reports the results of a series of 
experiments on matrine which a major alkaloid from ku shen. The experiments include: cell viability 
assay, cell cycle analysis, and apoptotic assay for matrine and the positive control drug oxaliplatin. 
Chapter 8: The molecular mechanisms of action of Sophora flavescens and its constituent 
compounds  
This chapter reviews and discusses the likely molecular mechanisms of action of the major constituent 
compounds of Sophora flavescens, including matrine, which are relevant to the management of CRC 
based on the results of in vitro and in vivo studies. 
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Chapter 9: General discussion and directions for future research 
Chapter 9 discusses the approaches taken in this project, including the strengths and weakness, and 
provides directions for future clinical and/or experimental research into the effects and applications of 
herbal medicines in CRC management. It includes conclusions relating to each of the research 
questions. 
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Chapter 2. Literature Review of the Epidemiology, Physiology, Aetiology 
and Management of Colorectal Cancer 
2.1 Introduction to Chapter 2 
In this chapter, the CRC literature was reviewed. This includes the anatomic location and 
physiological functions of the large intestine; CRC epidemiology, etiology, and tumour immunology; 
CRC diagnosis and staging systems; current management of CRC in conventional medicine; Chinese 
herbal medicine (CHM) in the treatment of cancer, especially for CRC; integrative management of 
CRC; and a summary of laboratory studies of CHMs for CRC.  
2.2 Large intestine anatomic location and physiological functions 
The colon and rectum are generally referred to as the large intestine, which is a muscular tubal organ. 
The colon is the first and longest portion of the large intestine. It absorbs water and mineral nutrients 
from food substances, then the residue (faeces) passes to the rectum, which is the final part of the large 
intestine. The small intestine is attached to the colon at the cecum. The colon is divided into four 
sections, the small intestine is attached to the ascending colon which then attaches to the transverse 
colon, the descending colon, and the sigmoid (‘S’ shaped) colon, which joins to the rectum (American 
Cancer Society, 2008). 
The colon is also divided into the proximal colon and distal colon. The proximal colon includes the 
cecum, ascending colon, and transverse colon, whereas, the descending colon and sigmoid colon are 
parts of the distal colon. The proximal colon and distal colon have different embryologic origins. The 
proximal colon derives from the midgut, and its function involves nutrient absorption, while the distal 
colon derives from the hindgut, and is mainly for storage (Bufill, 1990). 
The wall of the large intestine is structured as five main layers. From the inside lumen outwards are: 
the mucosa, submucosa, circular muscles, longitudinal muscles and serosa. The mucosa is composed 
of columnar glandular epithelium and muscles. The glandular epithelium secretes mucus to lubricate 
the movement of food along the colon and protect the colon from digestive enzymes. Underneath the 
epithelium is the lamina propria. This contains myofibroblasts, blood vessels, nerves, and immune 
cells. The crypts of Lieberkuhn are glands found in the epithelial lining of the large intestine, which 
secrete various enzymes. Mutative crypts initiate colorectal cancer. The submucosa contains nerves, 
lymphoid tissue, blood vessels and elastic fibres with collagen that construct the shape of the intestine. 
Longitudinal and circular smooth muscles help with continual peristalsis which moves digested 
material along and out of the colon. The serosa is a layer of thin loose connective tissue which secretes 
mucus as a lubricant to prevent friction damage from the intestine rubbing against adjacent organs 
(Williams & Warwick, 1980). 
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2.3 Colorectal cancer epidemiology review 
Demographic and geographic data on CRC are reviewed in this section. 
 General incidence and mortality 2.3.1
According to the WHO 2012 Cancer Report (Ferlay et al., 2014), WHO estimated there were 14.1 
million new cancer cases and 8.2 million cancer deaths worldwide in 2012. Among these, CRC 
accounted for 1.361 million cases, and 694,000 deaths (Table 1). CRC was the third most common 
cancer worldwide. Compared with the WHO 2008 Cancer Report (Ferlay et al., 2010), CRC increased 
in both incidence and mortality.  
CRC incidence and mortality varies across world regions. Overall, it is ranked as the fourth most 
common cancer in developed regions and the fifth most common cancer in less developed regions 
(Ferlay et al., 2014). In China in 2011, CRC was ranked fifth in terms of incidence in men and third in 
women. It was the fifth leading cause of cancer death in both men and women (Chen et al., 2015). In 
Australia, Cancer Council figures showed that CRC was the second most common cancer in both 
sexes. Overall, CRC had the third highest mortality of the cancers. Translated to figures, there were 
16,682 new cases in 2017, and 4,114 people died from CRC in 2017 (Australian Institute of Health 
and Welfare, 2017). Overall, the mortality rate due to CRC in Australia has declined from 28 to 16 per 
100,000 between 1991 and 2010 (Australian Institute of Health and Welfare, 2012). 
Table 2.1: Colorectal Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012 
Estimated numbers 
(thousands)/ Regions 
Men Women Both sexes 
Cases Deaths 5-
year 
prev. 
Cases Deaths 5-
year 
prev. 
Cases Deaths 5-
year 
prev. 
World 746 374 1953 614 320 1590 1361 694 3544 
More developed regions 399 175 1164 338 158 966 737 333 2130 
Less developed regions 347 198 789 276 163 624 624 361 1414 
Africa region  16 11 32 15 11 31 31 22 63 
Americas region  125 57 362 121 55 342 246 112 705 
E. Mediterranean region 18 12 40 15 10 33 33 21 73 
Europe region  255 120 686 216 108 573 471 228 1258 
South-East Asia region  68 48 122 52 37 93 120 85 216 
Western Pacific region  264 125 711 195 100 518 460 225 1229 
IARC membership1 418 187 1181 351 167 976 769 353 2157 
United States of America 69 29 214 65 27 199 134 55 413 
China 147 79 338 107 60 245 253 139 583 
India 37 28 50 27 21 37 64 49 87 
European Union  193 83 536 152 69 417 345 152 953 
Data from International Agency for Research on Cancer (IARC): 24 countries (adapted from Ferlay et al., 2014) 
prev.: prevalence 
A recent study showed the trend towards increase in the CRC incidence rate has stabilised in the most 
developed countries, but it was increasing in economic transition countries across Eastern Europe, a 
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large part of Asia, and some parts of South America. From 1998-2002, the incidence rates in the 
Czech Republic, Slovakia, and Japan in male populations have exceeded the traditionally high CRC 
countries such as the United States, Canada, and Australia (Center et al., 2009).  
 Incidence and mortality by age 2.3.2
The incidence and mortality rates of colorectal cancer increase with age: 82.1% of new cases and 
89.9% of deaths occur in people 55 and older for both genders. The median ages at diagnosis and 
death due to CRC were 70 for men and 75 years for women (Ries et al., 2008). In Australia, CRC is 
the most commonly diagnosed cancer and the third most common cause of death from cancer in 
people aged 65 years or over based on 2013 data (Australian Institute of Health and Welfare, 2017). 
 Incidence and mortality by gender 2.3.3
The 2012 global CRC incidence rates in men were estimated at 10.0%, which was higher than in 
women (9.2%), and the estimated mortality rates for men and women were 8.0% and 9.0% 
respectively. In men, CRC was the third most common cancer and the second highest cause of death 
due to cancer in developed regions, whereas, in less developed regions, it was the fifth most common 
cancer and the fourth cause of death from cancer. In women, CRC was the second most common 
cancer and the third highest cause of cancer death in developed regions, while it was the fourth most 
common cancer and the fifth cause of cancer death in less developed regions (Ferlay et al., 2014).  
In Australia, the estimated CRC incidence in males was 9,127, and in females was 7,555 in 2013. In 
men the estimated incidence rate declined from 76 per 100,000 in 1991 to 73 per 100,000 in 2012. The 
incidence rate for women varied between 51 and 55 per 100,000 from 1991 to 2009 but it was about 
20% lower than men during this time period. Overall, the mortality rate has declined from 28 to 16 per 
100,000 between 1991 and 2010 (Australian Institute of Health and Welfare, 2012). 
The number of cancer deaths from CRC in Australia was estimated at 2,136 for men and 1,978 for 
women in 2013 (Australian Institute of Health and Welfare, 2017). The mortality rate decreased from 
1991 to 2010 for both men (from 34 to 20 per 100,000) and women (from 24 to 13 per 100,000) 
(Australian Institute of Health and Welfare, 2012). The reasons for the higher risk in men are 
unknown. It may be associated with the higher rate of obesity, smoking, and drinking in men, and 
hormonal therapy in women post-menopause or other factors (American Cancer Society, 2008). 
 Incidence by cancer location 2.3.4
The ratio of tumour initiation in the colon and rectum is different between high-risk countries and low-
risk countries (Muir et al., 1987). In the USA, from 1975 to 2007 the proportion of colon cancer and 
rectal cancer in both sexes in all races among all colorectal cancers was 41.07 (colon) and 15.84 
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(rectum) per 100,000 population age-adjusted respectively (Altekruse et al., 2010). In Australia, CRC 
incidence projections estimated there were 9,753 new cases of colon cancer and 5,027 cases of rectal 
cancer in 2010 (Australian Institute of Health and Welfare, 2008).  
In contrast, the ratio of patients with rectal cancer was larger than colon cancer in China. However, 
there is a trend towards an increasing proportion of colon cancer and a decreasing proportion of rectal 
cancer. In the 1980s, the proportions of colon cancer and rectal cancer were 27.4% and 71.2%, but that 
changed to 33.1% and 66.7% respectively in the 1990s (Ming & Gu, 2005).  
In addition, many investigators worldwide have reported a shift in the location of CRC toward the 
proximal colon (Rhodes et al., 1977; Mamazza & Gordon, 1982; Bufill, 1990; Mensink et al., 2002; 
Takada et al., 2002; Ming & Gu, 2005). Tumours in the proximal colon and distal colon are different, 
in terms of embryologic origin, genetic changes, molecular and clinical characteristics, and biologic 
identity (Distler & Holt, 1997; Gervaz et al., 2001). Proximal tumours and distal tumours appear to 
develop through different pathogenesis mechanisms. Proximal tumours are more genetically stable and 
the possible genesis appears to be from the same mechanisms as for inherited nonpolyposis colon 
cancer. In contrast, distal tumours are associated with genetic instability and may share the same 
mechanisms with polyposis-associated colorectal cancer syndromes (Bufill, 1990). 
 Incidence by ethnicity 2.3.5
CRC incidence and/or morbidity also vary among ethnic populations within a country. In the USA, 
African American men and women had the highest CRC incidence and mortality. Compared with 
white Americans, African Americans had a 20% higher incidence rate and 45% higher mortality. 
These differences may reflect socio-economic differences – African Americans generally have higher 
amounts of fat in their diet, have lower physical activity, and have an increased obesity rate; while 
white Americans generally have had greater access to and use of recommended screening tests as well 
as proper treatments (American Cancer Society, 2008). 
Similar phenomena have been evident in Singapore and Israel, where ethnic Chinese had higher CRC 
incidence compared to Malays, and the Jewish population had higher CRC incidence compared to the 
non-Jewish population. However, in both countries there has been a reversal of these trends in 
incidence rates over the last two decades, as Malays and non-Jews have almost doubled their incidence 
rates of CRC, while ethnic Chinese and the Jewish populations have only experienced a 10-30% 
increase (Center et al., 2009).  
Even within the same ethnicity, populations living in different regions of the same country show 
variation in the incidence rates of CRC. An epidemiological study of four regions of Guangdong 
province in China found that the Pearl River delta area, a highly developed region, had the highest 
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incidence of CRC compared with other regions (Xu et al., 2010). In Japan, records from registries 
demonstrated that in the male population, the incidence rate has increased more than 90% in Yamagata 
and Miyagi prefectures (both rural areas) during the last two decades; in comparison, there was only a 
35% increase in Osaka prefecture (an urban area) (Center et al., 2009). This suggests that CRC has 
been increasing faster in rural areas along with the modernisation of lifestyle.  
McMichael et al. (1980) have studied migrant epidemiology in Australia for decades. From the 1960s 
to the 1980s, migrants from Europe (England, Scotland, Ireland, Poland, Yugoslavia, Greece, and 
Italy) had showed increasing CRC incidence with increasing duration of stay in Australia (McMichael 
et al., 1980). However, the migrant sub-group from southern Europe (Italy, Greece, Yugoslavia, and 
Malta) whose native risk of colon cancer was about half that of the Australian population, have had a 
consistently lower rate of incidence in comparison with their counterpart migrants over the same 
duration. This was probably related to this sub-group’s adherence to their Mediterranean dietary habits 
(McMichael & Giles, 1988). 
Studies have also demonstrated that Chinese and Japanese migrants increased their risks of CRC in the 
USA, and that this change was associated with a lifestyle lacking in physical activity and a diet rich in 
saturated fat compared with their compatriots in China and Japan (Whittemore et al., 1990; 
Maskarines & Noh, 2004).  
Overall, the demographic and geographic evidence show that high-risk ethnicities or countries 
continue to lead the rate of incidence/mortality worldwide for CRC, but that there has been a slowing 
of the trend towards rising CRC incidence in these groups. On the other hand, the rates are sharply 
increasing in some former low risk ethnicities that migrated to the high CRC risk countries or in 
countries that are experiencing economic transition. This suggests that differences in genetics and 
culture, as well as lifestyle and environmental factors all influence the etiology and incidence of CRC. 
In addition, utilization of modern technology for screening and treatment in the precancerous stages 
may have contributed to a slowdown in the trend towards increasing incidence of CRC in high risk 
countries. 
 Prevalence and burden 2.3.6
GLOBOCAN 2012 estimated there were 3,544,000 people who had been diagnosed with CRC and 
had survived for 5 years or more in 2008 (Bray et al., 2013). In USA, 64.9% of people who had been 
diagnosed with CRC had survived 5 years or more in 2005-2011 and it was estimated that in 2012, 
1,168,929 people who has been diagnosed with CRC were still alive (Howlader et al., 2015).  
In Australia, the 5 years prevalence of CRC at the end of 2009 was 48,596 people (men: 26,700; 
women: 21,896) (Australian Institute of Health and Welfare, 2014). The total burden of disease and 
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injury was expressed as the disability-adjusted life year (DALY). The burden of CRC was estimated to 
be 38,800 DALYs for men and 30,700 DALYs for women in 2012 (Australian Institute of Health and 
Welfare, 2012). The direct cost of CRC was $427.35 million, which represented 9.4% of all cancer 
expenditure in 2008-09 (Australian Institute of Health and Welfare, 2013). Of all the cancers, in 2011 
CRC accounted for the second highest cancer burden of disease in males and was the third highest in 
females (Australian Institute of Health and Welfare, 2017). 
2.4 Risk factors for colorectal cancer 
Besides increased risk by age, a number of lifestyle-related factors (excessive consumption of red 
meat, diet high in animal fats, lack of exercise, alcohol, smoking etc), obesity, hereditary factors and 
chronic inflammatory bowel diseases are commonly thought to be factors that initiate and promote 
CRC. In contrast, consumption of vegetables and fruit, exercise, vitamin D, calcium, folic acid, non-
steroidal anti-inflammatory drugs (NSAIDs) and hormone replacement therapy (HRT) for 
postmenopausal women may reduce the risk of CRC (American Cancer Society, 2008). 
 Diet 2.4.1
A review of epidemiological studies found that high consumption of red meats, saturated fat, and 
processed meat were all associated with increased risk of CRC. Risk was correlated with ingestion of 
fresh red meat (17% increased risk for 100 g/day increase in consumption) and processed meat (18% 
increase for 50 g/day increase in consumption) (Chan et al., 2011). In particular, long-term high 
consumption of red and processed meat appears to increase the risk of carcinoma of the distal colon 
and rectum (Chao et al., 2005). Several carcinogenic factors that are generated during processing, 
cooking, and digesting may be associated with increased risk, for instance, high fecal bile acids from 
high-fat diets, heterocyclic amines and polycyclic aromatic hydrocarbons from high temperature 
cooking, N-nitroso compounds and heme iron in red meat (Santarelli et al., 2008). 
Information from studies of the relation between the intake of fruits, vegetables and fibre, and CRC 
risk reduction are inconsistent. Several reports from prospective cohort studies and reviews found a 
diet with a higher intake of fruits, vegetables and grain fibre may reduce CRC risk (Fung et al., 2010; 
Gonzalez & Riboli, 201; Kirkegaard et al., 2010; Miller et al., 2010). Higher intake of wholegrain 
products (mainly insoluble, non-degradable fibre) decreased the chance of CRC in men, but not in 
women (Egeberg et al., 2010). However, a review found there was no strong evidence that supported 
the notion that high intake of fibre, including fruits and vegetables, has an influence on CRC risk 
(Doyle, 2007). The differences in these findings may be associated with study design, definition of 
which fruits, vegetables and other foods the study focussed on and the observation duration. 
Nevertheless, a balanced diet with more vegetables and fruits that contain nutrients such as 
carotenoids, folate, and ascorbate, and substances with anticarcinogenic properties, such as phenols, 
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flavonoids, isothiocyanates, and indoles are of benefit to health in general (Wattenberg, 1978; 
Steinmetz & Potter, 1991). 
 Vitamin D, Calcium, Folate, Vitamin B6 2.4.2
Epidemiological investigations have found that there was an inverse relationship between intake of 
vitamin D, calcium, folate vitamin B6 and risk of CRC. It was estimated that every 100 microg/day 
increase in total folate intake will result in a 2% risk reduction (95% CI 0-3%) in colon cancer, based 
on a pooled analysis of 13 prospective cohort studies (Kim et al., 2010). A prospective investigation of 
10 European countries on diet and cancer prevention that involved 519,978 participants (366,521 
women and 153,457 men), who were mostly aged 35-70 years, found that high intake of dietary fibre, 
fish, calcium, and vitamin D were correlated with reduction of CRC risk (Gonzalez & Riboli, 2010). A 
randomised controlled trial suggested vitamin D and calcium probably act together to reduce risk of 
colorectal adenoma recurrence (Grau et al., 2003). Pyridoxal 5'-phosphate (PLP) is an active form of 
vitamin B6. A meta-analysis of prospective studies that included nine studies on vitamin B6 intake and 
4 studies on blood PLP levels found up to 49% reduction in risk of CRC for every 100-pmol/mL 
increase in blood PLP levels (RR, 0.51; 95% CI, 0.38-0.69) (Larsson et al., 2010). 
 Physical Activity, Body Mass Index (BMI), Smoking, Alcohol 2.4.3
Evidence from various studies indicated physical inactivity, obesity, smoking, and high alcohol intake 
all increased the risk of CRC.  
A meta-analysis of 19 cohort studies found physical activities could significantly reduce colon cancer 
in men, with occupational activities (RR=0.79, 95% CI 0.72–0.87) showing similar reductions to 
recreational activities (RR=0.78, 95% CI 0.68–0.91). Only recreational activities reduced colon cancer 
for women (RR=0.71, 95% CI 0.57–0.88). No effect on rectal cancer in either sex was seen in this 
study (Samad et al., 2005). The American Cancer Society recommends that people should engage in 
moderate activity for at least 30 minutes each day, 5 days per week, and it is even better if a person 
takes 45 to 60 minutes of intentional physical activity (American Cancer Society, 2008). Prolonged 
sitting, including television viewing and sitting at work has been linked to an increased risk of CRC 
with an increase in sitting time of two hours a day showing significant increases (Ma et al., 2017; 
Milne et al., 2017).  
Larsson and Wolk (2007) conducted a meta-analysis of 30 prospective studies that investigated the 
correlation between obesity and CRC. The available evidence showed a 5-unit increase in body mass 
index (BMI; in kg/m2) correlated with a 30% increase in risk of colon cancer and a 12% increase in 
risk of rectal cancer in men. There was a 12% increase in risk of colon cancer in women but no effect 
on risk of rectal cancer. There was also a statistically significant positive correlation between both 
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waist circumference (per 10-cm increase) and waist-hip-ratio (per 0.1-unit increase) and colon cancer 
risk in men and women (Larsson & Wolk, 2007). 
A meta-analysis by Tsoi et al. (2009) which included a total of 1,463,796 participants who were 
involved in 28 prospective cohorts from America, Europe, and Asia, with a median follow-up of 13 
years (range, 4-30 years) concluded that smoking was associated with a significantly increased risk of 
CRC. The authors found there was a modest but significantly higher risk of CRC in current smokers 
than never smokers (RR 1.20; 95% CI [1.10, 1.30]), and the risk of CRC among smoking men (RR 
1.38; 95% CI [1.22, 1.56]) was significantly higher than in smoking women (RR 1.06; 95% CI [0.95, 
1.19]). The risk of rectal cancer was associated more with smoking than colon cancer (RR 1.36; 95% 
CI [1.15, 1.61]). Former smokers still demonstrated a higher risk of CRC than never smokers. This 
increased risk of CRC was dose-related. Higher consumption of cigarettes, in terms of the number of 
cigarettes per day, or the number of years of smoking, or the number of total pack-years of cigarette 
smoking, was associated with a higher risk of CRC (Tsoi et al., 2009).  
Based on evidence from the epidemical studies, the International Agency for Research on Cancer 
(IARC), has added CRC to the list of alcohol-related malignancies (Baan et al., 2007). Alcohol 
consumption of 30 g/day or more (approximately > or =2 drinks/day) was significantly associated with 
increased risk of CRC compared to non-drinkers (Cho et al., 2004).  
 Heredity and medical history 2.4.4
It was estimated that 5% to 10% of CRC patients have inherited gene alterations that predispose them 
to carcinogenesis. Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal 
cancer (HNPCC) are well known inherited diseases associated with CRC. Most of those with FAP and 
HNPCC will develop CRC by the age of 40 (Lynch & de la Chapelle, 2003). 
People who have a family history of CRC, especially in those who are closely related, are at higher 
risk of having CRC, and 20% of CRC patients have a family history of the disease (Lynch & de la 
Chapelle, 2003). The cohort of high CRC risk also includes people who have had one or more 
adenomatous polyps, or chronic inflammatory bowel disease such as ulcerative colitis and Crohn’s 
disease over a long duration (Schatzkin et al., 1994; Bernstein et al., 2001). 
2.5 Chemopreventive medicines 
Nonsteroidal anti-inflammatory drugs (NSAIDS) have been investigated for their chemoprevention of 
CRC. Pooled-data from RCTs found that aspirin 81-325 mg/day had a statistically significant effect 
with 21% reduction in the relative risk of adenoma recurrence in patients with a history of adenomas. 
The data also showed aspirin 300-1500 mg/day had a 26% reduction in CRC incidence over 23 years 
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of follow-up, but there was no effect in the first 10 years. However, high-dose aspirin has increased 
risk of gastrointestinal adverse reactions including peptic ulcers, gastrointestinal bleeding and 
hemorrhagic stroke. Celecoxib, a COX-2 inhibitor, at a dose of 400 mg/day showed a 34% decrease in 
the risk of adenoma recurrence in patients with a history of adenomas as well as a 55% decrease in the 
risk of advanced adenoma (generally defined as adenoma ≥ 1 cm in diameter, villous or tubulovillous 
adenoma, adenoma with severe dysplasia, or CRC). But given that celecoxib increased the risks of 
hypertension and renal toxicity, it is important to consider the risk-benefit effect before making a 
recommendation for using NSAIDS for chemoprevention (Cooper et al., 2010). The chemopreventive 
mechanisms of NSAIDs for colorectal neoplasia may be associated with restoration of apoptosis in 
APC-deficient cells and inhibition of angiogenesis (Thun et al., 2002). 
Epidemiological studies have found that the CRC morbidity and mortality in men was higher than in 
women. Postmenopausal hormone therapy (PHT) may contribute to this difference. A study by 
Grodstein et al. (1999) found there was a 20% reduction in colon cancer and a 19% reduction in rectal 
cancer in women who had used postmenopausal hormones in the past compared with never users. In 
women who were currently using PHT there was a 34% decrease in the risk of CRC compared to those 
who had never used. However, there was no correlation between the duration of use of PHT and 
reduction of CRC risk (Grodstein et al., 1999). 
2.6 Bowel cancer screening programs 
CRC is a curable disease if detected at early stage. Adenoma polyps at each stage are detectable by an 
endoscope or on x-ray, and are removable by surgery. This can greatly prevent CRC onset. In the 
USA, the national Polyp Study found that periodic colonoscopy screening could prevent 76% to 90% 
of colon cancers (Winawer et al., 1993). People who have a strong family history of FAP or HNPCC 
or colorectal cancer or other risk factors for adenoma polyps or cancer should start screening at a 
younger age and/or get screened more frequently. 
Based on data from four RCTs, a Cochrane review found that CRC screening programs in average-risk 
adults aged 50 years or older that used the modality of fecal occult blood testing (FOBT), including 
guaiac FOBT (gFOBT) and immunochemical FOBT (iFOBT) reduced the mortality of CRC by 16% 
(RR 0.84, 95% CI [0.78, 0.90]), and potentially decreased CRC incidence by removal of adenomas 
(Hewitson et al., 2007).  
CT colonography (CTC) screening was of comparable sensitivity to colonoscopy for CRC and large 
adenomas (10 mm or larger). But it was of lower sensitivity for smaller polyps (6 mm or larger). 
Colonoscopy is the most accurate screening test for CRC. However, serious harms due to colonoscopy 
are about ten times more common (3.1 per 1,000 procedures) than harms due to fecal tests (3.4 per 
10,000 procedures) (Whitlock et al., 2008). 
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The Australian Bowel Cancer Screening Pilot Program followed people aged 55 to 74 years in three 
cities (Mackay, Adelaide and Melbourne) between 6 November 2002 and 1 October 2004. The 
program used FOBT with follow-up colonoscopy for people with FOBT positive results. 45.4% of 
invitees (25,840 out of 56,907 invitations) responded by returning a completed FOBT. The positive 
predictive value that was defined by the authors as ‘the proportion of FOBTs with cancers and 
adenomas detected out of all positive FOBTs that are followed up with a colonoscopy’ was 19.4% for 
cancers and advanced adenomas across both tests (Stevenson & Hotstone, 2005). A recent study 
reported that the Australian National Bowel Cancer Screening Program (NBCSP) significantly 
reduced risk of CRC recurrence and death compared with patients with a symptomatic presentation 
(Ananda et al., 2016). Overall, an appropriate bowel cancer screening program can reduce CRC 
morbidity and mortality. 
Clinical practice guidelines for the prevention, early detection and management of colorectal cancer 
were approved by the National Health and Medical Research Council (NHMRC) on 27 October 2017 
(https://www.nhmrc.gov.au/guidelines-publications/cp62). 
2.7 Etiology of colorectal cancer 
Although the exact causes of CRC are unclear, epidemiological studies have demonstrated that 
environmental factors, lifestyle, hereditary factors and chronic inflammatory bowel diseases are 
common causes that initiate and promote CRC. 
The formation of CRC has a long progressive duration associated with the accumulation of genetic 
mutations. Three main genetic pathways of CRC have been proposed:  
1. The Chromosomal Instable (CSI) pathway: caused by accumulation of mutations in tumour 
suppressor genes and specific oncogenes (e.g. APC, KRAS, PIK3CA, BRAF, SMAD4, TP53, 
etc) which result in chromosomal abnormalities characterised by loss of heterozygosity. In 70% 
of CRC and FAP, carcinogenesis is via this pathway; 
2. The Microsatellite Instability (MSI) pathway: initiated by mutation in mismatch repair (MMR) 
genes, including MLH1 and MSH. The mutation of MMR genes that is characterised by 
hypermethylation which leads to deficiency of DNA repair. MSI is found in HNPCC and 15% 
of sporadic CRC;  
3. The CpG Island Methylation (CIMP) pathway: cytosine methylation inside genes that can 
silence the genes was found in most MIS colon tumours. BRAF mutations and MLH1 
methylation, and KRAS mutations were related to CIMP.  
However, the formation of CRC could be the result of multi-pathways (Bogaert & Prenen, 2014). 
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Most CRC is believed to initiate from adenoma and progress to carcinoma. The characteristics of an 
early adenoma are small in size and mildly dysplastic with a tubular architecture, while advanced 
adenoma will be large in size, highly dysplastic, and with a villous architecture (Hayat, 2009). 
2.8 Tumour immunology 
Tumour immunology specifically studies the immune response to tumours in which the cell-mediated 
immunity (CMI) response plays a major role. The immune responses express the dual actions of host-
protection (tumour immunosurveillance) and tumour-sculpting (tumour immunoediting) on the 
processes of tumour development (Dunn et al., 2002). In this section the functions of the human 
immune system and its role in the immune response to tumours is briefly reviewed. In addition, since 
surgical procedures are important in CRC treatment, the immunosuppression induced by surgical 
procedures was also included in this section. 
 Outline of the human immune system  2.8.1
The human immune system consists of innate immunity and adaptive immunity. Both these types have 
cell-mediated and humoral components. The CMI response is a process that activates cytotoxic cells to 
cause death by apoptosis, and releases cytokines in response to antigens. Humoral immune response 
involves antibody secretion by immune cells, mainly B-type lymphocytes, and binding to antigens. 
The binding complex of antibody and antigen is ingested by phagocytic cells, including macrophages, 
neutrophils, and dendritic cells (DC), and the cell is destroyed (Janeway et al., 2001). 
Innate immunity is the body’s first line of defence. It involves the skin and mucous membranes as 
physical barriers, as well as innate immune cells and molecules (Scholl & Babu, 2012). The innate 
immunity is able to respond rapidly when pathogens or damaged cells are identified by pattern 
recognition receptors (PRRs) that are germline-encoded and expressed by innate immune cells. These 
cells include, phagocytes, mast cells, eosinophils, basophils, and natural killer (NK) cells (Medzhitov, 
2007). 
Adaptive immunity is activated by the innate response, and requires specific antigen presentation. In 
this process, antigens are caught by innate immune cells and marked to enable their recognition by 
lymphocytes, which are special types of leukocytes. The lymphocytes involved in adaptive immunity 
are classified as T cells and B cells. The T cell is a cell-mediated response cell, whereas the B cell is a 
humoral response cell (Janeway et al., 2001).  
Both B cells and T cells clonally express a large repertoire of antigen receptor molecules that 
recognise specific antigens. When primitive T and B cells come across antigens in lymph nodes or the 
spleen, they differentiate into various effector cells (Vivier et al., 2011). These effector cells are 
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recruited to the site of the target, mediated by cytokines and chemokines that are secreted from the 
innate immune system (Medzhitov, 2007). 
T cells can recognise antigens when they bind to the major histocompatibility complex (MHC), a cell 
surface molecule that mediates interactions of leukocytes. In humans, MHC is also called human 
leukocyte antigen (HLA) (Kuo & Hood, 1987). There are two sub-groups of MHC — class I and class 
II. A T cell that recognises antigens combined to a Class I MHC moleculeis called a T killer cell; and a 
T cell that recognises antigens combined to Class II MHC molecules is referred to as a T helper cell. T 
cell receptor (TCR) is a molecule on the surface of T cells that recognises antigens bound to MHC 
molecules. When a T cell approaches a specific antigen bound to a MHC, its TCR recognises and 
binds to the MHC assisted by a co-receptor called cluster of differentiation (CD), a transmembrane 
glycoprotein bound to MHC, so the T cell is activated and exerts its immune function (Medzhitov, 
2007). 
The anti-tumour immune responses are primarily dominated by cell-mediated immunity (CMI). NK, 
CD4+ and CD8+ T cells are the main types of lymphocytes in cell-mediated immunity and play a 
central role in the induction of efficient immune responses against tumours. There are two major 
cytotoxic mechanisms involved: 1. causing target cell lysis by releasing cytolytic granules such as 
perforin and granzymes; and 2. inducing cell apoptosis by expressing death-receptor ligands such as 
tumour necrosis factor–related apoptosis-inducing ligand (TRAIL), or Fas Ligand (FasL) (Dunn et al., 
2002). 
The CD4+ molecule is expressed on the surface of T helper cells (Miceli et al., 1993). CD4+ is a co-
receptor that aids binding of TCR to Class II MHC. These cells do not kill target cells directly, but 
they are important to switch a B cell's production of antibodies from one class to another, to activate 
cytotoxic T cells, and for optimising the anti-bacterial activity of phagocytes such as macrophages 
(Janeway, 2005).  
There are two major sub-types of T helper cells, referred to as Type 1 and Type 2 T helper cells. Type 
1 T helper cells secrete gamma-interferon (IFN-γ), interleukin (IL)-2, and IL-12, and stimulate the 
cellular immune system to promote the killing effect of macrophages and the proliferation of cytotoxic 
CD8+ T cells. Type 2 T helper cells secrete IL-4, IL-5, and IL-10, and stimulate the humoral immune 
system to promote proliferation of B cells and antibody production (Kidd, 2003). Each sub-type of T 
helper cell acts to preserve its own response by producing cytokines to inhibit another sub-type of T 
helper cell. The balance of Type 1 T helper cells / Type 2 T helper cells maintains the homeostasis of 
immunity (Abbas et al., 1996).  
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Since CD4+ T helper cells play an important role in optimizing CD8+ T cell activation, an adequate 
number of CD4+ T helper cells are required to sustain the cytotoxic function against tumour cells of 
CD8+ T cells (Gerloni & Zanetti, 2005). 
Besides T helper cells, there is another subset of CD4+ T cells, the regulatory T cells (Treg cells). 
Once activated, T helper cells mediate the activation of CD8+T cells. Conversely, Treg cells attenuate 
the immune reaction to maintain immunotolerance and suppress autoreactive T cells (Buckner, 2010). 
CD8+ is a co-receptor that aids TCR and is specific for Class I MHC. The CD8+ molecule is 
commonly expressed on the surface of killer T cells, but can express on NK cells, cortical thymocytes, 
and dendritic cells as well (Gao & Jacksen, 2000). The T cell that expresses CD8+ surface protein is 
called a CD8+ T cell. When an activated CD8+ T cell binds to a target cell that expresses Class I 
MHC molecule, it kills the target cell by releasing cytotoxins or granulysin, or induces the target cell 
to undergo apoptosis by the upregulation of the FasL pathway (Harty et al., 2000; Radoja et al., 2006). 
NK cells are a type of cytotoxic lymphocyte that represents 5-20% of peripheral lymphocytes. Small 
portions of NK cells are also present in the thymus, lymph nodes, and bone marrow. In humans, NK 
cells bear a CD3-negative mark. NK cells also express CD56, CD16 and CD94 (Arina et al., 2007). 
NK cells play a critical role in the innate immune response, and can kill infected cells or transformed 
cells rapidly without previous antigen exposure or MHC binding. Studies have also found that NK 
cells can act as part of the adaptive immune response (Wallace & Smyth, 2005).  
There are several pathways linked to the cytotoxicity of NK cells, including: 1. direct cytotoxic 
activity without initiation by any specific antigen recognition mechanisms; 2. antibody-dependent cell-
mediated cytotoxicity (ADCC), in which the target cell with antigen-specific antibody expression 
activates NK cells through the CD16 receptor, causing release of cytolytic granules, as well as 
secretion of IFNγ, Tumour necrosis factor (TNF) α, or T cell recruiting chemokines which result in the 
apoptosis or lysis of the target cell; 3. secretion of T helper 1-type cytokines such as IFNγ and TNFα. 
Macrophages are activated by IFNγ and exert phagocytosis and lysis, whereas TNFα promotes direct 
killing of tumour cells by NK cells; and 4. NK cell interactions with dendritic cells, e.g. the cytokines 
IL-12 and IL-2 that are secreted by mature dendritic cells, induce the secretion of IFNγ by NK cells. 
Meanwhile the activated NK cells secrete T helper 1-type cytokines, such as IFNγ and TNFα, that 
promote the maturation and activation of dendritic cells (Terunuma et al., 2008). 
 Tumour immunosurveillance 2.8.2
The hypothesis of tumour immunosurveillance was proposed by Macfarlane Burnet and Lewis 
Thomas (Burnet, 1967). The major concept of this hypothesis is that the immune system, especially 
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the cell-mediated immunity (CMI), is able to detect and eliminate a tumour in its formation stage. This 
immunity involves both the innate and adaptive immune systems (Dunn et al., 2002). 
Tumour-specific T cells (CD8+ cytotoxic T cells and CD4+ helper T cells) mediate immunity by 
detecting and eliminating tumour cells. They rely on recognition of the tumour associated antigen 
(TAA) that is presented by MHC-class molecules on the surface of tumour cells. Types of TAA are: 1. 
neoantigen, 2. self-antigen, and 3. modified self-antigen. Most tumours express self-antigen and 
modified self-antigen. Inactive T cells are activated by dendritic cells that have encountered dead 
tumour cells and present TAA with MHC class molecules to T cells. Thus, the T cells are activated 
and exert their protective effects (Topfer et al., 2011). 
Dunn et al. (2002) summarised the process of immune surveillance in four phases: 1. the innate 
immune system (NKT, NK, γδ Τ cells, macrophages and dendritic cells) is alert to the formation of 
tumour cells and produces IFN-γ; 2. IFN-γ induces a series of innate immune system responses, such 
as releasing angiostatic chemokines to block new vessel growth in the forming tumour, recruiting 
innate immune effector cells to the tumour site and exerting cytotoxic effects. Tumour cells and debris 
of dead tumour cells are ingested by dendritic cells and are transported to the draining lymph node; 3. 
the tumour is continuously surveilled by innate immune effector cells, meanwhile, CD4+ and CD8+ T 
cells marked with specific tumour antigens are developing; 4. the matured CD4+ and CD8+ T cells are 
recruited to the tumour site, where they recognise and kill tumour cells that are bearing specific 
tumour antigens (Dunn et al., 2002). 
Extensive studies support the tumour immune surveillance hypothesis. Laboratory studies have found 
that animals in which different components of immunity were deleted were more susceptible to 
tumour formation induced by chemicals or growth of transplanted tumours than wild-type controls 
(Dighe et al., 1994; van de Broek et al., 1996; Kaplan et al., 1998; Girardi et al., 2001; Shankaran et 
al., 2001; Street et al., 2001). In human studies, researchers found that organ transplant patients who 
used immune-suppressants, people who were inherently immune-deficient, and AIDS patients were 
more at risk of cancer development (Buell et al., 2005; Goedert & Bower, 2012; Kubica & Brewer, 
2012). In addition, researchers have found that cancer patients who presented with tumour infiltrating 
lymphocytes (TIL) in tumour sites had better survival rates than those with an absence of TIL 
(Clemente et al., 1996; Naito et al., 1998; Kawai et al., 2008).  
Recently, immunotherapies have shown promising results. Ipilimumab, the human antibody inhibiting 
CTLA-4, improved overall survival (OS) of patients with unresectable stage III or stage IV melanoma 
in a phase III trial. Thus, ipilimumab was approved by the FDA in 2011. Ipilimumab also 
demonstrated benefit in elevating treatment response in patients with metastatic renal cell carcinoma 
and patients with metastatic prostate cancer (Postow et al., 2011). This evidence from both animal and 
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human studies indicates that the immune system plays important roles in tumour formation, prognosis 
and treatments. 
 Tumour immunoediting 2.8.3
Although the immune system exerts host-protective functions in tumour formation, researchers have 
also found tumour selection and tumour escape effects which can explain why tumours can occur in 
immunocompetent individuals (Urban et al., 1982; Engel et al., 1997; Iwashiro et al., 2001). Tumour 
immunoediting is a concept that has been incorporated into tumour immunosurveillance theory to 
further describe the immune system’s dual host-protecting and tumour-sculpting actions on the 
processes of tumour development. It comprises three processes: elimination, equilibrium and escape. 
The elimination process is inherent in the concept of tumour immune surveillance discussed earlier. 
The equilibrium process is characteristic of dynamic interactions of the host immune system and 
tumour cell variants that survived the elimination process. In this process, the host immune system 
continually selects and kills immunologically sensitive tumour cell variants, meanwhile, due to the 
genetic instability of tumour cells, they rapidly produce new mutated variants that allow them 
increased resistance to the host’s immune system killing ability. The escape process refers to tumour 
cell variants that survive detection and elimination by the host immune system through various 
mutations that gain them immunological insensitivity. This results in clinical malignant disease (Dunn 
et al., 2002). 
Based on laboratory and clinical studies, a review by Topfer et al. (2011) proposed the following five 
mechanisms of tumour escape from immune surveillance, mainly from T cells: 
1. Recognition of tumours by activated T cells is defective due to inhibition of MHC I class 
molecule expression. There are several pathways that have been observed in various cancer 
studies: 1. mutations or deletions of heterozygosity on chromosome 6p21 of human 
lymphocyte antigen (HLA) (Maleno et al., 2002; Maleno et al., 2004); 2. mutations of β2-
microglobulin (β2m) on MHC I class molecules damage the transport of MHC class I 
molecules to the cell surface (Chen et al., 1996); 3. hyper-methylated DNA of HLA class I 
causing transcriptional inactivation (Nie et al., 2001); 4. down-regulation of HLA mRNA 
transcription by inhibited expression of locus-specific transcription factors such as CCAAT 
(nucleotides) and Sp1-like sequence (Soong & Hui, 1992); 5. suppressing expression of 
transporters associated with antigen processing 1 and 2 (TAP1 and TAP2) and the proteasome 
subunits of low-molecular mass polypeptides 2 and 7 (LMP2 and LMP7) (Korkolopoulou et 
al., 1996; Seliger et al., 1998); and 6. impairment of IFN-γ signalling or deficiencies in 
interferon regulatory factor-1 (IRF-1) resulting in reduced MHC class I expression (White et 
al., 1996; Hobart et al., 1997; Respa et al., 2011). In addition, inhibition of cell adhesion 
molecule expression helps cancer cells escape host immune attack (Madhavan et al., 2002). 
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2. T Cell-mediated killing activity is resisted by cancer cells. Cancer cells can resist apoptosis via 
a number of pathways: 1. T cells can induce cancer cell apoptosis by the calcium-dependent 
‘perforin /granzyme pathway’ but cancer cells can resist T cell attack by expression of serine 
protease inhibitor PI-9/SPI-6 that blocks apoptosis via the perforin /granzyme pathway 
(Medema et al., 2001); 2. the TRAIL-mediated apoptosis pathway can be blocked by cancer 
cells’ expression of the anti-apoptotic regulator FLICE inhibitory protein (c-FLIP) (Griffith et 
al., 1998; Dutton et al., 2006); 3. via the calcium-independent ‘death receptor pathway’ cancer 
cells can down-regulate or inactivate death receptors CD95/FAS and TRAIL through 
oncogenic Ras expression (Peli et al., 1999 ), somatic mutations in Fas (Apo-1/CD95) gene 
(Park et al., 2001) and/or mutations of TRAIL-R1 and -R2 genes) (Shin et al., 2001); also, 4. 
cancer cells can release soluble decoy receptors that competitively inhibit death receptor or 
Fas ligand signaling (Pitti et al., 1998). 
3. Suppression of cytotoxic effects of T cells. Activated T Cells are suppressed by tumour cells 
expressing inhibitory co-stimulatory B7 molecules, CD80 (B7.1), CD86 (B7.2), and B7-
homolog 1 (B7-H1), which are types of extracellular membrane proteins that can bind to T 
cell inhibitory co-receptors of cytotoxic T lymphocyte antigen-4 (CTLA-4) and program 
death-1 (PD1) in the surface of the T cell to decrease T cell activity (Zou & Chen, 2008). In 
addition, tumour growth factor β (TGF-β) suppresses CD8+ T cells’ cytotoxic effect in the 
tumour microenvironment (di Bari et al., 2009). Increased cyclooxygenase-2 (COX-2) and 
prostaglandin E2 (PGE2) expression is associated with reduction of T cells and dendritic cells 
in cancer patients (Pockaj et al., 2004).  
4. Active T cells are counter attacked by tumour cells. Active T cells are regulated by the process 
of T cell activation-induced cell death (AICD) that is mainly mediated by CD95/FAS death 
receptor. Tumour cells were found to express Fas ligand (FasL) that may induce apoptosis of 
antigen-specific T cells. This proposal was supported by an animal study that demonstrated 
there was delayed growth of FasL positive melanoma cells in lpr-positive mice (lpr: 
lymphoproliferation gene; which encodes mutated non-functional CD95/FAS in these mice) 
when compared to wild-type controls (Hahne et al., 1996). However, this theory is in 
contradiction to a study that found FasL can also induce pro-inflammatory and anti-tumour 
effects in vivo (Arai et al., 1997).  
5. Promoting expression of immunosuppressive FoxP3+, CD4+CD25+Tregs and myeloid-
derived suppressor cells (MDSCs). CD4+ CD25+ Tregs expression of the transcription factor 
forkhead box P3 (FoxP3) is important to maintain immune homeostatic peripheral tolerance 
(Thompson & Powrie, 2004). The expression of CD4+ CD25+ Tregs is higher in cancer 
tissues and peripheral blood of cancer patients than in healthy cohorts. Over-expression of 
FoxP3+, CD4+ CD25+ Tregs suppressed tumour-specific T cell immunity in cancer patents, 
and was correlated with poorer survival (Curiel et al., 2004). MDSCs are immature myeloid 
cells, including macrophages and DCs. MDSCs over-expression in the peripheral blood of 
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cancer patients is associated with DC dysfunction in immune surveillance. MDSCs also 
directly suppress tumour-specific T cell response (Almand et al., 2001). 
 Immunosuppression induced by surgical procedures 2.8.4
Surgery is the primary treatment for CRC, but surgical procedures can suppress the immune system, 
especially the cell-mediated immunity (CMI) (Ogawa et al., 2000). After reviewing animal studies and 
human studies, Neeman (2012) proposed several surgery-related factors that promote cancer 
metastasis:  
1. surgical procedures increase the chance of cancer cells entering into the blood and lymphatic 
circulation by manipulating the tumour and its vasculature;  
2. surgery promotes cancer cell proliferation and resistance to apoptosis;  
3. surgery enhances residual cancer cell invasion by up-regulating matrix metalloproteinases 
(MMP) and adhesion-molecules on cancer cells;  
4. surgery reduces the expression of tumour-related anti-angiogenic factors (e.g. angiostatin and 
endostatin), and promotes the expression of pro-angiogenic factors (e.g. VEGF);  
5. surgical wounds stimulate secretion of growth factors (e.g. EGF) that promote local and 
distant recurrence;  
6. finally, the most important factor is surgery suppresses cell-mediated immunity (CMI) that is 
associated with the neuroendocrine system, especially the hypothalamo-pituitary-adrenal axis 
and the autonomic nervous system through increasing secretion of immune suppressing 
hormones (e.g. cortisol), decreasing the numbers and activity of NK, Th1 and CTL cells, and 
reducing the pro-CMI type-1 cytokines (e.g. IL-12 and IFN-γ).  
As a consequence of these factors, residual cancer cells in the peripheral blood system could 
potentially escape the host’s immune surveillance. It may improve the prognosis if the cell-mediated 
immunity (CMI) is quickly restored from the immusuppressed state in the peri-operative period 
(Neeman & Ben-Eliyahu, 2012).  
However, researchers have also found that reducing tumour burden by surgical resction could reduce 
tumoural immunosuppressive status, and restore patients’ cell-mediated immunity (CMI) (Wang et al., 
1999). Thus, surgical resection is a double-edged sword. It is important to consider the risk-benefit 
effect before making a recommendation for patients. 
2.9 Diagnosis and management of colorectal cancer 
In this section the literature on CRC diagnosis and staging systems, current management of CRC in 
conventional medicine, the use of CHM in cancer treatment, especially for CRC, the potential anti-
cancer mechanisms of HMs, and integrative management of CRC were reviewed. 
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 Symptoms and diagnosis 2.9.1
Early stage CRC often has no signs and symptoms. For people, especially those over 50 years old with 
symptoms of progressive constipation, blood in the stool, changing shape of stool, loss of appetite, 
unexplained weight loss or unexplained anaemia are warning signs (Astin et al., 2011). The diagnosis 
of CRC relies on pathological tests of samples taken from the suspicious area of the large intestine 
often via colonoscopy or sigmoidoscopy. The cancer cell type and grade are determined by pathology 
tests. A CT scan is often used to determine the extent of CRC. Other tests such as MRI or PET scan 
can be used if necessary (Cunningham et al., 2010).  
 Staging 2.9.2
The staging of CRC is critical to predict prognosis and determine treatment in CRC management. It 
describes the extent to which the CRC has developed, in terms of the size of the tumour, how deep 
(how many layers) into the wall of the large intestine it has penetrated, and whether it has invaded 
adjacent organs or metastasized to lymph nodes (if so, how many) and to distant organs.  
CRC staging initially used the Dukes stage system, which was invented by Dr. Cuthbert Dukes in 
1932 (Dukes, 1932), and has since been developed into several modified versions (Astler & Coller, 
1954). The Dukes system involved four stages from A (local tumour) to D (metastasis). The current 
American Joint Committee on Cancer (AJCC) staging system classifies CRC from stage 0 to stage IV 
with stage 0 indicating no carcinoma and stage IV indicating the most severe stage of the disease 
(Frederick et al., 2002). The AJCC stages I to IV are roughly equivalent to Dukes stages A to D 
(AJCC, 2010). 
The TNM staging system, originally created by Pierre Denoix (Denoix, 1946), was developed by the 
International Union Against Cancer, which was later renamed Union for International Cancer Control 
(UICC). Today, the TNM staging system is widely used for CRC staging in clinical practice 
internationally. ‘T’ for tumour, denotes the extent of invasion of the intestinal wall, ‘N’ for lymphatic 
nodes, indicates the amount of lymphatic node involvement, and ‘M’ refers to metastasis. The AJCC 
also uses the TNM classification, which has the same definitions for each stage and sub-group as the 
UICC. The two systems were unified into a single system in 1987 (Sobin, 2003). 
The TNM system has been modified several times over the decades as scientists learn more about 
cancer. The latest edition was published in 2009 (Sobin et al., 2009). A recent review showed the 7th 
edition is better than the previous edition in predictive capacity for CRC (Gao et al., 2013). However, 
this system does not cover all survival discrepancies, especially with stage II of CRC. Therefore, other 
prognostic factors should be considered for decision making with regard to therapy (Hari et al., 2013). 
The modifications between the 6th edition and the 7th edition are shown in Table A in Appendix A. The 
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major staging principles in the 6th edition were retained in the 7th edition, but additional sub-groups in 
stage II, III, and IV were added. 
Table 2.2: AJCC-6 stages with corresponding TNM system and descriptors 
AJCC-6 
stage 
TNM TNM stage criteria for colorectal cancer 
Stage 0 Tis N0 M0 Tis: Tumour confined to mucosa; cancer-in-situ 
Stage I T1 N0 M0 T1: Tumour invades submucosa 
Stage I T2 N0 M0 T2: Tumour invades muscularis propria 
Stage II-A T3 N0 M0 T3: Tumour invades subserosa or beyond (without other organs involved) 
Stage II-B T4 N0 M0 T4: Tumour invades adjacent organs or perforates the visceral peritoneum 
Stage III-A T1-2 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2. 
Stage III-B T3-4 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4. 
Stage III-C Any T, N2 M0 N2: Metastasis to 4 or more regional lymph nodes. Any T. 
Stage IV Any T, any N, 
M1 
M1: Distant metastases present. Any T, any N. 
From: Frederick et al., 2002. AJCC cancer staging manual, 6th edition 
More than 96% of CRCs are adenocarcinomas (Stewart et al., 2006). Survival rates vary according to 
the stage of the carcinoma. The 5-year relative survival rate of CRC greatly depends on the stage at 
initial diagnosis, with up to 90% for stages I and II, 68% for stage III, and 11% for stage IV. In 
addition, 57% of CRC patients have developed regional lymph node or distant metastasis at diagnosis, 
and about 35% of CRC patients die within 5 years (Ries et al., 2008). In the 42% of post adjuvant 
treatment patients who relapsed within 5 years, 80% of recurrences occurred in the first three years 
and 91% of them died within five years. The median survival time was 12 months for this cohort 
(Sargent et al., 2005). 
 Conventional treatment of colorectal cancer 2.9.3
The conventional treatment of CRC mainly includes surgical resection, chemotherapy, and 
radiotherapy. In recent years, bio-targeted monoclonal antibody medicines have been used in addition 
to chemotherapy for ACRC treatment. In this section, chemotherapy and bio-targeted monoclonal 
antibody therapy is reviewed. 
2.9.3.1 Chemotherapy drugs 
Chemotherapy employs a cytotoxic drug or a combination of such drugs to kill cancer cells and reduce 
tumour size. Cancerous tumours have the characteristics of uncontrolled rapid growth of cells, with 
invasion of adjacent tissues or organs and metastasis to distant organs (Fenton & Longo, 2010). Most 
chemotherapeutic drugs aim at killing fast-dividing cells, such as cancer cells, by causing DNA 
damage or disruption of normal RNA processes and functions, thereby causing impaired mitosis (cell 
division) and inducing cells to undergo apoptosis (programmed cell death) (William & Kastan, 1994; 
Johnstone et al., 2002). However, due to this specific feature of killing fast-dividing cells, cytotoxic 
drugs also have adverse effects on normal cells in the body, especially on normal fast-dividing cells 
   
26 
such as the cells in hair, skin, the gastrointestinal (GI) tract and bone marrow (DeHaven, 2007). 
Therefore, the common side effects of chemotherapy include myelosuppression, gastrointestinal 
distress, fatigue, and hair loss. Thus, the adequate management of the chemotherapeutic side effects 
can improve patients’ quality of life and assist in the delivery of optimal treatment. Chemotherapeutic 
drugs can be used singly or in combinations that aim to enhance their anti-cancer effects. The 
following are the main chemotherapy agents that are commonly used for CRC treatments. 
5-Fluorouracil (5-FU) 
5-fluorouracil (5-FU) was introduced over 40 years ago and has remained a backbone of treatment 
regimens for colorectal cancer (CRC), both alone and in combination with other agents (Hirsch & 
Zafar, 2011). 5-FU inhibits thymidylate synthase (TS), which is important for methylation of 
deoxyuridine monophosphate (dUMP) into thymidine monophosphate (dTMP) (Carreras & Santi, 
1995). dTMP is essential for DNA synthesis and repair (Longley et al., 2001). When 5-FU is 
transferred intracellularly, it is converted to a number of metabolites: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate 
(FUTP) (Longley et al., 2003). 
FdUMP and 5,10-methylenetetrahydrofolate (CH2THF) together bind to thymidylate synthase, to 
form a ternary complex, and block thymidylate synthase binding to dUMP. Thus, it disrupts dTMP 
synthesis (Santi et al., 1974). Without CH2THF presence, the FdUMP binding to TS is reversible 
(Danenberg & Danenberg, 1978). FdUTP is incorporated into DNA cleavage and repair, and 
eventually leads to DNA damage and cell death. FUTP is also incorporated into RNA, and disrupts 
normal RNA process and function (Longley et al., 2003). However, after administration 5-FU will be 
rapidly catabolised by dihydropyrimidine dehydrogenase (DPD) and converted to dihydrofluorouracil 
(DHFU) thereby losing its bioactivity (Santi et al., 1974). 
The common side effects of 5-FU include granulocytopenia, diarrhoea, stomatitis, and vomiting 
(Leichman et al., 1995). The incidences of these side effects are dose-dependent, i.e., the higher the 
systemic exposure to 5-FU, the higher the incidence of 5-FU toxicity (Boisdron-Celle et al., 2002).  
5-FU is administered intravenously and has been tested in a variety of different schedules to optimise 
the clinical effect and minimise toxic events in CRC. The single-agent 5-FU infusion regimen has 
demonstrated an overall survival (OS) that was two months longer than 5-FU bolus therapy (i.e. rapid 
administration of a large dose) with fewer high-grade toxic events of granulocytopenia and diarrhoea 
(Leichman et al., 1995).  
Leucovorin (LV) 
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Leucovorin (folinic acid) is not cytotoxic but it can enhance the effect of 5-FU. Intracellularly, 
leucovorin (LV) converts to CH2THF, which is then polyglutamated by folylpolyglutamate 
synthetase. The polyglutamation increases the concentration of CH2THF in the cell and increases the 
stability of the thymidylate synthase ternary complex, thereby enhancing the effect of 5-fluorouracil in 
inhibiting DNA synthase (Radparvar et al., 1989). 
Capecitabine 
Capecitabine is an oral fluoropyrimidine, which converts to fluorouracil in tumour cells through three 
sequential enzymatic reactions (Walko & Lindley, 2005). The first enzymatic reaction is in the liver by 
carboxylesterase to 5'-deoxy-5-fluorocytidine (5'-dFCyd); the second is by Cyddeaminase to 5'-deoxy-
5-fluorouridine (5'-dFUrd) in the liver and tumour tissues; and the third is by thymidine phosphorylase 
(TP) to 5-FU in tumours (Miwa et al., 1998). In a comparison of the toxic profiles of capecitabine 
versus 5-FU/LV, the most common adverse events for both capecitabine and 5-FU/LV were fatigue 
(21.1% vs. 25%) and vomiting (23.3% vs. 27%). Capecitabine had a higher rate of hand-foot 
syndrome (HFS) (53.3% vs. 6.2%), whereas 5-FU/LV caused more stomatitis (24.3% vs. 61.6%), 
alopecia (6.0% vs. 20.6%), neutropenia (1.2% vs. 10.3%), diarrhoea (47.7% vs. 58.2%), and nausea 
(37.9% vs. 47.6%) (Walko & Lindley, 2005). 
Oxaliplatin (OXA) 
Oxaliplatin is a third-generation platinum drug, which contains a 1,2-diaminocyclohexane (DACH) 
carrier ligand. The cytotoxicity of oxaliplatin is effected through the DACH carrier ligand combining 
with DNA to form adducts that inhibit DNA repair and replication, resulting in cell death (Raymond et 
al., 1998). Adverse events associated with oxaliplatin treatment include: neuropathy, hematologic 
toxicities, and gastrointestinal (GI) tract toxicities. However, unlike other platinum derivatives, 
nephrotoxicity has not been reported in oxaliplatin regimen trials (Cassidy & Misset, 2002). 
Hematologic toxic events clinically present as anaemia, neutropenia, and thrombocytopenia. Anaemia 
and thrombocytopenia usually occur as grade 1 or 2 events (Cassidy & Misset, 2002). The anaemia 
incidence was found to be similar in both the oxaliplatin and control arms in phase III trials. Cassidy et 
al. (2000) suggested the incidence is probably an implication of the disease state.  
The incidence of neutropenia and thrombocytopenia was associated with the method of 5-FU/LV and 
oxaliplatin administration. In a phase III trial (Giacchetti et al., 2000), using chronomodulated 
administration of 5-FU/LV and oxaliplatin (FOLFOX) induced 32% neutropenia and 21% 
thrombocytopenia. These rates were lower than those from a FOLFOX4 continuous-infusion which 
had 70.3% neutropenia and 76.2% thrombocytopenia (de Gramont et al., 2000). The chronomodulated 
administration method is based on the biologic rhythms of DNA synthesis to reduce bone marrow 
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sensitivity to cytotoxic chemotherapy along the 24-hour scale (Smaaland et al., 1991). However, the 
effects of the chronomodulated administration of 5-FU/LV and oxaliplatin on gastrointestinal toxic 
events were not better than in the FOLFOX4 regimen. 
Oxaliplatin combined with 5-FU increases the incidence of neutropenia. In monotherapy using 
oxaliplatin (130 mg/m2, 2-hour infusion on day 1, every 21 days), there was 5.2% of grade 3/4 
neutropenia (Becouarn et al., 1998), whereas a FOLFOX4 regimen induced 41.7% incidence (de 
Gramontet al., 2000). This may be associated with the oxaliplatin reducing 5-FU plasma clearance by 
inhibiting 5-FU catabolism (Boisdron-Celle et al., 2002). 
Gastrointestinal tract toxicity clinically appears as nausea, vomiting, diarrhoea, and mucositis. Nausea 
and vomiting is mild to moderate and can be controlled by standard antiemetic treatment. In the de 
Gramont et al. (2000) phase III trial, grade 3/4 nausea and vomiting was experienced in 11.5% of 
ACRC patients with FOLOFOX4. Other grade 3/4 events were 11.9% for diarrhoea, and 5.8% for 
mucositis (de Gramont et al., 2000). However, these gastrointestinal tract toxicities were manageable 
by dose modification and generally did not cause discontinuation of treatment (Cassidy & Misset, 
2002). 
Oxaliplatin related neurologic toxicity describes two different types of neurological symptoms. The 
first type is reversible acute paresthesia and dysesthesia that occurs during or immediately after the 
end of the infusion. Patients experience transient peripheral sensory disorder in the hands, feet and 
perioral region with jaw tightness, sometimes accompanied with muscular contractions. The 
symptoms can be triggered or enhanced by exposure to cold or increased by repeated administration. 
The second type is chronic neuropathy that is usually late-onset deep sensory loss, sensory ataxia and 
functional impairment, jaw pain, eye pain, ptosis, leg cramps and visual and voice changes (Pasettoet 
al., 2006). It correlates with the cumulative-dose of oxaliplatin (over 540 mg/m2) (Cersosimo, 2005). 
In the de Gramont et al. (2000) phase III trial, 68% of patients in the FOLFOX4 group experienced 
oxaliplatin-related neurologic toxicity (all grades), but only 18% of this group of patients had grade 3 
events (de Gramont et al., 2000). Moreover, the acute neuropathy was usually mild and completely 
reversible after discontinuation of the treatment. Chronic neuropathy related to the cumulative-dose of 
oxaliplatin may be reversible with a median time to recovery from grade 3 neurotoxicity of 13 weeks 
(Grothey & Goldberg, 2004). 
Irinotecan 
Irinotecan is a topoisomerase I inhibitor anti-cancer drug that is a derivative of camptothecin (CPI). 
Camptothecin is a quinoline alkaloid isolated from the bark and stem of Camptotheca acuminata (xi 
shu) that was used traditionally for cancer treatment in CHM (Efferth et al., 2007). Topoisomerase I 
(Top 1) breaks down single DNA strands that allow DNA replication and transcription (Wang, 2002). 
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Irinotican prevents DNA unwinding and replication by inhibiting topoisomerase I (Liu et al., 2000). 
Diarrhoea and myelosuppression are common adverse effects of irinotecan (Saad & Hoff, 2005). It is 
also called hydroxycamptothecine (HCPT). 
Methotrexate (MTX) 
MTX inhibits purine synthesis, which is the precursor of CH2THF that is essential for dTMP synthesis 
(Gorlick & Bertino, 1999). In methotrexate-treated cells, MTX leads to accumulation of cellular 5-
phosphoribosyl-1-pyrophosphate (PRPP) (Sant et al., 1992), which correlates to increased 
concentrations of intracellular FUTP that inhibits RNA synthesis by incorporating into RNA process 
and function. This accounts for the MTX-5FU synergism (Cadman et al., 1979). 
Vincristine 
Vincristine is a vinca alkaloid that was originally isolated from Vinca rosea (Catharanthus roseus). It 
induces tumour cell death by suppressing microtubule dynamics, blocking mitosis at the 
metaphase/anaphase transition. Its toxic side effects are: peripheral neuropathy, hyponatremia, 
constipation, and hair loss (Jordan, 2002) 
Doxorubicin 
Doxorubicin (ADM) is an anti-tumour antibiotic. It binds to DNA-associated enzymes, to produce a 
range of cytotoxic effects. The side-effects of ADM are mainly in the brain, liver, kidney and heart 
(Tacar et al., 2013).  
Semustine (MeCCNu) 
Semustine is a chloroethyl nitrosoureas that causes DNA damage by inducing DNA interstrand cross-
links (Agarwal et al., 2015). The side effects are nausea and vomiting, myelosuppression, stomatitis, 
alopecia, anaemia, anorexia, hepatotoxicity, and neurotoxicity (Wasserman et al., 1975). 
Mitomycin (MMC) 
Mitomycin is a natural antibiotic that derives from Streptomyces caespitosus or Streptomyces 
lavendulae. It belongs to the family of aziridine, and exhibits anti-tumour effects that induce DNA 
damage, DNA interstrand and intrastrand cross-links and alkylation of DNA (Tomasz & Palom, 1997). 
Its toxicity includes delayed bone marrow toxicity, hemolytic uremic syndrome (HUS), lung fibrosis 
and renal damage. Permanent bone marrow damage may occur with prolonged use (Saif et al., 2013). 
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2.9.3.2 Clinical trials of chemotherapy 
Chemotherapy is classed in three settings based on the aim of treatment in CRC: adjuvant, palliative, 
and neoadjuvant (Braun & Seymour, 2011). This section is focussed on adjuvant and palliative 
chemotherapy. 
Adjuvant chemotherapy 
Clinical trials indicate that adjuvant chemotherapy reduces risk of CRC recurrence and prolongs 
survival for stage III CRC and confers a modest benefit for stage II after curative surgery when 
compared to observation (no treatment) alone. A 5-FU/LV regimen as adjuvant chemotherapy has 
demonstrated significant improvement in both disease free survival (DFS) (63% vs. 47% over 3½ 
years) and overall survival (OS) (71% vs. 55% over 3½ years) for stage III CRC (Moertel et al., 1990). 
In another study of 5-FU/LV, the 3-year recurrence rate for stage III CRC was 35.5% and the 3-year 
survival rate was 71% (Kerr et al., 2000). However, the 5-FU/LV treatment benefits are modest for 
stage II CRC, with only 3.6% increase in survival for patients who received chemotherapy, and almost 
no difference between the chemotherapy group and observation group in 2 years recurrence [144/1127 
(12.8%) vs. 132/1040 (12.7%), p=0.94] (Gray, 2007).  
Addition of oxaliplatin to the 5-FU/LV regimen has proven more effective for treating stage II /III 
CRC compared to control groups which received 5-FU/LV alone. Significant improvements in 3 years 
DFS were consistent in two important international trials (78.2% for MOSAIC trial, 76.1% for NSABP 
trial). MOSAIC also reported significant improvements in OS in the stage III cohort of patients who 
received oxaliplatin (72.9% vs. 68.7%, p=0.023), but there was no difference in stage II patients. 
However, the regimens were not the same in these two trials (MOSAIC - FOLFOX: 5-FU 4000mg/m2, 
LV 800mg/m2 bolus plus infusion, OXA. 340mg/m2 per cycle; NSABP - FLOX: 5-FU 3000 mg/m2, 
LV 3000mg/m2 bolus, OXA. 255mg/m2, per cycle). 
The incidence of grade 3/4 neurotoxicity was higher in the MOSAIC trial than in the NSABP trial 
(12.4% vs. 9.6%) due to the higher cumulative dose of oxaliplatin in MOSAIC. Grade 3/4 
gastrointestinal toxicity, including diarrhoea, vomiting and nausea, was significantly higher in NSABP 
patients. This indicated the infusional 5-FU schedule (used in MOSAIC) had less GI toxicity than the 
bolus schedule of 5-FU (used in NSABP). FOLFOX regimens have been recommended as standard 
first line adjuvant chemotherapy for CRC (Kuebler et al., 2007; Sharif et al., 2008; Andre et al., 2009; 
Gravalos et al., 2009). 
Palliative chemotherapy 
For ACRC, where the disease is so locally advanced that curative surgery becomes impossible or there 
is distant metastasis, chemotherapy aims to downgrade ACRC in order to enable potentially curative 
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surgery, or to palliatively treat ACRC to improve the quality of life (QoL) or to prolong survival time. 
5-FU/LV monotherapy or plus oxaliplatin or irinotican has been used extensively in ACRC (Hind et 
al., 2008). 
A meta-analysis study based on individual patient data, that compared various 5-FU based palliative 
chemotherapy regimens versus supportive care alone for ACRC found that the median overall survival 
(mOS) was improved by 3.7 months (11.7 vs. 8 months), and the median progression free survival 
(mPFS) was calculated at 10.0 months for the chemotherapy group but only 4.0 months for the 
supportive care group (Simmonds, 2000). 
In a multi-centre trial that compared a monthly schedule of low-dose LV and 5-FU bolus with a 
bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with ACRC, 
the bimonthly infusion regimen was more effective and less toxic than the monthly bolus regimen. The 
mPFS was 22 weeks for monthly bolus regimen and 27.6 weeks for bimonthly infusion regimen (P = 
0.0012). The mOS was 56.8 weeks for the monthly bolus regimen and 62 weeks for the bimonthly 
infusion regimen (P = 0.067). Grade 3-4 toxic events occurred in 23.9% of patients in the monthly arm 
compared with 11.1% of those in the bimonthly arm (P = 0.0004) (de Gramont et al., 1997). 
Hind’s review of 11 RCTs of ACRC demonstrated that the OS varied from 15 to 20.6 months for 
oxaliplatin plus 5-FU/LV and 14.8 to 21.1 months for irinotecan plus 5-FU/LV as first line treatments; 
PFS was 7.9 to 9.0 months for the oxaliplatin regimen and 7.5-8.8 months for the irinotican regimen. 
The tumour response rate (tRR) was between 31-54% for the two regimens when 5-FU was 
administered by infusion. Different toxicity profiles appeared in the two regimens. Based on grade 3 
and 4 toxicity, diarrhoea, vomiting/nausea, stomatitis and febrile neutropenia were more prevalent in 
patients who received irinotican plus 5-FU/LV, whereas patients who received oxaliplatin plus 5-
FU/LV generally had a higher incidence of neuropathy and neutropenia. However, there was no 
significant difference between the two regimens in overall, quality of life (QoL) (Hind et al., 2008). 
Oral administration of capecitabine has been used to replace intravenous 5-FU in treating CRC. When 
used as monotherapy or in combination with oxaliplatin, capecitabine has been demonstrated to be as 
effective as the 5-FU/LV intravenous setting in terms of tRR, DFS/PFS and OS. The common severe 
toxicities (grade 3/4) of capecitabine are hyperbilirubinemia, hand and foot syndrome, diarrhoea, 
nausea/vomiting, and neutropenia (Twelves et al., 2005; Cassidy et al., 2008). 
The staging of chemotherapy strategies (starting with a single drug and modifying to combination 
regimens upon progression) and intermittent chemotherapy have not shown significant impacts on 
overall survival (OS), when compared with initial combination chemotherapy, but have shown lower 
toxicity profiles (Braun & Seymour, 2011). 
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2.9.3.3 Bio-targeted monoclonal antibody therapy 
Bio-targeted monoclonal antibody therapy refers to the use of monoclonal antibodies to bind 
monospecifically to certain cells or proteins in order to stimulate the patient's immune system to attack 
those cells. Bio-targeted monoclonal antibody medicines used in addition to chemotherapy for ACRC 
include: cetuximab and panitumumab, which target epidermal growth factor receptors (EGFR), and 
bevacizumab, an anti-vascular endothelial growth factor (VEGF). The addition of cetuximab to an 
irinotecan based regimen (i.e. FOLFIRI) demonstrated improvement in PFS in patients with wild-type 
KRAS gene but not in patients with mutant KRAS gene. However, there was an increased rate of 
adverse events in the cetuximab plus FOLFIRI group (Van Cutsem et al., 2009). Cetuximab plus an 
oxaliplatin based regime (i.e. FOLFOX) found an improvement in tRR for the wild-type KRAS but not 
for the mutant KRAS gene groups. However, there was no difference in overall survival (OS) or PFS 
between the cetuximab plus FOLFOX and the FOLFOX groups (Maughan et al., 2011). As in the 
previous study, the skin and gastrointestinal toxicity were greater in the cetuximab group (Van Cutsem 
et al., 2009; Maughan et al., 2011). Although the addition of EGFR agents showed benefits for wild-
type KRAS CRC, the potential for increased toxicities needs to be considered when applying these 
agents (Braun & Seymour, 2011). 
In two studies, the addition of bevacizumab to FOLFOX regimes increased the mOS and mPFS by 1-2 
months for metastatic CRC as first line or second line treatment. Adverse events associated with 
bevacizumab included hypertension, bleeding, and vomiting, which appeared to be tolerable 
(Giantonio et al., 2007; Saltz et al., 2008). Therefore, the decision to add bevacizumab for ACRC 
should depend more on the effectiveness rather than on the toxicities (Braun & Seymour, 2011).  
Overall, with advances in technology, which include early detection via screening programs, 
development of novel drugs, and new combination chemotherapy regimes, CRC has become a curable 
disease when detected at an early stage.  
 Herbal medicine in cancer therapy 2.9.4
Herbal medicine (HM) has been used to treat cancers and many other ailments for centuries in China 
and in other Asian countries. Chinese HM (CHM) alone or in combination with conventional therapy is 
accepted by both oncologists and patients in China as an approach to treating a range of cancers 
including CRC (Saif et al., 2010). In accordance with Traditional Chinese Medicine (TCM) etiology 
and pathology, tumours belong to the categories of ‘zhengjia’ (癥痂), and ‘jiju’ (积聚). These result 
from the combination of ‘zhengxu’ (正虚) - asthenia of healthy vital energy ‘qi’, and ‘xieshi’ (邪实) – 
excess of unhealthy energy (xie 邪). In TCM, zhengxu refers to deficiency of vital qi and blood, 
whereas xieshi refers to constitutional qi stagnation, blood stasis, phlegm coagulation, or gathering 
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toxins. Zhengxu and xieshi both can be induced by unhealthy mental state, malnutrition/poor diet, and 
adverse environmental conditions (Huang, 2004). 
The TCM principle of treatment for cancer is referred to as ‘fuzheng quxie’ (扶正驱邪) which means 
‘support the normal and dispel the perverse’, since the typical features of a cancer patient’s 
constitutional state are ‘zhengxu xieshi’ (正虚邪实) which means that the normal energy of the patient 
is empty or weak while the perverse disease, i.e. the cancer, is abundant. CHM aims to address the 
emptiness of the patient’s normal energy which impedes their ability to resist the progression of the 
cancer whilst dispelling the invasion of the cancer. Therefore, the CHMs used for cancer are mainly 
composed of herbs in the categories of fuzheng 扶正 and quxie 驱邪 (Huang, 2004). 
In TCM, fuzheng herbs are those that can tonify the internal organs, invigorate the vital qi and enrich 
the blood in order to support the normal functioning of the patient’s body. Quxie herbs, from a TCM 
perspective, are those that disperse pathogenic phlegm, remove blood stasis, detoxify the body and 
resolve masses (Bensky & Gamble, 2004).  
Treatment typically involves the administration of multi-herb formulas orally as decoctions, tablets or 
capsules, and/or the intravenous use of extracts. The composition of a herbal formula is based upon the 
methodology of TCM pattern differentiation (bian zheng 辩证) and determined using TCM principles 
at each consultation. The formula may or may not be modified by the practitioner according to the 
patient’s constitution and response over the course of the treatment.  
CHMs are also used for the local treatment of cancers. For instance, in CRC treatment, herbal liquid 
from CHM decoctions can be administered via enema to relieve symptoms such celialgia, tenesmus, or 
blood and pus in the faeces (Li & Li, 1999). Javanica oil injected through transcatheter arterial 
chemoembolization (TACE) is used in treating metastatic liver cancer from CRC (Zhang & You, 
2008). 
Experimental studies have demonstrated that bio-active components in a number of single Chinese 
HMs and multi-herb formulas possess anti-cancer potential. Based on multiple studies, the anti-cancer 
mechanisms of Chinese HMs have been summarised as having multi-actions and multi-targets, in 
terms of induction of tumour cell apoptosis and tumour cell differentiation; mediation of cellular 
transduction pathways; suppression of tumour angiogenesis; inhibition of telomerase activity; 
regulation of immunofunction; and reversal of multiple drug resistance (Han & Li, 2009, Parekh et al., 
2009). 
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 Integrative medicine 2.9.5
Integrative medicine (IM) refers to combining conventional medicine with complementary and 
alternative medicine (CAM), in order to obtain optimal health and healing outcomes. The western 
model of IM requires complementary and alternative medicine to be based on scientific evidence. 
CAM research and educational institutions have been established in western countries including 
Australia, USA, Germany, Great Britain. Two-thirds of medical schools in the USA had introduced 
CAM methods into medical education curricula by 1999, and since 2003 German medical students 
have been required to include integrated CAM programs into their curricula by law (Dobos & Tao, 
2011). Some conventional medical centres in USA and Germany have introduced CAM care into their 
established therapeutic programs (Dobos et al., 2012; Chan et al., 2010). 
CAM products and therapies include dietary therapy, exercise, stress reduction, mind/body therapy, 
manual and massage therapy, reflexology, acupuncture, vitamin and mineral therapy, and HM. 
Chinese and Western forms of HM are popular among patients including cancer patients. For many 
patients, the option of both CAM and conventional medicine is preferable. CAM use in conjunction 
with conventional treatments without the knowledge of medical doctors is common. A challenge for 
IM in the west is how safe and effective this form of healthcare is. Many CAM therapies lack 
sufficient scientific evidence to support their use, and herbal products have the potential for herb-drug 
interactions. Consequently, IM may not be suitable for widespread use in western countries until there 
is sufficient research evidence (Robinson, 2011). 
In China, the IM approach in cancer is typically a combination of TCM, which includes CHM, 
acupuncture, massage (tuina), diet, nutrition and exercise (including tai chi), and conventional 
Western medicine. Since 1949, TCM has been an essential part of health care in China and plays an 
important role in the health care system (Robinson, 2011). A review showed more than 60% of cancer 
patients in China used IM for cancer treatment, and among them, 98.5% of patients used CHM 
treatment (Liu et al., 2011). In China, CHM is used as an adjuvant therapy to chemotherapy in order to 
alleviate adverse reactions induced by conventional cancer therapy, improve the effectiveness of 
cancer treatment, improve quality of life (QoL), and eventually prolong overall survival (OS) 
(Konkimalla & Efferth, 2008; Molassiotis et al., 2009). 
Due the popularity of herbal medicines among cancer patients, the potential for herb-drug interaction 
is of concern to the medical profession. Currently, herb-drug interaction research is mostly based on 
the pharmacokinetic interaction between the active constituents of herbal medicines and drugs. The 
majority of potential herb-drug interactions are associated with metabolising-enzyme cytochrome 
P450 (CYP), ABC transporters, and p-glycoprotein (P-gp), each of which mediates the metabolism 
and disposition of drugs. CYP3A4, CYP3A5, CYP2D6, CYP2C19 are critical members in CYP 
superfamily (Cheng et al., 2018). Active constituents of herbal medicines can inhibit or induce activity 
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of CYP, drug transporters and P-gp protein, so there is potential for interaction with drugs, at least 
theoretically.  
In addition to these pharmacokinetic factors, other factors such as pharmacodynamics, the patients’ 
individual condition, use of narrow therapeutic index drugs (e.g. anticancer drugs, anti-HIV drugs) 
should all be considered when interpreting the potential for herb-drug interactions in clinical practice 
(Hermann and Richter, 2012). 
2.9.5.1 Clinical studies of integrative medicine for colorectal cancer 
In this section, studies of CHM integrated with conventional chemotherapy for CRC were reviewed. 
Zhong et al. (2012) systematically reviewed RCTs of CHM as an addition to chemotherapy for CRC. 
In comparison to chemotherapy alone, the meta-analysis results showed the combination of CHM and 
chemotherapy significantly increased 1-year survival rate, and 3-year survival rate (OR 2.40, 95% CI 
[1.49, 3.87]) based on 5 studies of 396 patients. The combined therapy significantly improved tumour 
response rate (tRR) (OR 1.89, 95% CI [1.26, 2.88]) based on 7 studies with 475 patients and quality of 
life (QoL) (OR 3.43, 95% CI [2.35, 5.02]) based on 9 studies with 649 patients. The integrative 
medicine therapy also had positive effects in immunoregulation (Zhong et al., 2012). 
A Cochrane review pooled data from four RCTs (342 CRC patients) of CHM as adjuvant therapy to 
chemotherapy compared to the same chemotherapy alone in the control. The results showed the 
addition of the CHM alleviated the chemotherapy side effects of nausea and vomiting and leucopenia. 
The CHM also increased the proportions of T-lymphocyte subsets: CD3; CD4 and CD8. No adverse 
effect was reported from the CHM interventions (Wu et al., 2005). 
Another systematic review assessed the combination of jianpi 健脾 ‘strengthen spleen’ type CHMs 
with chemotherapy in CRC. Six RCTs which included 334 patients were pooled. This review found 
that the integrative approach significantly reduced the incidences of grade I and grade II leucopenia 
(grade I: RR 0.50 [0.31, 0.80]; grade II: RR 0.37 [0.21, 0.66]), and grade II nausea and vomiting (RR 
0.51 [0.31, 0.84]) in patients who were received CHM treatment concurrently with chemotherapy, 
compared to patients who had chemotherapy alone. There was a trend favouring the integrative 
interventions in reduction of the incidence of neurotoxicity reactions, but this was not statistically 
significant for grade I: (RR 0.84 [0.57, 1.24]); grade II: (RR 0.73 [0.45, 1.19]; or grade III: (RR 0.40 
[0.13, 1.25]) (Liu & Zhu, 2009).  
In a retrospective study, 103 CRC patients, who mostly were ACRC (4 stage II, 7 stage III, 92 stage 
IV), were divided into a group that was treated with CHM plus conventional treatment which included 
chemotherapy and/or surgical resection, and a control group that was treated with conventional 
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treatment alone. The baselines were balanced between groups in terms of age, gender, pathology, 
stage, distant metastasis, and history of surgery. 1-, 3-, 5- years survival rates and median survival 
times were compared. The results showed there was a significant improvement in median survival 
times in the combination treatment group (27 months vs. 16 months, p=0.03), and better overall 
survival rates at 1-, 3-, and 5-years (82%, 32%, 6% vs. 64.2%, 13.2%, 1.9% respectively) (Ren et al., 
2010). 
In a consecutive case series study with a 10-year follow-up conducted in the USA, 193 colon cancer 
patients who used HM and vitamins combined with standard chemotherapy were compared to controls 
who only used standard chemotherapy, based on data from the California Cancer Registry (n=1,1678) 
and Kaiser Permanente Northern California (n=1987). The Kaplan-Meier survival curve and traditional 
Cox regression showed motality was reduced in the combination treatment group by 95% for stage I, 
64% for stage II, 29% for stage III, and 75% for stage IV, when compared with matched controls from 
the cancer registries who received standard chemotherapy alone (McCullock, 2011). 
Overall, despite the possibility of methodological weaknesses in some studies, the results from many of 
these studies suggest that integrative HM may be able to provide an alternative approach to the care of 
CRC. 
 Laboratory studies of HM for colorectal cancer 2.9.6
The following CHMs have been studied for their effects on CRC cell-lines or CRC-bearing animals.  
2.9.6.1 Astragalus saponin extracts 
An astragalus saponin extract (AST), derived from Astragalus membranaceus, was found to inhibit 
proliferation of HT-29 human colon cancer cells. AST treated HT-29 cells were arrested at S phase and 
G2/M, through up-regulation of cyclin-dependent kinase inhibitor protein p21 expression and inhibited 
cyclin-dependent kinase activity in vitro. AST also induced apoptosis in HT-29 cells, in which DNA 
fragmentation and nuclear chromatin condensation was observed in a time and dose dependent manner. 
It was suggested that apoptosis was through activation of the caspase-3 signaling pathway and cleavage 
of poly (ADP-ribose) polymerase (PARP). In the same study, the effect of AST on tumour growth in 
xenografts of HT-29 cells in nude mice was investigated. The tumour–bearing mice were randomly 
assigned into a control group with phosphate-buffered saline (PBS) alone and various treatment 
groups, including: AST alone group, AST+5-FU group, and 5-FU+OXA group. AST alone treatment 
reduced tumour volume by 35-38%, which was similar to the effect of 5-FU monotherapy. When AST 
+ 5-FU was compared to 5-FU + OXA, the results for shrinkage of tumour volume were 66% for AST 
+ 5-FU and 61% for 5-FU + OXA at day 21. Importantly, treatment with 5-FU + OXA caused 33% 
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mortality in the animals and significant loss of body weight, but no deaths were recorded in the AST + 
5-FU treatment group, and there was a minor drop in body weight (Tin et al. 2007). 
2.9.6.2 Ganoderma lucidum 
The medicinal mushroom Ganoderma lucidum (Curtis) P. Karst is regarded as a tonic and has been 
used for millennia in China. Today, it is a popular CHM in adjuvant cancer treatment in the Chinese 
community. A G. lucidum triterpene extract (GLT) was found to suppress proliferation in HT-29 cells 
and GLT inhibited tumour growth in a xenograft model of colon cancer HT-29 cells in nude mice 
through cell cycle arrest at G0/G1, and induced programmed cell death type II – autophagic through 
the inhibition of p38 mitogen-activated kinase (p38 MAPK) (Thyagarajan et al., 2010). 
2.9.6.3 Ginseng saponins 
Ginseng saponins (known as ginsenosides) are derived from Panax ginseng C.A Meyer, P. 
quinquefolium L (American ginseng) and P. notoginseng (Burkill) F.H.Chen (sanqi). These are the 
main compounds with anti-cancer effects in the ginseng family. Among them, ginseng Rg3, Rh2, IH-
901 (compound K) and protopanaxadiols (PPD) have shown inhibition of the growth of different 
cancer cells (Nag et al., 2012). 
American ginseng (which mainly contains ginsenosides Rg3 and Rh2), induced apoptosis in SW-480 
human colorectal cancer cells mainly via mitochondrial pathways (Wang et al., 2009). 20S-ginsenoside 
Rg3 (20S-Rg3) induced apoptosis in HT29 colon cancer cells and suppressed cell proliferation. 
Proteomic analysis found that 20S-Rg3 up/down regulated proteins associated with apoptosis. 20S- 
Rg3 mediated anti-proliferation by inhibition of mitosis, DNA replication and repair, and growth factor 
signalling in HT29 cells (Lee et al., 2009). 
2.9.6.4 Isoliquiritigenin 
Isoliquiritigenin from liquorice, combined with tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL), induced apoptosis in TRAIL resistant colon cancer HT29 cells by accumulation of 
DR5 protein among TRAIL receptors (Yoshida et al., 2008). 
2.9.6.5 Tanshinone I 
Tanshinone I isolated from dan shen (Salvia miltiorrhiza Bunge) has been shown to induce apoptosis 
through both p21 mediated cell differentiation arrest at G0/G1 phase, and mitochondrial-mediated 
intrinsic cell-death pathways in human colon cancer Colo 205 cells in vitro (Su et al., 2008). 
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2.9.6.6 Pseudolaric acid B 
Pseudolaric acid B (PAB) is a natural diterpenoid extracted from Pseudolarix kaempferi Gordon (jin 
qian song 金钱松). In HT29 cells, PAB has been reported to induce apoptosis and suppress cell cycle 
progression which was related to cell cycle arrest at G2/M phase, modulate cyclin expression and 
down-regulate the proto-oncogene c-myc. PAB concomitantly increased the protein and gene 
expression of the nonsteroidal anti-inflammatory drug-activated gene (NAG-1), and inhibited 
cyclooxygenase-2 (Cox-2) (Ko et al., 2007). 
2.9.6.7 Farnesol and Geranylgeraniol  
Farnesol (FOH) and geranylgeraniol (GGOH) are two isoprenoids (terpenes) that are commonly 
present in the essential oils of herbs and fruits. They have both induced apoptosis in HT-29 and 
HCT116 colon cancer cells in vitro through caspase-3 activation, and PARP cleavage (Kim et al., 
2005; Au-Yeung et al., 2008). 
2.9.6.8 Chinese mistletoe lectin-55 
In one study, BALB/c mice were subcutaneously inoculated with the colon cancer cell line CT26 (5 x 
10 (5) cells). The mice were orally administered Chinese mistletoe lectin-55 (ACML-55), an active 
compound from Loranthus parasiticus (L) Merr., at a daily dose of 200 μL/mouse (2 mg/mL) or 
phosphate-buffered saline (PBS) at a daily dose of 200 μL/mouse as the negative control, for 2 weeks. 
The investigators found that compared to PBS treatment, ACML-55 significantly inhibited tumour 
formation and reduced tumour size in xenograft mice. An immunology study demonstrated that 
ACML-55 intervention promoted both activation and proliferation in CD4+, CD8+ T cell subsets, and 
increased production of CD8+ T cells in response to IFN-γ. Moreover, ACML-55 intervention 
increased gammadelta T cells (γδT cells), a specific subset of T cells that are important for tumour 
immune surveillance through furnishing an early source of IFN-γ. This study indicated that ACML-55 
has anti-cancer potential by promoting both specific T cells and IFN-γ, which are essential to tumour 
immune surveillance (Ma et al., 2008). 
2.10 Chapter 2 summary 
Overall, CRC incidence and mortality are increasing worldwide. CRC is a curable disease if it is 
diagnosed in early stage using the advancing technologies of early detection. For advanced CRC, the 
tumour response rate and overall survival rate are improving since the development of new 
chemotherapeutic drugs, bio-targeted monoclonal antibody medicines, and cancer immunotherapy 
technology. HMs are used in China and in other Asian countries as part of integrative medicine (IM) 
for CRC treatment, particularly as adjuvant therapy to chemotherapy, since the IM approach appears 
to improve cancer treatment response, improve patient’s quality of life, and eventually prolong 
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survival time. Constituent compounds in certain HMs have demonstrated inhibition of CRC 
proliferation in vitro and in vivo. However, many HM therapies lack sufficient scientific evidence and 
herbal products have the potential for herb-drug interactions. Consequently, the efficacy and safety of 
HMs require further research. 
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Chapter 3. Research Methodology 
3.1 Introduction to Chapter 3 
This chapter details the research methods and procedures used in each stage of the project. These are 
linked with the specific research questions, which the methods are designed to answer. This chapter 
presents the methods and procedures for: 
• The systematic reviews of clinical trials by using Cochrane collaboration method 
• Sensitivity analysis for the selection of specific herbs for further research 
• Laboratory studies of compounds from promising herbs 
• The review of experimental studies of the mechanisms of action of the compounds in 
promising herbs 
The methods in 3.1 to 3.3 were used for Chapters 4, 5 and 6 are included in the following published 
papers:  
1. Chen M, May BH, Zhou IW, Xue CC, Zhang AL. (2014). FOLFOX 4 Combined with herbal 
medicine for advanced colorectal cancer: A systematic review. Phytother Res, Jul, 28(7): 976-
91. doi: 10.1002/ptr.5092. DEpub 2013 Dec 17. 
2. Chen MH, May BH, Zhou IW, Zhang AL, Xue CCL (2016b). Integrative Medicine for Relief 
of Nausea and Vomiting in the Treatment of Colorectal Cancer Using Oxaliplatin-Based 
Chemotherapy: A Systematic Review and Meta-Analysis. Phytother Res, 30(5):741-53 doi: 
10.1002/ptr.5586. Epub 2016 Feb 23. 
3. Chen MH, May BH, Zhou IW, Xue CCL, Zhang AL (2016a). Meta-analysis of oxaliplatin-
based chemotherapy combined with traditional medicines for colorectal cancer: contributions 
of specific plants to tumor response. Integr Cancer Ther, Mar;15(1):40-59. DOI: 
10.1177/1534735415596424 
4. Chen M, May BH, Zhou IW, Sze DM, Xue CC, Zhang AL (2016c). Oxaliplatin-based 
chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: A 
meta-analysis of the contributions of specific plants. Crit Rev Oncol Hematol, Sep;105:18-34. 
doi: 10.1016/j.critrevonc.2016.07.002. Epub 2016 Jul 7 
3.2 Search methods for identification of clinical studies 
Three approaches were used to identify clinical trials for consideration in the systematic reviews:  
1. Online database searches;  
2. Hand searches of journals; and  
3. Searches of reference lists in review articles and clinical studies. 
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 Search strategies for electronic databases. 3.2.1
Searches were conducted of the major international biomedical databases: PubMed, Cochrane 
CENTRAL, CINAHL, ScienceDirect and PsycINFO; and the major Chinese language databases: 
China Academic Journals (CNKI) and Chinese Sci &Tech Journals (CQVIP).  
Search terms were divided into three groups:  
1. Disorder: colorectal cancer and related terms;  
2. Intervention: Chinese medicine, herbal medicine and related terms;  
3. Study type: controlled trial, randomised and related terms.  
Individual terms were linked by the Boolean operator “OR”. Then, the three groups of terms were 
combined using the “AND” operator to limit the retrieved articles to those that were related to clinical 
trials, colorectal cancer and HM. 
No limits were imposed. Publication dates were from the inceptions of the respective databases to the 
present. The search strategies for each of the electronic databases are detailed in Appendix B. 
Hand searches of printed journals and reference lists of published articles 
Hand searches were conducted of journals in RMIT library: Australian Journal of Acupuncture and 
Chinese medicine 2008-2009; Chinese Journal of Integrated Traditional and Western Medicine 1995- 
2002; Journal of Traditional Chinese Medicine 1991-2009; American Journal of Chinese Medicine 
1993-2002; and the Journal of Chinese Medicine 1991-2009, since these journals are relevant to HM 
but were not indexed in PubMed. The reference lists of articles obtained (including those from 
previously published systematic reviews) were checked to identify any additional relevant reports. 
 Inclusion and exclusion criteria 3.2.2
Retrieved citations were combined in an Endnote library. The ‘find duplicate’ function in the 
Endnote Library was used to find duplicated copies which were then excluded. The titles and 
abstracts of the remaining citations were then filtered according to the following inclusion and 
exclusion criteria. 
Inclusion criteria 
1. Study type: Randomised controlled trials (RCTs) of HM interventions alone or combined with 
conventional interventions in a test arm, regardless of blinding were included. No restrictions were 
placed on language or publication year; 
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2. Types of participants: Patients (aged 18 to 80 years) diagnosed with primary colorectal cancer 
based on histological/pathological results. There was no restriction on pathological sub-group, 
stage, new or recurrent; 
3. Types of interventions: 1. herbal medicine combined with conventional medicine versus 
conventional medicine alone; 2. herbal medicine versus conventional medicine; 3. herbal medicine 
versus placebo or no intervention; 
4. Types of outcome measures: The study provides data on at least one of the CRC related primary or 
secondary outcome measures detailed below; 
Provides the identities of the key herbs used in the study. 
Exclusion criteria 
1. Study subjects with benign colorectal tumour or secondary malignant tumour without primary 
CRC;  
2. In-vitro and in-vivo studies; 
3. Case reports and case series studies; 
4. Clinical trials other than RCTs; 
5. Interventions that are not considered as primarily herbal – such as purified compounds. 
 Outcome measures 3.2.3
3.2.3.1 Primary outcome 
Tumour response rate (tRR). Assessment criteria referred to the WHO standard for solid tumour 
response rate (Miller et al., 1981), or the Response Evaluation Criteria In Solid Tumours (RECIST), 
which was firstly published in 2000 by an international collaboration including the European 
Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United 
States, and the National Cancer Institute of Canada Clinical Trials Group (Eisenhauer et al., 2009). For 
details of these two assessments see C1 and C2 in Appendix C. 
3.2.3.2 Secondary outcomes 
• Overall survival rate (OS): defined as the percentage of people who survive for a certain period of 
time after they were diagnosed with or treated for a disease. The overall survival rate is often 
referred to as a five-year survival rate in clinical trials;  
• Progression free survival (PFS): in clinical trial, it is defined as ‘the time interval from the 
randomization date to the date of disease progression or, if the patient died without evidence of 
progression, to the date of death’ (de Gramont et al., 2000, p 2940); 
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• Time to progression (TTP): the difference between PFS and TTP is that TTP is only interested in 
the event of disease progression. Both PFS and TTP in a clinical study have often been used as 
surrogate end points (Beauchemin et al., 2014);  
• Disease free survival (DFS): in a clinical trial, it was defined as ‘the time from randomisation to 
the first event of either recurrent disease or death’ (Sargent et al., 2005, p. 8665); 
• Alleviation of the side effects of chemotherapy: mainly including neutropenia, anaemia, 
thrombocytopenia, diarrhoea, nausea and vomiting, and neuropathy. The criteria for assessment of 
chemotherapy toxicity are found in WHO Recommendations for Grading of Acute and Subacute 
Toxicity (Miller et al., 1981). These are detailed Table C1 in Appendix C; 
• Improvement in a validated quality of life (QoL) measure: Karnofsky performance status (KPS) 
(Yates et al., 1980) or other validated measure. See details Table C2 in Appendix C;  
• Improvement in immune function (CD3, CD4, CD4/CD8, NK, TNF-α); 
• Adverse events from the HMs. 
The full texts of all potentially included studies were obtained through RMIT library for further 
scrutiny to determine whether the inclusion criteria were satisfied. Records were kept of the numbers 
of studies at each stage in the search and selection process. These were summarised in the form of a 
flowchart according to the PRISMA guidelines for systematic reviews (Moher et al., 2009). Eligible 
studies were included in the review. Excluded studies were categorised into sub-groups for future 
reference.  
 Data extraction 3.2.4
Data were extracted from each included study using pre-designed data collection forms. The following 
items were extracted: 
• Authors and year of publication; 
• Participant’s baseline information: source of participants, number of participants, gender, age 
(mean/median), TNM/Duke’s stages, performance status, etc; 
• Diagnostic criteria: pathological/histological; 
• Intervention: name of herbs/regimen, dosage, routes of administration, period of intervention, etc; 
• Methodological information: generation of allocation sequence, allocation concealment, blinding, 
drop-outs, follow-up; 
• Outcomes: tRR, OS, PFS/TTP, Karnofsky performance status (KPS), immune function, side-effects 
of chemotherapy, etc; 
• Adverse events for HM interventions; and 
• Name of each HM in the included studies. 
Data were checked for accuracy by a second researcher (Dr Jing Cui and/or Dr Iris Zhou). 
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 Risk of bias assessment: 3.2.5
Risk of bias was assessed using the Cochrane Risk of Bias assessment method which includes the 
following categories of bias: selection bias, performance bias, detection bias, attrition bias, reporting 
bias, and other bias. The approach was according to the Cochrane Handbook version 5.1.0 (Higgins & 
Green, 2011). This assessment approach emphasizes the risk of bias in outcomes for which the results 
have possibly overestimated or underestimated the true treatment effects. Each domain was labelled as 
‘low risk’ or ‘high risk’ or ‘unclear risk’, with the last category indicating that there was insufficient 
information to judge the potential for bias. The judgment criteria for the six domains of risk of bias are 
presented Table D in Appendix D. 
The risk of bias assessments were conducted by two reviewers independently (Meng Chen & Iris 
Zhou). Any differences were mediated by Anthony Zhang or Brian May. The results of assessment 
were presented as a ‘Risk of bias graph’ figure that illustrates the percentage of studies with each of 
the judgements, and as a ‘Risk of bias summary’ table that shows all of the judgements as a cross-
tabulation for each study. 
 Assessment of the quality of reporting 3.2.6
The quality of reporting was assessed by using a modified version of the CONSORT checklist (total of 
39 items) based on the ‘CONSORT 2010 Explanation and Elaboration’ (Moher et al., 2010). Each 
item was given a ‘yes’ or ‘no’ depending on whether the item was included in the study report. This 
method is detailed the following published paper: 
Chen, M., Cui, J., Zhang, A.L., Sze, D.M., Xue, C.C., May, B.H. (2018). Adherence to CONSORT 
Items in Randomised Controlled Trials of Integrative Medicine for Colorectal Cancer Published in 
Chinese Journals. Journal of Alternative and Complementary Medicine, 24(2), 115-24. doi: 
10.1089/acm.2017.0065. 
 Analysis and presentation of results: 3.2.7
The included studies were categorised into two major groups according to the HM intervention in the 
test arm:  
1. HM alone versus chemotherapy, or placebo, or no treatment; 
2. HM combined with chemotherapy versus chemotherapy.  
All included studies were narratively synthesized with regard to their characteristics, findings, adverse 
events, and validity of outcomes. The characteristics of the studies also were summarised in tabular 
form.  
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RevMAN 5.1 was used for meta-analysis when there were more than two studies using the same 
outcome measure. The aim of the meta-analysis was to statistically express whether there was 
evidence of an effect of the intervention, to estimate the size of the effect and to investigate whether 
the effect was consistent across studies. The Z-test was used to test the overall effects. The differences 
between the test groups and the control group were considered to be statistically significant when p < 
0.05. 
Risk ratio (RR) and risk difference (RD) was used for dichotomous outcomes, which included the data 
for tRR, KPS, BW and chemotherapy adverse events. The RR is the proportion of clinically effective 
cases/events in the test groups divided by the proportion of clinically effective cases/events in the 
control groups. The RD is the risk in the test groups minus the risk in the control groups. The RR 
represents the relative effect between the two groups, whereas RD is the absolute effect. Time-to-event 
data, such as survival rate, were analysed as dichotomous data. Mean difference (MD) was used for 
continuous outcomes. This is the absolute difference of the mean value between the test and control 
groups. A Confidence interval (CI) of 95% was selected and a Fixed-effect or a Random-effect model 
was used according to the degree of heterogeneity (Higgins & Green, 2011). 
Where possible, missing data were analysed as ‘intent to treat’ (ITT) regardless of which treatment 
they actually received, time of drop-out, or whether data on the outcome were actually collected. 
Irretrievable missing data were imputed and sensitivity analysis (worst case/best case scenarios) were 
undertaken where possible. Heterogeneity of data between studies was examined by chi² and I² (%) 
tests. Large chi² and small p-values indicate that there is more heterogeneity than explicable by 
chance. When p<0.10 it is statistically significant. I² is the proportion of heterogeneity. The guideline 
for the interpretation of I² was adopted from Cochrane Handbook 5.1.0 (Higgins & Green, 2011). 
When I² was more than 50%, a sensitivity analysis was undertaken and/or the analysis model was 
changed from Fixed-effect to Random-effect. Publication bias was tested by a funnel plot test if there 
were more than 10 studies in a meta-analysis group. Overall, if studies were highly heterogeneous i.e. 
clinically diverse, or poor in methodological quality, or there was serious publication and/or reporting 
bias, meta-analysis was considered inappropriate. 
The results of the meta-analyses were presented in both narrative form and graphically as Forest plots 
and tables. 
3.3 Construction of the Chinese herbal medicine short-list 
In clinical practice, CHM is commonly applied as a formula that contains several herbs. These herbs 
are rationally combined to synthesise the efficacy of herbs that have the same or similar clinical 
effects, and to minimize unwanted side effects (Scheid et al., 2009). The aim of this section was to 
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identify particular herbs that were the most likely to have contributed to the significant meta-analysis 
results. 
 Data collection 3.3.1
Each single herb that was used in the included studies was entered into a database along with the key 
features of the study and its outcomes. Frequency of usage was calculated for each herb included in all 
the studies that contributed to a particular meta-analysis pool. In addition, for the higher frequency 
herbs, their combinations with each other and with other herbs were calculated. 
 Sensitivity analysis 3.3.2
A series of meta-analyses were conducted of studies that contained higher frequency herbs. Studies of 
multi-ingredient orally administered HM interventions which had plant-based ingredients in common 
are identified. Then analyses were conducted for groups of studies that employed HM interventions 
that contained the same herbal ingredients.  
The hypothesis was that, if a particular herb was effective (or ineffective) in improving a certain 
outcome, this would be reflected in the pooled RR outcomes of the studies that employed this herb as 
an intervention. Therefore, by investigating the pooled RR of all studies that used the same HM in the 
intervention, specific HMs that showed potential for further research could be identified and 
shortlisted. Similarly, combinations of herbs could also be identified. 
These sensitivity analyses were only conducted for the multi-ingredient oral HM interventions since 
these are the most comparable in terms of dosage and bioavailability. Injections were excluded since 
these were likely to vary according to manufacturer and administration.  
The following method was used to identify groups of studies that used comparable oral interventions 
and to assess the effects of individual herbs on the RR for the outcome measure. 
Firstly, herbs that were present in two or more of the multi-ingredient oral HM interventions used in 
the RCTs were identified. Then all combinations of two, three and more herbs present in the HM 
interventions used in two or more RCTs were identified. Meta-analyses of each of these sub-groups of 
RCTs were conducted to determine which combinations of HMs produced greater or lesser changes in 
RR values for the outcome measure. The following multi-stage procedure was used:  
1. Pooled RR was calculated for each group of studies that contained the same herb as an 
ingredient in the intervention. The pooled RRs were listed in ascending order and any significant 
results were noted. 
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2. Pairs of herbs present in two or more studies were identified. The pooled RRs were calculated, 
listed in ascending order, and any significant results were noted. 
3. The same procedure was conducted for groups of 3, 4 and more herbs as the data set allowed. 
This produced a matrix of results for RR, with 95% CI. The heterogeneity also was calculated for 
each pool. 
In assessing the combinations of HMs used in the RCTs, only independent combinations were 
included. For example, although herb 1 might be paired with herb 2 in the data matrix, all the HM 
interventions that contained herb 1 + herb 2 may also include herb 3. In such cases, the RR of this 
group of RCTs reflected the combination of all 3 herbs (as well as any other herbs present), so no 
independent contribution from herb 1 + herb 2 as a pair could be assessed. Therefore, in this case only 
the group herb 1 + herb 2 + herb 3 was included in the RR matrix. This procedure eliminated spurious 
combinations. 
 Criteria for herbal medicine identification 3.3.3
To identify HMs for further research, the following criteria were used: 
1. Significantly improved (decrease/increase) RR relative to controls; 
2. The RR was equal or greater/lesser than the total pooled RR for all multi-ingredient oral HM 
interventions;  
3. Lack of important heterogeneity (I2 not greater than 30%); 
4. Consistent RR results at multiple levels of combination i.e. as single herbs, in pairs with other 
herbs, in triplets with other herbs. 
When combinations of herbs produced RRs that were greater/lower than those of the herbs 
individually, these were identified as possible examples of a synergistic effect. 
 Searches of experimental literature research on selected herbal medicines 3.3.4
For the herbs identified as promising for further research based on their use in the clinical trials 
identified in the systematic reviews, additional searches were conducted of online databases to identify 
the following types of data: 
• In-vitro studies of the herb’s pharmacological actions; 
• In-vivo studies of the herb’s activity with regard to cancer; and 
• Analytical studies of the constituents of the herbs. 
In selecting herbs for further research the following two criteria were used: 
1. The herb appeared to make a significant contribution to the meta-analysis results based on the 
sensitivity analyses; 
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2. There was evidence of effect as well as plausible mechanism(s) of action in terms of the 
proteins regulated by the herbal extracts or active constituents in-vitro and/or in vivo. 
Herbs that satisfied these conditions were considered for further analysis. 
3.4 Experimental in vitro studies of herbal medicine compounds 
Experimental studies to explore the potential anti-tumour effects of HM compounds and the 
underlying mechanisms were conducted at the Sun Yat Sen University, China. We tested a chemical 
compound derived from the short-listed of herbs that showed potential anti-cancer effects in CRC to 
determine its effects in CRC cells in vitro. No human or animal model was used and thus ethics 
application was not sought. The results will be beneficial to inform future studies (outside of the scope 
of this thesis) on its anti-cancer effects in vivo and its molecular mechanisms. 
The study was designed with three arms: 
1. Test compound arm (matrine, 4 concentrations); 
2. Negative control arm (growth medium); and 
3. Positive control arm (oxaliplatin, 4 concentrations). 
Qxaliplatin (OXA) is a chemotherapy drug known to have an effect in CRC. The comparison with the 
negative control was to identify whether the test compound had an effect, or no effect; whereas the 
comparison with the positive control aimed to assess the relative effect against a valid CRC drug. 
The following steps were carried out: 
 Cell line culture  3.4.1
The human colorectal adenocarcinoma cell lines were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum in a humidiﬁed incubator at 37 °C in a 
humidified atmosphere (45-65% humidity) with 5 % CO2. 
 Maintenance of cell lines 3.4.2
Cells were maintained in cell culture flasks and kept in a humidified atmosphere (45-65% humidity) 
with 5% CO2 at 37°C inside an incubator. During the culture of the cells, the morphology of the cells 
was examined (i.e., their shape and appearance) every 1 to 2 days using an optical microscope. The 
culture medium was pre-warmed to 37oC before medium renewal. The medium was changed to fresh 
medium 2-3 times per week. When the cells’ confluence reached 80-90%, they were trypsinized and 
harvested. Then, the cells were sub-cultured into fresh medium once again to yield a consecutive 
passage number. 
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 Detaching cell lines and sub-culturing 3.4.3
The culture medium was removed and discarded. The cell layer in the petri dish was rinsed with 
phosphate buffered saline (PBS) (approximately 2 mL per 10 cm2 culture surface area) twice to 
remove any traces of serum, calcium, and magnesium that would inhibit the action of trypsin. 
Approximately 0.5 mL per 10 cm2 of 0.25% (w/v) trypsin solution was added to the dish. The dish was 
incubated at room temperature for 5-7 minutes, with checking for dissociation every 30 seconds, until 
more than 90% of cells were detached. The detached cells were washed with 10-30 mL of PBS and 
transferred to a 15 mL conical tube. The cells were centrifuged at 400 x g for 5 min using benchtop 
centrifuges. The supernatant was discarded, and the cells were re-suspended in a minimal volume of 
pre-warmed fresh culture medium and counted for the total number of cells and percent viability using 
a hemacytometer. Appropriate aliquots of cell suspension were seeded to new cell culture dishes. The 
cells were incubated at 37oC in a humidified atmosphere containing 5% CO2. 
 Cell viability assays 3.4.4
Cytotoxicity activity was assayed by Cell Counting Kit-8 (CCK-8) according to the manufacturer’s 
instructions. Briefly, cells were collected in the phase of logarithmic growth and seeded into 96-well 
plates at a density of 5×103 cells/well, and cultured in the DMEM with a 5% (v/v) FBS for 24h. Then 
they were divided into: vehicle groups (negative control) that contained the same medium with 0.9% 
saline solution or 5% GS (100 μl/well); OXA groups as positive controls in series of concentrations 
(100μl/well); and matrine groups in series of concentrations (100μl/well). After incubation for 24, 48 
and 72h, the medium was replaced with 10μl of 10% CCK-8 solution dissolved in 90μl PBS and all 
the cells were incubated for another 1h at 37°C in the dark. Absorbance at 450nm was measured with 
a microplate reader. All the experiments were repeated three times in sextuplicate wells. To calculate 
the cell viability, the absorbance readings were plotted and analysed. Results were expressed as a 
percentage of the control. The inhibition rate was calculated based on the percentage of cell viability 
for each cell line (means of 6 wells) by the following formula: 
Inhibition rate(IR) =(1- Sample solution OD value
Vehicle OD value
)×100% 
(Formula 1) 
 Morphological changes of colorectal cancer cells 3.4.5
CRC cells were seeded into 6-well plates (1×105 cells/well, 2 mL/well). Low-dose and high-dose 
matrine groups were set for each cell line according to the IC50 calculated by the CCK-8 assay. OXA 
was set as the positive control for the CRC cell lines and concentrations were also set by IC50. The 
vehicle group was the negative control. Morphological changes in each cell line were observed by 
optical microscope every 12h and pictures were taken after 48 h. 
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 Cell cycle analysis 3.4.6
Flow cytometry (FCM) was used to measure DNA content for cell cycle phases. CRC cells were 
seeded into 6-well plates (1×105 cells/well, 2 mL/well) and allowed to attach for an additional 12h. 
Then the medium was replaced with matrine (low-dose and high-dose) or OXA. The cells were 
incubated in humidified atmosphere with 5% CO2 at 37°C for 24 h. The cells were collected, washed 
twice with cold PBS, and incubated with 500 µL RNase A (50 µg/mL) for 30 min at 37 °C, then the 
cells were washed again with PBS and fixed in 70% cooled ethanol at 4°C overnight. Finally, they 
were stained with propidium iodide (PI) at room temperature in the dark for 30min. After the staining, 
the fluorescence intensity of all the cells were analysed using a FCM. All the experiments were 
repeated three times. 
 Apoptosis analysis 3.4.7
The Annexin V-FITC/PI double staining assay was used to observe cellular apoptosis. CRC cells were 
seeded into 6-well plates (1×105 cells/well). They were exposed to DMEM (control), matrine or OXA 
(2 mL/well) for 24h. According to the manufacturer’s instructions, the cells were harvested by 
centrifugation, washed twice with cold PBS, then the collected cells were resuspended in 200μl 
binding buffer and incubated with RNase A (50 μg/mL) at 37°C for 30 min. Then cells were incubated 
with Annexin V- FITC (5μl) and PI (5μl) for 15min at room temperature in the dark followed by the 
FCM analysis. All experiments were repeated three times. The apoptotic rate was calculated as the 
percentage of both early apoptotic cells and late apoptotic cells: 
Apoptosis %=
Early apoptotic cells + Late apoptotic cells
Total cell count
×100% 
(Formula 2) 
 Statistical analysis 3.4.8
Results were expressed as the mean ± standard deviation (SD) using Student’s t-test and one-way 
analysis of variance (ANOVA) with the Dunnett correction. Mean values were calculated from 
experimental data that were measured in triplicate. The IC50 in the CCK-8 assay was calculated by 
probit regression. All statistical analyses were performed using the SPSS 13.0 software (SPSS Inc., 
Chicago, IL). P values were two-tailed, and a P value ˂0.05 was considered statistical significance. 
The above results are documented and analysed in Chapter 7. 
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3.5 Review of experimental studies of the selected herb in colorectal cancer 
This review aimed to comprehensively investigate the literature on the molecular mechanisms of the 
potential anti-cancer effects in CRC of the selected herb (i.e. ku shen – Sophora flavescens). The 
results will direct future studies. 
PubMed and CNKI were searched (to December 2016) to locate experimental studies of the selected 
herb, its extracts and its principal compounds when tested in CRC cell lines or animal models of CRC.  
 
The search terms included: 
• names of the selected herb in Chinese characters, Chinese pinyin, botanical names; or 
• the principal constituent compounds in the herb (species); and  
• colorectal cancer, or colon cancer, or bowel cancer; and 
• in vitro or in vivo study.  
 
Studies that tested the selected herb, herb extract or its compounds for anti-cancer properties in CRC 
models in vitro or in vivo were included. Studies published in Chinese and English were included. 
Retrieved citations were combined in an Endnote library. The ‘find duplicate’ function in the Endnote 
Library was used to find duplicated copies, which were then excluded. The titles and abstracts of the 
remaining citations were filtered according to the inclusion criteria. The full texts of all potentially 
included studies were obtained through RMIT library for further scrutiny to determine whether the 
inclusion criteria were satisfied. 
Data were extracted from each included study using pre-designed data collection forms.  
The following items were extracted: 
• Authors and year of publication; 
• Study design: in vitro or in vivo; 
• Name of cell line, animal model, assay name; 
• Name of compound, extract; 
• Test compound dose, treatment time, method of experimention, targeted protein(s);  
• Experimental results including:  
o anti-proliferative activity;  
o induction of apoptosis;  
o induction of cell cycle arrest;  
o anti-angiogenic activity;  
o anti-metastatic activity;  
o anti-multi-drug resistance activity;  
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o activities related to cell migration and/or adhesion, and 
o any proposed metabolic pathway and any adverse reactions. 
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Chapter 4. Systematic Review of Herbal Medicines in the Management 
of Colorectal Cancer 
4.1 Introduction to Chapter 4 
This chapter presents the results of the search strategy described in Chapter 3 and the meta-analyses of 
clinical outcomes. Firstly, the characteristics of included studies, characteristics of participants, types 
of interventions, outcome measures, risk of bias assessments and quality reporting are summarised 
narratively and tabled. Secondly, meta-analyses were performed where possible for major outcome 
measures to statistically express whether there was evidence of an effect, estimate the size of the 
effect, the certainty surrounding the effect, and to investigate whether the effect was consistent across 
studies. Meta-analysis was carried out in two major groups according to the intervention(s) in the test 
arm: 
1. HM alone versus chemotherapy (CMT), placebo, or no treatment; 
2. HM combined with chemotherapy (CMT) versus the same chemotherapy alone. 
4.2 Summary of search results 
The initial systematic search of biomedical databases was conducted in 2011. The numbers of 
potential citations were as follows: PubMed 280, Cochrane Central 284, ScienceDirect 41, CINAHL 
70, PsycINFO 57, CNKI 878, and CQVIP 317. A follow-up search was conducted in December 2013. 
The above databases were searched with the same search terms and EMBASE was searched as an 
additional database. The additional citations were: PubMed 32, Cochrane Central 89, ScienceDirect 
29, CINAHL 37, PsycINFO none, CNKI 346, CQVIP 34 and EMBASE 20. In addition, 54 potential 
citations were identified by checking reference lists and print journals in the RMIT University library. 
Thus, 2,514 potentially relevant citations were identified. 
The screening procedures followed the PRISMA Statement flow diagram 2009 (Moher et al., 2009). 
After the removal of duplicates, non-RCTs and studies that did not satisfy the selection criteria, 88 
studies were included in this review (see the flow diagram Figure 4.1). Eighty-four studies were 
conducted in China and were published in Chinese journals. Eighteen of the studies conducted in 
China were funded by state or provincial Chinese governments. Four studies were published in 
English: two were carried out in Japan (Torisu et al., 1990; Kono et al., 2013), one in Germany 
(Schink et al., 2007), and one in Romania (Cazacu et al., 2003). The publication year of the studies 
ranged from 1990 to 2013.   
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Figure 4.1: Flow diagram of the search and selection process of RCTs of herbal medicine 
(HM) for colorectal cancer (CRC) 
 
4.3 Characteristics of study participants 
Two out of 88 studies (Wang et al., 2000; Li et al., 2000) employed three arms that compared HM vs. 
HM + CMT vs. CMT, thereby providing the comparisons HM vs. CMT and HM + CMT vs. CMT. 
Therefore, there were 90 comparisons in this review. The 88 studies enrolled 6,385 participants with 
3,357 participants in the test groups and 3,028 participants in the control groups. All participants were 
diagnosed with primary CRC by pathology. While most of the participants were in-patients, three 
studies included some out-patients (Mao & Huang, 2005; Xiao et al., 2003; Yang et al., 2005). Two 
studies did not provide information about the in- or out- patient status of the participants (Kono et al., 
2013; Wang et al., 2007), and one study (Torisu et al., 1990) conducted a long-term trial, so it was 
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probable that the setting was out-patients. The included studies were mostly at a single centre. Six 
studies were conducted at two or more centres (Dong et al., 2011; Liu et al., 2013; Wand et al., 2011; 
Yang et al., 2007; Cao et al., 2011; Kono et al., 2013). Torisu et al. (1990) did not provide information 
on the site. The characteristics of the 88 included studies are presented in Table E1 and Table E2 in 
Appendix E. In Table E1, studies in group one investigated HM alone versus chemotherapy (CMT), or 
placebo, or no treatment, and in Table E2, studies of group two compared HM combined with CMT 
with the same CMT. 
Dukes staging system and the Union for International Cancer Control (UICC) TNM staging system 
were the most commonly used diagnostic criteria in the included studies. Thirty-six studies used the 
UICC staging criteria, twenty-eight studies applied Dukes staging criteria, four studies adopted the 
1978 Chinese National CRC Staging Standard, which is the same as the Dukes system. Participants 
were simply categorised as ‘advanced CRC’ in 16 studies, and no staging information was reported in 
4 studies (Mao & Huang, 2005; Zhang et al., 2007; Tang, 2009; Zhang et al., 2010) (Table E1; Table 
E2 in Appendix E). 
Seventy-five studies provided information on participants’ ages as means or medians. Participants in 8 
studies were under the mean/median age of 50 years; in 69 studies the mean or median age ranged 
from 50 to 70 years; 2 studies (Li et al., 2007; Schink et al., 2007) enrolled at least some participants 
who were over 70 years old. Six studies only provided the age of participants as a range without a 
mean or median. Three studies (Zhang et al., 2010; Wang, 2013; Qin & Zhu, 2011) did not specify 
participants’ ages (Table E1; Table E2 in Appendix E). No studies were excluded based on the age of 
participants. 
For 417 patients from five studies, gender was not specified (Torisu et al., 1990; Cazacu et al., 2003; 
Zheng & Sun, 2005; Zhang et al., 2010; Qin & Zhou, 2011). Of the remaining 5,968 patients in 83 
studies, 3,584 (60.1%) were male and 2,384 (39.9%) were female (Table E1; Table E2 in Appendix 
E). 
Nineteen of the studies did not provide information on participants’ physical performance status in the 
inclusion criteria. Two studies (Cao et al., 2011; Kono et al., 2013) used the ECOG measurement; and 
sixty-seven studies used the KPS measurement system. For details of participants’ characteristics see 
(Table E1; Table E2 in Appendix E). 
4.4 Study design and types of interventions 
Herbal medicine (HM) alone as the test arm versus chemotherapy (CMT), or placebo, or no treatment 
was used in 11 studies (Table E1 in Appendix E). These included the two studies that involved three 
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arms (Li et al., 2000; Wang et al., 2000). In these two studies the comparisons were separated for 
analysis i.e. HM vs. CMT, and HM plus CMT vs. CMT. 
HM combined with CMT as an integrative medicine (IM) intervention was used in the test arm, and 
was compared to the same CMT regimen as the control group in 79 studies (Table E2 in Appendix E), 
which included the two studies that involved three arms (Li et al., 2000; Wang et al., 2000). 
 Herbal medicine interventions 4.4.1
Orally administered multi-herb decoctions were the most common interventions and were used in 46 
of the 88 studies. Eighteen studies used manufactured orally administered HM tablets; 21 studies used 
a HM extract that was injected intravenously; enema interventions were investigated in two studies (Li 
et al.,1999; Wang et al.,1999); and treatment using Javanica oil transcatheter arterial 
chemoembolization (TACE) for liver metastasis was reported in one study (Zhang & You, 2008) 
(Table E1; Table E2 in Appendix E). 
 Chemotherapy interventions 4.4.2
Intravenous infusions of combinations of chemotherapeutic agents were the most common CMT 
interventions. This type of CMT was in two main groups: 
1. Oxaliplatin-based regimens: 5-FU+LV+oxaliplatin (FOLFOX), or capecitabine + 
oxaliplatin (XELOX/CAPOX) were reported in 56 of the included studies; and 16 of these 
56 studies used the FOLFOX4 regimen (Table 4.2; Table 4.6). 
2. 5-FU regimens administered by intravenous infusion were used in 19 studies. These 
included: 5-FU + LV regimen (n=8); 5-FU + MMC (n=2); 5-FU + MMC + ADM (n=1); 5-
FU + LV + MeCCNu (n=3); 5-FU + MeCCNu + vincristine (n=1); 5-FU + LV + HCPT 
(n=2); 5-FU + cisplatin (n=1); and single agent 5-FU (n=1). Others included HCPT 
administered by intravenous infusion (n=1), and orally administered capecitabine (n=1) 
(Table E1; Table E2 in Appendix E).  
Besides intravenous infusion, other chemotherapeutic methods used were: 5-FU enema (n=1), 5-
FU+cisplatin intraperitoneal hyperthermic perfusion (n=1), and 5-FU transcatheter arterial 
chemoembolization (TACE) (n=2). Six studies provided supportive care without any chemotherapy 
(Table E1; Table E2 in Appendix E). Overall, HMs combined with the FOLFOX regimen in both 
adjuvant and palliative settings for CRC was the most common combination in the test groups. 
4.5 Assessment of risk of bias and the quality of reporting for included studies 
This section includes three parts: assessment of risk of bias, assessment of the quality of reporting, and 
a discussion of methodological reporting issues. 
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 Assessment of risk of bias 4.5.1
Included studies were assessed using the Cochrane Risk of Bias (selection bias, performance bias, 
detection bias, attrition bias, reporting bias, and other bias) approach in the Cochrane Handbook 
Version 5.1.0 (Higgins & Green, 2011). The method is described in Chapter 3. For the summary of 
risk of bias see Figure 4.2 that is based on the review authors' judgements about each risk of bias item 
presented as percentages across all 88 included studies, and Table E3 in Appendix E that is based on 
the review authors' judgements about each risk of bias item for each of the eighty-eight included 
studies. 
All studies claimed to be randomised, but only 27 studies (30.7%) stated a proper method for the 
generation of a randomisation sequence and the risk of bias was judged to be low. One study used an 
inadequate method of randomisation and was judged to be high risk (Wang et al., 2000). The other 
studies did not describe what method was used to generate the randomisation sequence, so the risk of 
bias was judged to be unclear. Two of the studies (Cao et al., 2011; Kono et al., 2013) described the 
procedure for allocation concealment and were therefore judged to be low risk. Other studies did not 
describe a method of allocation concealment and were judged as unclear (Figure 4.2; Table E3 in 
Appendix E). 
A placebo group was used in four of the studies (Torisu et al., 1990; Yang et al., 2007; Cao et al., 
2011; Kono et al., 2013) and these studies reported using a double-blinding method. One study (Deng 
& Shen, 2010) claimed to be a single-blind trial. These five studies were judged to be low risk for 
blinding of participants. There is generally no blinding in oncology trials (Hind et al., 2008) so the 
other studies were assumed to be open to participants and personnel. Thus, in these studies there was 
possible performance bias and detection bias for subjective outcomes such as Karnofsky Performance 
Status (KPS). Therefore, a high risk of bias was judged for blinding of outcome assessment for 
subjective outcome measures. Radiologists and pathologists measured the objective outcomes, such as 
objective tumour response, and laboratory tests. Outcome data on survival rate, and time to 
progression were obtained from medical records that were unlikely to have been influenced by any 
lack of blinding. So, the judgement of low risk of bias was made for blinding of outcome assessment 
of these objective outcomes (Figure 4.2; Table E3 in Appendix E). 
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Figure 4.2: Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies 
Eight studies reported the number of participants who dropped out, were excluded during the trial or were lost to 
follow-up (Guo et al., 1999; Hou et al., 2009; Li et al., 2007b; Pan et al., 2003; Qin & Zhou, 2011; Xu et al., 
2006; Yang et al., 2007; Zhang et al., 2010; Zhang et al., 2010a) but these missing data were not analysed as 
intent-to-treat. Therefore, a high risk of attrition bias was judged (Figure 4.2; Table E3 in Appendix E). 
Only one of the studies (Kono et al., 2013) had published a study protocol. In 83 of the studies that did 
not publish a protocol, the study objectives and outcome measures were stated in the study method 
section and were reported in the results section. These studies were judged to have a low risk of 
selective reporting. In the other three studies (Wang et al., 2000; Li et al., 1999; Qin & Zhou, 2011) 
there were no pre-statements of the measured outcomes, and these were judged to be high risk of 
selective reporting (Figure 4.2; Table E3 in Appendix E). 
The assessment of ‘other bias’ was based on the source of funding for the study. If a study was funded 
by an organisation with a vested interest in the outcome, the outcome is more likely to be in favour of 
the interests of the organisation (Lundh et al., 2012). For studies conducted in China, there is evidence 
that if the study was funded by an official state source, the study was more likely to be an authentic 
RCT (Wu et al., 2009). Twelve studies conducted in China claimed that the studies were funded by an 
official state source and were judged to be low risk of bias in this domain. One study was partly 
funded by a pharmaceutical company (Cazacu et al., 2003), so there was possible bias related to 
funding source and it was judged to be high risk of bias. The other studies were judged to be unclear 
because no funding source had been reported by the authors (Figure 4.2; Table E3 in Appendix E). 
 Assessment of the quality of reporting 4.5.2
The issue of whether the conduct of randomised controlled trials reported in Chinese journals have 
been in accord with international standards was raised in a study by Wu et al. (2009) who reported that 
only 6.8% of studies published in Chinese medical journals adhered to established RCT methodology, 
however they found there was no difference between trials of conventional and of traditional medicine 
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in terms of methodological quality. In their stratification analysis, all pre-market drug trials were 
authentic RCTs and 51.6% of government funded studies were considered authentic. In China, 
hospitals are categorised into three grades according to their level and size, the highest level being 
level 3 which are hospitals affiliated to medical universities and provincial hospitals, other hospitals 
are classified as level 2 or below. The authors found that hospitals affiliated to medical universities 
were better in conducting RCTs than other level 3 hospitals and level 2 hospitals.  
Since 84 out of the 88 studies included in this chapter were reported in Chinese publications, to further 
investigate this issue, we focussed on the studies published in Chinese and published in Chinese 
medical journals and assessed the quality of reporting in each study using the modified CONSORT 
2010 checklist (Moher et al., 2010). This section is based on the published paper (Chen et al 2018).  
CONSORT 2010 contains 25 items but a number of these include sub-items, so there are 37 items in 
total. Items 1 to 22 were included in CONSORT 2001 (Moher et al., 2001) and items 23 to 25 (other 
information) were added in CONSORT 2010. Two sub-items were modified to facilitate assessment 
and scoring as follows: item 6a was split into 6a (1) Primary & secondary outcomes, and 6a (2) End 
points (time of data measured); and 13a Flow of participants was divided into 13a (1) Flow diagram as 
figure, and 13a (2) Flow of participants (verbal) (Table 4.1). For each study the number of items 
reported was calculated (items 1 to 25, maximum score=39). 
Of the 84 studies that were published in China, one study was written in English and two were 
Chinese theses published in CNKI. These three studies were excluded from the main analysis which 
focussed on articles in medical journals written in Chinese. In the remaining 81 studies, the total mean 
score of the CONSORT 2010 check-list items was 10.44 (SD ± 2.40) out of a maximum score of 39. 
Two items were reported by all studies (items 6a and 22) and 12 items were not reported at all (items 
3b, 6b, 7a, 7b, 9, 10, 12b, 13a (1), 14b, 17a, 17b, 23, and 24) (Table 4.1). Reporting rates were above 
70% for ten items (1b, 2a, 4a, 4b, 5, 6a (1), 6a (2), 12a, 14a, and 22).  
For the items on RCT methodology, item 9 (allocation concealment), and item 10 (implementation of 
randomisation) were not reported in any study. Item 8a (sequence generation) was reported by 29.6% 
of studies, item 13b (losses and exclusions) was reported by 12.35% of studies, item 16 (intent-to-treat 
analysis) was reported by 4.94% of studies, and item 11a (blinding) was reported by 2.47% of studies. 
These items were the main contributors to the analyses. Eighteen studies mentioned a form of public 
funding, none mentioned commercial funding, and no studies mentioned published protocols or trial 
registration (Table 4.1).  
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Table 4.1: Scores on Consort 2010 checklist (modified) 
CONSORT checklist Item no., Criteria This review (n=81) 1998-2013, n (%) 
Title/Abstract 
1a. Identification as a RCT in the title 2(2.47) 
1b. Structured summary of trial design, methods, results, and conclusions 69(85.19) 
Introduction 
2a. Background and objectives 67(82.72) 
2b. Specific objectives or hypotheses 10(12.35) 
Methods 
Trial design 
3a. Description of trial design 6(7.41) 
3b. Changes to methods after commencement 0(0) 
Participants 
4a. Eligibility criteria for participants 58(71.60) 
4b. Setting and locations of data collections 80(98.77) 
Interventions 
5. Details of interventions in each group 67(82.72) 
Outcomes 
6a (1) Primary & secondary outcomes 81(100) 
6a (2) End points (time of data measured) 79(97.53) 
6b. Any changes to trial outcomes after the trial commenced, with reasons 0(0) 
Sample size 
7a. Sample-size determination 0(0) 
7b. Explanation of any interim analyses and stopping guidelines (if applicable) 0(0) 
Randomisation 
8a.* Method used to generate the random allocation sequence 24(29.63) 
8b.* Type of randomisation with details of any restriction (such as blocking) 2(2.47) 
9.* Allocation concealment 0(0) 
10.* Implementation of random-allocation sequence 0(0) 
11a.* Blinding of participants (and others) to group assignment 2(2.47) 
11b.* Description of the similarity of interventions (if relevant) 1(1.23) 
12a. Statistical methods 75(92.59) 
12b. Methods for additional analyses (e.g. sub-group analyses) 0(0) 
Results 
13a (1). Flow diagram as figure 0(0) 
13a (2). Flow of participants (verbal) 2(2.47) 
13b.* For each group, losses and exclusions after randomisation, with reasons 10(12.35) 
14a. Dates of recruitment and follow-up 78(96.3) 
14b. Why the trial ended or was stopped 0(0) 
15. Baseline and demographic clinical characteristics (table) 13(16.05) 
16.* For each group, number of participants (denominator) included in each analysis 
and whether used intent-to-treat  
4(4.94) 
17a. Outcomes and estimated effect size with 95% confidence interval 0(0) 
17b. For binary outcomes, presentation of both absolute (RD) and relative (RR) effect 
sizes 
0(0) 
18. Sub-group analyses/ancillary analyses 1(1.23) 
19. Adverse events/harms 5(6.17)1 
Discussion 
20. Trial limitations, sources of potential bias, imprecision, etc. 9(11.11) 
21. Generalisation (external validity) of findings 2(2.47) 
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22. Interpretation consistent with results, balancing benefits and harms, and other 
relevant evidence 
81(100) 
Other information 
23. Registration number, name of trial registry 0(0) 
24. Protocol 0(0) 
25. Funding(public) 18(22.22) 
* Eight items closely related to RCT methodology. Reference: Moher et al., 2010 
 Discussion of issues relating to risk of bias and reporting of the RCTs 4.5.3
Assessment of the quality of a clinical trial depends on whether the design, conduct, and analysis are 
adequately reported in the publication. There is no uniform international guideline for reporting the 
results of clinical trials but the CONSORT statement is broadly endorsed by international journals and 
several editorial groups. It comprises checklists that provide guidance for authors to report their trials 
clearly and completely (Moher et al., 2010). In addition, the Cochrane collaboration’s risk of bias tool 
provides a convenient method of assessing key aspects of the reporting of RCT methodology which 
could compromise the results if these methods were not properly adhered to (Higgins & Green, 2011). 
An analysis of 70 Cochrane reviews of TCM interventions published during or before 2008 concluded 
that the results of most of the TCM reviews were inconclusive due to the poor methodological quality 
of the included studies and the high heterogeneity in the meta-analyses (Manheimer et al., 2009). This 
judgement mainly relied on the quality of the reporting of these studies in published journal articles. 
Wang et al. (2007) have shown that only 39.4% of the 30 items on the modified CONSORT checklist 
were reported across all trials and a number of key components of RCTs were incompletely reported. 
For instance, sample-size calculation was reported in 1.1% of RCTs; 7.9% reported randomisation 
sequence; 0.3% mentioned allocation concealment; 0% described the implementation of the random 
allocation sequence; and 0% conducted analysis using intention to treat. This finding was based on 
6,093 identified RCTs of TCM studies from 13 TCM journals published from 1999 to 2004 in 
mainland China. However, this study also found the quality of reporting of RCTs according to the 
mean Jaded score improved during this time (1999: 0.85 ± 0.53 versus 2004: 1.20 ± 0.62, p<0.001). 
Similarly, incomplete reporting of key components of RCTs was found in a subsequent study of 6994 
articles that published in Chinese medical journals from 2005 to 2012, using CONSORT 2010 items 
for scoring (Li et al., 2014).  
A major factor in poor reporting is the low level of endorsement of CONSORT in China. Li et al. 
(2012) reported that 6 of 195 high-impact medical journals (3.08%) mentioned CONSORT in the 
author guidelines (Li et al., 2012) and Song et al. (2015) reported that 7 of 1221 (0.57%) medical 
journals endorsed CONSORT (Song et al., 2015). Only 1 of 90 journals of Chinese traditional 
medicine (the English version only) and one specialist oncology journal endorsed CONSORT. 
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In this review, the 81 studies that were published from 1990 to 2013 in 53 Chinese journals in China 
were assessed using a modified CONSORT checklist. No endorsement of CONSORT in the author 
guidelines was found in any of the 53 journals. Overall, only 5.1 % (2/39) of items were reported by 
all studies. The incomplete reporting of key components of RCTs, such as ‘sample-size calculation’, 
‘randomisation sequence’, ‘allocation concealment’, ‘implementation of the random allocation 
sequence’, and ‘intention to treat’ were similar to the proportions in Wang et al.(2007) and Li et al. 
(2014). 
However, the incomplete reporting of clinical trial information is an international issue. For instance, 
in 2006, 34% of 616 RCTs indexed in PubMed reported information on the method of assigning 
participants to comparison groups, 54% defined a primary endpoint, and 45% reported a sample size 
calculation (Hopewell et al., 2010). 
In the assessment of risk of bias there is the issue of whether a study was a real RCT. Proper 
randomisation that includes adequacy of sequence generation and allocation concealment are critical 
components of a high quality RCT (Altman, 1991). All the studies included in this review were 
reported to be randomised trials, but only 24 (29.63%) studies reported a proper method of 
randomisation sequence generation and only one study reported allocation concealment. This raises 
the question of whether the remaining studies were inadequately reported RCTs or not really RCTs at 
all. 
Nevertheless, internationally, the reporting of the method of randomisation of participants to 
interventions is generally inadequate (Moher et al., 2010). For instance, only 9% of 206 reports of 
supposed RCTs in obstetrics and gynaecology journals described both randomisation sequence 
generation and allocation concealment (Schulz et al., 1994). Up to 81.3% of RCTs reported in 
pediatric complementary and alternative medicine journals had unclear allocation concealment (Moher 
et al., 2002). In a study of oncology RCTs in ten well-known international journals, allocation 
concealment was reported in 51% of articles, while 31% adequately described randomisation sequence 
generation (Peron et al., 2012). 
Blinding of personnel and participants was also not implemented in all but one study, so the risk of 
bias for this aspect must be judged as high. However, the lack of blinding appears partly due to the 
nature of cancer studies (Hind et al., 2008) as well as due to the difficulty of blinding the 
administration of HMs, especially of a HM decoction which has a very distinct colour and taste. 
Nevertheless, the use of objective outcomes, such as tumour response and other outcomes that rely on 
laboratory test results, were considered to warrant a judgement of low risk of bias, because these 
outcomes were in the form of x-ray images or laboratory test results, which were assessed by 
specialists who are usually remote from the trial. Therefore, bias in outcome assessment was 
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considered unlikely and would not be expected to have influenced these objective outcomes. Outcome 
data on survival rate and time to progression was obtained from medical records, which were also 
unlikely to have been influenced by lack of blinding. 
A low dropout rate was found in most of the 81 studies. All participants were hospital in-patients who 
were cared for by professional nurses and doctors. In China, these patients tend to be compliant and 
follow doctors’ orders, especially over the relatively short period of these trials. Other factors (e.g. on-
time administration of medicine, transportation issues, and the timely treatment of the side effects of 
chemotherapy) all influence a participant’s acceptance of the treatment and reduce the chance of 
dropouts. Therefore, small numbers of dropouts are not unusual in trials conducted in Chinese 
hospitals, but the issue of unreported attrition bias remains. 
4.6 Approach to meta-analyses 
Studies were grouped according to the main comparisons and sub-grouped according to the 
chemotherapy type as follows: 
Group 1: HM vs. chemotherapy or no treatment or placebo (11 studies) 
Group 2: HM + chemotherapy vs. chemotherapy (79 studies), and sub-groups: 
HM combined with local chemotherapy (4 studies) 
HM combined with systemic chemotherapy (75 studies) 
4.7 Results for Group 1: Herbal medicine vs. chemotherapy or no treatment or 
placebo 
In this section, all the studies employed a HM intervention alone as the test group and compared it 
with a control group that received no specific intervention (4 studies) or a placebo (2 studies) or 
chemotherapy (5 studies). These studies were sub-grouped into: 
1. The influence of HM therapy on immunity in the peri-operative period (3 studies); 
2. HM alone as adjuvant therapy for stage II/III CRC patients after radical surgery (3 studies); 
3. HM vs. CT for advanced CRC (ACRC) (4 studies); 
4. Javanica oil emulsion versus chemotherapeutic drugs for liver metastatsis (1 study). 
In sub-groups 1, 2 and 4 the outcomes are presented as a narrative summary with significance tests 
performed where possible for individual studies. In group 3, meta-analyses were conducted on the 
pooled data where possible. The characteristics of this group of studies are presented in Table E1 in 
Appendix E. 
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 Influence of herbal medicine therapy on immunity in the peri-operative period 4.7.1
Three studies reported on measures of cell-mediated immunity (CMI) in the peri-operative period 
including NK cell killing activity, the percentages of CD3+, CD4+ and CD8+ cells and the ratio of 
CD4+/CD8+ cells. In general, improvement in CMI is indicated by increases in NK cell killing 
activity, and the percentages of CD3+ and CD4+ cells, while increase in the percentage of CD8+ cells 
and a decrease in the ratio of CD4+/CD8+ cells are indicative of suppression of CMI. 
Iscador® M special injection, which is an extract of a fermented aqueous preparation of Viscum album 
L. (mistletoe); Xuebijing injection, an extract of a combination of herbs; and Chang'ai Kangfu oral 
decoction, are three different HMs that are used as immune-regulators in peri-operative patients. These 
HMs were investigated in three separate studies in CRC patients, who had just undergone tumour 
surgical resection procedures (Schink et al., 2007; Gu & Huo, 2009; Li et al., 2000). The main 
outcomes were measures of cell-mediated immunity (CMI). 
In the study by Schink et al. (2007) patients in the test group received Iscador® M special infusion and 
general supportive care during the operation, whereas the control group only received general 
supportive care. Immune status was assessed pre-operation, post-operation and at seven days post-
operation (Table E1 in Appendix E). The results showed that the NK cell killing activity (%) pre-
operation was not significantly different between two groups (MD -0.10, 95% CI -3.25-3.05, p=0.95). 
In both groups, the NK cell killing activity dropped at day one post-operation. At day seven, NK cell 
killing activity in the test group was higher than the pre-operation level, in the control group, NK cell 
killing activity remained lower than the pre-operation level. Overall, NK cell killing activity was 
significantly higher in the test group than in the control group at both day one (MD 5.50, 95% CI 
[1.37, 9.63], p=0.009) and day seven (MD 5.30, 95% CI [0.25, 10.35], p=0.04) after the operation. 
In the study by Gu et al. (2009), the effect of Xuebijing injection on regulation of cell immunity in 
peri-operative CRC patients was investigated. In addition to general supportive care, the test group 
(n=24) received Xuebijing injection at one to five days post-operation day, whereas the control group 
(n=23) only received the same general supportive care as the test group. In both groups, the 
percentages of T cell subsets (CD4, CD8, CD4/CD8) in peripheral venous blood were measured at one 
and five days post-operation and compared to the pre-operation values (Table E1 in Appendix E). 
CD4+ expression in both the test and the control groups was lower at day one and day five post-
operation compared to the pre-operation values within the groups. However, CD4+ expression in the 
test group was significantly more than in the control group at post-operation day one and day five. 
CD8+ expression was suppressed during the observation period in both the test and the control groups 
and there was no significant difference between the two groups at both time points. The ratio of 
CD4/CD8 in both the test and the control groups had decreased at day one and day five post-operation, 
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compared with the pre-operation values within both groups. The ratio of CD4/CD8 was significantly 
higher in the test group than in the control group at day one and day five post-operation (Table 4.2). 
Table 4.2: Gu et al. (2009) comparison of T cell subsets and NK cell between test and control 
group 
End-point CD4 + / % (MD) CD8 + / % (MD) CD4 + / CD8 + (MD) 
Pre-operation -1.30 [-3.19, 0.59], 
p=0.18 
-0.61 [-2.73, 1.51], 
p=0.57 
0.05 [-0.03, 0.13], 
p=0.19 
Post-operation day1 1.87 [0.23, 3.51], 
*p=0.03 
1.40 [-0.15, 2.95], 
p=0.08 
0.07 [0.01-0.13], 
*p=0.02 
Post-operation day5 3.40 [1.36, 5.44], 
*p=0.001 
-1.11 [-2.41, 0.19], 
p=0.10 
0.16 [0.07, 0.25], 
*p=0.0003 
*statistically significant; (-): favours control group, (+): favours test group, p<0.05: statistically significant, MD: mean 
difference 
The study by Li et al. (2000) tested the effect of oral administration of Chang'ai kangfu decoction on 
CMI for Dukes B/C CRC patients who had undergone curative surgery. In this study, CHM was 
compared with CMT. The CHM group (n=16) received Chang'ai kangfu decoction, while the CMT 
group (n=17) was treated with 5-FU+MMC as adjuvant CMT. The CMI parameters included T cell 
subsets (CD3+, CD4+, CD8+, CD4+/CD8+), and NK cell activity in serum at different time points 
(Table E1 in Appendix E). In addition, thirty healthy adults were recruited as a reference group and 
blood samples were collected. The results of the T cell subsets and NK cells were referred to as the 
normal parameters based on this healthy reference group (Li et al., 2000). 
The CMI pre-operation parameters in both the CHM group and the CMT group were both lower than 
in the healthy group. This indicated the cancer patients had lower than normal immunity at baseline. 
At first week after operation, CD3+, CD4+, and NK cell expression and the CD4+/CD8+ in both the 
CHM and the CMT groups were lower than the pre-operation values within these groups. Conversely, 
the CD8+ was increased and higher than in the pre-operation period in both groups. This indicated the 
host’s immunity, especially the CMI, was in a suppressed state after the operation. There was no 
significant difference between the two groups in the above CMI parameters. At the first month post-
operation, CD3+, CD4+, and NK cell expression as well as the ratio CD4+/CD8+ recovered and were 
higher than pre-operation values within the CHM group. The CMT group recovered slowly and CMI 
parameters still remained lower than the pre-operation level within this group at this end-point. There 
was a significant difference between two arms at the first month after operation. The CMI of 
participants continuously recovered in both the CHM and CMT groups until the third month post-
operation. At this point there was no significant difference between the two groups in CMI parameters, 
except for CD3+ cell which remained higher in the test group. At three months after the operation, the 
parameters in the test group were not different to the healthy group, but the control group was still 
slightly below the healthy group (Table 4.3). This study showed the restoration of the CMI was 
quicker in the CHM group than in the CMT group during the post-operative period.  
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Table 4.3: Li et al. (2000) comparison of T cell subsets and NK cell between test and control 
group 
End-point CD3+ CD4+ CD8+ CD4+/CD8+ NK cell 
Pre-operation 
-1.10 [-7.05, 
4.85], p=0.72 
-0.80 [-5.78, 
4.18], p=0.75 
1.40 [-3.23, 
6.03], p=0.55 
-0.03 [-0.31, 
0.25], p=0.83 
0.70 [-2.81, 4.21], 
p=0.70 
Post-operation 
first week 
-1.10 [-7.05, 
4.85], p=0.72 
-0.90 [-6.23, 
4.43], p=0.74 
-1.40 [-7.88, 
5.08], p=0.67 
0.17 [-0.22, 
0.56], p=0.40 
-0.70 [-4.19, 
2.76], p=0.69 
Post-operation 
first month 
8.2 [3.49, 
12.91], 
*p=0.0006 
8.70 [2.40, 15.00], 
*p=0.007 
-2.90[-8.63, 
2.83], p=0.32 
0.41 [0.06, 
0.76], *p=0.02 
5.20 [1.73, 8.67], 
*p=0.003 
Post-operation 
second month 
7.60 [2.27, 
12.93], 
*p=0.005 
3.40 [-0.21, 7.01], 
p= 0.06 
-3.80 [-9.88, 
2.28], p= 0.22 
0.24 [-0.16, 
0.64], p=0.24 
1.60 [-1.35, 4.55], 
p=0.29 
Post-operation 
third month 
9.3, [3.66, 
14.94], 
*p=0.001 
1.5, [-3.31, 6.31], 
p=0.54 
1.7 [-3.08, 
6.48], p=0.49 
0.05 [-3.4, 0.44, 
p=0.80 
1.70 [-2.05, 5.45], 
p=0.37 
*statistical significant; (-): favours control group, (+): favours test group, p<0.05: statistically significant, MD: mean 
difference 
 Discussion of effects of herbal medicines on immunity after surgical resection in colorectal 4.7.2
cancer 
Surgery is the primary treatment for loco-regional CRC (Saif et al., 2006). Also, up to 76.6% of 
patients who have distant metastasis of CRC receive surgical resection of the primary tumour (Lin et 
al., 2011).  Although surgical removal of the primary tumour has a curative intent or aims to stop 
disease progression, the surgical procedure itself and the physical and psychological response to the 
surgical stress could suppress the patient’s immunity, especially the CMI. This immunosuppression 
response during the peri-operative period is one of the important risk factors for inducing 
micrometastases that can initiate new metastases. Thus, up-regulating the patient’s immunity, 
especially the CMI, during the peri-operative period may be critical to long-term cancer prognosis 
(Neeman & Ben-Eliyahu, 2012). 
In these three studies, the investigators observed the suppression of CMI induced by the surgical 
procedure. They found the suppression of NK cell activity and T cell subsets in the test groups were 
less than in the control groups after the operation. The NK+ cells, CD4+ cells and the ratio of 
CD4+/CD8+ recovered more quickly in the HM groups than in the CMT groups. These outcomes 
suggested that the HM interventions in each of these studies may have up-regulated CMI during the 
peri-operative period and post-operative period. The results were consistent with other studies (Ogawa 
et al., 2000; Neeman et al., 2012). 
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 Herbal medicine alone as adjuvant therapy for stage II/III colorectal cancer patients after 4.7.3
radical surgery 
Three studies made comparisons between HM interventions and control groups that received no 
treatment or placebo in stage II and III CRC patients who had received radical surgery. The outcomes 
included overall survival (OS) and disease-free survival (DFS). 
In Shen et al. (2003) (n=101), the authors investigated the effect of Changbian capsule on the three-
year survival rate compared to patients who received no specific treatment as the control group. The 
data were treated as ITT (Table E1 in Appendix E). The follow-up rates for the test group and control 
group were 78.43% and 80.00% respectively (Shen et al., 2003). The three-year survival rate for 
Dukes B patients was 74.07% (20/27) for the test group and 76.92% (20/26) for the control group (RR 
0.96, 95% CI [0.71, 1.31], p=0.81); for Dukes C it was 70.38% (17/24) for the test group and 41.67% 
(10/24) for the control group (RR 1.70, 95% CI [0.99, 2.91], p=0.05). Therefore, the three-year 
survival rate was significantly higher in the test group than in the control group in these Dukes C 
patients. 
The result of the three-year disease-free survival (DFS) showed there was no significant difference 
between the two treatment groups (all stages) (RR 1.31, 95% CI [0.96, 1.78], p=0.09). The stratified 
analysis found the Changbian capsule treatment significantly prolonged the three-year DFS for Dukes 
C patients (RR 2.13, 95% CI [1.14, 3.96], p=0.02), but no benefit was found for Dukes B patients (RR 
0.96, 95% CI [0.69, 1.35], p=0.83). No obvious adverse reactions due to Changbian capsule were 
found (Shen et al., 2003). 
Yang et al. (2007) studied the influence of Quxie Capsule on median time to progression (TTP), KPS, 
and immunity, in 23 participants who received Quxie Capsule for 6 months consecutively. The control 
group (n=21) only received an identical placebo capsule for the same period (Table E1 in Appendix 
E). All participants were TNM II or III. They were followed up for three years. The results showed a 
statistically significant improvement (MD 12.5, 95% CI [5.75, 19.22], p=0.0003) in the mean TTP for 
the test group (31.500 ± 7.778 months) compared with the control group (19.000 ± 13.856 months). 
After six months treatment, the test group showed greater improvement in B-lymphocytes (MD 2.54, 
95% CI [0.92, 4.15], p=0.02) compared with the control group, as well as an improved CD4 to CD8 
ratio (MD 0.44, 95% CI [0.03, 0.86], p=0.04). There was no difference between treatment groups in 
CD3+ (MD 1.03, 95% CI [-8.78, 10.84], p=0.84), CD4+ (MD 2.62, 95% CI [-6.46, 11.70], p=0.57), 
CD8+ (MD 2.57, 95% CI [-3.07, 8.22], p=0.37), NK cell activity (MD -2.64, 95% CI [-9.26, 3.98], 
p=0.43), or in KPS scores (MD 1.23, 95% CI [-2.39, 4.86], p=0.50). No obvious adverse events (AEs) 
due to Quxie Capsule were found (Yang et al., 2007). 
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Torisu et al. (1990) studied 111 post-surgical participants (Dukes C) who were randomly allocated 
with 56 in the test group and 55 in the control group. The test group received polysaccharide K 
powder. The control group received an identical placebo powder. The DFS and OS were examined and 
compared during the eight years follow-up (Table E1 in Appendix E). The Kaplan-Meier curves 
showed that the test group had higher disease-free survival (DFS) and overall survival (OS) than the 
control group, and the authers claimed that the differences between the two groups were significant 
(p<0.05), but the authors did not provide the numeric values (Torisu et al., 1990). 
 Discussion of results for herbal medicine versus placebo or no treatment post-surgery 4.7.4
These three studies compared different HMs to placebo or no treatment (Shen et al., 2003; Yang et al., 
2007; Torisu et al., 1990). The results showed that the HMs significantly improved DFS and OS for 
Dukes C CRC patients who were post curative surgery. The results were consistent with a study that 
analysed data from a ten-year follow-up case-control study which found that HM had benefit for 
overall survival for stage III CRC patients after surgery compared with the surgical treatment alone 
(McCulloch et al., 2011). In a large international RCT, adjuvant FOLFOX4 was found to only benefit 
overall survival and disease-free survival in stage III CRC patients after radical surgery. However, the 
benefit was unclear in stage II patients (Andre et al., 2009). 
In the above studies, Shen et al. (2003) found a similar effect with improved disease-free survival for 
the sub-group of Dukes C patients only, and the study by Torisu et al. (1990) reported improved 
overall survival in Dukes C patients. Yang et al. (2007) found improved TTP for HM treatment of 
stage II/III CRC patients post radical surgery. However, these results were based on single studies of 
different HMs. These HMs require further evaluation in future studies. 
 Herbal medicine vs. chemotherapy or supportive care for advanced colorectal cancer 4.7.5
Four RCTs provided data for comparisons between Chinese HMs and CMT or supportive care in 
advanced CRC (ACRC). 
Two studies (Xion et al., 2003; Yang et al., 2005) examined the efficacy of Changfukang capsule 
compared with 5-FU in ACRC treatment (Table E1 in Appendix E). The pooled results at the end of 
treatment showed there was no statistical difference in tumour response rate (tRR) between the 
treatment groups (RR 1.15, 95% CI [0.74, 1.78], p=0.55, I²=0%). For carcinoembryonic antigen 
(CEA), there was no difference between groups (MD -9.61, 95% CI [-27.74, 8.51], p=0.30, I²=25%). 
After treatment, the test group was significantly higher in KPS scores than the control group (MD 
22.46, 95% CI [19.81-25.11], p<0.00001, I²=27%). 
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Mutouhui Glycoside Pill (an extract of Patrinia heterophylla root) was compared with CMT (5-
FU+LV) for ACRC (Wang et al., 2000). The outcomes include: tRR, one-, two- and three-year OS, 
KPS, T cell subsets and CEA (Table E1 in Appendix E). There was no significant difference between 
the two treatment groups in tRR (RR 0.67, 95% CI [0.30, 1.48], p=0.32); one-year OS (RR 0.96, 95% 
CI [0.68, 1.36], p=0.82); two-year OS (RR 0.90, 95% CI [0.57, 1.42], p=0.65); or three-year OS (RR 
0.82, 95% CI [0.43, 1.59], p=0.56). The incidence of increase in KPS scores of 10 points or more was 
significantly higher in the CHM group than in the CMT group (RR 4.45, 95% CI [1.84, 10.74], 
p=0.0009). The immune function measures showed no significant differences between the two groups 
before treatment but were significantly increased in the CHM group after treatment (Table 4.4). CEA 
readings were not significantly different between the two arms before treatment (MD 3.40, 95% CI [-
17.88, 24.68], p=0.75) or after treatment (MD 5.10, 95% CI [-15.69, 25.89], p=0.63). 
Table 4.4: Wang et al. (2000) comparison of T cell subsets and NK cell between test and control 
group 
Cell type Before treatment After treatment 
NK cell activity (%) 3.00 [-1.32, 7.32], p=0.17 14.00 [10.08, 17.92], *p<0.00001 
CD3+ (%) -1.50 [-4.88, 1.88], p=0.38 8.2 [5.31, 11.09], *p<0.00001 
CD4+ (%) -3.30 [-7.10, 0.50], p=0.09 7.80 [3.58, 12.02], *p=0.0003 
CD8+ (%) 0.60 [-2.08, 3.28], p=0.66 -5.6 [-7.53, -3.67], *p<0.00001 
*statistically significant; (-): favours control group, (+): favours test group, p<0.05: statistically significant, MD: mean 
difference. 
Hou et al. (2009) investigated the efficacy of Fuzhengxiaoai Decoction I in ACRC patients who could 
not accept chemotherapy due to poor performance status. The control group only received the best 
supportive care. All patients were followed up for two to ten months. Outcome measures were tRR, 
OS, QoL and CHM toxicity (Table E1 in Appendix E). There was no significant difference between 
groups for tRR. The median overall survival was not significantly different between the two groups 
(test group 6.5 months vs. control group 5.5 months p>0.05). For KPS score, the control group was 
higher at baseline and there was no difference between groups after treatment. However, in the test 
group, the KPS score was not significantly different before treatment versus after treatment (MD 1.14, 
95% CI [-1.57, 3.85], p=0.41), but it significantly decreased in the control group (MD -7.73, 95% CI [-
2.06, -13.40], p=0.008). The AEs due to Fuzhengxiaoai Decoction I were mild with two cases of 
vomiting reported, and no serious AEs observed. 
 Discussion of Chinese herbal medicine vs. chemotherapy or supportive care 4.7.6
The two CHM tablets (Changfukang capsule, Mutouhui Glycoside Pill) did not demonstrate greater 
benefits in improved tRR, decreased serum CEA, or prolonged overall survival for ACRC compared 
with 5-FU regimens. But they appeared not to be significantly inferior to the 5-FU regimens in treating 
ACRC, and they improved ACRC patients’ KPS which is correlated with improvement of quality of 
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life (QoL) (Granda-Cameron et al., 2008). Patients in the Mutouhui Glycoside Pill group also showed 
better immune status than patients in the chemotherapy group. 
These CHM treatments may be an option for ACRC patients who are intolerant of chemotherapy. In 
the terminal stage of ACRC, alleviation of cancer symptoms and maintaining or improving quality of 
life (QoL) are treatment priorities. In terms of KPS, all the CHMs showed improvement relative to the 
controls. Therefore, further studies in advanced and terminal stage patients should be considered. 
 Javanica oil emulsion versus chemotherapeutic drugs for liver metastasis 4.7.7
In one study, CRC patients who had liver metastasis were treated with transcatheter arterial 
chemoembolization (TACE). In the test group, Javanica oil emulsion was used alone, whereas a 
combination of chemotherapeutic drugs (oxaliplatin, 5-FU and pirarubicin) was used in the control 
group. Patients in both groups had the procedure an average of 2.5 times (Table E1 in Appendix E). 
The results showed an improvement of KPS scores of ten points or more was significant in favour the 
test group compared with the CMT control group (RR 2.00, 95% CI [1.19, 3.36], p=0.009). The 
incidence of medium to severe post-interventional symptoms were significantly lower in the test group 
compared to the control group: fever (over 38 ºC) (RR 0.50, 95% CI [0.31, 0.80], p=0.004); abdominal 
pain (needing treatment) (RR 0.42, 95% CI [0.22, 0.81], p=0.009); and nausea and vomiting (over 3 
times/day) (RR 0.38, 95% CI [0.21, 0.67], p=0.0008). Neither tumour response rate (tRR) nor overall 
survival (OS) were reported (Zhang & You, 2008). 
 Discussion of Javanica oil emulsion 4.7.8
TACE is a medical procedure that restricts a tumour's blood supply and is commonly used for liver 
tumour treatment (Lo et al., 2002). Javanica oil is extracted from Brucea javanica seed. Its bioactive 
components are oleic acids and linoleic acids. Javanica oil emulsion has been found to reverse 
multidrug resistance and inhibit DNA topoisomerase in several sensitive and resistant tumour cells 
such as K562/A02 (drug resistant human erythroleukemia cells), MCF 7/ADM (drug resistant human 
breast adenocarcinoma cells) and KB/VCR (drug resistant human oral squamous carcinoma cells) in 
vitro (Tang et al., 2001). In China, Javanica oil emulsion has been used by by intravenous drip or 
TACE for the treatment of several cancers including liver cancer, stomach cancer, lung cancer, 
esophageal cancer, bladder cancer, ovarian cancer and prostate cancer (Zhao et al., 2014). 
Nearly 50% of metastasis in CRC is in the liver and TACE is an alternative therapy for patients whose 
liver tumours are unresectable, or show no reponse to systemic chemotherapy or to local liver 
therapies as adjuncts to systemic chemotherapy (Belinson et al., 2012). The severity of post-
interventional symptoms induced by CMTs used in TACE is one of the important factors affecting 
quality of life. According to Zhang (2008), the Javanica oil emulsion TACE for CRC with liver 
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metastasis showed a significant alleviation of post-interventional symptoms, and eventually elevated 
KPS. In other RCTs, Javanica oil emulsion TACE was reported to be not inferior to TACE using 
conventional drugs, in terms of tumour response rate (Tian et al., 2008) and overall survival (Yang et 
al., 2011) in treating primary liver tumours. It appears that Javanica oil emulsion is a potential 
surrogate for conventional drugs for primary or secondary liver tumours, especially for patients who 
are older or cannot tolerate conventional drugs. Large RCTs are needed to test these findings and 
determine the long-term toxicity profile of Javanica oil emulsion TACE. 
4.8 Results for Group 2: Herbal medicine plus chemotherapy vs. chemotherapy 
In this section, all the 79 included studies employed a Chinese HM intervention (CHM) in 
combination with chemotherapy (CMT) as the test group, and the control group received the same 
CMT intervention. Four of the 79 studies (Meng et al., 2003; Zeng et al., 2010; Wang et al., 1999; Li 
et al., 1999) employed local CMT, rather than systemic CMT administered by intravenous drip. 
Therefore, these four studies were analysed separately below. For the characteristics of the group 2 
studies see Table E2 in Appendix E. 
 Chinese herbal medicine combined with local delivery of chemotherapy 4.8.1
In one RCT, participants in the test group were treated with a CHM decoction (500 mL) mixed with 5-
FU (20mg/kg) via enema and the mixture was retained in the rectum for two hours, once a day for 
seven days before surgical resection. Paticipants in the control group were treated with 5-FU 
(20mg/kg) combined with 500 mL saline via enema using the same method (Table E2 in Appendix E). 
Histological studies of the resected tumours, tumour response rate (tRR) of unresectable tumours, 
immune response, and one-, three-, and five- year overall survival (OS) were reported. According to 
the Chinese Guidelines for the Diagnosis and Treatment of Commonly Encountered Malignancies 
(The Ministry of Health PRC, 1991), the histological appearance of resected tumour tissues is 
classified from grade 1 to 3. When more immune cells appear in tissues surrounding the tumour, a 
higher grade is awarded. Thirty-five out of 46 participants in the test group, and 31 out of 40 
participants in the control group had their tumours resected by surgery. This histological study found 
that 18 out of 35 resected tumour tissue samples were classed as grade 3 in the test group compared 
with five out of 31 in the control group. This difference was significant (RR 3.19, 95% CI [1.34, 7.57], 
p=0.009) (Wang et al., 1999). 
There was no statistical difference between the two treatment groups for one-year overall survival 
(OS) (RR 1.13, 95% CI [0.70, 1.80], p=0.62), three-year OS (RR 1.16, 95% CI [0.63, 2.15], p=0.64), 
and five-year overall survival (OS) (RR 1.16, 95% CI [0.44, 3.06], p=0.77). The ratio of CD4+ to 
CD8+ and the NK cell activity were significantly increased in the test group compared with the control 
group. There were 20 participants whose tumours were unresectable, 11 in the test group and none in 
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the control group. The tumour response rate was not significantly different between the two groups 
(RR 2.05, 95% CI [0.51, 8.16], p=0.31). The authors concluded that the pre-operation combination 
enema treatment improved the participants’ immunity, and would reduce the risk of tumour residue 
spreading during the operation. 
Meng et al. (2003) investigated the effect of CHM combined with chemo-therapeutic drugs in TACE 
for the treatment of CRC liver metastasis. The outcomes for tumour response rate (tRR), quality of life 
(QoL), side effects, one-, two-, and three- year overall survival (OS), and disease progression (i.e. the 
number of other organs that showed further metastasis during the study period) were assessed (Table 
E2 in Appendix E). The results found there was no significant difference between the two groups for: 
tRR (RR 1.90, 95% CI [0.55, 6.54], p=0.31); one-year OS (RR 1.02, 95% CI [0.67, 1.56], p=0.92); 
two-year OS (RR 1.27, 95% CI [0.54, 2.97], p=0.59); and three-year OS (RR 1.43, 95% CI [0.23, 
7.61], p=0.68). The median OS was 18.6 months for the test group and 14.3 months for the control 
group (no range data available). The European Organisation for Research Treatment of Cancer 
(EORTC) quality of life questionnaire QLQ-C30 was used. The total improvement rate was 40.5% for 
the test group, and 31.8% for the control group but it was not possible to test the statistical 
significance. For disease progression, in the test group, metastases in other organs were observed in 
two participants; in the control group, five participants showed metastasis occurrence in other organs 
(Meng et al., 2003). 
The combination of TACE treatment appeared to produce a better outcome in terms of quality of life, 
fewer metastases occurring during the trial, and extended median overall survival for the test group 
compared with the control group. However, there was no statistically significant benefit for improved 
tumour response rate or for one-year, two-year, or three-year overall survival. For each of these 
measures there was a trend towards improvement but the small sample size may have resulted in a lack 
of statistical power. 
Zeng et al. (2010) investigated an oral CHM decoction combined with 5-FU plus cisplatin 
intraperitoneal hyperthermic perfusion chemotherapy for post-operation ACRC. The control group 
only received the intraperitoneal hyperthermic perfusion chemotherapy. The outcomes for quality of 
life (QoL), adverse events (AEs), immune response, and one-year- and three-year overall survival 
(OS) were reported (Table E2 in Appendix E). For QoL, 34 out of 54 participants in the test group 
gained more than 10 points on KPS compared with 14 out of 50 in the control group (RR 2.38, 95% CI 
[1.47, 3.86], p=0.0004). The HM intervention significantly alleviated the following AEs compared 
with the control group: neutropenia (RR 0.42, 95% CI [0.23, 0.77], p=0.005); thrombocytopenia (RR 
0.11, 95% CI [0.04, 0.35], p=0.0001); diarrhoea (RR 0.46, 95% CI [0.26, 0.82], p=0.009); nausea and 
vomiting (RR 0.46, 95% CI [0.28, 0.75], p=0.002); and neurotoxicity (RR 0.45, 95% CI [0.20, 1.02], 
p=0.05). The addition of the CHM significantly improved CMI as measured by the ratio of CD4+ to 
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CD8+ cells (MD 0.32, 95% CI [0.23, 0.41], p<0.00001); and NK cell activity (MD 9.40, 95% CI 
[6.04, 12.76], p<0.00001), compared to the control group. The addition of the CHM also significantly 
prolonged the one-year OS (RR 2.67, 95% CI [1.25, 5.68], p=0.01) and the three-year OS (RR 3.26, 
95% CI [1.10, 9.64], p=0.03), compared to the control group (Zeng et al., 2010). 
The study by Li and Li (1999) enrolled 96 patients who had advanced CRC. All patients received 5-
FU intraperitoneal infusion plus mitomycin intravenous infusion. The test group of 60 patients 
additionally received a CHM decoction via retention enema. The outcomes of clinical symptoms, tRR, 
and one-year, two-year, and three- year OS were observed after 10 weeks of treatment (Table E2 in 
Appendix E). Clinical symptoms (abdominal ache, tenesmus, and sepsis) were alleviated for 73.3% of 
the test group, and 47.2% of the control group. The tRR was not statistically different between groups 
(RR 1.54 [0.98, 2.44], p>0.050, but the OS was significantly better in the test group at one-year 
(RR1.49 [1.11, 1.99], p<0.01), two-years (RR 2.03 [1.28, 3.22], p<0.01), and three-years (RR1.93 
[1.04, 3.61], p<0.05) (Li & Li, 1999). 
 Discussion of local chemotherapy plus Chinese herbal medicine 4.8.2
Three types of local administration of chemotherapeutic agents combined with CHM interventions 
were compared to local chemotherapy alone: intraperitoneal hyperthermic perfusion chemotherapy, 
TACE and enema. Both intraperitoneal perfusion chemotherapy and TACE have been reported to 
improve oncological outcomes in CRC management (Belinson et al., 2012; Sloothaak et al., 2014). 
The combination treatments improved quality of life in all four studies, but there were no differences 
in tumour response rate for test groups compared with the control groups in three studies. There were 
inconsistent results for overall survival (OS), with two studies reporting the combination treatments 
prolonged OS, but the other two studies found no difference in OS between the two groups. Factors 
such as stage of the disease, integrative intervention methods, and selection of chemotherapy agents 
may have influenced the outcomes. In the two studies that investigated local administration of HM via 
enema, the treatments appear to have relieved local symptoms and increased the number of immune 
cells surrounding the tumour tissues. The available information on these therapeutic methods is 
limited, so further studies are needed. 
 Chinese herbal medicine combined with systemic chemotherapy  4.8.3
The 75 studies of HM combined with systemic chemotherapy all employed Chinese HM (CHM) 
(Table E2 in Appendix E). Studies were grouped for meta-analysis according to the major outcomes as 
follows: 
• Tumour response (48 assessible studies) 
• The bio-marker, carcinoembryonic antigen (CEA) (9 assessible studies) 
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• Survival rate (31 assessible studies) 
• Quality of life (53 assessible studies) 
• Effect on adverse events associated with chemotherapy (47 assessible studies) 
• Effect on immunity (26 assessible studies) 
Within each of these main outcomes, studies were further sub-grouped for meta-analysis according to 
the chemotherapy regimen or other factors as appropriate. Meta-analysis methods were described in 
Chapter 3. 
4.8.3.1 Effect on tumour response rate and complete response 
All studies that reported numerical results for tumour response rate (tRR) and complete response (CR) 
were meta-analysed as a whole group. They were then divided into sub-groups based on the 
chemotherapy regimen and whether the patients had not been previously treated with CMT or whether 
they had previously received CMT since these factors were likely to influence tumour response. The 
bio-marker CEA, which was reported in nine studies, was analysed separately. 
In total, 48 studies reported and evaluated tRR. Forty-two of these studies used the WHO solid tumour 
response criteria (Miller et al., 1981), which used the following categories: complete response (CR), 
partial response (PR), stable disease (SD), and progressive disease (PD). The other six studies (Qin & 
Zhou, 2011; Wang et al., 2011; Wang, 2013; Wang & Peng, 2012; Zeng et al., 2013; Zhang et al., 
2010) used the Response Evaluation Criteria in Solid Tumours (RECIST) criteria, which uses similar 
categories (Park et al., 2003) so these were combined. In the palliative treatment setting, the tRR is an 
important outcome measurement that is used to assess the effectiveness of the anti-tumour treatment. 
The tRR is the sum of the CR plus PR, and was analysed as dichotomous data. Two sub-groups were 
based on CMT type: oxaliplatin group and non-oxaliplatin group. 
When the Risk Ratio (RR) is more than 1 it favours the test group. The RR translated to a percentage, 
(RR-1) % provides the relative improvement rate (IR), which is also called the relative risk reduction 
(RRR). The Risk Difference (RD) is the difference in risk of the event in the test and control groups, 
which is also called ‘absolute risk difference’. 
Table 4.5: Meta-analysis results of tumour response rate for herbal medicine combined with 
systemic chemotherapy (48 studies)  
Outcomes No. studies 
(participant 
No.) 
RR (95% CI, FE), I²; 
IR% 
RD (95% CI, FE), I² 
Total group (tRR) 48 (3487) 1.33 [1.23, 1.45], 
*p<0.00001, I²=0%; 33%. 
0.12 [0.09, 0.15], *p<0.00001, 
I²=0% 
Total group complete 
remission (CR) 
47 (3367) 1.81 [1.32, 2.47], 
*p=0.0002, I²=0%; 81%. 
0.02 [0.01, 0.03], *p=0.005, I²=0% 
   
75 
Outcomes No. studies 
(participant 
No.) 
RR (95% CI, FE), I²; 
IR% 
RD (95% CI, FE), I² 
Oxaliplatin regimens sub-
group (tRR) 
42 (3083) 1.31 [1.20, 1.42], 
*p<0.00001, I²=0%; 31%. 
0.11 [0.08, 0.14], *p<0.00001, 
I²=0% 
Oxaliplatin regimens sub-
group (CR) 
41 (2963) 1.80 [1.29, 2.51], 
*p=0.0005, I²=0%; 80%. 
0.01 [0.00, 0.03], *p=0.03, I²=0% 
Non-oxaliplatin regimens 
sub-group (tRR) 
6 (404) 1.73 [1.31, 2.28], 
*p<0.0001, I²=0%; 73%. 
0.19 [0.10, 0.27], p<0.0001, I²=0% 
Non-oxaliplatin regimens 
sub-group (CR) 
6 (404) 2.31 [1.01, 5.29], *p=0.05, 
I²=0%; 131%. 
0.04 [0.00, 0.08], *p=0.03, I²=0% 
tRR (previously untreated 
patients) 
7 (475) 1.25 [1.01, 1.55], *p=0.04, 
I²=0%; 25%. 
0.10 [-0.01, 0.18], *p=0.03, I²=0% 
CR (previously untreated 
patients) 
5 (281) 1.98 [0.81, 4.87], p = 0.13, 
I2 = 0% 
0.02 [-0.02, 0.06], p=0.30, I²=0% 
tRR (previously treated 
patients) 
3 (188) 1.65 [0.94, 2.91], p=0.08, 
I²=0%. 
0.14 [0.02, 0.25], *p=0.02, I²=0% 
tRR (Aidi injection) 2 (191) 1.31 [0.91, 1.88], p=0.15, 
I²=0%. 
0.11 [-0.03, 0.25], p=0.12, I²=0% 
tRR (Kang’ai injection) 2 (103) 1.07 [0.71, 1.61], p=0.76, 
I²=0%. 
0.03 [-0.16, 0.22], p=0.76, I²=0%. 
tRR (Jianpi huoxue 
decoction) 
2 (142) 1.16 [0.75, 1.82], p=0.50, 
I²=0%. 
0.06 [-0.11, 0.23], p=0.49, I²=0%. 
CR (Jianpi huoxue 
decoction) 
2 (142) 0.74 [0.12, 4.37], p=0.74, 
I²=0%. 
-0.01[-0.08, 0.06], p=0.75, I²=0%. 
*statistically significant; RR: risk ratio; IR: improvement rate; RD: risk difference; FE: fixed effect; I²: the proportion of 
heterogeneity. 
The 48 studies that reported on tRR included 3,487 participants who were at various stages of the 
disease and had received different chemotherapy regimens. The pooled result for the tRR (measured as 
RR and RD) showed that integration of CHM with chemotherapy produced a significant improvement 
in the tRR (RR 1.33, 95% CI [1.23, 1.45), I²=0%) without heterogeneity (Table 4.5; Figure 4.3). The 
relative improvement rate (IR) between groups was 33% in favour of the combined therapy groups 
and there was absolute increase of 12% in the incidence of tRR in the combined therapy groups (RD 
0.12, 95% CI [0.09, 0.15], I²=0%) without heterogeneity. In other words, we can be 95% sure that 
between 9% and 15% (average 12%) of the people who received combination therapy experienced 
increased tRR.   
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Figure 4.3: Forest plot of risk ratio for tumour response rate (total group, n=48) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The funnel plot of tRR for the 48 studies showed some asymmetry, which suggests that more positive 
small studies were published than small negative studies. But there were only two of these small 
studies so this is unlikely to have affected the overall result (Figure 4.4). 
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Figure 4.4: Funnel plot of 48 studies that reported tumour response rate (total group) 
In the 47 studies, with 3,367 participants, that reported data for complete response rate (CR), nine 
studies reported zero events in both groups and therefore could not contribute to the meta-analysis 
result. In the remaining 38 studies, there was a significant increase in CR in favour of the combination 
therapy groups (RR 1.81, 95% CI [1.32, 2.47], I²=0%) without heterogeneity. The relative 
improvement rate was 81% and there was an absolute improvement in CR of 2% in the combination 
therapy groups (RD 0.02, 95% CI [0.01, 0.03], I²=0%) (Table 4.5; Figure 4.5). The funnel plot for all 
47 studies was symmetric (Figure 4.6) indicating that the risk of publication bias was low.  
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Figure 4.5: Forest plot of risk ratio for complete response (total group, n=47) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 4.6: Funnel plot of 47 studies that reported complete response (total group) 
Sub-group analyses 
There was variation in the CMT regimens used in these studies. These CMT regimens can be 
classified as oxaliplatin regimens such as FOLFOX and non-oxaliplatin regimens, such as the 5-FU-
based older generation CMTs. Evidence from large international trials have found that oxaliplatin 
regimens achieved higher tRR than those of non-oxaliplatin regimens (de Gramont et al., 2000).  
Therefore, data was re-synthesized into two subsets: chemotherapy that employed oxaliplatin 
regimens, and non-oxaliplatin regimens. Among these studies, some provided separate data for 
participants who had been previously treated with chemotherapy and those who were previously 
untreated. Since the response to chemotherapy is known to be better in previously untreated 
participants, meta-analyses were conducted for these sub-groups where possible. In addition, when 
more than one study tested the same manufactured CHM intervention, data for these studies were 
pooled as sub-groups. 
Oxaliplatin group 
In the 42 studies (n=3,083) that used oxaliplatin regimens, one did not report CR (Cao et al., 2011), 
the test groups showed significantly improved tRR (RR 1.31, 95% CI [1.20, 1.42], I²=0%) (Figure 4.7) 
and CR (RR 1.80, 95% CI [1.29, 2.51], I²=0%) (Figure 4.8) compared to the control groups, without 
heterogeneity (Table 4.5). 
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Figure 4.7: Forest plot of risk ratio for tumour response rate (oxaliplatin group, n=42) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 4.8: Forest plot of risk ratio for complete response (oxaliplatin group, n=41) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The Funnel plot for tRR (Figure 4.9) was similar to that of the total group (Figure 4.6). The funnel plot 
was symmetric for CR (Figure 4.10).  
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Figure 4.9: Funnel plot of 42 studies that reported tumour response rate (oxaliplatin group) 
 
Figure 4.10: Funnel plot of 41 studies that reported complete response (oxaliplatin group) 
Non-oxaliplatin group 
The six studies (n=404) that employed a non-oxaliplatin regimen also showed significantly improved 
tRR (RR 1.73, 95% CI [1.31, 2.28], I²=0%) and CR (RR 2.31, 95% CI [1.01, 5.29], I²=0%) in favour 
of the integrated CHM and chemotherapy groups compared with the control groups without 
heterogeneity (Table 4.5; Figure 4.11 and 4.12). 
 
Figure 4.11: Forest plot of risk ratio for tumour response rate (non-oxaliplatin group, n=6) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.12: Forest plot of risk ratio for complete response (non-oxaliplatin group, n=6) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Previously treated/previously untreated colorectal cancer patients 
Previously treated ACRC patients have been found to be less responsive to current first-line settings of 
chemotherapy (Giantonio et al., 2007). Seven studies that reported tRR defined the participants as 
previously untreated. Three studies reported the tRR of previously treated participants who had 
ACRC. 
The pooled tRR of the previously untreated category (seven RCTs) was significantly different between 
the treatment groups and the control groups (RR 1.25, 95% CI [1.01, 1.55], I²=0%, n= 475) without 
heterogeneity in favour of the CHM plus chemotherapy groups (Figure 4.13). CR data was available 
for six of these studies of which one had zero events in both groups. The meta-analysis of the five 
studies showed that the difference between groups was not significant (RR 1.98, 95%CI [0.81, 4.87], p 
= 0.13, I2 = 0%, n=281) (Figure 4.14). 
 
Figure 4.13: Forest plot of risk ratio for tumour response rate (previously untreated colorectal 
cancer group, n=7) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.14: Forest plot of risk ratio for complete response (previously untreated colorectal 
cancer group, n=6) 
control: chemotherapy alone; experimental: HM + chemotherapy 
In the previously treated category, the tRR was not significantly different between the treatment 
groups (RR 1.65, 95% CI (0.94, 2.91), p=0.08, I²=0%) (Figure 4.15), but the data were based on only 
three RCTs (n=188 particpants) and the result for the RD showed a significant effect (RD 0.14, 95% 
CI [0.02, 0.25], p=0.02, I²=0%) (Table 4.5). There were insufficient data for meta-analysis of CR. 
 
Figure 4.15: Forest plot of risk ratio for tumour response rate (previously treated colorectal 
cancer group, n=3) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Manufactured CHM products  
The tRR of Aidi injection, Kang’ai injection, and Jianpi huoxue decoction combined with an 
oxaliplatin regimen were reported in two studies each. The pooled tRR of the trials of these three HMs 
showed no differences between the treatment and control groups. For CR, there was no difference 
between groups for Jianpi huoxue decoction but there were insufficient data for meta-analysis of CR 
for the Aidi injection and Kang’ai injection groups (Table 4.5; Figure 4.16a, b, c, d).  
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Figure 4.16a: Forest plot of risk ratio for tumour response rate (Jianpi huoxue herbs, n=2) 
 
Figure 4.16b: Forest plot of risk ratio for tumour response rate (AIDI injection, n=2) 
 
Figure 4.16c: Forest plot of risk ratio for tumour response rate (Kang'ai injection, n=2) 
 
Figure 4.16d: Forest plot of risk ratio for complete response (Jianpi huoxue herb, n=2) 
4.8.3.2 Discussion of tumour response rate results 
The meta-analysis found that chemotherapy, including oxaliplatin and non-oxaliplatin groups, 
combined with HMs significantly improved the tRR in CRC compared with the chemotherapy alone 
(Table 4.5). The review by Zhong et al. (2012) reported similar meta-analysis results. 
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In oxaliplatin and non-oxaliplatin groups, most of the available data were for oxaliplatin regimens, of 
which FOLFOX4 was the most common. There was a significant absolute increase of 11% in tRR in 
the combination therapy groups based on 42 RCTs with 3,070 participants with zero heterogeneity in 
the result. In the non-oxaliplatin chemotherapy sub-group, there were six RCTs (404 participants) in 
the pooled analysis and this also showed a significant increase in tRR in the combination therapy 
groups with an absolute difference of 4% between groups. 
In addition, the meta-analysis found that the combination treatment significantly improved the CR in 
the total group by 2% (RD 0.02, 95% CI [0.01, 0.03], I²=0%). In the sub-group of oxaliplatin 
regimens, the CR also showed a significant but small increase (1%) based on 41 RCTs, while the 
difference in the non-oxaliplatin regimens was much larger at 19% but this was based on only six 
studies. Overall incidence of CR was low, except in one study (Wang et al., 2000). When this study 
was excluded, the RD dropped to a marginal 4% (RD 0.04, 95% CI [-0.00, 0.08]) in the non-
oxaliplatin group. The improvement of CR may be more meaningful than the tRR, in terms of 
translating to OS. For more discussion of the relationship between the tRR and OS, see section 4.8.3.6 
(Discussion of results for survival and relationship with tumour response) below. 
Objective tumour response is an important outcome in ACRC therapy and has been reported to have 
improved with advances in chemotherapy in the last two decades. Monofluorouracil therapy only had 
a 10% response rate for ACRC (Piedbois et al., 1994), but bimonthly high-dose leucovorin and 
fluorouracil bolus plus continuous infusion achieved 32.6% tumour response (de Gramont et al., 
1997). Since irinotecan and oxaliplatin have became available in the last decade, several RCTs have 
demonstrated that 5-FU plus irinotecan or oxaliplatin elevated the tRR into the range 31% to54% 
(Hind et al., 2008). Despite the improved tRR with current first-line chemotherapy compared with the 
older generation chemotherapy, the CR improvement was still small (1.4% vs. 0.5%) (de Gramont et 
al., 2000). 
The meta-analysis results in this review have shown the combination of CHM treatment and 
chemotherapy improved tRR with low heterogeneity. The funnel plot tests showed mild asymmetry 
indicating that problematic publication bias was unlikely. Animal studies have also demonstrated a 
better suppression rate of tumour growth when HM was combined with 5-FU, compared to 
chemotherapy alone. This has been reviewed in Chapter 2 of the literature review (section 2.9.6). 
However, in the clinical studies, most of the CHMs were tested in the context of multi-CHM formulas, 
so it is difficult to determine which individual HMs were more or less effective. Identification of the 
potent HMs or the optimal groups of HMs that are most frequently used and effective in improvement 
of tRR is explored in Chapter 6. 
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4.8.3.3 Effect on carcinoembryonic antigen 
The carcinoembryonic antigen (CEA) results were treated as continuous data using mean difference 
(MD) with 95% interval. When the MD was negative, it was in favour of the combination groups. The 
CEA analysis, which pooled results from nine studies that included 651 participants who were at 
different stages of the disease, showed that the CHM interventions significantly reduced the CEA 
readings compared with the control groups (MD -3.97, 95% CI [-4.42, -3.52], I²=93%), but with 
considerable heterogeneity (Table 4.6; Figure 4.17a). 
Table 4.6: Meta-analysis results of carcinoembryonic antigen for herbal medicine combined with 
systemic chemotherapy (9 studies) 
Carcinoembryonic 
antigen (CEA) 
No. studies 
(participants) 
MD (95% CI, FE), I² 
Total group CEA 9 (651) -3.97 [-4.42, -3.52], *p<0.00001, I²=93% 
Palliative setting CEA 5 (387) -5.32 [-5.84, -4.80], *p<0.00001, I²=62% 
Adjuvant setting CEA 2 (133) 0.07 [-1.00, 1.13], p=0.90, I²=77% 
*statistically significant; MD: mean difference; FE: fixed effect; I²: the proportion of heterogeneity. 
Consequently, data were re-synthesized in two sub-groups: palliative therapy group (n=5) and 
adjuvant therapy group (n=2). Guo (1999) and Zheng (2011) included participants who had received 
either radical resection or palliative resection. Therefore, these studies were excluded from the sub-
group analysis. 
 
Figure 4.17a: Forest plot of risk ratio for carcinoembryonic antigen (total group, n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The pooled result for the palliative therapy group (5 studies) showed that the combination of HM 
significantly decreased the CEA level in serum (MD -5.32, 95% CI [-5.84, -4.80], I²=62%), with 
reduced heterogeneity (Table 4.6; Figure 4.17b). 
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Figure 4.17b: Forest plot of risk ratio for carcinoembryonic antigen (palliative setting, n=5) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Two studies were included in the adjuvant therapy group. The pooled result showed the CEA after 
treatment was not different between the two treatment groups, with reduced heterogeneity (Table 4.6; 
Figure 4.17c).  
 
Figure 4.17c: Forest plot of risk ratio for carcinoembryonic antigen (adjuvant setting, n=2) 
control: chemotherapy alone; experimental: HM + chemotherapy 
4.8.3.4 Discussion of carcinoembryonic antigen (CEA) results 
Carcinoembryonic antigen as a biomarker is not of value for screening detection of early CRC due to 
its low sensitivity and low specificity to asymptomatic early stage CRC, but it can assist in CRC 
diagnosis along with other diagnostic techniques. As a tool for assessing prognosis, for Dukes B or 
equivalent stage CRC patients, the pre-operational CEA test may provide independent prognostic 
information that could help in the management of the surgical procedure and inform the choice of 
future adjuvant therapies post-operation. When the CEA level fails to fall within six weeks post-
operatively, this may suggest recurrence or metastatic CRC. CEA has up to 80% sensitivity for 
detecting recurrence and metastasis of the disease. CEA is also used for surveillance of post-operative 
patients. In palliative therapy, CEA can help monitor the outcome of treatment and an increasing CEA 
level is mostly associated with progressive disease (Duffy et al., 2003). In general, an ACRC patient 
with a positive CEA response (reduction) during chemotherapy was likely to have a better outcome 
than one without a positive CEA response (Wang et al., 2001). In the trial by de Gramont et al. (2000), 
the prognostic factors in the univariate analysis showed the CEA was correlated with the PFS 
(p=0.0015) and OS (p=0.0001), but not the tRR (p=0.5406). 
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Overall, the combination treatment significantly reduced the CEA readings in serum compared to 
chemotherapy alone in the palliative setting. This positive result is consistent with the pooled result for 
overall survival in which the combination treatment demonstrated greater prognosis compared to the 
CMT alone. However, data were only available for five studies and the results still showed substantial 
heterogeneity. In the adjuvant setting studies there were no clear differences between the two 
treatments groups at the end of treatment. However, CEA is more relevant to long-term outcomes such 
as DFS and OS in the adjuvant setting, so the meta-analysis results are difficult to interpret. There is a 
need for long-term follow-up to detect recurrence or metastasis for post-radical surgery patients. The 
heterogeneity may be due to the base-line differences in the studies, and differences in laboratory 
methods and disease severity. 
4.8.3.5 Effect on measures of survival and disease progression 
Thirty-two studies compared overall survival (OS), median OS (mOS), disease-free survival (DFS) 
and/or time to progression (TTP) between the combination therapy groups and CMT groups. Overall 
survival time at the end-points of one-year, two-years, three-years and five-years were pooled in 
sixteen, seven, nine, and four studies respectively. Thirteen studies also reported median survival time 
(mOS). Only one study reported death rate during follow-up (Yang et al., 2008). Six studies reported 
DFS in the adjuvant therapeutic setting for stages I, II and III CRC participants. Five studies reported 
the outcome of TTP in the palliative setting for ACRC participants. 
Studies were grouped for each of these outcomes with sub-groups for adjuvant and palliative 
therapeutic settings. The data for OS and DFS at the end-points of one-year, two-years, three-years 
and five-years were treated as dichotomous data. The meta-analysis method was the same as that used 
for tRR.  
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Table 4.7: Meta-analysis results of time to event (survival data) for herbal medicine combined 
with systemic chemotherapy (32 studies) 
Outcomes No. 
studies 
(particip
ants) 
RR (95% CI, FE), I²; IR% RD (95% CI, FE), I² 
One-year OS 16 
(1265) 
1.06 [1.02-1.10], *p=0.005, 
I²=52%; 6% 
0.07 [0.04, 0.10], *p<0.0001, 
I²=47%. 
One-year OS 
(palliative setting) 
9 (696) 1.44 [1.25, 1.65], *p<0.00001, 
I²=0%;44% 
0.21 [0.14, 0.29], *p<0.00001, I²=0% 
One-year OS (adjuvant 
setting) 
5 (346) 1.01 [0.97, 1.06], p=0.63, 
I²=0%;1% 
0.01 [-0.03, 0.05], p=0.58, I²=0% 
Two-year OS 7 (494) 1.13 [1.02, 1.25], *p=0.02, 
I²=42%;13% 
0.11 [0.04, 0.18], *p=0.003, I²=37% 
Two-year OS 
(palliative setting) 
3 (231) 1.50 [1.18, 1.90], *p=0.0009, 
I²=0%;50% 
0.20 [0.09, 0.31], *p=0.0006, I²=0% 
Two-year OS (adjuvant 
setting) 
4 (263) 1.06 [0.94, 1.19], p=0.34, 
I²=15%;6% 
0.05 [-0.04, 0.14], p=0.30, I²=26% 
Three-year OS 9 (740) 1.27 [1.12, 1.42], *p<0.0001, 
I²=0%;27% 
0.14 [0.08, 0.20], *p<0.00001, I²=0% 
Three-year OS 
(palliative setting) 
2 (171) 2.01 [1.30, 3.10], *p=0.002, 
I²=0%;101% 
0.15 [0.06, 0.25], *p=0.002, I²=81% 
Three-year OS 
(adjuvant setting) 
5 (346) 1.18 [1.01, 1.37], *p=0.03, 
I²=0%;18% 
0.11 [0.01, 0.21], *p=0.03, I²=0% 
Five-year OS 4 (366) 1.38 [1.11, 1.73], *p=0.004, 
I²=0%;38% 
0.18 [0.08, 0.28], *p=0.0003, I²=0% 
Five-year OS (adjuvant 
setting) 
1 (83) 1.34 [0.84, 2.14], p=0.23;34% 0.13 [-0.08, 0.35], p=0.21 
Disease-free survival (DFS) 
One-year DFS 3 (142) 1.08 [0.99-1.18], p=0.09, I²=36%; 
8% 
0.08 [0.00, 0.16], *p=0.04, I²=34% 
Two-year DFS 2 (153) 1.23 [1.03, 1.47], *p=0.02, 
I²=0%;23% 
0.16 [0.03, 0.29], *p=0.02, I²=0% 
Three-year DFS 1 (70) 1.18 [0.90, 1.55], p=0.24; 18% 0.13 [-0.08, 0.33], p=0.22 
Five-year DFS 1 (70) 1.29 [0.84, 1.98], p=0.24; 29% 0.13 [-0.08, 0.34], p=0.23 
*statistically significant; RR: risk ratio; IR: improvement rate; RD: risk difference; FE: fixed effect; I²: proportion of 
heterogeneity. 
One-year overall survival 
The 16 studies that reported one-year OS included 1,265 participants at different stages of CRC. The 
pooled result showed a significantly improved one-year OS with 6% relative improvement rate (RR 
1.06, 95% CI [1.02, 1.10], I²=52%) when CHMs were combined with CMT interventions, with 
substantial heterogeneity (Table 4.7; Figure 4.18a). 
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Figure 4.18a: Forest plot of risk ratio for one-year overall survival (total group, n=16) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Sensitivity analysis showed that the tumour burden was substantially different between participants 
who have chemotherapy in the palliative setting compared with the adjuvant setting. Within a 
palliative setting, the participants’ tumours are usually at an advanced stage and unable to be removed 
by radical resection. Participants in an adjuvant setting are usually in the early stage of the disease and 
the tumours have been radically removed. Therefore, the outcome of overall survival was analysed 
separately for these two groups and data were re-synthesized in two sub-groups: palliative setting; and 
adjuvant setting. 
Nine studies were in the palliative settings for advanced CRC. The result showed that one-year OS 
was significantly improved in the combination groups compared with the control groups that used 
chemotherapy. Translated to a percentage, there was a 44% (RR 1.44, 95% CI [1.25, 1.65], I²=0%) 
greater chance of survival for one year when chemotherapy was combined with CHMs than for 
chemotherapy alone, with no heterogeneity. In absolute terms, 21% more participants survived for one 
year in the combination groups than in the control groups (RD 0.21, 95% CI [0.14, 0.29], p<0.00001, 
I²=0%) (Table 4.7; Figure 4.18b). 
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Figure 4.18b: Forest plot of risk ratio for one-year overall survival (palliative setting, n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Five studies were in the adjuvant settings for stage II or III CRC following resection. There was no 
statistically significant difference between the two treatment groups for one-year OS (Table 4.7; 
Figure 4.18c).
 
Figure 4.18c: Forest plot of risk ratio of one-year overall survival (adjuvant setting, n=5) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The funnel plot of the 16 studies that reported one-year OS was asymmetric (Figure 4.19.). There were 
more studies located in the positive zone, which indicates the possibility of reporting bias. 
 
Figure 4.19: Funnel plot of 16 studies that reported one-year overall survival 
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Two-year overall survival 
Seven studies reported two-year OS. Four hundred and ninety-six participants at different stages of the 
disease were involved. The result showed significantly improved two-year OS when CHMs were 
combined with the CMT interventions (RR 1.13, 95% CI [1.02, 1.25], I²=42%), with moderate 
heterogeneity (Table 4.7; Figure 4.20a). 
 
Figure 4.20a: Forest plot of risk ratio for two-year overall survival (total group, n=7) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Sensitivity analysis was undertaken. Data were re-synthesized into two sub-groups: palliative setting 
and adjuvant setting. Three studies (n=231) were included in the palliative setting for the ACRC 
group. The result showed significantly improved two-year OS in the combination groups compared 
with the control groups (RR 1.50, 95% CI [1.18, 1.90], I²=0%). The risk difference was similar to the 
one-year OS in the same setting (RD 0.20, 95% CI [0.09, 0.31], I²=0%) (Table 4.7; Figure 4.20b). 
 
Figure 4.20b: Forest plot of risk ratio for two-year overall survival (palliative setting, n=3) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Four studies were in adjuvant settings for stage II or III after radical surgery. There was no statistically 
significant difference between the two treatment groups for two-year OS (Table 4.7; Figure 4.20c), 
with no important heterogeneity.  
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Figure 4.20c: Forest plot of risk ratio for two-year overall survival (adjuvant setting, n=4) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Three-year overall survival 
Three-year OS was reported by nine studies involving 763 participants at different stages of the 
disease. The result showed significantly improved three-year OS when CHMs were combined with the 
CMTs, with zero percent heterogeneity (RR 1.27, 95% CI [1.12, 1.42], I²=0%), compared to CMT 
alone (Table 4.7; Figure 4.21a). 
 
Figure 4.21a: Forest plot of risk ratio for three-year overall survival (total group, n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The studies were divided into two groups: palliative setting and adjuvant setting. Two studies were of 
palliative settings for ACRC. The statistical result was significantly in favour of the combination 
group (n=171 participants) (RR 2.01, 95% CI [1.30, 3.10], I²=0%) (Table 4.7; Figure 4.21b). 
 
Figure 4.21b: Forest plot of risk ratio for three-year overall survival (palliative setting, n=2) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Five studies (n=346 participants) were of adjuvant settings for stage II or III after radical surgery. The 
combination groups had significantly improved three-year OS compared with the CMT control groups 
without heterogeneity (RR1.18, 95% CI [1.01, 1.37], I²=0%). The absolute three-year survival rate of 
the combination groups was 11% higher than the control groups (RD 0.11, 95% CI [0.01, 0.21], 
p=0.03, I²=0%) (Table 4.7; Figure 4.21c). 
 
Figure 4.21c: Forest plot of risk ratio for three-year overall survival (adjuvant setting, n=5) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Five-year overall survival 
Five-year OS was reported by four studies involving 366 participants at different stages of the disease. 
The result showed significantly improved five-year OS when CHMs were combined with the CMT 
interventions (RR 1.38, 95% CI [1.11, 1.73], I²=0%) (Table 4.7; Figure 4.22). 
 
Figure 4.22: Forest plot of risk ratio for five-year overall survival (total group, n=4) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Only one study reported the five-year OS in the adjuvant setting for stage II or III after radical surgery. 
There was no statistically significant difference between the two groups (Table 4.7). No data were 
separately reported for five-year OS in the palliative setting. 
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Median overall survival 
Twelve studies that were in the palliative setting reported median overall survival time (OS). 
Participants in these studies had stages III or IV. Four studies reported separate median OS data for 
stage IV, whereas the others reported median OS data for stages III and IV combined (Table 4.8). 
The median OS is the time at which 50% of the patients are alive. The median OS is commonly 
reported for survival outcome in medical studies. The hazard ratio (HR) and its variance, which 
express the chance of the event happening at a particular time point, are considered the most 
appropriate statistical analyses of the OS data (time to event) (Micheal et al., 2005). However, 12 
studies presented the OS as aggregate data for the groups without values for the variance. This made it 
impossible to use the log hazard ratio and its variance for analysis of the pooled effect of the additional 
CHM treatments on median OS. The data are presented as a histogram in Figure 4.23. The mean 
values and standard deviations (SD) were calculated using the formula in Excel. The mean was 15.84 
months for the test groups and 11.83 months for the control groups; the SD was 5.27 months for test 
groups and 4.47 months for control groups. The estimated mean difference significantly favoured the 
test groups (MD 4.01, 95% CI [0.25, 7.77], p=0.04).  
Table 4.8: The characteristics of 12 studies that reported median overall survival data without 
variance 
Study (first 
author, year) 
Participant 
(n) T/C 
Stage 
(n) T/C 
Intervention: T/C Median OS (m) 
T/C 
Cao B 2011 60/60 IV (all) Yiqi zhuyu decoction + FOLFOX4 vs. 
FOLFOX4 + placebo 
21.0/18.0 
Cao C 2005 33/29 IV (all) Shenmai injection + FOLFOX vs. FOLFOX 11.07/5.77 
Cazacu M 
2003 
47/37 III: 18/16 
IV: 29/21 
Mistletoe Viscum album + 5-FU/LV vs. 5-
FU/LV 
III: 24.9/18.0 
IV: 16.6/7.0 
Ding X 2010 30/30 Ad (all) Co-kushen injection + FOLFOX vs. FOLFOX 19.8/18.6 
Li H 2007 65/52 III: 27/19 
IV: 38/33 
Aidi injection + FOLFOX4 vs. FOLFOX4 12.5/10.8 (all 
stages) 
Liang Q 2009 76/76 III: 45/46 
IV: 31/30 
Shenqi Fuzheng injection + FOLFOX vs. 
FOLFOX 
7.75/7.0 (all 
stages) 
Lui W 2011 16/16 IV (all) Yierkang capsule+FOLFOX vs. FOLFOX 12.0/9.0 
Qin Y 2011 36/37 Ad (all) Fuzhongguben tang+FOLFOX vs. FOLFOX 15.6/11.2 
Wang H 2000 56/42 III: 25/17 
IV: 31/25 
Mutouhui Glycoside Pill + 5-FU/LV vs. 5-
FU/LV 
23.6/15.7 
Wang Z 2007 34/33 IV (all) Delisheng injection + FOLFOX vs. FOLFOX 10.6/9.5 
Yang Y 2008 18/19 Ad (all) Quxie capsule + FOLFOX vs. FOLFOX  17.0/13.0 
Zhang Y 2010 21/20 Ad (all) Jianpi Jiedu decoction + FOLFOX4 vs. 
FOLFOX4 
13.6/10.2 
Ad: advanced stage; m: month; 5-FU: 5-Fluorouracil; LV: Leucovorin; Ox.: Oxaliplatin; T/C: Test group 
/Control group; FOLFOX: Ox. + 5-FU + LV. 
Only one study in this review reported the hazard ratio (HR) result for median OS and median PFS. 
Cao B et al. (2011) studied Yiqizhuyu decoction (YZD) combined with FOLFOX4 in patients with 
metastatic colorectal cancer (MCRC). One hundred and twenty participants were randomly allocated 
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to the combination group or control group (FOLFOX4 + placebo for the CHM) in the ratio of 1:1. All 
participants were treated until disease progression or for 48 weeks. The median OS was 21.0 months 
for the test group and 18.0 months for the control group. There was a significant difference between 
the two treatment groups that favoured the test group (HR: 0.65, 95% CI [0.43, 0.99], p=0.043). The 
median PFS were 9.0 months for the test group and 8.0 months in the control group. There was no 
significant difference between the two groups (HR: 0.78, 95% CI [0.53, 1.15], p=0.215). 
 
Figure 4.23: Comparison of median overall survival between test and control group in palliative 
setting (data without variance) 
* data for stage IV; ◊ data for stage III; m: month; test group: HM + chemotherapy; control group: chemotherapy 
alone 
The disease-free survival (DFS) and time to progression (TTP) 
The DFS, TTP and/or PFS were reported in 10 studies. DFS is usually used as an outcome for patients 
who are post radical surgery to remove their tumour, whereas TTP and PFS is used as an outcome for 
patients who are at such an advanced stage that the tumour is unable to be totally removed (see 
Chapter 3). Both PFS and TTP in a clinical study have often been used as surrogate end points 
(Beauchemin et al., 2014). 
In one study, combined participants with post radical surgery and palliative surgery (Guo, 1999) 
reported a disease recurrence rate of 21.05 % for the test group compared with 48.34 % for the control 
group. Another study, Zhang et al. (2013), reported the disease progression rate instead of DFS. For 
the test group, this was 18.57% (6/32), compared with 34.38% (11/32) in the control group. The 
authors did not provide information on the censor time, so this study was not pooled with the other 
three studies. Therefore, DFS data at the end-points of one-year, two-years, three-years, and five-years 
were pooled for the remaining three studies as follows: 
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One-year disease-free survival: In three studies, 142 participants with stage II or III were included. 
The result showed no significant improvement in the one-year DFS when CHMs were added to the 
CMT interventions, with no important heterogeneity. However, the absolute improvement rate was 8% 
which showed a significant improvement (RD 0.08, 95% CI [0.00, 0.16]) (Table 4.7; Figure 4.24a). 
 
Figure 4.24a: Forest plot of risk ratio for one-year disease-free survival (n=3) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Two year DFS: Two studies involving stage I, II and III CRC participants (n=153) reported two-year 
DFS data. The result showed a statistically significant improvement when CHMs were added to the 
CMT intervention (Table 4.7; Figure 4.24b). 
 
Figure 4.24b: Forest plot of risk ratio for two-year disease-free survival (n=2) 
control: chemotherapy alone; experimental: HM + chemotherapy 
Three year disease-free survival: Qian et al. (2009) reported three-year DFS. The pooled result 
showed no statistically significant improvement when the CHM was added to the CMT intervention 
(Table 4.7). Qian et al. (2009) also reported that the addition of CHM significantly prolonged the 
mean recurrence time (in months) compared to the chemotherapy alone (MD 12.80, 95% CI [8.13, 
17.47], p<0.00001). 
Five year disease-free survival: Pan et al. (2003) reported the five-year DFS for 83 stage I, II or III 
CRC participants. The result showed an increased five-year DFS when CHMs were included in the 
intervention, but it was not statistically significant (Table 4.7). 
Time to progression and progression free survival (TTP/PFS): Since these outcomes are very similar, 
they were included in the same pool where possible. Five studies provided data for TTP or PFS which 
compared the median TTP/PFS between the HM plus FOLFOX regimen and the FOLFOX regimen 
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alone groups in the palliative setting. The data did not provide the variance. Therefore, the data were 
treated as in the median OS section and are presented in Table 4.9 and Figure 4.25. 
The estimated mean values and standard deviations (SD) were calculated using the formula in 
Microsoft Excel. The mean was 10.42 months for the test groups and 8.46 for the control groups; the 
SD was 3.43 months for test groups and 1.20 months for control groups. The mean difference was not 
significantly different (MD 1.96, 95% CI [-1.23, 5.15], p=0.23) between groups. Notably, the TTP 
reported by Xu et al. (2010) were considerably higher than the other studies. A likely reason is this 
study enrolled participants with various stages of CRC including some in Stage I and II whereas the 
other studies were of stage III or IV. 
Table 4.9: Five studies reported median time to progression and progression free survival (data 
without variance) 
Study (first 
author, year) 
Cao B 2011 Ding X 
2010 
Lao G 2012 Xu Y 2010 Zhang Y 
2010 
T gp; mTTP 
(m) 
9.0 9.2 9.3 16.5 8.1 
C gp; mTTP 
(m) 
8.0 8.7 8.5 10.2 6.9 
C gp: Control group (chemotherapy alone); T gp: test group (HM+chemotherapy); mTTP: median TTP; m: 
month. 
In addition, Cao et al. (2011) reported there was no significant difference in PFS between the two 
groups (HR 0.78, 95% CI [0.53, 1.15], p=0.215). Yang et al. (2008) (n=37) found that the mean TTP 
was 17.76 ± 5.62 months for the test group and was significantly higher than the mean of 12.68 ± 9.26 
months for the control group (MD 5.05, 95% CI [0.17, 9.99], p=0.04). 
 
Figure 4.25: Comparison of median time to progression between test group and control group 
(data without variance) 
test group: HM + chemotherapy; control group: chemotherapy alone; mTTP: median TTP; m: month. 
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4.8.3.6 Discussion of results for survival and relationship with tumour response 
The meta-analysis results showed that in palliative settings, the combination of CHM plus CMT 
treatment statistically significantly elevated the one-year, two-year, and three-year OS. The estimated 
difference in median OS was also significantly higher in the test groups. However, the funnel plot test 
showed an asymmetric distribution in the one-year OS, so the possibility of reporting bias cannot be 
ruled out. In the adjuvant setting, a statistical advantage of additional HM treatment appeared at three-
year OS, one-year DFS and two-year DFS. Most of the CRC patients in the adjuvant setting die from 
relapse of the disease. Up to 80% of these relapses occur during the first three years following radical 
resection of the tumour. The median time from relapse to death is 12 months (Sargent et al., 2005). 
Therefore, treatment in the adjuvant setting aims to prevent disease relapse. There were too few 
studies to assess the possibility of publication bias for the adjuvant setting. Overall, the results suggest 
combination treatment may prolong OS in the adjuvant setting and in the palliative setting. 
The combination of CHM with CMT treatment may have enhanced the anti-cancer effect of the CMT, 
in terms of improved tRR and CEA in the palliative setting, and this could have translated into 
improvements in one year, two-year, and three-year OS. The relation between tumour response and 
survival in first-line chemotherapy is an interesting issue in ACRC treatment. In the last two decades, 
palliative chemotherapy has shown great advances in the treatment of ACRC in terms of tRR. In 
contrast, the improvement in OS is relatively modest and is not always significantly different between 
test group and control group in ACRC trials (Buyse et al., 2000). 
In the last two decades, the tRR increased from approximately 10% in first-line monofluorouracil 
therapy (Piedbois et al., 1994) to 45%-56% in first-line oxaliplatin-based or irinotecan-based 
combination regimens (Hind et al., 2008). In addition, the median OS has also been elevated from 9.1 
months (5-FU monotherapy) to 20 months using the same settings. These results show that the 
improvements in chemotherapy have produced considerably greater gains in tRR than improvements 
in median OS. 
Thus, the question has been raised as to whether a therapy that significantly improves tRR in ACRC 
treatment will necessarily translate into significant benefits in OS. The evidence from RCTs has been 
contradictory. The Advanced Colorectal Cancer Meta-Analysis Project conducted a meta-analysis that 
included nine RCTs that compared 5-FU with 5-FU plus intravenous LV for the treatment of ACRC. 
The 5-FU plus LV regimens, administered either weekly or monthly, showed a highly significant 
benefit over single-agent 5-FU in tRR (23% vs. 11%; OR 0.45, p<0.0000001) but no significant 
difference in OS (OR 0.97, p=0.57) (Doroshow et al., 1992). Also, improvements in response rates in 
the FOLFOX4 regimen did not ultimately translate into extended OS when compared to 5-FU/LV 
(median OS 16.2 vs. 14.7 months, p =0.12) in a RCT (de Gramont et al., 2000). 
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In contrast, the Advanced Colorectal Cancer Meta-Analysis Project conducted another meta-analysis 
that was based on individual data of 1,178 patients included in eight RCTs comparing 5FU alone with 
5FU/MTX. The 5FU/MTX group generated almost twice the tRR of the 5FU alone control group 
(19% vs. 10%). This difference was highly significant (OR 0.51, 95% CI [0.37, 0.70], p < 0.0001). 
There was a small improvement in median OS for the 5FU/MTX groups (10.7 months vs. 9.1 months) 
which was significantly different (OR 0.87, 95% CI [0.77, 0.98], p = 0.024) (Piedbois et al., 1994). 
Buyse et al. (2000) also conducted a meta-analysis to test the relationship between tumour response to 
first-line 5-FU-based chemotherapy and survival in ACRC. The comparisons were between bolus 
fluoropyrimidines as a control treatment versus fluoropyrimidine modifications. The data comprised 
individual data from 3,791 patients enrolled in 25 RCTs of first-line treatment. These analyses 
demonstrated that the experimental fluoropyrimidine modification groups achieved higher rates of 
improved tRR (n= 454 / 2031, 22.4%) than the bolus fluoropyrimidine groups (n= 209 /1760, 11.9%) 
and there was a significant difference between groups (OR 0.48, 95% CI [0.40, 0.57], p<0.0001). 
However, the benefits to OS for the experimental fluoropyrimidine modifications treatments (n= 
223/2031, 11%) were considerably less obvious than the controls (n=180/1760, 10.2%) although the 
difference remained significant (HR 0.90, 95% CI [0.84, 0.97], p=0.003). This meta-analysis found 
that while there was a relationship between tumour response and survival time, it was relatively small 
with the survival hazard reduction being only an eighth of the response odds reduction (Buyse et al., 
2000).  
Investigators have proposed a number of hypotheses to explain this relatively small benefit to survival 
in ACRC. First, in the previous studies, the tRR were considerably higher than the CR. The clinically 
effective response, which is measured as tRR, is a combination of CR and PR (partial response). The 
duration of survival is related to the degree of tumour response. A meta-analysis by Graf et al. (1994) 
found the CRC median survival time decreased according to the degree of response as follows: 21 
months for CR, 15 months for PR, 12 months for SD, and 4 months for PD (logrank X2 (3) = 166, 
p<0.001) (Graf et al., 1994). However, there is generally a low CR in ACRC chemotherapy regardless 
of regimen. According to De Gramont et al. (2000), none of the first-line chemotherapy trials they 
reviewed reported high CRs in ACRC. Buyse et al. (2000) found that most of the trials had less than 
5% CR, but they found a higher survival rate in the CR cohort. 
A similar phenomenon was seen in a RCT which used three chemotherapy regimens in ACRC patients 
and evaluated the impact of CR on OS. The trial enrolled 1,508 patients who were randomised to three 
treatment arms: IFL (irinotecan + FU/LV); FOLFOX4 (oxaliplatin + FU/LV); and IROX (irinotecan + 
oxaliplatin). Among the 4% (62/1508) of the participants who achieved CR from first-line treatments: 
43 were from the FOLFOX4, 11 were from the IROX, and 8 were from the IFL (Dy et al., 2007). The 
median OS was 44.3 months for participants who achieved CR with CMT, and 17.1 months for 
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participants without CR. This relationship between higher CR and higher OS was consistent for both 
5-FU-based regimens and oxaliplatin-based regimens. The trial also found that the factors associated 
with the achievement of CR were FOLFOX4 treatment and patients with low tumour burden. 
The overall tRRs in ACRC trials have been low and were less than 50% in most of the phase 3 trials of 
up-to-date first-line settings (Hind et al., 2008). Although the tRR has doubled over the last two 
decades, an expectation of a high yield in OS is not realistic. The results of the various RCTs suggest 
that complete remission (CR) may be a more clinically meaningful measurement in predicting overall 
survival (OS) than tumour response rate (tRR). 
Second, unplanned second-line therapies tend to confound the outcomes of tRR and OS in RCTs. In 
ACRC trials, most of the patients whose disease progresses or fails to respond to first-line therapies 
receive second-line therapies. This approach has been observed to increase tRR and prolong OS. For 
example, in the de Gramont et al. (2000) study (see above) the total OS of 16.2 months for FOLFOX4 
included patients with and without second-line treatment, whereas for those who did not receive 
second-line treatment the median OS was 14.8 months. Also, when the control treatment fails to 
produce a response, patients in the control group often cross over to receive the experimental 
treatment. Consequently, the outcomes for OS could be overestimated in these patients. Thus, 
investigators have suggested that OS might no longer be an appropriate primary measure of the 
efficacy of first-line therapy in advanced CRC (de Gramont et al., 2000). Instead, the PFS is a more 
appropriate primary measure of efficacy for ACRC studies because it can measure the anti-tumour 
activity of first-line chemotherapy (Louvet et al., 2001). 
Third, the sample size of the study could affect the statistical power of the studies. In ACRC trials, 
most of the experimental therapies improve the outcome of OS by two to three months compared with 
the control therapies (Hind et al., 2008). Such a marginal difference may be undetectable in a trial in 
which the sample size is not large enough. A similar effect was evident in the review by Piedbois et al. 
(1994) that included eight relatively small RCTs. The results of the individual studies showed that 
only three of eight trials showed an improvement in tRR for 5-FU/MTX compared with 5-FU alone, 
and only one of these three trials reported an improvement in survival. However, the meta-analysis 
that gathered data from 866 individual patients confirmed there were significant improvements in both 
tRR and OS for 5-FU/MTX therapy (Piedbois et al., 1994). When the effect size is modest, a single 
trial may not be able to answer the question but a meta-analysis of a number of trials can enhance the 
power and find a statistically significant effect. 
Overall, the advanced chemotherapies significantly increase tRR and this translates into an increase in 
OS for patients with ACRC, but the effect on OS is small and is not always predictable. 
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In this review, the meta-analysis results showed the addition of the CHMs to the interventions 
improved the tRR (T/C: 45.78% vs. 33.84%) (Figure 4.3). More importantly, the CR rate of the 
combination groups was double that of the CMT alone groups (T/C: 7.57% vs. 3.74%) (Figure 4.5). 
These benefits were also present in the one-year, two-year, and three-year OS rates. The OS for test 
groups compared with control groups were: 63.03% vs. 42.50% (one-year OS in palliative setting) 
(Figure 4.18b); 62.30% vs. 39.45% (two-year OS in palliative setting) (Figure 4.20b); and 46.74% vs. 
20.25% (three-year OS in palliative setting) (Figure 4.21b). These meta-analysis results are consistent 
with the trends in the outcomes of international studies regarding the relationship between tRR and 
OS. 
4.8.3.7 Effect on Quality of life (QoL) 
Sixty-two studies reported quality of life (QoL) outcomes. Fifty-five studies used Karnofsky 
performance scale (KPS) as a measurement of QoL. Multi-dimensional assessments of QoL were 
reported in 6 studies. 
Karnofsky performance scale 
KPS is a single-dimension scale that provides a global measure of a patient’s physical function. The 
reliability and validity of the KPS have been investigated and verified (Granda-Cameron et al., 2008). 
Table 4.10: Meta-analysis results of quality of life for herbal medicine combined with systemic 
chemotherapy (n=40) 
Outcomes No. studies 
(participant
s) 
RR (95% CI, FE), I²; IR% MD (95% CI, 
FE), I² 
RD (95% CI, FE), 
I² 
KPS     
Total group 
(dichotomous data) 
40 (2973) 1.86 [1.68, 2.06], 
*p<0.00001, I²=0%; 86% 
NA 0.22 [0.19, 0.25], 
*p<0.00001, I²=21% 
Total group  
(continuous data) 
13 (827) NA 7.17 [6.20, 8.14], 
*p<0.00001, 
I²=80% 
NA 
Body weight     
Total group 7 (650) 1.95 [1.45, 2.62], *p<0.0001, 
I²=0%;95% 
NA 0.15 [0.09, 0.21], 
*p<0.00001, I²=0% 
*statistically significant; RR: risk ratio; IR: improvement rate; MD: mean difference; RD: risk difference; FE: 
fixed effect; I²: proportion of heterogeneity. 
Two approaches to reporting KPS scores were used in the included studies: 
1. Forty studies defined a KPS score gain ≥10 points as ‘improved’, KPS score reduction ≥10 
points as ‘worse’, and a change of less than 10 points as ‘stable’. For meta-analysis, the 
numbers of patients who were judged as ‘improved’ in each group were pooled as 
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dichotomous data. RR was used to compare the two intervention groups at the end of 
treatment.  
2. Thirteen studies reported the mean KPS score for each intervention group before treatment 
and at the end of treatment. These data were pooled as continuous data, and analysed as the 
MD between the two treatment groups at the end of treatment. There was no baseline 
imbalance before treatment. 
The pooled data of the ‘improved’ events for KPS for 40 studies (n=2,973) showed significantly 
improved KPS scores when CHMs were added to CMT interventions (RR 1.86, 95% CI [1.68, 2.06], 
I2= 0%) (Table 4.10; Figure. 4.26). However, the funnel plot was asymmetric (Figure 4.27) with more 
small studies located in the positive zone, which indicated the possibility of publication bias.  
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Figure 4.26: Forest plot of risk ratio for Karnofsky performance scale score gain ≥10 points 
(n=40) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.27: Funnel plot of 40 studies that reported Karnofsky performance scale score gain ≥10 
points 
Thirteen studies reported the mean scores of KPS for each treatment group. Eleven of these studies 
reported that the mean scores of KPS were increased in the combination therapy groups, while two 
studies reported that the mean scores were slightly reduced (Wu et al., 2010; Yang et al., 2005). 
Conversely, in the CMT control groups, only two studies reported the mean scores were slightly 
increased (Lao et al., 2012; Mao & Huang 2005), while the other 11 studies reported the mean scores 
were reduced after treatment. This suggests that CMT was generally associated with reduced KPS. 
 
Figure 4.28: Forest plot of mean difference for 13 studies that reported Karnofsky performance 
scale as mean ± SD scores 
control: chemotherapy alone; experimental: HM + chemotherapy; SD: standard deviation. 
Analysis of the pooled data for the 13 studies that reported mean KPS scores for each treatment group 
after the intervention were higher in the combination therapy groups (MD 7.17, 95% CI [6.20, 8.14], 
p<0.00001, I²=80%) with substantial heterogeneity (Table 4.10; Figure 4.28). The funnel plot showed 
asymmetric scatter, with two studies (Guo, 1999; Wu et al., 2010) outlying the 95% confidence zone 
(Figure 4.29). A sensitivity analysis was therefore conducted by excluding two small studies located in 
the bottom of the funnel plot (Lao et al., 2012; Mao & Huang, 2005), and the two outlier studies (Guo, 
1999; Wu et al., 2010) were excluded. The result showed a reduction in the magnitude of the 
difference but the KPS remained significantly improved in the combination treatment groups 
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compared with the CMT alone groups (9 studies, n= 561 participants, MD 5.76, 95% CI [4.68, 6.84], 
I2= 0%) (Figure 4.30). 
 
Figure 4.29: Funnel plot of 13 studies of Karnofsky performance scale reported as mean ± SD 
scores 
 
Figure 4.30: Forest plot of mean difference for 9 studies that reported Karnofsky performance 
scale as mean ± SD scores (outlier removal) 
control: chemotherapy alone; experimental: HM + chemotherapy; SD: standard deviation 
Multi-dimensional quality of life assessments 
Multi-dimensional assessments of QoL were reported in the following six studies:  
• Zhang et al. (2007) used the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al., 1993); the Self-reported 
Anxiety Scale (SAS); and the Depression Scale (SDS); 
• Yang (2008a) used Su Ying's QoL Questionnaire; and the KPS; 
• Jian et al. (2005) and Zheng (2011) used the Chinese 1990 version of the standard criteria for 
assessment of QoL of tumour patients (The Ministry of Health PRC, 1991); 
• Zhang et al. (2010) used a combination of: a visual analogue scale for pain; KPS; and body 
weight gain; and 
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• Jiang et al. (2013) used the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) 
(Ward et al., 1999). 
Since all the scales were different, there were few opportunities for data pooling. Therefore, most 
results were assessed for each study separately. 
Zhang et al. (2007) assessed changes in negative emotion (anxiety and depression) and QoL using the 
Chinese version of the European Organisation for Research and Treatment of Cancer (EORTC QLQ- 
C30) Questionnaire, Self-reported Anxiety Scales (SAS) and Depression Scales (SDS) on day 1 prior 
to the chemotherapy (B1), day 2 during chemotherapy (T2), day 7 (T7) and day 14 (T14) after 
chemotherapy. The results showed the negative emotion and global QoL of patients in both arms 
deteriorated at the T2 measurement point, but improved gradually at T7 to reach a peak at the T14 
measurement point. At T14, the improvements were greater in the combination therapy group 
compared with the CMT control (p<0.05) for the physical, role, and emotional sub-scales and the 
global QoL, but not for the cognitive or social sub-scales. For the symptom scales, significant benefits 
were found at T14 for relief of fatigue, insomnia, constipation, and diarrhoea but not for nausea and 
vomiting, pain or appetite. 
In Yang (2008a), QoL was measured by Su Ying's QoL Questionnaire (12 items) which uses a score 
from 5 to 1 according to increase in severity, the more severe the symptoms the lower the score. The 
total scores for the two treatment groups were balanced before treatment (MD -0.17, 95% CI [-1.69, 
1.35], p=0.83). When the two groups were compared after treatment, the result was significantly in 
favour of the combination therapy group (MD 4.10, 95% CI [2.36, 5.84], p<0.00001). 
Jian et al. (2005) and Zheng et al. (2011) used the 1990 version of the Chinese standard criteria for 
assessment of QoL that uses a scoring system that ranges from 60 to 0 according to increase in 
severity, the more severe the symptoms the lower the score (The Ministry of Health PRC, 1991). 
Patients who recorded a score more than 40 (which referred to as ‘satisfactory’) after treatment were 
pooled as dichotomous data. The difference between the two treatment groups was significantly in 
favour of the combination therapy groups (RR 1.35, 95% CI [1.06, 1.71], p=0.02, I²=47%) with no 
important heterogeneity (p=0.17). 
Zhang et al. (2010) assessed QoL using a combination of KPS, a visual analogue scale for pain, and 
body weight. However, the criteria used in assessment were not described in detail. The authors 
reported that 18 out of 21 patients (85.7%) were judged as receiving ‘clinical benefit’ in the 
combination therapy group, compared with 11 out of 20 patients (55.0%) in the control group. The 
difference between the two groups was significantly in favour of the combination therapy group (RR 
1.56, 95% CI [1.01, 2.40], p=0.04). 
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Jiang et al. (2013) used the FACT-C for assessment of QoL. The FACT-C questionnaire includes 
social/family, physical, emotional, and functional sub-scales, and a subscale of specific items for 
colorectal cancer (36 items in total). The scoring system ranges from 0 to 4 for each item, and the 
more severe the symptoms the lower the score (Ward et al., 1999). When the two groups were 
compared after treatment, the result was significantly in favour of the combination therapy group (MD 
50.1, 95% CI [34.44, 65.76], p<0.00001). 
Body weight 
Assessment of body weight was reported in 7 studies. A body weight gain of ≥1.0 kg was defined as 
‘improved’; a loss ≥1.0 kg was defined as ‘worse’; and a change between ‘improved’ and ‘worse’ was 
classified as ‘stable’. The ‘improved’ events for body weight were pooled. 
The pooled analysis for body weight gain in these seven studies (n=690) showed there was a 
significant difference in the incidence of ‘improved’ in favour of the combination treatment groups 
(Table 4.10, Figure 4.31). 
 
Figure 4.31: Forest plot of risk ratio for body weight gain ≥ 1.0 Kg (seven studies) 
control: chemotherapy alone; experimental: HM + chemotherapy 
4.8.3.8 Discussion of results for quality of life and body weight 
The results of the above meta-analyses showed that the combination treatments significantly elevated 
the QoL of CRC patients based on internationally well-recognised measurements such as the KPS, 
EORTC QLQ- C30 and FACT-C. These results were consistent with another review of CHM use in 
CRC (Zhong et al., 2012). 
As an outcome measure, QoL is as important as survival for assessing palliative chemotherapy 
(Seymour et al., 1997). QoL in the healthcare perspective refers to an individual’s well-being which 
includes emotional, social, and physical dimensions. KPS is a single-dimension scale that provides a 
global measurement of a patient’s physical function. Its reliability and validity have been investigated 
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and verified, and it is used as a surrogate measure for a global evaluation of a patient’s health status 
(Granda-Cameron et al., 2008). A high KPS score is associated with low symptom distress (Hwang et 
al., 2003). KPS can be rated by healthcare personnel or by patients themselves and it is extensively 
used in clinical trials on cancer patients (Yates et al., 1980). 
A multi-dimensional QoL scale, the EORTC QLQ- C30 (Chinese version) was used in one of the 
included studies (Zhang et al., 2007). The QLQ-C30 comprises nine multi-item scales: five functional 
scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and 
nausea and vomiting); and a global health and QoL scale. A multicultural clinical study found that the 
EORTC QLQ-C30 was a reliable and valid measure of the QoL for cancer patients (Aaronson et al., 
1993). Studies have also found that there is high correlation between EORTC QLQ-C30 and KPS in 
terms of physical functioning (Pearson's correlation r=0.62, p<0.05) (Guzelant et al., 2004) and in 
global health/ QoL scores (Pearson's correlation r = 0.39, p< 0.01) (Teunissen et al., 2004). 
Since only one of the included studies used EORTC QLQ- C30 (Chinese version), meta-analysis was 
not possible. The study reported a significant improvement in physical functioning in favour of the 
group taking a CHM formula containing Astragalus membranaceus after 14 days of treatment with 
significant benefits for the relief of fatigue, insomnia, constipation, and diarrhoea. Significant benefits 
also were found for the role sub-scale, emotional sub-scale and global QoL (Zhang et al. 2007).  
These findings suggest that the improvements in QoL reported for integrated HM treatment in ACRC 
patients may not be limited to physical functioning. There may be beneficial effects on broader QoL 
domains, including emotional state, which are not captured by KPS scores. The extent to which these 
effects are related to improvements in fatigue and other symptoms such as insomnia cannot be 
determined, but these results indicate that broader-based QoL scales should be used in future trials to 
further investigate such effects.  
It should be noted that the included studies did not provide detailed information on how the KPS 
assessments were implemented and whether the lack of blinding was considered. Therefore, the 
possibility of detection bias cannot be ruled out. The funnel plot test also suggested the possibility of 
reporting bias in this set of data. Since the QoL was not the primary outcome in most of the included 
studies, negative results for KPS are likely to have not been reported. 
Weight loss is a significant issue in ACRC patients with most tending to lose weight. However, most 
studies did not include this as a separate measure. To a certain extent, weight loss is captured in KPS, 
so this may account for the few studies that provided a separate measure. On the other hand, since all 
studies favoured the combination therapy groups there may have been selective outcome reporting of 
this aspect. 
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 Effects on adverse events (AE) associated with chemotherapy 4.8.4
In total, 47 studies reported data on the alleviation of CMT-related adverse events (AEs). The WHO 
toxicity criteria grades 0 to 4 (Miller et al., 1981) and the National Cancer Institute Common Toxicity 
Criteria (NCI-CTC) (National Cancer Institute, 1999) were used to assess the events. These systems 
use similar grading criteria, so pooling of data was undertaken where possible (Hind et al., 2008). The 
outcomes for nausea and vomiting, diarrhoea, myelosuppression (neutropenia, thrombocytopenia, and 
anaemia), neurotoxicity, alopecia, liver impairment, kidney impairment, and stomatitis were pooled. 
Neutropenia, nausea and vomiting, and diarrhoea were the most commonly reported adverse events. 
Analyses were based on all grades of the AEs. When the Risk Ratio (RR) is less than 1 (IV, Fixed, 
95% CI) it favours the test groups. Negative numbers for RD favour the test groups. 
Three studies (Deng et al., 2010; Fang et al., 2008; Zheng et al., 2011) used recombinant human 
granulocyte colony-stimulating factor (rhG-CSF) to stimulate granulopoiesis in some of the 
participants. The rhG-CSF can influence monocytes, lymphocytes and the hemostatic system 
(Anderlini, 2009). Therefore, these three studies were not included for the analysis of neutropenia, 
thrombocytopenia and anaemia. The sub-groups for oxaliplatin regimes and non-oxaliplatin regimes 
were analysed separately.  
Table 4.11 shows the overall meta-analysis results for the ten main categories of AE associated with 
chemotherapy. The results are given for the total pools followed by sub-groups based in the category 
of chemotherapy used. The most commonly reported outcomes were: neutropenia (38 RCTs); nausea 
and vomiting (35 RCTs); neurotoxicity (26 RCTs); and diarrhoea (22 RCTs). More detailed results for 
each of the ten categories are presented in the following sections. These include Funnel plots when 
there were ten or more RCTs in the pooled result for the particular AE, and forest plots for the total 
results and the sub-groups of oxaliplatin and non-oxaliplatin regimes. 
Table 4.11: Meta-analysis results of chemotherapy induced adverse events (56 studies) 
Outcomes/ groups No. studies 
(participants) 
RR (95% CI, FE), I²; IR% RD (95% CI, FE), I² 
Neutropenia    
Total group 38 (2,764) 0.57 [0.52, 0.62], *p<0.00001, 
I²=15%; -43% 
-0.24 [-0.27, -0.21], 
*p<0.00001, I²=35% 
Oxaliplatin group 29 (1,974) 0.61 [0.55, 0.67], *p<0.00001, I²=0%; 
-39% 
-0.26 [-0.30, -0.22], 
*p<0.00001, I²=0% 
Non-oxaliplatin group  8 (728) 0.35 [0.28, 0.46], *p<0.00001, I²=0%; 
-65% 
-0.23 [-0.28, -0.17], 
*p<0.00001, I²=77% 
Thrombocytopenia    
Total group  18 (1,254) 0.64 [0.53, 0.780], *p<0.00001, 
I²=0%; -36% 
-0.10 (-0.14, -0.06), 
*p<0.00001, I²=27% 
Oxaliplatin group  17 (1,185) 0.66 [0.54, 0.80], *p<0.00001, I²=0%; 
-34%% 
-0.09 [-0.13, -0.05], 
*p<0.0001, I²=25% 
Non-oxaliplatin group 1 (69) 0.49 [0.25, 0.96], *p=0.04; -51% -0.25 [-0.47, -0.03], 
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Outcomes/ groups No. studies 
(participants) 
RR (95% CI, FE), I²; IR% RD (95% CI, FE), I² 
*p=0.03. 
Anaemia    
Total group (oxaliplatin 
group) 
15 (1,083) 0.65 [0.54, 0.79], *p<0.0001, I²=0%; -
35% 
-0.13 [-0.18, -0.08], 
*p<0.00001, I²=14% 
Nausea & vomiting    
Total group  35 [2,407] 0.61 [0.55, 0.66], *p<0.00001, 
I²=40%; -39% 
-0.26 [-0.30, -0.23], 
*p<0.00001, I²=48% 
Oxaliplatin group  27 [1,843] 0.65 [0.59, 0.71], *p<0.00001, 
I²=28%; -35%. 
-0.24 [-0.28, -0.19], 
*p<0.00001, I²=50% 
Non-oxaliplatin group 8 (564) 0.36 [0.28, 0.47], *p<0.00001, I²=0%; 
-64% 
-0.34 [-0.41, -0.28], 
*p<0.00001, I²=27% 
Diarrhoea    
Total group  22(1483) 0.60 [0.51, 0.71], *p<0.00001, 
I²=13%; -40% 
-0.13 [-0.16, -0.09], 
*p<0.00001, I²=56% 
Oxaliplatin group  18 (1236) 0.65 [0.55, 0.76], *p<0.00001, I²=0%; 
-35% 
-0.10 [-0.15, -0.06], 
*p<0.00001, I²=33% 
Non-oxaliplatin group 4 (247) 0.22 [0.12, 0.40], *p<0.00001, I²=0%; 
-80% 
-0.20 [-0.27, -0.12], 
*p<0.00001, I²=83% 
Neurotoxicity    
Total group 
(oxaliplatin group) 
26 (1,803) 0.77 [0.70, 0.84], *p<0.00001, 
I²=25%; -23%. 
-0.13 [-0.18, -0.09], 
*p<0.00001, I²=39%. 
Alopecia    
Total group  9 (637) 0.53 [0.40, 0.71], *p<0.0001, I²=13%; 
-47% 
-0.12 [-0.17, -0.06], 
*p<0.0001, I²=65% 
Oxaliplatin group 5 (383) 0.82 [0.50, 1.330], p=0.41, I²=0%. -0.03 [-0.10, 0.04],  
p=0.36, I²=0% 
Non-oxaliplatin group 4(254) 0.41 [0.29, 0.60], *p<0.00001, I²=0%; 
-59%. 
-0.32 [-0.43, -0.21], 
*p<0.00001, I²=0% 
Liver impairment    
Total group  19(1307) 0.76 [0.63, 0.93], *p=0.007, I²=34%; -
24% 
-0.07 [-0.11, -0.04], 
*p<0.0001, I²=27% 
Oxaliplatin group 14(852) 0.85 [0.69, 1.05], p=0.12, I²=18%; -
15% 
-0.06 [-0.11, -0.01], 
*p=0.01, I²=16% 
Non-oxaliplatin group 5 (455) 0.37 [0.22, 0.65], *p=0.0005, I²=4%; -
63% 
-0.09 [-0.15, -0.04], 
*p=0.0006, I²=52% 
Kidney impairment    
Total group  6 (421) 0.80 [0.51, 1.26], p=0.33, I²=0%; -
20% 
-0.02 [-0.06, 0.03], 
p=0.48, I²=0% 
Oxaliplatin group 5 (359) 0.88 [0.55, 1.40], p=0.58, I²=0%; -
12% 
-0.01 [-0.05, 0.04], 
p=0.79, I²=0% 
Non-oxaliplatin group 1 (62) 0.31 [0.07, 1.43], p=0.13; -69% -0.14 [-0.30, 0.03], p=0.10 
Stomatitis    
Total group (oxaliplatin 
group) 
10 (801) 0.76 [0.61, 0.94], *p=0.01, I²=17%; -
24% 
-0.07 [-0.13, -0.02], 
*p=0.009, I²=42% 
*statistically significant; RR: risk ratio; IR: improvement rate; RD: risk difference; FE: fixed effect; I²: proportion of 
heterogeneity 
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4.8.4.1 Neutropenia 
In the 38 studies that reported assessable data for neutropenia, there was a statistically significant 
reduction in neutropenia when CHMs were added to the intervention for all grades of neutropenia (RR 
0.57, 95% CI [0.52, 0.62], I²=15%). The incidence of neutropenia in the test groups was 43% lower 
than in the control groups (Table 4.11; Figure 4.32). The funnel plot was asymmetric with the smaller 
studies showing a positive shift to the left side of the 95% confidence region (Figure 4.33). Therefore, 
reporting bias due to selective reporting or publication bias cannot be ruled out.  
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Figure 4.32: Forest plot of risk ratio for neutropenia (total group, n=38) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.33: Funnel plot of 38 studies that reported neutropenia (total group) 
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Since the studies employed different types of chemotherapy regimens, these were evaluated 
separately. Evidence from international studies has shown that patients treated with oxalipaltin 
regimens have a higher incidence of neutropenia than patients treated with the older generation of 5-
FU regimens (de Gramont et al., 2000). Therefore, studies were divided into two sub-groups: 
oxalipaltin group (n=29 studies) and non-oxalipaltin group (n=9 studies). The result showed the 
combination treatment significantly reduced neutropenia in both the oxalipaltin group (RR 0.61, 95% 
CI [0.55, 0.67], I²=0%) (Figure 4.34) and the non-oxalipaltin group (RR 0.35, 95% CI [0.28, 0.46], 
I²=0%) (Figure 4.35) compared to the CMT alone (Table 4.11). The funnel plot for the oxaliplatin 
group was asymmetric and similar to the total group of neutropenia (Figure 4.36). 
 
Figure 4.34: Forest plot of risk ratio for neutropenia (oxaliplatin group, n=29) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.35: Forest plot of risk ratio for neutropenia (non-oxaliplatin group, n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.36: Funnel plot of 29 studies that reported neutropenia (oxaliplatin group) 
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CHMs were added to the CMT intervention. In comparison with the CMT alone group, there was a 
36% reduction in incidence of thrombocytopenia in the combination group (Table 4.11, Figure 4.37a). 
Only one study (Guo, 1999) did not use an oxaliplatin regimen. Analysis of the 17 studies that used 
oxaliplatin showed the combination treatment significantly reduced thrombocytopenia (RR 0.66, 95% 
CI [0.54, 0.80], I²=0%) (Table 4.18; Figure 4.37b). The funnel plot was somewhat asymmetric with 
small studies showing a left shift (Figure 4.38).  
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Figure 4.37a: Forest plot of risk ratio for thrombocytopenia (total group, n=18) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.37b: Forest plot of risk ratio for thrombocytopenia (oxaliplatin group, n=17) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.38: Funnel plot of 18 studies that reported thrombocytopenia (total group) 
4.8.4.3 Anaemia 
Fifteen studies reported assessable data for anaemia. All studies were in the oxaliplatin group. There 
was a statistically significant reduction in anaemia (all grades) when additional CHMs were included 
in the intervention (RR 0.65, 95% CI [0.54, 0.79], I²=0%) (Table 4.11; Figure 4.39). There was a 35% 
reduction in anaemia incidence in the combination therapy group compared with the CMT alone 
group. The funnel plot was roughly symmetric (Figure 4.40). 
 
Figure 4.39: Forest plot of risk ratio for anaemia in comparison with two treatments (n=15) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.40: Funnel plot of 15 studies that reported anaemia 
4.8.4.4 Nausea and vomiting 
Thirty-five studies reported assessable data for nausea and/or vomiting. There was a statistically 
significant reduction in nausea and/or vomiting events (all grades) when additional HMs were 
included in the intervention with moderate heterogeneity (RR 0.61, 95% CI [0.55, 0.66], I²=40%). The 
improvement rate was 39% (Table 4.11; Figure 4.41). The funnel plot was asymmetric due to two 
studies on the bottom left side of the positive zone which may indicate reporting bias (Figure 4.42). 
However, the removal of these two studies did not affect the overall result (RR 0.61 [0.56, 0.67], 
I²=36%).  
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Figure 4.41: Forest plot of risk ratio for nausea and vomiting (total group, n=35) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
 
Figure 4.42: Funnel plot of 35 studies that reported nausea and vomiting (total group) 
The studies were divided into two groups: oxaliplatin group (n=27 studies) and non-oxaliplatin group 
(n=8 studies). The result showed that the combination of CHM treatment with oxaliplatin-based CMT 
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significantly reduced nausea and vomiting (RR 0.65, 95% CI [0.59, 0.71], I²=28%), with no important 
heterogeneity (Table 4.11; Figure 4.43a). The non-oxaliplatin group also showed significantly reduced 
nausea and vomiting (RR 0.36, 95% CI [0.28, 0.47], I²=0%) when CHMs were combined with CMT 
(Table 4.11; Figure 4.43b). The funnel plot for the oxaliplatin group was somewhat asymmetric due to 
a single small study which was unlikely to affect the overall result (Figure 4.44). 
 
Figure 4.43a: Forest plot of risk ratio for nausea and vomiting (oxaliplatin group, n=27) 
control: chemotherapy alone; experimental: HM + chemotherapy  
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Figure 4.43b: Forest plot of risk ratio for nausea and vomiting (non-oxaliplatin group, n=8) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.44: Funnel plot of 27 studies that reported nausea and vomiting (oxaliplatin group) 
4.8.4.5 Diarrhoea 
Twenty-two studies reported assessable data for diarrhoea. All grades of diarrhoea events were 
statistically significantly reduced when CHMs were added to the CMT interventions (Table 4.11; 
Figure 4.45), with no important heterogeneity (RR 0.60, 95% CI [0.51, 0.71], I²=13%). The reduction 
of diarrhoea was 40% more for CHMs integrated with CMT compared with CMT alone. The funnel 
plot was slightly asymmetric (Figure 4.46).   
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Figure 4.45: Forest plot of risk ratio for diarrhoea in comparison with two treatments (total 
group, n=22) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.46: Funnel plot of 22 studies that reported diarrhoea (total group) 
The oxaliplatin group (n=18) and non-oxaliplatin group (n=4) were analysed separately. The results 
showed that the combination treatments significantly reduced diarrhoea events in both the oxaliplatin 
group (RR 0.65, 95% CI [0.55, 0.76], I²=0%) (Table 4.11; Figure 4.47a) and the non-oxaliplatin group 
(RR 0.22, 95% CI [0.12, 0.40], I²=0%), (Table 4.11; Figure 4.47b). The funnel plot for the oxaliplatin 
group was roughly symmetric (Figure 4.48).  
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Figure 4.47a: Forest plot of risk ratio for diarrhoea (oxaliplatin group, n=18) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.47b: Forest plot of risk ratio for diarrhoea (non-oxaliplatin group, n=4) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.48: Funnel plot of 18 studies that reported diarrhoea (oxaliplatin group) 
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4.8.4.6 Neurotoxicity 
Neurotoxicity events were only reported for oxaliplatin regimen groups, with 26 studies reporting 
assessable data. There was a statistically significant reduction in neurotoxicity events (all grades) (RR 
0.77, 95% CI [0.70, 0.84], I²=25%) when CHMs were added to the CMT intervention (Table 4.11; 
Figure 4.49), and there was no important heterogeneity. The funnel plot was roughly symmetric 
(Figure 4.50).  
 
Figure 4.49: Forest plot of risk ratio for neurotoxicity (n=26) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.50: Funnel plot of 26 studies that reported neurotoxicity 
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4.8.4.7 Alopecia 
Nine studies reported assessable data for alopecia events. There was a statistically significant 
reduction in alopecia (all grades) when additional CHMs were combined with the CMT intervention, 
and there was no important heterogeneity (RR 0.53, 95% CI [0.40, 0.71], I²=13%) (Table 4.11; Figure 
4.51a).  
 
Figure 4.51a: Forest plot of risk ratio for alopecia (total group, n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.51b: Forest plot of risk ratio for alopecia (oxaliplatin group, n=5) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.51c: Forest plot of risk ratio for alopecia (non-oxaliplatin group, n=4) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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The oxaliplatin group (5 studies) and non-oxaliplatin group (4 studies) were analysed separately. The 
pooled results showed there was no significant difference between the two treatment groups for 
alopecia events in the oxaliplatin group (RR 0.82, 95% CI [0.50, 1.33], I²=0%) (Table 4.11; Figure 
4.51b). However, there was a significant reduction in alopecia events in the combination therapy 
groups for the non-oxaliplatin group (RR 0.41, 95% CI [0.29, 0.60], I²=0%) (Table 4.11; Figure 
4.51c). 
4.8.4.8 Liver impairment 
Nineteen studies reported assessable data for liver impairment. There was a statistically significant 
reduction in all grades of liver impairment events (i.e. elevated transaminases) when CHMs were 
combined with the CMTs (Table 4.11; Figure 4.52), and there was no important heterogeneity (RR 
0.76, 95% CI [0.63, 0.93], p=0.007, I²=34%). The Funnel plot was asymmetric (Figure 4.53).  
 
Figure 4.52: Forest plot of risk ratio for liver impairment (total group, n=19) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The oxaliplatin group (n=14) and non-oxaliplatin group (n=5) were analysed separately. In the 
oxaliplatin sub-group, the result showed the combination treatment did not significantly reduce liver 
impairment compared to the CMT alone control groups (RR 0.85, 95% CI [0.69, 1.05], I²=18%) 
(Table 4.11; Figure 4.54a). 
Oxaliplatin undergoes little metabolism in the the liver and is not excreted hepatically (Cassidy & 
Misset, 2002). Therefore, it is reasonable to expect that the two treatments groups would show no 
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significant difference in hepatic damage. However, in the non-oxaliplatin sub-group, the pooled result 
was significantly in favour of the combination treatments (Table 4.11; Figure 4.54b). The funnel plot 
was asymmetric for the oxaliplatin group suggesting that studies that found no difference between 
groups may not have reported this outcome (Figure 4.55). 
 
Figure 4.53: Funnel plot of 19 studies that reported liver impairment (total group) 
 
Figure 4.54a: Forest plot of risk ratio for liver impairment (oxaliplatin group, n=14) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.54b: Forest plot of risk ratio for liver impairment (non-oxaliplatin group, n=5) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 4.55: Funnel plot of 14 studies that reported liver impairment (oxaliplatin group) 
4.8.4.9 Kidney impairment 
Assessable data were available in 6 studies for kidney impairment events. The pooled results showed 
there was no difference between the two treatment groups for kidney impairment adverse events (RR 
0.80, 95% CI [(0.51, 1.26]), p=0.33, I²=0%) (Table 4.11; Figure 4.56a). 
The oxaliplatin group (n=5) and non-oxaliplatin group (n=1) were analysed separately. In the 
oxaliplatin group, the result also showed there was no difference between the two treatment groups for 
kidney impairment adverse events (RR 0.88, 95% CI [0.55, 1.40], p=0.58, I²=0%) (Table 4.18; Figure 
4.54b). The result for kidney impairment may be due to the mildness of kidney toxicity events in both 
treatment groups. This finding is consistent with other international studies that have shown that there 
are fewer kidney toxicity events when using third generation platinum drugs such as oxaliplatin 
(Cassidy & Misset, 2002). 
Zheng et al. (2011) was the only study that used non-oxaliplatin chemotherapy and reported kidney 
impairment events. The analysis showed there was no difference between the two treatment groups for 
kidney impairment (RR 0.31, 95% CI [(0.07, 1.44]), p=0.13) (Table 4.18). 
 
Figure 4.56a: Forest plot of risk ratio for kidney impairment (total group, n=6) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 4.56b: Forest plot of risk ratio for kidney impairment (oxaliplatin group, n=5) 
control: chemotherapy alone; experimental: HM + chemotherapy 
4.8.4.10 Stomatitis 
Stomatitis events were only reported for the oxaliplatin regimens group (n=10 studies). There was a 
significant difference between the groups for the stomatitis events in favour of the combination 
therapy groups (RR 0.76, 95% CI [0.61, 0.94], I²=17%) (Table 4.11; Figure 4.57). The funnel plot was 
symmetric for stomatitis (Figure 4.58). 
 
Figure 4.57: Forest plot of risk ratio for stomatitis (n=10) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.58: Funnel plot of 10 studies that reported stomatitis 
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4.8.4.11 Discussion of adverse events associated with chemotherapy 
The addition of CHMs to the CMT regimens significantly reduced the incidence of hematologic 
toxicity (neutropenia, thrombocytopenia, and anaemia events), and gastrointestinal toxicity (nausea 
and vomiting, diarrhoea) induced by the CMTs. The sub-group meta-analysis based on the type of 
CMT reduced the heterogeneity of the results for neutropenia, nausea and vomiting, and diarrhoea 
events. One of the reasons for this may be associated with differences in the hematologic toxicity and 
gastrointestinal toxicity between the oxaliplatin regimens and non-oxaliplatin regimens. 
Dose-dependant neurotoxicity is particularly associated with oxaliplatin regimens (Cassidy & Misset, 
2002). These toxicity events appear to have been alleviated when the CHMs were added to the 
oxaliplatin-based CMT regimens. Two previous CRC systematic reviews did not analyse these 
adverse events (Zhong et al., 2012; Guo et al., 2012). Kono et al. (2011) reported a retrospective study 
that enrolled 90 patients who received oxaliplatin regimen treatment for ACRC. The study compared 
adjuvant oxaliplatin-based CMT combined with the CHM formula GJG (group A), which is a 
combination of 10 HMs, with three other groups: calcium gluconate and magnesium sulfate + 
oxaliplatin regimen (group B); GJG + calcium gluconate and magnesium sulfate + oxaliplatin regimen 
(group C); and oxaliplatin regimen alone (group D). The authors found that the patients in group A 
had a 50% neurotoxicity incidence, whereas the other groups had higher neurotoxicity incidences: 
group B, 100%; group C, 78.9%; and group D, 91.7%, when the cumulative dose of oxaliplatin 
exceeded 500 mg /m2. Pre-clinical studies have suggested that GJG increases the level of dynorphin 
and nitric oxide. Dynorphin alleviates the symptoms of numbness or pallesthesia via the opiate system, 
and the nitric oxide increases the blood supply to nerve tissues (Kono et al., 2011). The same authors 
conducted a well-designed phase II, randomised, double-blind, placebo-controlled study with the same 
herbal formula in the test arm, and a placebo in the control arm. The results showed that the incidence 
of grade 2 or greater oxaliplatin-induced peripheral neurotoxicity (OPN) up until the 8th cycle of 
chemotherapy was 39% in the test arm versus 51% in the control arm (RR 0.76, 95% CI [0.47, 1.21]). 
The incidence of grade 3 OPN was 7% and 13% in the test arm and control arm respectively (RR 0.51, 
95% CI [0.14-1.92]). No concerns regarding toxicity emerged with the GJG treatment. The authors 
concluded that the GJG intervention delayed the onset of grade 2 or greater OPN without impairing 
FOLFOX efficacy (Kono et al., 2013). 
It is interesting to note that the RD analysis method generated more substantial heterogeneity (I2>50% 
or large Chi2 with p<0.1) than using the RR method for dichotomous data (Table 4.11). Empirical 
evidence had found that RD analysis was more likely to generate heterogeneity compared with OR or 
RR, since RD more directly correlates to the control group event rate (Engels et al., 2000). There is 
evidence that increasing the control group event rate is associated with higher heterogeneity in 
dichotomous data. In general, analysis using RR and OR produce more consistent results across 
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varying baseline risks than analysis using RD, and it appears that RR is more reliable for providing a 
consistent prediction clinically (Deeks et al., 2002). 
In a number of meta-analysis pools, asymmetric funnel plots indicated the possibility of publication 
bias or selective reporting within the group of studies for a particular outcome. Since the AEs induced 
by CMT were not the primary outcome in the majority of the included studies, a non-significant result 
may be not have been reported by the authors. The lack of a clinical trial protocol for the majority of 
the studies meant it was not possible to determine whether these assessments had been conducted and 
not reported or not conducted at all. It is also possible that small, pilot scale studies that did not show 
significant results were not published. 
 Effects on immunoregulation 4.8.5
Twenty-six studies investigated immune system activity during treatment. The percentages of T cell 
subsets (CD3+, CD4+, CD8+); the ratio of CD4+ to CD8+; CD4+CD25+ regulatory T (Treg) cells; 
and NK cell activity (%) in serum were reported. These immune parameters provided measurements of 
the status of the person’s cell-mediated immunity (CMI) which plays a critical role in defending the 
host against cancer and in reducing metastasis (Swann & Smyth, 2007). The MD results are presented 
for both the fixed effect model and random effect model. A positive result indicated increased T cell 
subsets (CD3+ and CD4+), increased ratio CD4+ to CD8+, or increased NK cell activity in serum, 
which are considered favourable. For CD8+ cells, and CD4+CD25+ regulatory T cells, decreases are 
favourable. 
4.8.5.1 CD3+ cells 
Fourteen studies reported assessable data for percentage of CD3+ cells. The addition of CHM 
interventions to the CMTs increased the mean percentage of CD3+ cells compared to before treatment. 
This general result was reported in all studies except one study in which the percentage of CD3+ 
decreased. In the control groups, five studies showed no change in the percentage of CD3+ cells after 
treatment, whereas the rest of the studies showed decreases. 
The pooled result at the end of treatment showed the CD3+ cells were significantly higher when 
CHMs were included in the intervention (MD 6.38, 95% CI [5.61,7.15], p<0.00001, I²=93%) 
compared with CMT alone, and there was important heterogeneity (Table 4.12; Figure 4.59). The 
results of the two analysis models were similar. The funnel plot was asymmetric (Figure 4.60). 
The cell-mediated immunity is influenced by stage, tumour burden, the treatments (Ji et al., 2010). 
Since the individual data for the participants was not available, it is difficult to determine the causes of 
the heterogeneity. A sensitivity analysis was therefore undertaken to investigate the sources of the 
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heterogeneity. Four outlying studies (Song & Zhang, 2012; You et al., 2010; Zeng et al., 2008; Zhang 
& Song 2013) that are scattered outside the 95% confidence interval zone of the funnel plot and one 
small study (Dong et al., 2011) that is isolated at the bottom of the funnel plot (Figure 4.60) were 
excluded from analysis. 
Table 4.12: Meta-analyses results for immunity regulation of herbal medicine in combination 
with systemic chemotherapy (26 studies) 
Outcomes No. studies 
(participants) 
MD (95% CI, FE), I² MD (95% CI, RE), I² 
CD3+ (%)    
Total group 14 (820) 6.38 [5.61, 7.15], *p<0.00001, 
I²=93% 
6.94 [3.72, 10.15], *p<0.0001, 
I²=93%  
Excluding outliers 9 (566) 4.97 [4.06, 5.88], *p<0.00001, 
I²=41% 
4.21 [2.79, 5.62], *p<0.00001, 
I²=41% 
CD4+ (%)    
Total group 15 (932) 7.27 [6.73, 7.82], *p<0.00001, 
I²=97% 
6.93 [3.43, 10.42], *p<0.00001, 
I²=97% 
Excluding outliers 9 (559) 4.82 [4.11, 5.53], *p<0.00001, 
I²=39% 
4.60 [3.53, 5.67], *p<0.0001, 
I²=39% 
CD8+ (%)    
Total group 14 (872) 1.68 [1.07, 2.28], *p<0.00001, 
I²=99% 
0.65 [-4.55, 5.85], p=0.81, 
I²=99% 
Excluding outliers 9 (520) -1.39 [-2.30, -0.48], *p=0.003, 
I²=37% 
-1.35 [-2.58, -0.13], *p=0.003, 
I²=37% 
CD4+/CD8+    
Total group 17 (1238) 0.32 [0.27, 0.360], *p<0.00001, 
I²=75% 
0.32 [0.22, 0.43], *p<0.00001, 
I²=75% 
Excluding outliers 15 (1110) 0.28 [0.23, 0.32], *p<0.00001, 
I²=17% 
0.26 [0.21, 0.32], *p<0.00001, 
I²=17% 
CD4+CD25+ 
Tregs (%) 
   
Total group 2 (78) -0.23 [-0.60, 0.15], p=0.23, 
I²=87% 
-1.24 [-3.73, 1.25], p=0.33, 
I²=87% 
Ma M 2010 1 (40) -2.67 [-4.42, -0.92], *p=0.003 na 
Zhang Y 2010a 1 (38) -0.11 [-0.49, 0.27], p=0.58 na 
NK cell activity 
(%) 
   
Total group 18 (1175) 9.13 [8.49, 9.77], *p<0.00001, 
I²=97% 
8.89 [5.11, 12.67], *p<0.00001, 
I²=97% 
Excluding outliers 11 (790) 5.57 [4.73, 6.41], *p<0.00001, 
I²=29% 
5.71 [4.65, 6.77], *p<0.00001, 
I²=29% 
*statistically significant; MD: mean difference; FE: fixed effect; RE: random effect; I²: proportion of heterogeneity; na: not 
applicable. 
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Figure 4.59: Forest plot of mean difference for CD+3 (n=14) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.60: Funnel plot of 14 studies that reported CD+3 
 
Figure 4.61: Forest plot of mean difference for CD+3 after removal of outliers (n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
The pooled result for this sub-group of studies, showed that the CHM interventions significantly 
increased the percentage of CD3+ cells (MD 4.97, 95% CI [4.06, 5.88], I2=41%) with a reduction in 
the effect size but no important heterogeneity (Figure 4.61). 
Study or Subgroup
Ding X 2010
Dong J 2011
Guo Z 1999
Li H 2000
Liu J 2005
Lu  Q 2010
Pan M 2003
Song W 2012
Wang H 2000
Wu G 2010
Yin X 2011
You J 2010
Zeng B 2008
Zhang W 2013
Total (95% CI)
Heterogeneity: Chi² = 189.92, df = 13 (P < 0.00001); I² = 93%
Test for overall effect: Z = 16.25 (P < 0.00001)
Mean
61.22
60.32
49.3
59.4
69.98
64.03
59.87
72.11
43.7
68.09
67.25
69.14
68.9
65.31
SD
5.44
14.05
2.6
7.9
9.06
10.83
8.3
3.24
6.2
10.97
6.22
6.32
9.2
4.24
Total
30
20
38
15
52
20
36
20
56
33
32
30
25
32
439
Mean
55.76
55.49
42.9
57.2
64.41
60.84
57.65
63.64
40.6
66.58
64.22
49.22
40.3
63.37
SD
5.23
12.17
2.8
9.8
10.95
8.35
6.8
5.36
6.7
10.43
5.58
6.35
8.1
5.16
Total
30
20
31
17
26
20
31
20
42
25
32
30
25
32
381
Weight
8.1%
0.9%
35.8%
1.6%
2.5%
1.6%
4.5%
7.9%
8.8%
1.9%
7.1%
5.8%
2.6%
11.1%
100.0%
IV, Fixed, 95% CI
5.46 [2.76, 8.16]
4.83 [-3.32, 12.98]
6.40 [5.11, 7.69]
2.20 [-3.94, 8.34]
5.57 [0.69, 10.45]
3.19 [-2.80, 9.18]
2.22 [-1.40, 5.84]
8.47 [5.73, 11.21]
3.10 [0.50, 5.70]
1.51 [-4.03, 7.05]
3.03 [0.13, 5.93]
19.92 [16.71, 23.13]
28.60 [23.80, 33.40]
1.94 [-0.37, 4.25]
6.38 [5.61, 7.15]
Experimental Control Mean Difference Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours control Favours experimental
-50 -25 0 25 50
0
1
2
3
4
5
MD
SE(MD)
Study or Subgroup
Ding X 2010
Dong J 2011
Guo Z 1999
Li H 2000
Liu J 2005
Lu  Q 2010
Pan M 2003
Song W 2012
Wang H 2000
Wu G 2010
Yin X 2011
You J 2010
Zeng B 2008
Zhang W 2013
Total (95% CI)
Heterogeneity: Chi² = 13.49, df = 8 (P = 0.10); I² = 41%
Test for overall effect: Z = 10.74 (P < 0.00001)
Mean
61.22
60.32
49.3
59.4
69.98
64.03
59.87
72.11
43.7
68.09
67.25
69.14
68.9
65.31
SD
5.44
14.05
2.6
7.9
9.06
10.83
8.3
3.24
6.2
10.97
6.22
6.32
9.2
4.24
Total
30
20
38
15
52
20
36
20
56
33
32
30
25
32
312
Mean
55.76
55.49
42.9
57.2
64.41
60.84
57.65
63.64
40.6
66.58
64.22
49.22
40.3
63.37
SD
5.23
12.17
2.8
9.8
10.95
8.35
6.8
5.36
6.7
10.43
5.58
6.35
8.1
5.16
Total
30
20
31
17
26
20
31
20
42
25
32
30
25
32
254
Weight
11.3%
0.0%
49.8%
2.2%
3.5%
2.3%
6.3%
0.0%
12.2%
2.7%
9.8%
0.0%
0.0%
0.0%
100.0%
IV, Fixed, 95% CI
5.46 [2.76, 8.16]
4.83 [-3.32, 12.98]
6.40 [5.11, 7.69]
2.20 [-3.94, 8.34]
5.57 [0.69, 10.45]
3.19 [-2.80, 9.18]
2.22 [-1.40, 5.84]
8.47 [5.73, 11.21]
3.10 [0.50, 5.70]
1.51 [-4.03, 7.05]
3.03 [0.13, 5.93]
19.92 [16.71, 23.13]
28.60 [23.80, 33.40]
1.94 [-0.37, 4.25]
4.97 [4.06, 5.88]
Experimental Control Mean Difference Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours control Favours experimental
   
135 
4.8.5.2 CD4+ cells 
Fifteen studies reported assessable data for CD4+ cells. Thirteen out of the 15 studies reported that the 
additional CHM interventions improved the percentage of CD4+ cells in serum. Wang et al. (2000) 
and Zeng et al. (2013) reported there were no differences before and after the CHM treatments. In the 
CMT control groups, only Wu et al. (2010) reported the CD4+ cells percentage were raised after 
treatment (Wu et al., 2010). The other studies all reported that the CD4+ cells were either not changed 
or reduced. 
In the comparison between the two treatment groups after treatment, the pooled CD4+ percentage was 
significantly higher in the CHM plus CMT groups (MD 7.27, 95% CI [6.73, 7.82], p<0.00001, 
I²=97%), and there was important heterogeneity. The effect size was similar in the two analysis 
models (Table 4.12; Figure 4.62). The funnel plot found that six studies were outside of the 95% 
confidence zone (Ding et al., 2010; Zeng et al., 2013; Zeng et al., 2008; Song et al., 2012; Zhang et al., 
2013; Zhou et al., 2012, Figure 4.63), so these studies were removed from the pool. The pooled result 
for the remaining nine studies was still significantly in favour of the combination therapy group (MD 
4.82, 95% CI [4.11, 5.53], p<0.00001, I²=39%), with reduced effect size but no important 
heterogeneity (Table 4.12; Figure 4.64). 
 
Figure 4.62: Forest plot of mean difference for CD+4 (n=15) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 4.63: Funnel plot of 15 studies that reported CD4+ 
 
 
Figure 4.64: Forest plot of MD for CD+4 after outlier removal (n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
4.8.5.3 CD8+ cells 
Fourteen studies reported assessable data for CD8+ cells. The majority of the studies (n=8) reported 
the CHM interventions decreased CD8+ cell percentages compared to baseline. There was a 
statistically significant reduction in CD8+ cells when CHMs were added to the CMT interventions 
(MD 1.68, 95% CI [-1.07, 2.28], p<0.00001, I²=99%) compared with CMT alone, with important 
heterogeneity (Figure 4.65). The two analysis models produced similar outcomes (Table 4.12). 
The funnel plot showed that five studies that were outliers (Ding et al., 2010; Guo, 1999; Zeng et al., 
2013; Zhang et al., 2013; Zhou et al., 2012; Figure 4.66), so they were removed from the pooled 
analysis. The pooled result of the 9 remaining studies still showed a statistically significant reduction 
in favour of the combination therapy groups (MD -1.39, 95% CI [-2.30, 0.48], p=0.003, I²=37%), and 
there was no important heterogeneity (Figure 4.67). 
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Figure 4.65: Forest plot of mean difference for CD+8 (n=14) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.66: Funnel plot of 14 studies that reported CD+8 
 
Figure 4.67: Forest plot of mean difference for CD+4 after outlier removal (n=9) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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baselines. In the comparison with the CMT control groups after treatment, the ratio of CD4+ to CD8+ 
was statistically significantly higher when CHMs were added to the interventions (MD 0.32, 95% CI 
[0.27, 0.36], p<0.00001, I²=75%), and there was important heterogeneity (Figure 4.68). 
The funnel plot found that two studies were the outliers (You et al., 2010; Zhou et al., 2012; Figure 
4.69), so they were removed from the pooled analysis. The pooled result of 15 studies still showed a 
significant difference in favour of the combination therapy (MD 0.28, 95% CI [0.23, 0.32], p<0.00001, 
I²=17%), and there was no important heterogeneity (Figure 4.70). The fixed model and random model 
showed the same effect sizes and I² values (Table 4.12). 
 
Figure 4.68: Forest plot of mean difference for CD4+/CD+8 (n=17) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.69: Funnel plot of 17 studies that reported CD4+/CD8+ 
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Figure 4.70: Forest plot of mean difference for CD+4/CD8+ after outlier removal (n=15) 
control: chemotherapy alone; experimental: HM + chemotherapy 
4.8.5.5 NK cell activity 
Eighteen studies reported assessable data for percentage of NK cell activity (%) in serum. Fifteen out 
of 18 studies reported the CHMs increased NK cell activity. The other three studies reported no 
change in NK cell activity after the CHM interventions compared with the baseline values. In the 
comparison with the CMT control groups, the NK cell activity was statistically significantly higher 
when the additional CHMs were included in the intervention (MD 9.13, 95% CI [8.49, 9.77], 
p<0.00001, I²=97%), and there was important heterogeneity (Figure 4.71).  
The funnel plot found that seven studies that were outliers (Li et al., 2000; Qin et al., 2011; Song et al., 
2012; Wu et al., 2010; Zeng et al., 2008; Zhang et al., 2013; Zhou, 2012) (Figure 4.72), so they were 
removed from the pooled analysis. The sensitivity analysis involved 11 studies. The pooled result still 
found that the combination treatment groups showed statistically significant increases in NK cell 
activity compared with the control chemotherapy groups (MD 5.57, 95% CI [4.73, 6.41], p<0.00001, 
I²=29%), with reduced effect size but no important heterogeneity, and the funnel plot was symmetric 
(Figure 4.73 and 4.74). Similar results were found in the fixed model and random model analyses 
(Table 4.12).  
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Figure 4.71: Forest plot of mean difference for NK cell activity (n=18) 
control: chemotherapy alone; experimental: HM + chemotherapy 
 
Figure 4.72: Funnel plot of 18 studies that reported NK cell activity 
 
Figure 4.73: Forest plot of mean difference for NK cell activity after outlier removal (n=11) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 4.74: Funnel plot of 11 studies that reported NK cell activity after outlier removal 
4.8.5.6 CD4+CD25+ Tregs 
Two studies reported data on the percentage of CD4+CD25+ Tregs in serum. The pooled result 
showed there was no statistically significant difference between the two treatment groups in 
CD4+CD25+ Tregs (MD -2.23, 95% CI [-0.60, 0.15], p=0.23, I²=87%), and there was important 
heterogeneity (Figure 4.75). The results of these two studies were inconsistent, so the individul studies 
were analysed separately. Zhang et al. (2010) was in in adjuvant setting and found no difference 
between the two treatment groups (MD -0.11, 95% CI [-0.49, 0.27], p=0.58). Ma et al. (2010) included 
patients in adjuvant or palliative settings, and showed a significant difference in favour of the 
combination treatment (MD -2.67, 95% CI [-4.42, -0.92], p=0.003).  
The expression of CD4+ CD25+ Tregs is higher in cancer tissues and peripheral blood of cancer 
patients than in healthy cohorts. Over-expression of FoxP3+, CD4+ CD25+ Tregs suppressed tumour-
specific T cell immunity in cancer patents and was correlated with poorer survival (Curiel et al. 2004). 
The reason for inconsistent results of these two studies may be due to participants being at different 
stages of the disease. 
 
Figure 4.75: Forest plot of mean difference for CD4+CD25+ Tregs (n=2) 
4.8.5.7 Discussion of effects on the immune system 
In general, CRC patients have lower cell-mediated immunity (CMI) characterised by lower 
percentages of CD3+, CD4+, CD4+/CD8+ and NK cells, but higher percentages of CD8+ cells in 
serum. The low CMI status is correlated with the stage of the disease and the tumour load (Ji et al., 
2010). Chemotherapy can induce myosuppression that will further damage the patients’ immunity, 
including the CMI. The results showed that the combination of CHMs with CMT improved the CMI, 
in terms of increased CD3+, CD4+, CD4+/CD8+, and NK cell activity in serum compared with CMT 
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alone groups. The finding of increased CD3+, CD4+, CD4+/CD8+ was consistent with the systematic 
review by Zhong et al. (2012) which included considerably fewer studies. 
However, the results of these meta-analyses showed important heterogeneity. The reasons may have 
been associated with base-line factors such as stage of the disease and tumour burden, the CHM and 
CMT interventions, treatment duration, and methods of measuring the T cell subsets. Due to the 
important heterogeneity in these meta-analysis results, there was the question of how to select an 
appropriate analysis model. In the fixed effect model, in which the assumption is that every study 
bears the same value, the analysis tries to estimate the true effect of the intervention in both magnitude 
and direction. That is, it aims to determine the best estimate of the effect of the treatment. The random 
effect model is based on the assumption that the effect in every study is not the same. It describes the 
average effect of the treatment (Higgins et al., 2011). In dealing with similar data, different systematic 
reviews have used different analysis models. Zhong et al. (2012), in the systematic review of HM 
combined CMT for CRC, used a random effect model in their meta-analysis, whereas the systematic 
review of CHM combined CMT for lung cancer by Chen et al. (2009) applied the fixed effect model. 
In this project, the goal was to assess the true effect of CHMs in the management of CRC. The 
majority of included studies had reported the addition of CHMs improved CMI and the data from the 
studies showed the direction of the effect on immunity generally to be positive. Therefore, the fixed 
effect model was adopted in the first place. 
In general, the approach for dealing with important heterogeneity was based on clinical aspects by 
grouping studies by type of CMT, and previously treated or untreated patients. However, in this 
section, the relatively fewer studies made this approach less applicable and when grouping by CMT 
type was tried but it did not reduce heterogeneity. Since the heterogeneity was unexplainable based on 
clinical factors, an alternative approach was used. Firstly, the analysis incorporated both fixed and 
random effect models. However, the comparison of the results between the fixed effect and the 
random effect models showed they were similar in effect sizes and I2 values so variation in the model 
did not resolve the issue. It was evident that there was asymmetry in the funnel plots with the obvious 
presence of outliers, so the sensitivity analysis method of excluding outliers to obtain a better measure 
of effect size was adopted. When there was substantial funnel plot asymmetry, then the outliers that 
were outside of the 95% confidence zone and any small studies that were isolated at the bottom of the 
funnel plot were excluded from the meta-analysis, to determine whether the outliers affected the 
overall result. After this process, the pooled results generally showed less heterogeneity, the effect 
sizes were reduced while the directions of the effect were not changed. Also, there was little difference 
between the fixed and random effect models after this procedure. Consequently, the resultant 
comparisons provided higher degrees of certainty in the estimates of treatment effects. Also, these 
analyses suggest that any effect of reporting or publication bias was not substantial enough to affect 
the overall result. 
   
143 
Nevertheless, the issue of possible reporting or publication bias remains. The heterogeneity in results 
could have been due to positive reporting bias or it could have been due the multiple factors that could 
have impacted on the results for CMI parameters including: participants being at different stages of the 
disease and or having differing tumour loads, for example partipants receiving Stage II and III patients 
receiving adjuvant chemotherapy could be expect to show very different CMI profiles to stage IV 
patient receiving palliative treatment; different chemotherapy regimens could have different effects on 
CMI; and the intensity and duration of chemotherapy is also likely to have influenced immunity with 
more cycles of chemotherapy resulting in more immunosuppression. 
In this review, non-individual participant data was used, so it was not possible to perform detailed 
analysis based on these clinical factors. Future studies of this topic could consider these factors. 
 Adverse events associated with Chinese herbal medicines 4.8.6
In total, ten studies reported on adverse events due the the CHM interventions. There were no serious 
adverse events reported that were associated with the CHMs. Common CHM adverse events were 
mild gastrointestinal symptoms such as nausea and diarrhoea (Table 4.13). Other HM reviews reported 
similar findings (Zhong et al., 2012; Guo et al., 2012). 
Table 4.13: Ten studies that reported herbal medicine (HM) adverse events 
Study Treatment Adverse events (AEs) 
Cao B (2011) Yiqi zhuyu decoction Hypertension, bleeding: not different between groups 
Hou A (2009) Fuzhengxiaoai decoction-I Two cases of mild vomiting. 
Kono T (2013) TJ-107 (goshajinkigan) Well tolerated. None of AEs were considered TJ-107 
related. 
Schink M (2007) Mistletoe extract None of the AEs in the treatment group were related to 
the Mistletoe extract. 
Shen H (2003) Changbi'an Capsule No HM related AEs were observed. 
Torisu M (1990) YunZhi powder Coriolus 
vesiocolor spores 
Pigmentation of nail, cough when taking the PSK, mild 
diahrroea, constipation. 
Xion S (2003) Changkangfu capsule Mild gastrointestinal symptoms were reorted. 
Yang Y (2008) Quxie capsule Mild diarrhoea. 
Yang Y (2007) Quxie capsule Mild diarrhoea. 
Yang Y (2008a) Kang'ai Injection No HM related AEs were observed. 
Zheng Y (2011) Shenqisan No HM related AEs were observed. 
4.9 Chapter 4 summary and conclusions 
Most of the RCTs of HM for CRC were conducted in China. Potential bias due to methodological 
issues was evident amongst the included studies, so any conclusions must be tentative. The HM 
interventions were diverse and included oral decoctions, tablets, powders, HM extracts for intravenous 
infusion, decoctions for enema, and HM extracts for TACE. The 78 CHM formulas included 146 
distinct plant-based HMs plus 20 items of insect or animal origin. Nevertheless, the same or similar 
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ingredients were included in multiple studies, so the degree of variation was less than these numbers 
suggest. 
In the section on HM treatments used alone, the HMs: 
• improved the immunosuppression status induced by surgical treatment during the peri-
operative period; 
• may have beneficial effects on OS and DFS for stage III CRC post surgery; 
• appeared not significantly different to the 5-FU regimens in treating ACRC in terms of tRR 
and OS; and 
• improved KPS in ACRC patients. 
Therefore these HMs may provide an additional therapeutic option for ACRC patients in the terminal 
stage of the disease. Also, Javanica oil emulsion (extracted from Brucea javanica seed) is a potential 
surrogate for chemo-therapeutic agents for liver tumours included those resulting from CRC liver 
metastasis. 
In the section on integrative therapy, the meta-analyses found that CMTs including oxaliplatin and 
non-oxaliplatin regimens, combined with CHMs: 
• significantly improved the tRR in CRC compared to the same chemotherapy alone; 
• elevated the one-year, two-year, three-year, and five-year OS; 
• the mean OS in the combination therapy groups was significantly better than in the CMT 
alone groups.  
These results suggest that the additional CHM treatments may have synergetic anti-cancer effects to 
the CMT, enhance the anti-cancer effects of the CMT, or provide additional anticancer effects. The 
results were broadly consistent with the study by Zhong et al 2012 for tRR and survival. 
Also, the combination of CMT and CHM treatment significantly: 
• improved KPS and other meaures of QoL; 
• alleviated the chemotherapy-related adverse events of neutropenia, thrombocytopenia, 
anaemia, nausea and vomiting, diarrhoea, neurotoxicity, aloplecia, stomatitis, and 
impairment of liver function; and 
• improved cell-mediated immunity status. 
In terms of the safety of the HMs, most of the AEs were mild gastrointestinal symptoms and there was 
no report of death, vital organ damage or undesirable herb-drug interactions caused by the application 
of HMs for CRC management in the studies included in this review. 
Previous reviews included fewer studies, with four studies in Wu 2005 and 20 studies in Zhong et al 
2012, all of which were of integrative medicine. In this systematic review and meta-analysis the 
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number of included studies (88 RCTs) and consequently the sample sizes in the meta-analyses were 
considerably larger, and the scope of the review was not restricted to Chinese herbal medicine or to 
integrative medicine. Nevertheless, most of the 88 RCTs of HM for CRC were conducted in China and 
most were of integrative medicine. In addition, the meta-analyses were sub-grouped into non-
oxaliplatin group, oxaliplatin group, adjuvant setting group, palliative setting group, previously treated 
group, and previously untreated group. This process improved the validity of data sets and reduced the 
statistical heterogeneity of the meta-analysis results. Moreover, the effects of various HM 
administration routes were examined. These included oral administration, intravenous drip, 
transcatheter arterial chemoembolization (TACE), intraperitoneal hyperthermic perfusion and enema. 
However, the studies tended to have small sample sizes, be of short durations, and were mainly single-
centre RCTs. There were number of reporting issues, such as over-simplified or incomplete reporting 
of outcomes that may have been associated with a lack of clear guidelines for trial reporting in the 
journals published in China, or inadequacies in the original trial protocols. Since the analyses are 
based on published data, the original patient-level data are unavailable, and few studies had available 
protocols, it is difficult to judge the accuracy and methodological rigor of the original studies. In this 
chapter, the results are estimations based on the pooled results from multiple studies so the results 
summaried above and the associated conclusions must be tentative. Since some of the results are 
promising further investigations should be conducted using sufficiently powered, rigorously designed 
RCTs. 
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Chapter 5. FOLFOX4 Combined with Herbal Medicine for Advanced 
Colorectal Cancer 
 
5.1 Introduction to chapter five 
This chapter is based on the published paper: Chen M, May BH, Zhou IW, Xue CC, Zhang AL. 
(2014). FOLFOX 4 Combined with herbal medicine for advanced colorectal cancer: A systematic 
review. Phytother Res. Jul, 28(7): 976-91.  
It also includes one additional study (Cao et al., 2011) which was identified in the update search 
(December 2013), so there are some differences to the published version. 
The FOLFOX regimen refers to 5-fluorouracil (5-FU) plus leucovorin (LV) combined with 
oxaliplatin. It is a standard first line combination chemotherapy setting for advanced CRC (ACRC) 
(Lee & Chu, 2007; Prescrire Editorial Staff, 2010). A number of modalities of FOLFOX regimens, 
which consist of varying doses and schedules of 5-FU, LV and oxaliplatin, have been studied in 
palliative settings. Of these, FOLFOX4 has been the most widely investigated (Waddell & Solimando, 
2005). The FOLFOX4 regimen has a fixed dosage and schedule in each cycle, so in studies that 
employed FOLFOX4, there is lesser variation in the chemotherapy that could contribute to 
heterogeneity in results. Also, in this systematic review all participants were at the advanced stage of 
CRC, so variation due to differences between participants was reduced. 
FOLFOX4 comprises a 2-hour infusion of LV (200 mg/m2/d), followed by a 5-FU bolus (400mg/m2/d) 
and a 22-hour infusion (600 mg/m2/d) for 2 consecutive days every 2 weeks, together with oxaliplatin 
85mg/m2 as a 2-hour infusion on day 1. It is used in conjunction with anti-nausea medications. The 
regimen is repeated every 14 days until disease progression or unacceptable toxicities force cessation 
(De Gramont et al., 2000). 
This section focuses on CHMs as adjuvants to FOLFOX4 in the treatment of ACRC. It aims to 
determine if CHMs demonstrate evidence of efficacy and safety in the treatment of ACRC and/or the 
management of the side effects of FOLFOX4. Since the FOLFOX4 regimen has fixed dosage and 
schedule, and the participants were all in the late stage of CRC, this sub-group of studies shows 
elevated similarity between studies and reduced heterogeneity in treatment and participant 
characteristics. Consequently, this meta-analysis was suitable for identifying the best available 
evidence for the effects of CHM in ACRC (Research question 6). 
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5.2 Search results 
Fourteen studies (Cao et al., 2011; Ding et al., 2010; Fang & Li, 2008; Li et al., 2007b; Li et al., 
2007c; Qiu, 2011; Wu et al., 2010; Xu & Wang, 2010; Yang, 2008; Zeng et al., 2009; Zeng et al., 
2008; Zhang et al., 2008; Zhang et al., 2010a; Zhang et al.,2010b) that investigated a combination of 
CHM plus FOLFOX4 versus FOLFOX4 for ACRC were included in this review. 
The 14 studies enrolled 1,060 assessable in-patient participants with 546 participants in the CHM plus 
FOLFOX4 test groups and 514 participants in the FOLFOX4 alone control groups. All studies were 
conducted in China and published in Chinese medical journals from 2007 to 2011. Participant 
characteristics, interventions and outcome measurements are summarised in Table F1 in Appendix F. 
Thirteen different test interventions were used. Seven studies employed commercially available CHM 
extracts. Kang’ai Injection was used in two studies. Compound Kushen injection, Ginsenoside Rg3 
capsules, Aidi injection, Gubenxiaoliu Capsule and Javanica oil injection were each used in one study. 
Seven studies used multi-herbal decoctions. In total, 61 different herbs and/or their extracts were used, 
with the six most frequent being: 
• Huang qi: Astragalus membranaceus (Fisch.) Bge. root (eight studies) (Cao et al., 2011; Li 
et al., 2007b; Li et al., 2007c; Qiu, 2011; Yang, 2008; Zeng et al., 2008; Zhang et al., 2008; 
Zhang et al., 2010b);  
• Yi yi ren: Coix lachryma-jobi L. seed (six studies) (Li et al., 2007c; Wu et al., 2010; Xu & 
Wang, 2010; Zeng et al., 2008; Zhang et al., 2008; Zhang et al., 2010a);  
• Ren shen: Panax ginseng C.A. Mey. root (six studies) (Cao et al., 2011; Li et al., 2007b; 
Qiu, 2011; Yang, 2008; Zeng et al., 2009; Zhang et al., 2010a);  
• Ku shen: Sophora flavescens Ait. root (six studies) (Cao et al., 2011; Ding et al., 2010; Qiu, 
2011; Yang, 2008; Zeng et al.,2008; Zhang et al., 2008); 
• Bai zhu: Atractylodes macrocephala Koidz. Root (six studies) (Cao et al., 2011; Li et al., 
2007c; Xu and Wang, 2010; Zeng et al., 2008; Zhang et al., 2008; Zhang et al., 2010b); and 
• Fu ling: Poria cocos (Schw) Wolf sclerotium (four studies) (Li et al., 2007c; Wu et al., 
2010; Xu & Wang, 2010; Zhang et al., 2008). 
5.3 Meta-analysis results 
Meta-analyses were performed for each of the following outcomes. The numerical data are presented 
in Table 5.1.  
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  Effect on tumour response 5.3.1
The tumour response rate (tRR) ranged from 30% to 54.1% for the test groups and from 20% to 46.6% 
for the control groups in the 13 studies (1,000 participants). There was a significant improvement in 
tRR for CHMs plus FOLFOX4 (test groups) compared to FOLFOX4 alone (Table 5.1; Figure 5.1). 
The pooled tRR in the test groups was elevated to 43.8% (RD 9.1%). The total numbers of complete 
remissions (CRs) in the test and control groups were 19 and 8 patients, respectively, but this difference 
was not significant (RD 2.3%). 
The tRR data included 234 (24.9%) participants who were previously treated with chemotherapy for 
ACRC, but separate results were reported for only 126 of these. Previously treated ACRC patients 
have been found to be less responsive to current first-line settings of chemotherapy (Giantonio et al., 
2007). When the sub-groups of previously treated (two studies) and previously untreated (four studies) 
patients were analysed, the RD of the pooled tRR was 8.7% for previously treated and 9.0% was 
previously untreated but there was no significant difference between test and control groups. For the 
two studies of Kang’ai Injection, the RD was 3.0% but there was no significant difference between 
groups (Table 5.1). 
Thirteen studies reported on tRR so a Funnel Plot was used to assess publication bias (Figure 5.2). The 
symmetry of the Funnel Plot suggests the risk of publication bias was low for these studies. 
 
Figure 5.1: Forest plot of risk ratio for tumour response rate in advanced colorectal cancer 
(n=13) 
control: chemotherapy alone; experimental: HM + chemotherapy 
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Figure 5.2: Funnel plot of the 13 studies that reported tumour response rate in advanced 
colorectal cancer 
Table 5.1: Results of meta-analyses for each outcome measure in Chapter 5 
Outcomes No 
Studies*SN 
(participants) 
Meta-analysis results (between 
groups at end of treatment): 
95%CI 
Incidence % (n/N) or 
MD ± SD 
RD 
(%) 
Tumour response     
Tumour response rate 
(tRR) 
131-13 (1000) RR 1.25[1.07, 1.46], *p=0.004, 
I²=0%, FE 
T: 43.8% (226/516) 
C: 34.7% (168/484) 
9.1 
Complete remission 
(CR) 
122-13 (880)  RR 1.94 [0.89, 4.25], p =0.10, 
I²=0%, FE  
T: 4.2% (19/456) 
C: 1.9% (8/424) 
2.3 
tRR (previously 
treated patients) 
23,10 (126) RR 1.41 [ 0.77, 2.61], p =0.27, 
I²=0%, FE 
T: 29.7% (19/64) 
C: 21.0% (13/62) 
8.7 
tRR (previously 
untreated patients) 
31,3,5,9 (221) RR 1.21 [ 0.92, 1.59], p =0.17, 
I²=0%, FE 
T: 47.3% (70/148) 
C: 38.3% (51/133) 
9.0 
tRR (Kang'ai 
Injection sub-group) 
25,8 (103) RR 1.07 [ 0.71, 1.61], p =0.76, 
I²=0%, FE 
T: 48.1% (25/52) 
C: 45.1% (23/51) 
3.0 
Overall survival 
(OS) 
    
One year OS 33,12,13 (279) RR 1.51 [1.19, 1.90], *p =0.0006, 
I²=0%, FE 
T: 62.3% (91/146) 
C: 42.1% (56/133) 
20.2 
mOS 41,2,4, 14 (339) MD 2.33 [39, 3.27], *p<0.00001. NA NA 
mTTP 41,2,8,14 (343) MD 2.25 [63, 2.87], *p<0.00001. NA NA 
Quality of life     
Karnofsky 
Performance Status 
(KPS) 
93-5,7,9-13 (669) RR 1.84 [1.54, 2.19], p<0.00001, 
I²=0%, FE 
T: 60.9% (210/345) 
C: 32.1% (104/324) 
28.8 
mean KPS (Wu 2010) 16 (58) MD 12.18 [96, 16.40], *p<0.00001  T: before 74.38 ± 
11.16, after 73.94 ± 
6.35 
C: before 75.16 ± 
12.78, after 61.76 ± 
9.23 
NA 
Su Ying’s QoL 
Questionnaire (Yang 
2008a) 
18 (60) MD 4.10 [2.36, 5.84], *p<0.00001 T: before 40.73 ± 3.49; 
after 42.30 ± 3.88 
C: before 40.90 ± 2.44; 
after 38.20 ± 2.91 
NA 
Body weight (BW) 38,9,13 (169) RR 1.88 [1.14, 3.08], *p =0.01, 
I²=0%, FE 
T: 38.4% (33/86) 
C: 19.5% (16/82) 
18.9 
Chemotherapy 
toxicity 
    
Neutropenia events 
(grade 3/4) 
101-6,8,10,12,13 
(692)  
RR 0.33 [0.18, 0.60], *p=0.0003, 
I²=0%, FE 
T: 3.9% (14/359) 
C: 12.6% (42/333) 
8.7 
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Outcomes No 
Studies*SN 
(participants) 
Meta-analysis results (between 
groups at end of treatment): 
95%CI 
Incidence % (n/N) or 
MD ± SD 
RD 
(%) 
Nausea & vomiting 
(grade 3/4) 
91-8,13 (633)  RR 0.34 [0.18, 0.66], *p=0.001, 
I²=0%, FE 
T: 3.0% (10/330);  
C: 12.5% (38/303) 
9.5 
Neurotoxicity (grade 
3/4) 
71-4,12,13 (529)  RR 0.39 [0.15, 1.00], *p =0.05, 
I²=0%, FE 
T: 2.2% (6/277)  
C: 6.0% (15/252) 
3.8 
Diarrhoea (grade 3/4) 52,3,6,8,12 (448) RR 0.39[0.11, 1.42], p =0.15, I²=0% 
FE 
T: 0.9% (2/236)  
C: 3.3% (7/212) 
2.4 
Anaemia (grade 3/4) 36,12,13 (220) RR 0.30 [0.05, 1.89], *p =0.20, 
I²=0% FE 
T: 0% (0/114)  
C: 2.9% (3/105) 
2.9 
Thrombocytopenia 
(grade 3/4) 
113 (42) RR 1.00, [0.07, 14.95], p =1.00, FE T: 4.8% (1/21)  
C: 5.0% (1/20) 
NA 
Stomatitis (grade 3/4) 22,3 (210) RR 0.43 [0.08, 2.31], p =0.33, 
I²=0%, FE 
T: 1.8% (2/113)  
C: 4.1% (4/97) 
2.3 
Constipation (grade 
3/4) 
13 (117) RR 0.40 [0.04, 4.29], p =0.45, FE T: 1.5% (1/65)  
C: 3.8% (2/52) 
NA 
Kang'ai Injection 
Sub-group 
    
Neutropenia events 
(grade 3/4) 
25,8 (103) RR 0.19[0.04, 0.83], *p =0.03, 
I²=0%, FE 
T: 3.8% (2/52)  
C: 21.6% (11/51)  
17.8 
Nausea & vomiting 
(grade 3/4) 
25,8 (103) RR 0.27[0.08, 0.89], *p =0.03, 
I²=0%, FE 
T: 5.8% (3/52) 
C: 21.6% (11/51) 
15.8 
Zhang et al. (2008)     
Myolesuppression 
(grade 3) 
111 (60) RR 0.47[0.04, 4.89], p =0.53, FE T: 3.23% (1/31) 
C: 6.90% (2/29) 
NA 
Zeng et al. (2009)     
Neutropenia (all 
grades) 
110 (67) RR 0.72 [0.54, 0.96], *p=0.02, FE T: 62. 9% (22/35) 
C: 87. 5% (28/32) 
NA 
Neurotoxicity (all 
grades) 
110 (67) RR 0.87 [0.58, 1.30], p=0.5, FE T: 54.3% (19/35) 
C: 62.5% (20/32) 
NA 
Nausea, vomiting, 
diarrhoea (all grades) 
110 (67) RR 0.82 [ 0.65, 1.03], p=0.08, FE T: 74.3% (26/35) 
C: 90.6% (29/32) 
NA 
Immune function     
CD3+ cells (%) 21,6 (118) MD 4.70 [2.27, 7.13], *p=0.0001, 
I²=37%, FE 
NA NA 
CD4+ cells (%) 21,6 (118) MD 9.08 [0.10, 18.05], *p=0.05, 
I²=95%, RE 
NA NA 
CD8+ cells (%) 21,6 (118) MD -4.47 [-9.54, 0.61], p=0.08, 
I²=87% RE 
NA NA 
Ratio CD4+/CD8+ 21,12 (180) MD 0.28 [0.14, 0.43], *p=0.0002, 
I²=13%, FE 
NA NA 
NK cells (%) 31,6,12 (238) MD 4.03 [0.51, 7.55], *p=0.02, 
I²=88%, RE 
NA NA 
Zeng et al. (2009)     
CD3+ cells (%) 110 (67) MD 8.80 [7.34, 10.26], *p<0.00001, 
FE 
T*: 3.6±2.31, C: -
5.2±3.60 
NA 
CD4+ cells (%) 110 (67) MD 9.40 [8.51, 10.29], *p<0.00001, 
FE 
T*: 3.2±1.42, C: -
6.2±2.18 
NA 
CD8+ cells (%) 110 (67) MD 7.80 [6.62, 8.98], *p<0.00001, 
FE 
T*: 1.3±1.92, C: -
6.5±2.86 
NA 
Ratio CD4+/CD8+ 110 (67) MD 0.22 [0.16, 0.28], *p<0.00001, 
FE 
T*: 0.04±0.09, C: -
0.18±0.28 
NA 
   
151 
T: test group; C: control group; RR: risk ratio; N: total number of participants in group(s); n: number of incidence(s) in 
group(s); I²: test of heterogeneity of meta-analysis of pooled data, over 50% represents substantial heterogeneity; MD: mean 
difference; SD standard deviation; RD: Risk difference; NA: not applicable; T*: Mean change; FE: Fixed Effect model; RE: 
Random Effect model; *p≤ 0.05: statistic significant. 
*SN: study No (superscript) (1st author (year)). 1. Cao B 2011; 2. Ding X 2010; 3. Fang M 2008; 4. Li H 2007; 5.Li Y 2007; 
6. Qiu Z 2011; 7.Wu G 2010; 8. Xu Y 2010; 9. Yang Y 2008a; 10. Zeng D 2009; 11. Zeng J 2008; 12. Zhang H 2008; 13. 
Zhang Q 2010; 14. Zhang Y 2010. 
  Effect on overall survival and time to progression 5.3.2
Three studies reported one-year overall survival (OS). There was a significant difference in favour of 
the test groups (RD 20.2%) (Table 5.1). No long-term (two-year or more) OS data were reported. 
Median OS and median time to progression (TTP) were each reported in four studies. The estimated 
mean values of median OS and median TTP were significantly increased when FOLFOX4 was 
combined with CHMs compared with the FOLFOX4 treatment alone (Table 5.1). 
  Effect on quality of life and body weight 5.3.3
Ten studies used Karnofsky Performance Status (KPS) to measure quality of life (QoL) (Li et al., 
2007b; Li et al., 2007c; Qiu, 2011;Wu et al., 2010; Xu & Wang, 2010; Zeng et al., 2009; Zeng et al., 
2008; Zhang et al., 2008; Zhang et al., 2010a; Zhang et al., 2010b). Three studies (Yang, 2008; Zeng 
et al., 2009; Zhang et al., 2010b) included body weight (BW) measurement. 
Clinical effectiveness was defined as ‘improved’ for KPS and as ‘improved’ for BW. To minimise 
bias resulting from small changes in scores, the meta-analyses only included patients who recorded a 
KPS score that was 10 or more points higher after the intervention compared to prior to the 
intervention and patients who had gained 1 kg or more. Patients who achieved a stable KPS score 
and/or stable BW after the intervention were excluded from the analyses. 
The KPS improvement was significantly greater in the test groups based on nine studies (RD 28.8%) 
(Table 5.1). In Wu et al. (2010), KPS was presented as mean plus standard deviation (SD). There was 
no statistically significant difference before and after the treatment in the test group (MD 0.44, 95% CI 
-3.94 to 4.82, p = 0.84), but there was a significant decline after treatment in the control group (MD 
13.40, 95% CI 7.22 to 19.58, p<0.0001), so the mean KPS after treatment was significantly higher in 
the test group, indicating a relative improvement in the test group (Table 5.1). 
Yang (2008) reported Su Ying’s QoL questionnaire which comprised 12 items that are scored from 5 
to 1 according to increase in severity, so the more severe the symptoms the lower the score. In the test 
group, the total score was not significantly different before and after the treatment (MD 1.57, 95% CI -
3.44 to 0.30, p = 0.10), but it significantly decreased in the control group after treatment (MD 2.70, 
95% CI 1.34 to 4.06, p<0.0001). The between-group scores after treatment were significantly different 
in favour of the test group (Table 5.1). 
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For body weight, there was a significant difference in body weight improvement in favour of the test 
group based on three studies (RD 18.9%) (Table 5.1). 
  Effect on alleviation of chemotherapy-related adverse events 5.3.4
All 14 studies reported that the CHMs alleviated chemotherapy toxicity. Zhang et al. (2008) reported 
events as gastrointestinal reactions or myelosuppression, while Zeng et al. (2009) and Cao et al. (2011) 
reported toxicity events as totals (all grades). Therefore, these three studies were not included in the 
meta-analyses. 
Most of the AEs were mild (grades 1–2). The three most commonly reported AEs were nausea and 
vomiting, neutropenia and neurotoxicity. The meta-analyses included toxic events at grades 3 and 4 
only (i.e. severe toxicity) (Table 5.1). The pooled grade 3 and 4 events for neutropenia (n = 10, RD 
8.7%), nausea and vomiting (n = 9, RD 9.5%) and neurotoxicity (n = 7, RD 3.8%) were significantly 
fewer in the test groups. For the Kang’ai Injection sub-group (n = 2), significant reductions were 
found for neutropenia (RD 17.8%) and nausea and vomiting events (RD 15.8%). No significant 
difference between groups was found for the pooled grade 3 and 4 events for: diarrhoea (five studies, 
RD 2.4%); anaemia (three studies, RD 2.9%); stomatitis (two studies, RD 2.3%); thrombocytopenia 
(one study); or constipation (one study). Adverse events specific to the CHMs were not reported in 
any of the 14 studies. 
  Effect on immune function 5.3.5
Four studies reported effects on immune function, in terms of the percentage of T-lymphocyte subsets 
and Natural Killer (NK) cell activity in serum. One study reported benefits for T cells and NK cells 
but data were presented as difference scores, so these could not be included in pooling (Zeng et al., 
2009).  
There was a significant improvement in the pooled data for CD3+ cells (Wu et al., 2010) and ratio 
CD4+/CD8+ cells (Ding et al., 2010; Zhang et al., 2010a) (Table 5.1). For CD4+, CD8+ cells and NK 
cells, there were benefits reported in some studies but the pooled results were too heterogeneous to be 
meaningful. 
5.4 Discussion of CHMs combined with FOLFOX4 for advanced colorectal cancer 
All 14 studies included in this meta-analysis were published after 2007 and all employed FOLFOX4 
as a single regimen. Since this is currently the most commonly used first-line chemotherapy regimen 
for ACRC, the results of this section are of direct clinical relevance. 
   
153 
Internationally recognised measurement systems were used in all included studies, including the TNM 
staging system, WHO criteria for solid tumour response and grading of acute and subacute toxicity, 
and the KPS scoring system. Participants’ age was in the range 48–60 years in nine studies and one 
study enrolled participants whose mean age was 72.7 years (Li et al., 2007). The majority of the cohort 
was younger than the general population of CRC patients internationally, whose median age is over 70 
years. A tendency for trial participants to be younger than the average CRC patient has been found in 
other ACRC trials but younger patients did not appear to respond better or experience less toxicity 
than older patients (Hind et al., 2008), so this difference was judged as not likely to affect the 
generalizability of results. Overall, the heterogeneity of meta-analyses was low for the clinical 
outcome measures. 
The pooled data indicate the addition of the CHMs significantly improved tRR when compared to 
FOLFOX4 alone (Table 5.1). In the sub-group analysis of tRR for previously treated and untreated 
ACRC participants, the results showed a similar benefit for the CHM in both groups but this did not 
reach significance (Table 5.1). A non-significant result was also found in the CR pooling. It is possible 
that the small number of participants in these sub-groups meant there was insufficient statistical power 
to detect a difference. It is also notable that FOLFOX4 itself has not yielded high CRs in ACRC 
(Cassidy et al., 2008; De Gramont et al., 2000; Goldberg et al., 2004; Goldberg et al., 2006). Overall, 
these results suggested that the CHMs conferred an additional benefit to tRR when combined with 
FOLFOX4 for ACRC, but these results need to be verified by a large scale clinical trial. 
One year-OS, median OS and median TTP were greater in the CHM plus FOLFOX4 groups compared 
to FOLFOX4 alone (Table 5.1). Participants in the test groups were more likely to show a KPS 
improvement than in the control groups (RD 28.8%). 
For chemotherapy-related AEs, significant reductions were found in the test groups for grade 3 and 4 
neutropenia (T: 3.9% vs. C: 12.6%), nausea and vomiting (T: 3.0% vs. C: 12.5%) and neurotoxicity 
(T: 2.2% vs. C: 6.0%) (Table 5.1). These findings were generally consistent with the results in Chapter 
4 and earlier reviews of CHM adjuvant to chemotherapy for CRC (Liu and Zhu, 2009; Wu et al., 
2005; Zhong et al., 2012). 
The results for T-lymphocyte subsets suggest that some CHMs may have immune enhancing effects 
but these data were only available for a few studies and there was substantial heterogeneity in some of 
the meta-analyses (Table 5.1). The substantial heterogeneity was similar to that found in the Chapter 4 
meta-analyses of T-lymphocyte subsets. It is notable that the following CHMs that were used in the 
studies, Astragalus, P. ginseng, Atractylodes, Poria and Coix, have been reported to have 
immunomodulatory effects (Gong, 2010; Yang et al., 2002; Yang et al., 2011). 
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From the clinical perspective, these findings suggest that combining CHMs, which contain the above 
main herbs, with FOLFOX4 was clinically beneficial in advanced CRC since the addition of the 
CHMs to this commonly used chemotherapy regimen appeared to reduce a number of the adverse 
events associated with FOLFOX4. Also, adding the CHMs did not appear to reduce the effectiveness 
of FOLFOX4 since tRR and survival were not reduced, rather they appear to have been enhanced. In 
addition, these CHMs are in common use and did not appear to produce additional severe AEs. 
 Comparison with other studies of FOLFOX4 5.4.1
The improvement in tRR of 20.0% to 46.6 % (average 34.9%) for the control groups in the 12 studies 
was consistent with the results of a review by Lu et al. (2010) that pooled 27 clinical studies of 
FOLFOX4 for ACRC conducted in China (879 participants), none of which involved a comparison 
with CHM. The review by Lu et al. found the following tRRs: total 26.10 to 57.14% (27 studies); 
previously untreated patients 30.8 to 65.0% (12 studies); and previously treated patients 16.6 to 47.6% 
(12 studies). In this section, the pooled tRRs of 34.7% for all control group participants, 38.3 % for 
previously untreated participants and 21.0% for previously treated participants all fell within these 
ranges, so the results for the control groups in this section were broadly consistent with non-CHM 
studies conducted in China on FOLFOX4. In the control groups in this review, the median OS was 
10.2 to 18.6 months and the TTP was 6.9 to 10.2 months, which were similar to the ranges found in 
the review by Lu et al. (OS 9.0 to 17.7 months, TTP 5.47 to 9.00 months). 
It was evident that the average tRR (34.7%) in the control groups in this review and in the review of 
Chinese FOLFOX4 studies (Lu et al., 2010) were both relatively low compared to large international 
trials (Cassidy et al., 2008; De Gramont et al., 2000; Goldberg et al., 2004; Goldberg et al., 2006) in 
which the tRRs were in the range 45.0 to 58.5%. These international trials only included previously 
untreated ACRC, whereas in this review the trial participants were both previously treated and 
untreated ACRC participants and there were no second line treatments in the Chinese trials. Both of 
these factors could adversely affect the outcomes for tRR (de Gramont et al., 2000; Giantonio et al., 
2007). 
In the included studies, the most common FOLFOX4-related grade 3 and 4 AEs were neutropenia, 
nausea and vomiting, diarrhoea and neurotoxicity, which are the same as in the international studies 
(Cassidy et al., 2008; de Gramont et al., 2000; Goldberg et al., 2004; Goldberg et al., 2006). However, 
the incidence rates for grade 3/4 neutropenia, neurotoxicity and diarrhoea in the pooled control group 
data were less than in the international studies. A likely reason for this difference is the relatively 
shorter duration of treatment in the studies in this review, since neutropenia and neurotoxicity tend to 
become more severe the longer the chemotherapy continues (Boisdron-Celle et al., 2002; de Gramont 
et al., 2000). 
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The grade 3/4 nausea and vomiting rate was comparable to the international studies. This may be due 
to the preventive use of anti-emetic drugs and dose modification in FOLFOX4 protocols which enable 
control of the severity of nausea and vomiting even with longer treatment, or inclusion of previously 
treated and untreated participants without reporting separate results for these two groups who could be 
expected to show differential responses to interventions. 
 How the Chinese herbal medicines might work 5.4.2
Except for Kang’ai injection, which was tested in two studies, different multi-herb decoctions or 
manufactured products were tested in each study. Therefore, on the basis of the clinical trial results 
alone, it was difficult to determine which individual herbs could have contributed to the reported 
effects. The main rationale for combining CHMs with chemotherapy was the alleviation of AEs due to 
chemotherapy. Of the six most commonly used herbs in these RCTs, Astragalus membranaceous, 
Panax ginseng, Atractylodes lanceolata, Poria cocos and Coix lachry-jojobi are traditionally used for 
fatigue, poor appetite, diarrhoea and other gastrointestinal disorders (Bensky et al., 2004) and each of 
these herbs has been reported to have immunomodulatory effects (Gong, 2010; Shergis et al., 2012; 
Yang et al., 2011). These actions may at least partially account for the reported improvements in AEs. 
In addition, recent experimental research into each of the six herbs used most frequently in the 13 
studies indicates that each has effects that may contribute to the suppression of tumour growth. The 
findings of some of these studies are discussed briefly below. 
Astragalus polysaccharides have been shown to have anti-proliferative effects in cell-line studies 
(Zong et al., 2012). Astragalus saponins inhibited proliferation in a human colorectal cancer HT-29 
cell line regardless of the p53 status, demonstrated tumour suppressive effects in a nude mice 
xenograft model, enhanced the cytotoxic effect of 5-FU (Tin et al., 2007) and have demonstrated anti-
angiogenic effects (Law et al., 2012). Astragalus flavonoids have also been reported to have pro-
apoptopic effects in colon cancer HCT-116 cells (Auyeung & Ko, 2010). 
A number of studies have found ginsenosides and ginseng polysaccharides to have anti-proliferative 
and pro-apoptopic effects (Nag et al., 2012; Zong et al., 2012). The ginsenoside Rg3 inhibited growth 
of tumours in-vivo in HCT-116 cells (He et al., 2011) and has shown anti-angiogenic activities (Wang 
et al., 2009b). Also, the ginseng saponin metabolite, compound K, has been reported to inhibit 
metastatic growth in hepatocellular carcinoma both in vitro and in vivo (Ming et al., 2011). 
Coix seed has a long history as an anti-cancer agent in China and has been developed into an 
injectable product (Kanglaite Coix oil extract) (Li, 2007; Woo et al., 2007). Coix extracts have been 
shown to have anti-inflammatory and anti-carcinogenic effects in animal models of CRC (Chung et 
al., 2010; Li et al., 2011). Polysaccharides from Poria cocos appear to potentiate immune response by 
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up-regulating immune stimulators and down-regulating immune suppressors and have shown anti-
tumour activity in various cancer cell lines by suppressing tumour angiogenesis (Rios, 2011). 
Compounds derived from Atractylodes have shown bio-activity in vitro. Anti-inflammatory effects 
have been reported for atractylenolide I and atractylenolide III (Li et al., 2007a) and atractylenolide II 
inhibited proliferation of B16 cells, induced G1 cell cycle arrest and induced apoptosis (Ye et al., 
2011). In mouse splenocytes, Atractylodes glycoproteins stimulated both Th1 and Th2 lymphocyte 
proliferation with a greater effect on Th1 lymphocytes (Lee et al., 2007). In an RCT of cachetic cancer 
patients (n = 64), the administration of a lactone from Atractylodes improved mid-arm muscle 
circumference, reduced the serum levels of interleukin-1 (IL-1) and tumour necrosis factor alpha 
(TNF-alpha) and reduced urine proteolysis-inducing factors (PIF) (Liu et al., 2005). 
The alkaloids matrine and oxymatrine found in Sophora root have been developed into anti-cancer 
agents in China and Sophora flavonoids appear to have anti-tumour activity (Sun et al., 2012); for 
example, sophoflavescenol has shown cytotoxicity in a number of cancer cell lines as well as having 
antioxidant, anti-inflammatory and apoptotic activities (Jung et al., 2011). 
While it appears possible that at least some of the CHMs used in these studies may have contributed to 
tumour response directly, it is also possible that this effect was indirect via alleviating AEs and 
thereby enabling patients to better tolerate the chemotherapy. Further research is needed to investigate 
these issues. 
 Limitations of this meta-analysis 5.4.3
In interpreting the findings of these meta-analyses a number of factors need to be considered including 
methodological issues, trial duration, the nature and size of study samples and variation in the CHMs 
used. All studies claimed to be randomised but only six stated an appropriate method of sequence 
generation and none provided information on allocation concealment procedures, so there was 
potential for selection bias. Lack of blinding increases the risk of bias for subjective outcomes such as 
KPS and AEs such as nausea, so the results for these outcomes should be considered less reliable than 
for more objective measures such as tRR and OS. Three studies did not report reasons for dropouts or 
loss to follow-up. Methodological issues of these types have been found in trials of both conventional 
medicine and CHM conducted in China (Wu et al., 2009). Clinical trial reporting needs to be clear, 
complete and transparent (Moher et al., 2010), so there is a pressing need for improvements in the 
conduct of clinical trials in China and for proper reporting of methods and results in Chinese journals. 
Most the studies were relatively small and small trials appear to overestimate true effects (Higgins & 
Green, 2011). Some of the trials appear to have included both previously treated and untreated 
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participants without reporting separate results for these two groups who could be expected to show 
differential responses to interventions. 
Other issues were quality control of the medicines prepared by the investigators’ hospitals and the use 
of test medicines that comprise multiple ingredients which may vary in quality from batch to batch and 
may be affected by decoction conditions. These factors limit the comparability of studies. While there 
was no apparent publication bias based on the Funnel Plot for tRR, there may have been bias in favour 
of positive trials for other outcomes. 
5.5 Chapter 5 summary and conclusions 
Whereas previous reviews included a range of regimens in the meta-analysis pools (Wu et al 2005, 
Zhong et al 2012), this chapter focussed on FOLFOX4 to provide the best available clinical evidence 
for CHM in the treatment or management of ACRC. The meta-analysis results suggest the addition of 
these CHMs to a FOLFOX4 regimen increased tumour response rate (tRR) and one-year survival but 
evidence was lacking for longer term effects. Six individual plants were frequently used as ingredients 
of the CHMs, and each has shown bioactivity of relevance to cancer, but it was not possible to 
determine which of these made the greatest contributions to the improvements in tumour response or 
other outcomes. Overall, the addition of the CHM interventions appears to have improved quality of 
life and reduced the incidence of severe neutropenia, nausea, vomiting, and neurotoxicity associated 
with FOLFOX4 chemotherapy. 
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Chapter 6. Contributions of Specific Plants to Tumour Response, 
Neutropenia, Nausea and Vomiting 
6.1 Introduction to Chapter 6 
In the previous two chapters, the meta-analysis found that when HMs were combined with 
chemotherapy (including oxaliplatin regimens and non-oxaliplatin regimen groups), the tRRs were 
improved, and there were reductions in a number of the adverse events associated with chemotherapy, 
including nausea and vomiting, diarrhoea, neutropenia, thrombocytopenia, and neurotoxicity. This 
chapter aims to answer the research question: Which herbs and herbal combinations are most 
frequently used and effective in CRC treatment and for alleviation of the side effects of conventional 
CRC treatments? 
The largest group of interventions in this review were oxaliplatin regimens combined with CHM. The 
main oxaliplatin regimens included: FOLFOX regimens, which all combine oxaliplatin, 5-fluorouracil 
(5-FU) and leucovorin (LV); and XELOX, which is oxaliplatin combined with oral capecitabine 
(Hirsch and Zafar, 2011). Capecitabine converts to 5-FU in the body and was found to be as effective 
as intravenous 5-FU/LV (Twelves, et al., 2005; Cassidy, et al., 2008). FOLFOX regimens have several 
modifications but their effectiveness and their AEs were reported to be similar (Hind et al., 2008).  
The sensitivity analyses undertaken in chapter required a relatively large data set for multi-level 
grouping, and this data set needed to have low heterogeneity. In the meta-analyses in Chapter 4 the 
oxaliplatin regimens showed low heterogeneity, as did the FOLFOX4 for ACRC meta-analyses in 
Chapter 5. The approach taken in Chapter 5 reduced heterogeneity associated with the interventions 
and participants, and this was reflected in the lack of important statistical heterogeneity. However, this 
approach also reduced the size of the data set. Therefore, the groups of studies that combined 
oxaliplatin regimens with CHMs for CRC was selected for the analyses of the contributions of 
individual HMs presented in this chapter. 
This chapter provides results of a series of meta-analyses of oxaliplatin regimens combined with 
CHMs for:  
1. Tumour response rate (tRR) (42 included studies); 
2. Alleviation of nausea and vomiting (27 included studies); and 
3. Alleviation of neutropenia (29 included studies). 
Each meta-analysis includes a sensitivity analysis aimed to select short lists of HMs and combinations 
of HMs that are potentially effective for each of these outcomes. It also reviewed the experimental 
literature on the short-listed herbs for tumour response rate, neutropenia and nausea and vomiting. 
Other outcomes such as thrombocytopenia and neurotoxicity were not included due to insufficient data 
availability. For the methods used in the sensitivity analyses, see Chapter 3. 
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The results reported in this chapter have been published in three articles: 
• Chen MH, May BH, Zhou IW, Xue CC, Zhang AL. Meta-Analysis of Oxaliplatin-Based 
Chemotherapy Combined with Traditional Medicines for Colorectal Cancer: Contributions of 
Specific Plants to Tumour Response. Integr Cancer Ther. 2016a;15(1):40-59. 
• Chen MH, May BH, Zhou IW, Zhang AL, Xue CC. Integrative Medicine for Relief of Nausea 
and Vomiting in the Treatment of Colorectal Cancer Using Oxaliplatin-Based Chemotherapy: 
A Systematic Review and Meta-Analysis. Phytother Res. 2016b; 30(5):741-53. 
• Chen MH, May BH, Zhou IW, Sze DM, Xue CC, Zhang AL. Oxaliplatin-based chemotherapy 
combined with traditional medicines for neutropenia in colorectal cancer: A meta-analysis of 
the contributions of specific plants. Crit Rev Oncol Hematol. 2016c; 105:18-34. 
This chapter represents an amalgam of these three papers. The methods are detailed in Chapter 3. In 
this chapter the abbreviation CHM refers to a Chinese herbal medicine formula or commercial 
product; HM refers to a single herbal medicine – most of which are plants. 
6.2 Meta-analysis of oxaliplatin-based chemotherapy combined with herbal medicine 
for tumour response rate 
  Background and rationale 6.2.1
In Chapter 5, the meta-analyses of CHMs combined with FOLFOX4 found that the systemic CHMs 
conferred benefits to ACRC patients in terms of tumour response rate (tRR), quality of life and some 
chemotherapy-induced adverse events, when compared to FOLFOX4 alone. Although it is likely that 
the most frequent HMs in the multi-component formulae were contributors to the pooled outcomes, it 
is possible that other lower frequency HMs may be of research interest, particularly with regard to 
their effect on tumour response rate (tRR), which is the most frequently reported primary outcome in 
cancer trials (Saad & Katz, 2009). In addition, one traditional rationale for using multi-ingredient HMs 
is the concept of synergetic action, so it was possible that certain combinations of HMs may be more 
effective than these HMs individually. 
In this section, the aim was to identify which HMs, and which combinations of HMs, were associated 
with elevated tRRs in the clinical trials of the integrated treatment of CRC. These sensitivity analyses 
of RCTs of HMs combined with oxaliplatin regimens for CRC were conducted in order to select HMs 
for further clinical and experimental research regarding their effects on tumour growth. 
  Included studies and characteristics 6.2.2
Fourty-two studies that reported tRR were included in the meta-analyses. These 42 studies enrolled 
3,070 assessable participants with 1,613 in the test groups and 1,457 in the controls. All studies were 
published from 2005 to 2013. Forty-one studies were conducted in China and one in Japan (Kono, et 
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al., 2013). Participant characteristics and interventions are summarised in Table G1 in Appendix G. 
Thirty-one studies used the CHMs orally. Eleven studies employed commercially available CHM 
injections. The oxaliplatin regimens included the following: FOLFOX regimens in 39 studies, and 
XELOX in 3 studies. 
 Meta-Analysis of Tumour Response 6.2.3
Meta-analyses were conducted for complete response (CR) and tRR. When risk ratio (RR) is more 
than +1 (IV model, fixed, 95% CI), it favours the test group. Meta-analyses were performed for the 
following groups: 
1. Total (42 studies);  
2. Non-oral (injection) group (11 studies); and 
3. Oral administration group (31 studies). 
6.2.3.1 Total group 
In the 42 studies (n = 3,070), the test groups showed significantly improved tRR (RR 1.30 [1.20, 1.42], 
I2 = 0%), without heterogeneity (Figure 6.1).  
6.2.3.2 Oral administration group 
In 31 studies (n = 2,145), the CHMs were administered orally as decoctions, capsules, or tablets. Two 
studies by the same author used the same multi-ingredient CHMs (Liu et al., 2005a, Liu et al., 2005b). 
The pooled tRR showed significant improvement (RR 1.27 [1.15, 1.41], I2 = 0%), without 
heterogeneity (Figure 6.1).  
6.2.3.3 Non-oral group  
Ten different injection products were tested in 11 studies (n = 938). There were significant 
improvements for tRR (RR 1.36 [1.18-1.57], I2 = 0%) I2 = 0%) compared to controls, without 
heterogeneity (Figure 6.1).  
 Sensitivity analyses for selection of herbs for tumour response rate 6.2.4
A series of multi-level sensitivity analyses were conducted for the multi-ingredient oral CHM 
interventions. The multi-ingredient CHM formulae tended to differ in name but there was considerable 
similarity in their main ingredients. The effects on tRR of the HMs used in multiple studies were 
reported below at the level of the single HM, pair of HMs, and groups of 3 or more HMs. Since the 
aim was to select HMs for further research, only HMs with significant tRR results that were equal or 
greater than the pooled tRR were reported in this chapter. For details of the method, refer to section 
3.3. See Table 6.1 for all significant tRR results. 
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Figure 6.1: Forest plot of risk ratio for tumour response rate of oxaliplatin-based regimens 
combined with Chinese herbal medicines (included oral and non-oral sub-groups) 
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6.2.4.1 Level 1: Single herbal medicines 
All plant-based ingredients (n=87) in the formulae were recorded in a spread-sheet. The number of 
HMs per formula averaged 12 and ranged from 2 to 25. Thirty one out of 87 HMs were used in two or 
more formulae. For each HM, the full botanical name was given in the first instance together with the 
plant part used and the Chinese name in pinyin. Thereafter, the name was shortened to the genus only. 
Table 6.1: Effects of specific herbal medicines on tumour response: single herbal medicines and 
combinations 
Level Chinese herbal Medicine (CHM) RR 95% CI N. studies 
(part.) 
I²% 
1 Coptis 1.49 [1.18, 1.89] 3 (221) 29 
1 Sanguisorba 1.49 [1.18, 1.89] 3 (221) 29 
1 Aucklandia 1.45 [1.16, 1.80] 5 (340) 0 
1 Paeonia 1.44 [1.18, 1.77] 5 (409) 0 
1 Sophora 1.44 [1.17, 1.77] 5 (401) 0 
1 Akebia 1.41 [1.09, 1.83] 5 (310) 16 
1 Sparganium 1.36 [1.13, 1.64] 6 (491) 0 
1 Curcuma 1.34 [1.14, 1.58] 11 (797) 0 
1 Citrus 1.3 [1.07, 1.59] 6 (420) 0 
1 Pinellia 1.28 [1.02, 1.59] 7 (514) 0 
1 Coix 1.25 [1.08, 1.46] 19 (1283) 0 
1 Hedyotis 1.25 [1.06, 1.49] 10 (687) 0 
1 Astragalus 1.24 [1.08, 1.43] 18 (1194) 0 
1 Scutellaria 1.24 [1.04, 1.49] 9 (599) 0 
1 Atractylodes 1.23 [1.08, 1.41] 23 (1549) 0 
1 Poria 1.23 [1.06, 1.43] 19 (1213) 0 
1 Codonopsis 1.23 [1.07, 1.41] 17 (1206) 0 
2 Sophora + Aucklandia 1.51 [1.18, 1.92] 3 (221) 27 
2 Sparganium + Curcuma 1.36 [1.13, 1.64] 6 (491) 0 
2 Paeonia + Astragalus 1.31 [1.04, 1.65] 4 (311) 0 
2 Codonopsis + Citrus 1.3 [1.07, 1.59] 6 (420) 0 
2 Astragalus + Hedyotis 1.26 [1.06, 1.51] 9 (647) 0 
2 Poria + Coix 1.26 [1.06, 1.49] 15 (981) 0 
2 Curcuma + Astragalus 1.25 [1.04, 1.49] 9 (635) 0 
2 Coix + Atractylodes 1.25 [1.06, 1.47] 17 (1105) 0 
2 Astragalus + Scutellaria 1.24 [1.04, 1.49] 9 (599) 0 
2 Codonopsis + Hedyotis 1.23 [1.03, 1.46] 8 (575) 0 
2 Atractylodes + Hedyotis 1.23 [1.00, 1.51] 9 (624) 0 
2 Astragalus + Codonopsis 1.23 [1.05, 1.43] 13 (902) 0 
2 Poria +Atractylodes 1.23 [1.05, 1.44] 17 (1105) 0 
2 Atractylodes + Astragalus 1.23 [1.05, 1.44] 17 (1131) 0 
2 Poria + Codonopsis 1.21 [1.02, 1.43] 14 (923) 0 
2 Atractylode + Codonopsis 1.21 [1.04, 1.41] 16 (1143) 0 
3 Sophora + Paeonia + Curcuma 1.44 [1.16, 1.78] 4 (341) 8 
3 Sophora + Astragalus + Scutellaria 1.31 [1.04, 1.65] 4 (303) 0 
3 Curcuma + Astragalus + Hedyotis 1.3 [1.05, 1.60] 5 (363) 0 
3 Astragalus + Hedyotis + Scutellaria 1.28 [1.04, 1.56] 6 (431) 0 
3 Pinellia + Coix + Poria 1.28 [1.02, 1.59] 7 (514) 0 
3 Codonopsis + Scutellaria + Hedyotis 1.26 [1.03, 1.56] 5 (371) 0 
3 Astragalus + Codonopsis + Scutellaria 1.26 [1.04, 1.53] 7 (469) 0 
3 Curcuma + Astragalus + Codonopsis 1.25 [1.04, 1.52] 7 (513) 0 
3 Coix + Poria + Atractylodes 1.25 [1.05, 1.49] 14 (923) 0 
3 Curcuma + Astragalus + Scutellaria 1.24 [1.02, 1.51] 6 (441) 0 
3 Astragalus + Codonopsis + Hedyotis 1.24 [1.03, 1.49] 7 (535) 0 
3 Atractylodes + Astragalus + Hedyotis 1.24 [1.00, 1.54] 8 (584) 0 
3 Coix + Poria + Astragalus 1.22 [1.01, 1.48] 13 (827) 0 
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Level Chinese herbal Medicine (CHM) RR 95% CI N. studies 
(part.) 
I²% 
3 Poria+ Atractylodes+ Astragalus 1.21 [1.00, 1.46] 12 (787) 0 
3 Poria+ Atractylodes+ Codonopsis 1.21 [1.02, 1.43] 14 (923) 0 
3 Atractylodes + Astragalus + Codonopsis 1.2 [1.00, 1.44] 12 (839) 0 
4 Sophora + Paeonia + Sparganium + Curcuma 1.45 [1.16, 1.80] 3 (281) 38 
4 Astragalus + Hedyotis + Aucklandia + Scutellaria 1.31 [1.00, 1.70] 3 (183) 0 
4 Sophora + Scutellaria + Hedyotis + Astragalus 1.3 [1.02, 1.66] 3 (243) 0 
4 Astragalus + Codonopsis + Citrus + Hedyotis 1.29 [1.01, 1.64] 4 (256) 0 
4 Curcuma + Astragalus + Scutellaria + Codonopsis 1.28 [1.03, 1.57] 5 (371) 0 
4 Pinellia + Coix + Atractylodes + Poria 1.27 [1.00, 1.60] 6 (456) 0 
4 Sparganium + Curcuma + Astragalus + Codonopsis 1.25 [1.01, 1.53] 5 (393) 0 
4 Coix + Atractylodes + Poria + Codonopsis 1.23 [1.02, 1.49 11 (741) 0 
5 Sanguisorba + Coptis + Sophora + Paeonia + 
Curcuma 
1.49 [1.18, 1.89] 3 (221) 29 
5 Sophora + Scutellaria + Aucklandia + Astragalus + 
Hedyotis 
1.33 [1.00, 1.76] 2 (123) 0 
5 Codonopsis + Scutellaria + Citrus + Hedyotis + 
Astragalus 
1.29 [1.00, 1.65] 3 (183) 0 
5 Curcuma + Codonopsis + Hedyotis + Scutellaria + 
Astragalus 
1.27 [1.02, 1.58] 4 (311) 0 
6 Sophora + Curcuma + Scutellaria + Astragalus + 
Codonopsis + Paeonia 
1.29 [1.02, 1.65] 3 (243) 0 
6 Sparganium + Curcuma + Hedyotis + Astragalus + 
Scutellaria + Codonopsis 
1.27 [1.01, 1.61] 3 (251) 0 
8 Paeonia + Curcuma + Hedyotis + Sophora + 
Sparganium + Codonopsis + Astragalus + 
Scutellaria 
1.29 [1.00, 1.66] 2 (183) 0 
RR: Risk Ratio for tumour response; 95% CI: 95% Confidence Interval; N. studies (part.): number of studies 
(participants); I² %: measure of heterogeneity of result 
The most frequently used HMs are listed below as: species. plant part [pinyin name] family 
(frequency). 
• Atractylodes macrocephala Koidz. root [bai zhu] Asteraceae (n=23);  
• Coix lacryma-jobi L. seed [yi ren] Gramineae (n=19);  
• Poria cocos (Schw) Wolf sclerotium [fu ling] Polyporaceae (n=19);  
• Astragalus membranaceus (Fisch.) Bge.root [huang qi] Fabaceae (n=18);  
• Codonopsis pilosula (Franch.). Nannf.root [dang shen] Campanulaceae (n=17);  
• Curcuma zedoaria (Berg.) Rosc. or C. phaeocaulis Val. rhizome [e zhu] Zingiberaceae 
(n=11);  
• Hedyotis diffusa Willd. Aerial parts [she she cao] Rubiaceae (n=10);  
• Scutellaria barbata D. Don. aerial parts [ban zhi lian] Labiatae (n=9); and 
• Pinellia ternata (Thunb.) Breit. tuber [ban xia] Araceae (n=7). 
The tRRs of the group of studies that included each particular HM were calculated. These tRRs were 
sorted from high to low, significant tRRs were identified (n=25), and groups with moderate 
heterogeneity (I2> 30%) were excluded (n= 8), leaving 17 different HMs in the following analyses 
(Table 6.1). The pooled tRR results were divided into three groups: 1. tRR significant and greater or 
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equal to the tRR of the total pool (RR 1.27); 2. tRR significant but less than the total pool; and 3. tRR 
no significant (results not reported). 
The first group, in descending order of tRR, included 10 HMs: Sanguisorba officinalis L. root [di yu] 
Rosaceae (n=3); Coptis chinensis Franch. root [huang lian] Ranunculaceae (n=3); Aucklandia lappa 
Decne. root [mu xiang] Asteraceae (n=5); Sophora flavescens Ait. root [ku shen] Fabaceae (n=5); 
Paeonia lactiflora Pall. or P. veitchii Lynch. Root [chi shao] Ranunculaceae (n=5); Akebia quinata 
(Thunb.) Decne. fruit [ba yue zha] Lardizabalaceae (n=5); Sparganium stoloniferum Buch.-Hamil. 
root [san leng] Sparganiaceae (n=6); Curcuma (n=11); Citrus reticulata Blanco. peel [chen pi] 
Rutaceae (n=6); and Pinellia (n=7) (Table 6.1). 
In the second group, the following seven HMs showed significant tRRs that were slightly lower than 
the average tRR of the pool: Coix, Hedyotis, Astragalus, Scutellaria, Atractylodes, Poria and 
Codonopsis (Table 6.1). The frequency of each HM was plotted against the tRR to explore any 
relationships. It was evident that the high frequency HMs tended to be closer the tRR of the pool, 
while the lower frequency HMs showed a broader distribution above and below the pool (Figure 6.2). 
Non-significant HMs had frequencies of 6 or less, and all HMs excluded due to heterogeneity had 
frequencies of 2 or 3. Therefore, all the higher frequency HMs remained in the analysis. 
6.2.4.2 Level 2: Pairs of herbal medicines 
HMs that showed significant tRR results (n=17) were paired with other HMs from groups 1 or 2 
above. When HMs from group 3 were included in pairings or higher level combinations, the results 
were always at or below the tRR for the pool so these combinations are not reported. The four pairs 
that showed tRRs that were above or equal to the total pool, in descending order of tRR were: Sophora 
+ Aucklandia (n=3), Sparganium + Curcuma (n=6), Paeonia + Astragalus (n=4), and Codonopsis + 
Citrus (n=6). A further 12 pairs were significant but had tRRs lower than the total for the pool (Table 
6.2). 
6.2.4.3 Level 3: Combinations of three herbal medicines 
The significant pairs from level 2 were combined with other HMs that showed significant tRRs at 
level 1. The five triplets that showed tRR values above or equal to the total pool, in descending order 
of tRR were: Sophora + Curcuma + Paeonia (n=4), Sophora + Astragalus + Scutellaria (n=4), 
Curcuma + Astragalus + Hedyotis (n=5), Pinellia + Poria + Coix (n=7), and Astragalus + Hedyotis + 
Scutellaria (n=6). An additional 11 triplets showed significant tRRs that were lower than the total for 
the pool (Table 6.2). 
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Figure 6.2: Frequency of Chinese herbal medicine in data set versus risk ratio (RR) for tumour 
response rate (tRR) 
6.2.4.4 Level 4: Combinations of four herbal medicines 
The significant combinations from level 3 were combined into groups of four. Six combinations 
showed tRRs above or equal to the total pool: Sophora + Paeonia + Sparganium + Curcuma (n=3), 
Astragalus + Hedyotis + Aucklandia + Scutellaria (n=3), Sophora + Scutellaria + Hedyotis + 
Astragalus (n=3), Astragalus + Codonopsis + Citrus + Hedyotis (n=4), Curcuma + Astragalus + 
Scutellaria + Codonopsis (n=5), and Pinellia + Coix + Atractylodes + Poria (n=6). An additional two 
combinations showed significant tRRs that were lower than the pool total (Table 6.2). 
6.2.4.5 Level 5: Combinations of five herbal medicines 
The significant combinations from level 4 were combined into groups of five. Four combinations 
showed tRRs equal or higher than the pool: Sanguisorba + Coptis + Sophora + Paeonia + Curcuma 
(n=3), Sophora + Scutellaria + Aucklandia + Astragalus + Hedyotis (n=2), Codonopsis + Scutellaria + 
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Citrus + Hedyotis + Astragalus (n=3), and Curcuma + Codonopsis + Hedyotis + Scutellaria + 
Astragalus (n=4) (Table 6.2). 
6.2.4.6 Level 6: Combinations of six or more herbal medicines 
The significant combinations from level 5 were further combined. There were two combinations of six 
HMs. One showed a tRR higher than the pool: Sophora + Curcuma+ Scutellaria + Astragalus + 
Codonopsis + Paeonia (n=3), and the other was equal to the pool: Sparganium + Curcuma + Hedyotis 
+ Astragalus + Scutellaria + Codonopsis (n=3). There were no combinations of seven HMs and one 
combination of eight which showed a tRR equal to the pool: Paeonia + Curcuma + Hedyotis + 
Sophora + Sparganium + Codonopsis + Astragalus + Scutellaria (n=2) (Table 6.2). 
 Herbal medicines with consistent results at multiple levels 6.2.5
Combinations of up to eight HMs produced tRR results that were equal or higher than the total for the 
pool. Seven HMs appeared at all levels: Astragalus, Codonopsis, Scutellaria, Hedyotis, Sophora, 
Curcuma and Paeonia. Of these, Sophora, Curcuma and Paeonia showed significant tRR results that 
were equal or higher than the total for the pool at each level. This suggested that when these HM were 
included in a formulation, the tRR tended to be elevated. 
 Potential synergistic effects of herbal medicines 6.2.6
Three HM pairs showed higher tRRs as pairs than for the HMs singly: Sophora + Aucklandia, Coix + 
Poria, and Astragalus + Hedyotis (Table 6.2). Of these, the first pair was also had a tRR higher than 
the pool. 
Three HM triplets showed potential synergistic effects: Astragalus + Hedyotis + Scutellaria, 
Astragalus + Codonopsis + Scutellaria, and Codonopsis + Hedyotis + Scutellaria. Of these, the tRR of 
the first triplet was also higher than the pool (Table 6.2). 
The combination Sophora + Paeonia + Sparganium + Curcuma showed an improved tRR as a group, 
compared to the pooled results of the single HMs but there was moderate heterogeneity (I2=38%). The 
group of five HMs Sanguisorba + Coptis + Sophora + Paeonia + Curcuma had a tRR that was equal 
or superior to the single HMs (Table 6.2). 
  Discussion of the results for tumour response rate 6.2.7
All 42 included studies employed oxaliplatin regimens in the test and control groups. These are 
currently first-line chemotherapy regimens for CRC in the palliative setting, so the results of these 
meta-analyses are of direct clinical relevance. The heterogeneity of all meta-analyses was low for the 
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tRR. The pooled data indicated the addition of the HMs significantly improved tRR when compared to 
oxaliplatin regimens alone. Benefits were evident in the sub-groups for injections and orally 
administered CHMs (Figure 6.1). These results were consistent with the results for CHM combined 
with FOLFOX4 in Chapter 5 and the CHM combined oxaliplatin group in Chapter 4, which included 
the same studies.  
In this section, the most frequently used herbs were Atractylodes, Coix, Poria and Astragalus but the 
specific aim of this section was to identify HMs that showed promise for further research into their 
effects on tumour growth, so the contribution of each individual HM to the meta-analysis results for 
tRR was used as the basis for selection. It was reasoned that some CHM formulae may not have aimed 
at improving tRR, and may have been focussed on improving outcomes relating to adverse effects of 
chemotherapy and/or improving quality of life. Therefore, some HMs would not be expected to make 
individual contributions to the tRR results. 
The results found that the most frequent HMs, such as Astragalus, showed tRRs that were significant 
but slightly lower than the tRR of pool. This is likely to be a statistical effect since these frequent HMs 
were the main contributors to the pooled result. It is notable that there were no significant negative 
tRRs for any of the HMs or their combinations, which suggests that the HMs were not inhibiting the 
actions of the chemotherapy. 
With regard to selecting the most promising HMs for further research, it was evident that many HMs 
showed significant tRRs, either singly or in combination with other HMs. For example, Coptis and 
Sanguisorba appeared the most promising at level 1 based on their individual tRRs (Table 6.2) but 
these HMs were infrequent overall and did not appear at each level, so they could not show consistent 
results at multiple levels. In contrast, Sophora, Paeonia and Curcuma all appeared at seven levels of 
combination, with tRRs that were significant and equal or above the pool at each level without 
heterogeneity, hence they showed consistent benefit and were selected as the most promising for 
further research. Nevertheless, this does not mean that Coptis and Sanguisorba and other HMs with 
high tRRs at level 1 show no promise. 
The results suggest synergistic actions for some HM combinations. Hedyotis, Astragalus and 
Scutellaria all appeared frequently in the formulae and each has been reported to inhibit CRC in vitro 
and in vivo (Tin et al., 2007; Lin et al., 2013; Cai et al., 2012). These HMs showed significant tRRs 
but all were slightly lower than the pool at level 1. However, these HMs showed higher tRRs in 
combinations at levels 3 to 6 and all are in the final group of eight HMs. These results suggest that this 
grouping should also be subject to further research to explore potential synergistic effects between 
these plants and their compounds on tumour response as well as their effects when combined with 
oxaliplatin. 
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An advantage of this approach to the identification of HMs for further research is that it was based 
directly on the effects of CHM formulae that contain the individual HMs on tumour response rather 
than on the overall frequency of the HM in the formulae contained in the meta-analysis pool. This 
procedure allowed identification of potentially effective HMs which appeared at relatively lower 
frequencies within the total data set. Had frequency been used as the criterion for selection, 
Atractylodes, Poria and Astragalus would have been identified but Sophora, Paeonia and Curcuma 
may have been missed. 
Conversely, a limitation to this method for selecting HMs and HM combinations is that the data set 
provided a restricted number of actual HM combinations at each level. Therefore, all the possible 
combinations could not be assessed. Also, as the levels increased, the number of significant 
combinations that remained in the data set declined and so did the number of studies from which the 
data were derived. Consequently, the procedures used removed very low frequency HMs from the data 
set. Also, the number of levels used in assessing combinations of HM was arbitrary. It was based on 
what was possible given the available data. This also had the effect of limiting the HM available for 
selection and may have eliminated promising HM. 
6.2.7.1 Experimental studies of Paeonia, Curcuma and Sophora 
These three HMs have all shown evidence of anti-tumour activity in experimental studies. These are 
summarised briefly below. 
Anti-cancer actions of Paeonia (chi shao) 
The HM chi shao can be derived from the roots of Paeonia lactiflora and Paeonia veitchii, both of 
which can contain paeonol and paeoniflorin (Xu et al., 2009; Zhu et al., 2015). In human colon cancer 
LoVo cells, paeonol blocked cell cycle at the G1 to S transition and induced apoptosis (Li et al., 2013). 
In HT-29 CRC cells, paeonol inhibited proliferation (Ye et al., 2009) and showed a synergetic 
antiproliferative effect when combined with 5-FU (Ji et al., 2005). In human oesophageal 
adenocarcinoma cells, paeonol showed a dose-dependent growth-inhibitory effect and this effect was 
synergistic when combined with cisplatin (Wan et al., 2008). Paeonol appears to influence multi-drug 
resistance. It showed reversal of resistance in a paclitaxel-resistant human breast cancer cell line (Cai 
et al., 2014) and reversed endoplasmic reticulum (ER) stress induced resistance to doxorubicin in 
human hepatocellular carcinoma cells (Fan et al., 2013). Paeoniflorin has shown growth-inhibitory, 
pro-apoptotic effects in human cervical cancer HeLa cells (Zhang and Zhang, 2011) as well as anti-
inflammatory effects in a colitis model (Zhang et al., 2014) and in human umbilical vein endothelial 
cells (Xu et al., 2013). 
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The combination of extracts of Paeonia and Astragalus were found to synergistically induce the 
expression of leukotriene B4-12-hydroxydehydrogenase (LTB4DH) in a dose- and time-dependent 
manner leading to cell cycle arrest in HepG2 cells by controlling the leukotriene B4 pathway (Wei et 
al., 2011). Although this combination has not been investigated in colon cancer, the leukotriene B4 
pathway plays an important role in the proliferation of colon cancer cells (Ihara et al., 2007). 
Anti-cancer actions of Curcuma (e zhu) 
The official sources of e zhu are Curcuma wenyujin Y. H. Chen et C. Ling, C. phaeocaulis Val., and 
C. kwangsiensis S. G. Lee et C. F. Liang (Lu et al., 2012), but older references use the name C. 
zedoaria Roscoe (Jiangsu New Medical Academy, 1986). The rhizomes contain multiple aromatic 
compounds including elemenes and non-volatile compounds such as curcumins (Lu et al., 2012). 
Curcumin has been investigated in multiple cancer cell-lines (Lu et al., 2011). In human colon cancer 
HT-29 and HCT-15 cells it dose-dependently inhibited proliferation (Hanif et al., 1997) and induced 
apoptosis in colorectal carcinoma HCT116 cells and human colorectal cancer LoVo Cells (Lu et al., 
2011; Guo et al., 2013). A study of curcumin combined with FOLFOX in two colon cancer cell-lines 
(HCT-116 and HT-29) reported a synergistic growth-inhibitory effect which appeared to involve the 
EGFR and IGF-1R growth factor pathways (Patel et al., 2008). 
Delta-elemene was found to dose-and time-dependently induce apoptosis in colorectal 
adenocarcinoma (DLD-1) cells (Xie et al., 2009). Beta-elemene has shown growth-inhibitory activity 
in multiple cancer cell-lines including CCL-222 and CCL-225 colon carcinoma cells (Li et al., 2010). 
In colo-205 colorectal adenocarcinoma cells it also increased cisplatin cytotoxicity (Li et al., 2013). 
Beta-elemene exhibited low toxicity in normal cells, having much weaker anti-proliferative effects in 
normal human lung fibroblast CCD-19 Lu cells, human bronchial epithelial NL20 cells, and human 
ovary epithelial IOSE-397 cells, compared to the corresponding cancer cell-lines ( Lu et al., 2012). 
Anti-cancer actions of Sophora flavescens (ku shen) 
The dried roots of Sophora flavescens Aiton. contain a number of alkaloids, including matrine, 
oxymatrine, sophoridine and sophocarpine, and flavonoids such as kurarinone (Miao et al., 2001). It is 
traditionally used to treat solid tumours and inflammatory diseases (Sun et al., 2007). Since 1992, 
products containing total Sophora alkaloids, oxymatrine and matrine have been approved by the 
Chinese State Food and Drug Administration (SFDA) for the treatment of various types of solid 
tumours (Sun et al., 2012). 
In human colon cancer HT-29 cells, Xiao et al (2013) reported that a range of ethanol and aqueous 
extracts of Sophora roots inhibited the cell growth in-vitro (Xiao et al., 2013). In a mouse model of 
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cancer cachexia, sophocarpine and matrine both reduced cachexia symptoms in BALB/c mice 
inoculated with colon-26 adenocarcinoma cells and suppressed the expression of the pro-inflammatory 
cytokines TNF-α and IL-6 (Zhang et al., 2008). 
Huang et al. (2007) reported that matrine dose-dependently inhibited human colon cancer HT-29 cell 
proliferation by promoting apoptosis (Huang et al., 2007). Chang et al. (2013) also reported that 
matrine inhibited proliferation of HT-29 cells. Matrine appeared to activate caspase-3 and caspase-9 
and release cytochrome-C to induce apoptosis (Chang et al., 2013). In human colon cancer LoVo cells, 
Zhang et al. (2014) reported that matrine inhibited proliferation in a time- and dose- dependent 
manner. They found the mechanisms of action of matrine were via inducing cell cycle arrest at the G1 
phase by down-regulation of cyclin D1 and up-regulation of p27 and p21. Apoptosis was induced by 
reduction of the Bcl-2/Bax ratio and caspase-9 activation. Matrine was reported to have an upstream 
effect on these proteins by inactivating Akt (Zhang et al., 2014). 
In a mouse model using transplanted colon tumour SW480 cells, sophoridine reduced tumour weight 
and volume and reduced expression of p53 and VEGF67 (Wang et al., 2010). In xenografts of SW480 
cells in mice, Liang et al (2012) reported that sophoridine inhibited tumour growth with no apparent 
toxicity, and in an SW480 cell-line study its action was via caspase-9, caspase-3, caspase-7 and PARP 
(Liang et al., 2012). 
Matrine and oxymatrine have shown synergistic effects with different anti-cancer agents (Liu et al., 
2014). Matrine showed synergistic effects when combined with celecoxib, trichostatin A and 
rosiglitazone against proliferation and VEGF expression in MDA-MB-231 breast cancer cells (Yu et 
al., 2009), and enhanced the activity of trichostatin A in human non-small cell lung cancer A549 cells 
(Zhang et al., 2009). In a transplanted human gastric cancer SGC-7901 model in nude mice, the 
inhibitory effect of matrine combined with 5-FU was greater than either compound used individually, 
without increasing bone marrow inhibition (Hu et al., 2005). 
In a study that compared the antitumour activities of total Sophora alkaloids (KS-As) and flavonoids 
(KS-Fs), Sun et al. (2007) reported higher growth inhibitory effects for KS-Fs, and for kurarinone in 
particular, than for KS-As in multiple cancer cell-lines including human colorectal cancer CaCo-2 
cells. There was little effect on the peripheral blood cell numbers in normal mice treated with KS-Fs. 
KS-Fs also enhanced the cytotoxicity of taxol and adriamycin (Sun et al., 2007). 
  Summary of the results for tumour response rate 6.2.8
The meta-analyses suggested that the combination of the CHMs with oxaliplatin-based regimens 
significantly increased tRR in the treatment of CRC. Benefits were evident for both injection products 
and orally administered CHMs. Detailed sensitivity analyses of specific plant-based HM ingredients of 
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the oral CHMs found that Paeonia, Curcuma, and Sophora produced consistent contributions to the 
tRR results. Compounds in each of these HMs have shown growth-inhibitory effects in CRC cell-
lines. There were no instances of HMs reducing the tRR of the chemotherapy. Specific combinations 
of HMs appear to produce higher contributions to tRR than the HMs individually. Notable among 
these is the combination of Hedyotis, Astragalus, and Scutellaria. Further studies are required to 
investigate the effects of the HMs identified in this study and the possible synergistic effects of the 
HM combinations. 
6.3 Meta-analysis of oxaliplatin-based chemotherapy combined with herbal medicine 
for relief of nausea and vomiting 
  Background and rationale 6.3.1
The management of chemotherapy-induced nausea and vomiting (CINV) remains an issue in the 
treatment of colorectal cancer using oxaliplatin based regimens. Risk factors for CINV following 
chemotherapy include type of chemotherapeutic drug, patient’s age less than 50, female, history of low 
prior chronic alcohol intake, and history of previous chemotherapy-induced emesis. Over seventy 
percent of patients receiving oxaliplatin regimens experience CINV (Navari, 2009). CINV tends to get 
worse as the number of treatment cycles increases. This significantly reduces the quality of life of 
patients, can result in poor compliance with their chemotherapy schedule and can lead to deterioration 
of physical and mental status (Lohr, 2008). 
The mechanisms of CINV are complex. CINV can be initiated by enterochomaffin cells in the 
gastrointestinal tract releasing serotonin (5-HT) in response to damage of gastrointestinal epithelium 
and activation of the chemoreceptor trigger zone which detects potential toxins. Activation of vagal 
afferent fibres stimulates the vomiting centre in the medulla, which in turn sends impulses via efferent 
fibres to activate the vomiting response. Antiemetic drugs act by blocking neuronal pathways involved 
at various stages in the emetic response, mainly via antagonism of 5-hydroxytryptamine (5-HT3) 
receptors, dopamine receptors, neurokinin-1 (NK-1) and/or acetylcholine, corticosteroid, histamine, 
cannabinoid, and/or opiate receptors (Lohr, 2008; Navari, 2009). 
Oxaliplatin regimens used in colorectal cancer (CRC) are considered to have moderate emetic risk and 
the preventative use of 5-HT3 antagonists combined with dexamethasone is recommended, with the 
additional use of NK-1 antagonists in selected patients (NCCN, 2012). Despite the introduction of 
these effective anti-emetic agents, CINV remains a significant issue for people undergoing 
chemotherapy (Navari, 2009). 
Certain HMs with histories of use for nausea and vomiting have been integrated with conventional 
therapies for CINV. Ginger (Zingiber officinale Roscoe) has been used for nausea and evidence from 
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animal studies suggests anti-CINV effects (Handiadka et al., 2012a). However, a systematic review of 
seven randomised controlled trials (RCTs) of ginger in CINV management in various cancers found 
inconsistent results between studies (Marx et al., 2013). Other HMs that have been reported to 
alleviate CINV in animal models include: Panax ginseng C. A. Mey.; Panax quinquefolius L.; Panax 
notoginseng (Burk.) F. H. Chen; Scutellaria baicalensis Georgi; Ganoderma lucidum (Fr.) Karst.; 
Mint oil (Mentha spp); and grape seed extract (Handiadka et al., 2012b). 
A number of possible mechanisms for the reported anti-CINV actions of these HMs have been 
proposed. These include inhibition of 5-HT3 receptors; substance P and NK1 receptors; antioxidant 
and free radical scavenging activity; anti-inflammatory actions; chemo and radio-protective effects; 
immunomodulation; neuromodulation; anti-spasmodic effects; and regulation of gastrointestinal 
motility. Since these HMs may contain multiple bioactive compounds it appears likely that multiple 
mechanisms are involved (Handiadka et al., 2012b, Suzuki et al., 2013). 
In this section, the meta-analyses aimed to assess whether integrative management of CRC, in which 
CHMs were added to oxaliplatin regimens, reduced the incidence of CINV. The sensitivity analysis 
aimed to determine whether any particular HMs showed promise for further research into their anti-
emetic and/or nausea alleviating effects. 
  Included studies and characteristics 6.3.2
Twenty-seven studies published from 2005 to 2013, which enrolled 1,843 (T: 960/C: 883) assessable 
participants, were included in the meta-analyses. Six studies employed commercially available 
injections and 21 studies (1,322 participants) used orally administered CHMs (Table G2, in Appendix 
G). 
  Meta-analysis of alleviation of chemotherapy-induced nausea and vomiting 6.3.3
Meta-analysis was conducted for all grades of nausea and vomiting combined since severe nausea and 
vomiting (grade 3/4) was relatively infrequent. Also, nausea and vomiting are unpleasant symptoms at 
any grade, so allevation of any grade would be of clinical relevance. A lower RR indicated a lower 
risk of nausea and vomiting. When RR was less than +1 (IV model, fixed, 95% CI), it favoured the 
test group. 
6.3.3.1 Total group 
For all 27 studies, the test groups showed significantly reduced nausea and vomiting (RR 0.65 [0.59, 
0.71], I²=28%) without important heterogeneity (Figure 6.3). The absolute risk reduction was 24% 
compared to controls (RD= -0.24 [-0.28, -0.19], I²=48%). In the 17 studies for which anti-emetic 
drugs, such as ondansetron or granisetron, were used in both groups, the RR was 0.68 [0.60, 0.77], 
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I²=32%, whereas in the studies that did not mention use of anti-emetic drugs (n=10) the RR was 0.60 
[0.51, 0.70], I²=19%, which was similar. 
6.3.3.2 Injection group 
Four different injection products were tested in 6 studies (Table 6.3). There was a significant reduction 
in nausea and vomiting (RR 0.73 [0.61, 0.86], I²=60%, RD= -0.20 [-0.29, -0.12], I²=50%) in the HM 
plus oxaliplatin groups. The heterogeneity was moderate to substantial (Figure 6.3). Co-kushen 
Injection (n=2) (Ding et al., 2010; Tao and Xu, 2013) showed significantly reduced nausea and 
vomiting (RR 0.66 [0.50, 0.86], I² =64%), but there was substantial heterogeneity. Kang'ai Injection 
(n=2) (Qiu 2011; Yang, 2008) showed a significant reduction with no important heterogeneity (RR 
0.47 [0.29, 0.77], I² =28%). 
6.3.3.3 Oral administration group 
The CHMs were administered orally as decoctions, capsules or tablets in 21 studies. The combination 
of CHMs plus oxaliplatin showed a significant reduction in nausea and vomiting incidence compared 
to the same oxaliplatin regimens (RR 0.62 [0.55, 0.69], I²=5%) without important heterogeneity 
(Figure 6.3). The absolute risk reduction was 25% (RD -0.25 [-0.30, -0.20], I²=49%). 
 Sensitivity analyses for selection of herbs for chemotherapy-induced nausea and vomiting 6.3.4
The orally administered CHMs contained 98 different plant-based HMs with an average of 12 HMs 
per CHM intervention. The 48 HMs that were used in two or more studies were included in the 
following sensitivity analyses. Thirty of these HMs showed significant RRs for reduction of incidence 
of CINV with low heterogeneity (I² < 30%). The effects of these herbs were also assessed when they 
appeared as pairs, triplets and higher level combinations in the HM interventions. Significant RR 
results with low heterogeneity that were equal or lower than the total pool for the oral interventions 
RR 0.62 [0.55, 0.69] are reported in Table 6.2. The full botanical name and Chinese name in pinyin of 
each herb is given the first time it appears in this chapter. Subsequently, the name is shortened to 
genus only. 
6.3.4.1 Level 1: Single herbal medicines 
The following seven herbs did not always appear in association with another particular herb, so they 
were suitable for further analysis. Of these, Panax G (n=4) had the lowest RR (0.51 [0.39, 0.66], 
I²=0%); followed by Poria (n=16) (RR 0.61 [0.54, 0.69], I²=15%); Coix (n=14) (RR 0.61 [0.53, 0.70], 
I²=29%); Codonopsis (n=12) (RR 0.61 [0.52, 0.72], I²=28%); Panax N (n=4) (RR 0.61 [0.43, 0.87], 
I²=0%); Atractylodes (n=16) (RR 0.62 [0.54, 0.71], I²=13%); and Astragalus (n=13) (RR 0.65 [0.55, 
0.76], I²=0%) (Table 6.2). The following herbs were the most frequently used in the CHM 
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interventions: Poria (n=16); Atractylodes (n=16); Coix (n=14); Astragalus (n=13); and Codonopsis 
(n=12). 
 
Figure 6.3: Forest plot of risk ratio for Chinese herbal medicine alleviation of chemotherapy-
induced nausea and vomiting (included oral and non-oral sub-groups) 
6.3.4.2 Level 2: Pairs of herbal medicines 
Seven pairs of herbs showed RRs that were lower than the total pool (Table 6.2). The lowest RRs were 
for: Panax G. + Astragalus (n=4) (RR 0.49 [0.35, 0.67], I²=0%); followed by Poria + Dioscorea (n=5) 
(RR 0.56 [0.47, 0.67], I²=0%). 
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6.3.4.3 Level 3: Combinations of three herbal medicines 
Six different triplets showed significant RRs that were lower than the total pool (Table 6.2). The 
combination of Dioscorea + Coix + Poria (n=3) had the lowest RR (0.49 [0.37, 0.65], I²=0%); 
followed by Panax G + Atractylodes + Coix (n=3) (RR 0.52 [0.39, 0.69], I²=0%). 
6.3.4.4 Level 4: Combinations of four herbal medicines  
Atractylodes + Poria + Coix + Glycyrrhiza was the only combination, among nine combinations, that 
was significant and lower than or equal to the pool (RR 0.51 [0.38, 0.70], I²=0%, n=3) (Table 6.2).  
6.3.4.5 Level 5: Combinations of five herbal medicines 
Three combinations of five herbs showed RRs lower than the total pool. Astragalus + Atractylodes + 
Coix + Lycium barbarum L. (gou qi zi) + Scutellaria barbata D. Don. (ban zhi lian) (n=3) had the 
lowest RR (0.58 [0.41, 0.83], I²=0%) (Table 6.2). 
6.3.4.6 Level 6: Combinations of six herbal medicines 
Six combinations of six HMs showed significant RRs lower than the total pool. The lowest RR (0.50 
[0.36, 0.69], I²=0%) was for Panax G + Dioscorea + Coix + Glycyrrhiza + Atractylodes + Poria 
(n=2). 
Table 6.2: Effects of specific combinations of herbal medicines on chemotherapy induced nausea 
and vomiting: Levels 1-9 
Level HM botanical name (pinyin) N studies 
(part.) 
RR [95% CI] I2 
1 Hordeum vulgare L. (mai ya) 2 (98) 0.47 [0.33, 0.68] 0 
1 Crataegus pinnatifida Bge (shan zha) 2 (98) 0.47 [0.33, 0.68] 0 
1 Massa medica fermentata (shen qu) 2 (120) 0.47 [0.30, 0.73] 0 
1 Panax ginseng C. A. Mey. (ren shen)* 4 (222) 0.51 [0.39, 0.66] 0 
1 GlycyrrhizauralensisFisch (gan cao)* 3 (170) 0.51 [0.38, 0.70] 0 
1 Magnolia officinalis Rehd. et Wils (hou po) 3 (179) 0.54 [0.38, 0.77] 0 
1 Amomum kravanh Pierre ex. Gagnep. (bai dou kou) 2 (117) 0.54 [0.36, 0.81] 0 
1 Dioscorea opposita Thunb. (shan yao) 5 (321) 0.56 [0.47, 0.67] 0 
1 Sophora flavescens Ait. (ku shen) 2 (92) 0.56 [0.35, 0.92] 0 
1 Lycium barbarum L. (gou qi zi) 3 (168) 0.58 [0.41, 0.83] 0 
1 Cornus officinalis Sieb. Et Zucc. (shan zhu yu) 2 (139) 0.59 [0.46, 0.75] 0 
1 Paeonia suffruticosa Andr. (mu dan pi) 2 (139) 0.59 [0.46, 0.75] 0 
1 Alisma orientalis (Sam.) Juzep. (ze xie) 2 (139) 0.59 [0.46, 0.75] 0 
1 Rehmannia glutinosa Libosch. (shu di huang) 3 (199) 0.60 [0.47, 0.75] 0 
1 Nelumbo nucifera Gaertn. (lian zi) 2 (110) 0.60 [0.41, 0.88] 0 
1 Poria cocos (Schw) Wolf (fu ling)* 16 (1012) 0.61 [0.54, 0.69] 15 
1 Coix lacryma-jobi L. (yi ren)* 14 (945) 0.61 [0.53, 0.70] 29 
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Level HM botanical name (pinyin) N studies 
(part.) 
RR [95% CI] I2 
1 Codonopsis pilosula (Franch.). Nannf. (dang shen) 12 (747) 0.61 [0.52, 0.72] 28 
1 Paeonia lactiflora Pall. (bai shao) 5 (272) 0.61 [0.48, 0.76] 0 
1 Panax notoginseng (Burk.) F.H. Chen (tian qi) 4 (245) 0.61 [0.43, 0.87] 0 
1 Atractylodes macrocephala Koidz. (bai zhu)* 16 (976) 0.62 [0.54, 0.71] 13 
1 Eclipta prostrata L. (mo han lian) 2 (129) 0.63 [0.41, 0.97] 0 
1 Sophora japonica L. (huai hua) 3 (150) 0.63 [0.46, 0.86] 0 
1 Scutellariabarbata D. Don. (ban zhi lian) 6 (356) 0.64 [0.50, 0.81] 0 
1 Astragalus membranaceus (Fisch.) Bge. (huang qi)* 13 (733) 0.65 [0.55, 0.76] 0 
1 Ligusticum chuanxiong Hort. (chuan xiong) 2 (114) 0.65 [0.46, 0.92] 0 
1 Angelica sinensis (Oliv.) Diels. (dang gui) 2 (118) 0.68 [0.50, 0.92] 11 
1 Hedyotis diffusa Willd. (she she cao) 4 (228) 0.69 [0.51, 0.93] 0 
1 Akebia quinata (Thunb.) Decne. (ba yue zha) 5 (264) 0.70 [0.51, 0.95] 0 
1 Curcuma zedoaria (Berg.) Rosc. or C. phaeocaulis Val. 
(e zhu) 
7 (439) 0.71 [0.57, 0.88] 0 
1 Spatholobus suberectus Dunn (ji xue teng) 3 (192) 0.73 [0.55, 0.98] 0 
2 Panax G + Astragalus 3 (162) 0.49 [0.35, 0.67] 0 
2 Poria + Dioscorea 5 (321) 0.56 [0.47, 0.67] 0 
2 Sophora F +Astragalus 2 (92) 0.56 [0.35, 0.92] 0 
2 Glycyrrhiza + Rehmannia 2 (110) 0.59 [0.39, 0.88] 0 
2 Poria + Coix 12 (755) 0.59 [0.50, 0.69] 31 
2 Poria + Rehmannia 3 (199) 0.60 [0.47, 0.75] 0 
2 Atractylodes + Coix 12 (767) 0.60 [0.51, 0.70] 28 
2 Poria + Paeonia 5 (272) 0.61 [0.48, 0.76] 0 
2 Poria + Atractylodes 14 (865) 0.63 [0.54, 0.72] 22 
2 Atractylodes + Astragalus 12 (701) 0.66 [0.56, 0.78] 0 
2 Atractylodes + Akebia quinata 5 (264) 0.70 [0.51, 0.95] 0 
2 Atractylodes + Curcuma 7 (439) 0.71 [0.57, 0.88] 0 
2 Astracgalus + Curcuma 6 (375) 0.72 [0.56, 0.93] 0 
3 Dioscorea + Coix +Poria 3 (168) 0.49 [0.37, 0.65] 0 
3 Panax G + Atractylodes + Coix 3 (180) 0.52 [0.39, 0.69] 0 
3 Amomum + Poria + Coix 2 (117) 0.54 [0.36, 0.81] 0 
3 Dioscorea + Poria + Atractylodes 3 (174) 0.56 [0.43, 0.73] 2 
3 Coix + Paeonia + Poria 3 (168) 0.56 [0.41, 0.75] 0 
3 Dioscorea + Paeonia + Poria 3 (172) 0.58 [0.44, 0.75] 0 
3 Poria + Codonopsis + Artactylodes 12 (751) 0.63 [0.53, 0.74] 32 
3 Poria + Atractylodes + Ligusticum 2 (114) 0.65 [0.46, 0.92] 0 
3 Atractylodes + Paeonia + Poria 4 (213) 0.65 [0.50, 0.83] 0 
3 Coix + Astragalus + Atractylodes 10 (596) 0.66 [0.55, 0.79] 0 
3 Poria + Astragalus + Atractylodes 10 (590) 0.68 [0.57, 0.81] 0 
3 Poria + Atractylodes + Spatholobus 3 (192) 0.73 [0.55, 0.98] 0 
4 Glycyrrhiza + Atractylodes + Poria + Coix 3 (170) 0.51 [0.38, 0.70] 0 
4 Coix + Astragalus + Atractylodes + Eclipta prostrata 2 (129) 0.63 [0.41, 0.97] 0 
4 Sophora J + Atractylodes + Paeonia + Poria 3 (150) 0.63 [0.46, 0.86] 0 
4 Coix + Scutellaria + Atractylodes + Astragalus  6 (356) 0.64 [0.50, 0.81] 0 
4 Codonopsis + Astragalus + Atractylodes + Poria 9 (522) 0.66 [0.54, 0.80] 0 
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Level HM botanical name (pinyin) N studies 
(part.) 
RR [95% CI] I2 
4 Poria + Angelica sinensis + Atractylodes + Coix 2 (118) 0.68 [0.50, 0.92] 11 
4 Poria + Atractylodes + Codonopsis + Hedyotis 4 (228) 0.69 [0.51, 0.93] 0 
4 Codonopsis + Atractylodes + Poria + Paeonia 3 (164) 0.69 [0.50, 0.94] 0 
4 Atractylodes + Astragalus + Coix + Curcuma 5 (3110 0.70 [0.52, 0.93] 0 
4 Codonopsis + Atractylodes + Poria + Curcuma 6 (369) 0.73 [0.58, 0.93] 0 
5 Scutellaria +Lycium + Astragalus + Atractylodes + Coix 3 (168) 0.58 [0.41, 0.83] 0 
5 Rehmannia + Atractylodes + Glycyrrhiza + Poria + Coix 2 (110) 0.59 [0.39, 0.88] 0 
5 Scutellaria + Curcuma + Atractylodes + Astragalus + 
Coix 
4 (158) 0.62 [0.45, 0.86] 0 
6 Panax G + glycyrrhiza + Atractyludes + Coix + Poria 
+Dioscorea  
2 (110) 0.50 [0.36, 0.69] 0 
6 Magnolia + Atractylodes + Poria + Coix + Astragalus + 
Codonopsis 
3 (179) 0.54 [0.38, 0.77] 0 
6 Lycium + Astragalus + Atractylodes + Coix + Scutellaria 
+ Poria 
2 (98) 0.57 [0.36, 0.91] 0 
6 Dioscorea + Cornus + Poria + Rehmannia + Paeonia S + 
Alisma 
2 (139) 0.59 [0.46, 0.75] 0 
6 Coix + Panax N + Curcuma + Astragalus + Atractylodes 
+ Scutellaria 
3 (198) 0.60 [0.42, 0.87] 0 
6 Sophora J + Atractylodes + Paeonia L + Poria + Coix + 
Nelumbo 
2 (110) 0.60 [0.41, 0.88] 0 
6 Poria + Scutellaria + Astragalus + Atractylodes + Coix + 
Codonopsis 
5 (286) 0.65 [0.50, 0.85] 0 
7 Hordeum + Astragalus + Atractylodes + Codonopsis + 
Coix + Poria + Crataegus 
2 (98) 0.47 [0.33, 0.68] 0 
7 Glycyrrhiza + Atractylodes + Poria + Coix + Astragalus 
+ Codonopsis + Massa medica 
2 (120) 0.47 [0.30, 0.73] 0 
7 Coix + Hedyotis + Scutellaria + Astragalus + 
Atractylodes + Poria + Codonopsis 
3 (188) 0.69 [0.49, 0.98] 0 
9 Codonopsis + Panax N + Astragalus + Atractylodes + 
Poria + Coix + Hedyotis + Scutellaria + Curcuma 
2 (128) 0.61 [0.37, 1.00] 0 
*Included in the final six CHMs; RR: Risk Ratio for CINV; 95% CI: 95% Confidence Interval; N. studies (part.): 
number of studies (participants); I² %: measure of heterogeneity of result 
6.3.4.7 Level 7: Combinations of seven herbal medicines and more 
Two combinations of seven HMs were lower than the total pool: Codonopsis + Atractylodes + 
Astragalus + Coix + Poria + Crataegus pinnatifida Bge (shan zha) + Hordeum vulgare L. (mai ya) 
(n=2) (RR 0.47 [0.33, 0.68], I²=0%), Glycyrrhiza + Atractylodes + Poria + Coix + Astragalus + 
Codonopsis + Massa medica (n=2) (RR 0.47 [0.30, 0.73], I²=0%). In only one combination of nine 
HMs was the RR higher than the total pool (Table 6.2). 
  Herbal medicines with consistent results at multiple levels 6.3.5
Six herbs showed significantly reduced RRs lower than or equal to the pool, with low heterogeneity at 
multiple levels. Atractylodes, Poria and Coix appeared at all seven levels when used as components of 
various HMs interventions; Glycyrrhiza appeared at five levels; while Astragalus and Panax G 
appeared at four levels. 
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 Potential synergistic effects of herbal medicines 6.3.6
Combinations of HMs that showed RRs that were lower than those of the HMs singly included two 
pairs: Panax G + Astragalus; and Coix + Atractylodes; two triplets Poria + Coix + Dioscorea, Poria + 
Coix + Paeonia lactiflora Pall (bai shao); and one group of six HMs Panax G + Coix + Atractylodes + 
Poria + Dioscorea + Glycyrrhiza (Table 6.2). 
  Discussion of the results for chemotherapy-induced nausea and vomiting 6.3.7
The meta-analyses showed reductions in CINV in both the injection and oral groups but there was 
substantial heterogeneity in the injection group (I²=60%) compared to the oral group (I²=5%). In the 
oral intervention studies the absolute risk reduction was 25%, which was higher than for the injection 
group (20%). In a previous meta-analysis of tumour response rate, the injection groups appeared more 
effective than the oral groups (Figure 6.1). One likely reason for these differences is the injection 
products were mainly aimed at aiding tumour response rather than reducing CINV. Nevertheless, the 
result for the two studies of Kang’ai injection, which is composed of Panax ginseng, Astragalus and 
Sophora flavescens Ait., showed a significant reduction in CINV incidence, without important 
heterogeneity (I²=28%).  
It has been suggested that combining certain HMs with anti-emetic drugs results in greater benefit 
(Dong, 2012). In the total group, there was a slightly reduced benefit in the 17 studies that used anti-
emetic drugs compared to the ten that did not. However, it is possible that some studies did not report 
the use of anti-emesis medications since these are in routine use. Therefore this result is difficult to 
interpret. This issue warrants further investigation. 
The following six herbs appeared at multiple levels of combination in the oral interventions: 
Atractylodes (n=16), Poria (n=16), Coix (n=14), Astragalus (n=13), Glycyrrhiza (n=5), and Panax G 
(n=4). This list contains the herbs with the highest overall frequencies, such as Atractylodes and Poria, 
and also some lower frequency plants such as Glycyrrhiza and Panax G. Conversely, some relatively 
frequent herbs such as Curcuma (n=7) did not show a reduced RR for CINV. Therefore, the selection 
process did not simply reflect overall frequency of the herb within the data set.  
Ginger was not included in the final analyses, although it appeared to significantly reduce CINV (RR 
0.43 [0.31, 0.61]), since it was used in only two studies and the heterogeneity was substantial 
(I²=69%), leading to its exclusion from Table 6.2. 
The effects of extracts and compounds derived from the six herbs identified as potentially reducing 
CINV have received research attention in experimental models in animals and cell-lines to assess their 
effects on emesis, pica, gastrointestinal motility and gastro-protection. The volume of published 
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research is variable, with Ginseng, Atractylodes, and Poria having received the most attention. This 
research is briefly reviewed for each of the six herbs below. 
6.3.7.1 Actions of Panax ginseng relevant to nausea/vomiting 
The anti-emetic effect of Korean red ginseng total extract (KRGE) on nausea and vomiting was 
investigated in ferrets administered intraperitoneal cisplatin (7.5mg/kg) which induced both nausea 
and vomiting with one-hour latency. The animals were monitored every 30 mins and the total number 
of episodes of nausea and vomiting were marked. Pre-treatment with orally administered KRGE, one 
hour and two hours before cisplatin, significantly attenuated the cisplatin-induced nausea and vomiting 
in a dose-dependent manner. No significant effect was evident when KRGE was administered 4 hours 
prior to cisplatin (Kim et al., 2005). 
In rodents, emetics do not produce vomiting but instead induce pica (the eating of kaolin). In rats, the 
effects of an extract of Korean ginseng (KG) administered before and after cisplatin, on pica, food 
intake, body weight, haematological parameters and histopathology was investigated by Raghavendran 
et al (2011). Pre-treatment with KG one hour before cisplatin significantly reduced kaolin intake at 24, 
48, and 72 hours post-cisplatin. Normal food intake significantly improved compared to the group that 
received cisplatin alone and there was less reduction in body weight. Post-treatment KG showed 
similar effects. The increases in the levels of white blood cells, neutrophils, lymphocytes induced by 
cisplatin were significantly lower in the rats pre-treated with KG, suggesting that KG reduced 
cisplatin-induced inflammation. Cisplatin-induced damage to the gastric mucosa and small intestine 
was reduced by pre-treatment, but not by post-treatment with KG (Raghavendran et al., 2011). A 
similar result was obtained using American ginseng berry extract (AGBE) and ginsenoside Re, which 
is one of its constituents. Pre-treatment reduced cisplatin-induced pica and improved food intake. 
When tested for antioxidant actions, both AGBE and ginsenoside Re were found to scavenge 
superoxide and hydroxyl radicals (Mehendale et al., 2005).  
Pre-treatment with ginsenoside Rg2 has been reported to have an inhibitory effect on human 5-HT3A 
receptors expressed in Xenopus oocytes that was dose dependent and reversible (Choi et al., 2003). 
Using the same model, similar effects have been reported for two ginsenoside metabolites: compound 
K (CK) or M4, which is derived from protopanaxadiol (PD) ginsenosides, and protopanaxatriol (PT) 
ginsenosides, respectively (Lee et al., 2004). These studies suggest that the reported effects of ginseng 
on nausea and vomiting may be via antagonism of the 5-HT3A receptor. 
6.3.7.2 Actions of Poria cocos relevant to nausea/vomiting 
Tai et al. (1995) investigated the effects of a range of triterpenes extracted from Poria in frogs orally 
administered copper sulphate as an emetic. The latency to first emesis was significantly prolonged 
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compared to controls by some, but not all, of the triterpenes. Those showing a significant anti-emetic 
effect had an exo-methylene group at C24 in their side chain. 
The effects of three Poria-derived triterpenoids [PA: Pachymic acid; DA: dehydroeburicoic acid; and 
HA: 3β-hydroxylanosta-7,9 (11), 24-trien-21-oic acid] on human 5-HT3A receptors was investigated 
in Xenopus oocytes using a two electrode voltage-clamp technique. Each triterpenoid showed 
concentration dependent, reversible, inhibition on 5HT-induced inward current, with HA showing the 
highest potency (Lee et al., 2009). 
6.3.7.3 Actions of Atractylodes macrocephala relevant to nausea/vomiting 
The effects of an extract of Atractylodes on restitution of the intestinal mucosa after damage was 
investigated in a cell migration model using intestinal epithelial (IEC-6) cells treated with: 
Atractylodes extract; spermidine (SPD, 5 μmol/L) as the positive control; the polyamine inhibitor 
alpha-difluoromethylornithine (DFMO, 2.5mmol/L) as the negative control; and a no treatment 
control. At doses of 100mg/L and 200mg/L, Atractylodes significantly increased IEC-6 cell migration 
after wounding compared to no treatment, and the effect was comparable to that of SPD. The effect of 
Atractylodes was retained when combined with DFMO. Atractylodes exposure increased cellular 
polyamine content and other markers indicating a polyamine dependent mechanism (Song et al., 
2015). In human gastric mucosa epithelium, Atractylodes extract promoted the growth of human 
gastric mucosa cells, DNA synthesis and pepsin secretion, but had no effect on acid secretion (Zhu et 
al., 2003). 
Atractylodes has been reported to enhance gastric emptying and small intestinal motility in mice fed 
Atractylodes extract plus the marker Blue dextran 2000, compared to a saline control (Li et al., 1996). 
This prokinetic effect could be blocked by atropine in a study of isolated mouse ileum, which 
indicated the effect may be mediated via muscarinic receptors (Ma et al., 1996). In guinea pig colon 
sections, Atractylodes extract was reported to increase smooth muscle contraction (Ding et al., 2005). 
6.3.7.4 Actions of Astragalus membranaceus relevant to nausea/vomiting 
A number of studies have investigated the effect of Astragalus on gastrointestinal motility. In healthy 
dogs, the investigators measured the myoelectric activity in the duodenum and jejunum after a 25% 
concentrated solution (1 mL/kg) of Astragalus extract was injected into the dog’s empty stomach. The 
duration of each myoelectric cycle, each phase of the cycle and the electrical potential were measured. 
The results showed Astragalus could significantly extend the duration of myoeletric cycles in the 
duodenum and jejunum but the motility enhancing effect was most pronounced in the jejunum (Yang 
et al., 1993). In normal mice, Astragalus significantly enhanced small intestine motility and 
antagonized the inhibitive effects of atropine and the non-selective beta-adrenergic agonist 
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isoproterenol. In the stomach, Astragalus also antagonized inhibition of gastric emptying induced by 
atropine (3mg/kg), but did not antagonize the dopamine-serotonin receptor antagonist metoclopramide 
(0.8mg/kg) (Zheng et al., 2003). 
In healthy humans, small intestine transmission time was measured by using a hydrogen breath test to 
determine the peak value of lactose absorption after taking 18 g lactose orally. After taking Astragalus 
for one week, the time to the peak value of lactose absorption was significantly shortened, compared 
to before administration of Astragalus, suggesting increased motility (Qiaoet al., 2001). 
6.3.7.5 Actions of Glycyrrhiza (liquorice) relevant to nausea/vomiting 
The effects of aqueous extracts of several HMs, including Glycyrrhiza, Astragalus and Atractylodes, 
were tested in isolated smooth muscle strips taken from different gastric regions of the rat. 
Glycyrrhiza, Astragalus, and Atractylodes increased longitudinal and circular fundic muscle tension; 
Glycyrrhiza and Atractylodes enhanced longitudinal muscle tension in strips from the gastric body; 
while Glycyrrhiza increased the motility index of pyloric circular muscle (Zheng et al., 1998). 
A study that investigated the effects of isoliquiritigenin (a flavonoid in Glycyrrhiza spp.) on 
gastrointestinal motility in mice fed a charcoal meal, found an inhibitory effect at low doses (0.003, 
0.03 mg/kg) and a prokinetic effect at high doses (3 and 30 mg/kg). Subsequent in vitro studies 
indicated that the spasmogenic effect involved activation of muscarinic receptors, while the 
spasmolytic effect was associated with blockade of calcium channels (Chen et al., 2009). 
Sato et al. (2006) investigated the effect of glycycoumarin, a compound from Glycyrrhiza, on 
carbamylcholine (CCh)-induced contraction of mouse jejunum and reported an antispasmodic effect 
related to the inhibition of the phosphodiesterase 3 pathway. 
6.3.7.6 Actions of Coix relevant to nausea/vomiting 
The effect of de-hulled Coix seed was examined in an indomethacin-induced gastric lesion model in 
rats. Erosion of the gastric mucosa was examined by imaging and by histopathological observation. 
Coix extract was found to produce dose-dependent gastroprotection against indomethacin. This effect 
was at least partially due to antioxidant actions of the phenolic acids in Coix (Chung et al., 2011). A 
methanol extract of Coix seeds was found to reduce nitric oxide and superoxide production in RAW 
264.7 macrophages (Seo et al., 2000). 
 Safety of the herbal medicine interventions 6.3.8
The included studies did not report any serious adverse events associated with the CHMs and the 
meta-analyses results did not show increased CINV in any of the studies. When combined with anti-
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emetic drugs the CHMs did not appear to reduce their effectiveness rather, the results were suggestive 
of enhanced effect (tRR: RR 1.29 [1.14, 1.46], I2 0%). 
  Summary of the results for chemotherapy-induced nausea and vomiting 6.3.9
In nausea and vomiting associated with oxaliplatin-based chemotherapy for CRC, the addition of 
CHMs appeared to significantly reduce incidence based on a meta-analysis of 27 studies. This effect 
was most pronounced in the group of 21 studies that administered the CHMs orally. There was low 
statistical heterogeneity in this group, the oxaliplatin regimens and CINV measurements were 
consistent across studies, and there was considerable similarity in the HMs used. Further sensitivity 
analysis based on individual HM ingredients, identified six herbs (Atractylodes, Poria, Coix, 
Astragalus, Glycyrrhiza, and Panax G) that were associated with significant reductions in CINV 
without important heterogeneity in the sensitivity analysis results. Experimental studies of these six 
herbs have reported inhibitory effects on nausea and vomiting (or its animal equivalent), regulation of 
gastrointestinal motility, gastro-protective effects, and/or antioxidant actions which may at least 
partially explain the effects identified in the meta-analyses of the clinical trial results. These herbs 
warrant further experimental and/or clinical research into their efficacy as anti-emetics, the underlying 
anti-emetic mechanism, and the safety of concurrent administration with chemotherapeutic drugs to 
explore their possible addition to chemotherapy regimens in patients whose CINV is not sufficiently 
well-controlled by conventional therapies.  
6.4 Meta-analysis of oxaliplatin-based chemotherapy combined with herbal medicine 
for chemotherapy induced neutropenia 
  Background and rationale 6.4.1
Chemotherapy induced neutropenia (CIN) is a decline in absolute neutrophil count (ANC) as a result 
of myelosuppression induced by systematic chemotherapy (Dale, 2002). Neutropenia can lead to life-
threatening infections so it is common practice to decrease dose intensity or cut short treatment cycles 
when serious neutropenia is evident, but this will directly affect the effectiveness of the chemotherapy 
(Crawford et al., 2004). CIN severity is classified into four grades based on decline in ANC (Koini et 
al., 2015). Febrile neutropenia (FN) is a serious condition that combines elevated body temperature, 
sepsis and severe neutropenia (Koini et al., 2015, Aapro et al., 2010). Risk factors for CIN include age, 
performance status, nutritional status, chemotherapy dose intensity, and low baseline blood cell counts 
(Lyman et al., 2005). 
CIN is one of the most common adverse reactions in CRC treatment using oxaliplatin regimens (Hind 
et al., 2008). In CRC clinical trials the incidence of grade 3/4 CIN was found to vary from 37% to 
56% in different populations (Sugihara et al., 2012), and CIN incidence has been found to be higher in 
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regimens that combine oxaliplatin with 5-FU compared to single 5-FU regimens (Becouarn et al., 
1998; de Gramont et al., 2000). This may be associated with oxaliplatin reducing 5-FU plasma 
clearance by inhibiting 5-FU catabolism (Boisdron et al., 2002). 
Granulocyte colony-stimulating factor (G-CSF) initiates the proliferation of granulocyte precursor 
cells and their differentiation into mature granulocytes in bone marrow. Clinical trials have found that 
recombinant G-CSF significantly reduced the incidence of grade 3/4 CIN and accelerated cancer 
patients’ recovery from CIN after chemotherapy, thereby making higher-intensity treatment regimens 
possible (Saarinen et al.,1992; Lydaki et al., 1995; Gomez et al., 2006; Hecht et al., 2010). In the past, 
G-CSF treatment was expensive (Hendler et al., 2011) but the advent of biosimilars has made G-CSF 
support for CIN/FN prophylaxis more cost-effective (Gascón et al., 2011). 
In advanced CRC (Chapter 5), the meta-analysis of RCT results showed FOLFOX4 combined with 
CHMs reduced grade 3/4 CIN by 8.7% compared to FOLFOX4 alone (Chen et al., 2014). In this meta-
analysis, the aims were: 1. assessment of the clinical trial literature on the effects of HMs on CIN 
associated with the use of oxaliplatin regimens for CRC; 2. identification of which HMs, or 
combinations of HMs, were associated with CIN alleviation when used in combination with 
oxaliplatin regimens in the clinical trials; and 3. identification of directions for further clinical and 
experimental research. 
Meta-analysis of RCTs of CHMs combined with oxaliplatin regimens for CRC which reported data on 
CIN incidence was conducted. Then sensitivity analyses were used for sub-groups of studies that used 
the same or similar HM interventions to assess the potential contributions of individual plant-based 
HMs to the meta-analysis results. For the HMs that appeared most likely to be contributing to reduced 
CIN incidence, the experimental literature was reviewed to identify possible mechanisms of action. 
Sub-group analyses were planned for: route of HM administration – intravenous (IV) or oral; and 
studies employing G-CSF. Data analysis for CIN was stratified by: FN, CIN grade 4, CIN grade 3, 
CIN grade 3/4, CIN grade 1/2, and CIN all grades. To determine if the addition of the HMs interfered 
with the effectiveness of the chemotherapy, meta-analysis of tumour response rate (tRR) was 
conducted for the studies in the groups for CIN grade 3/4 and all grades. 
  Included studies and characteristics 6.4.2
Thirty-two studies (2,224 participants) that combined an oxaliplatin regimen with a CHM versus the 
same oxaliplatin regimen and reported outcome data for CIN, were included. Of these, two studies 
(Deng & Shen, 2010; Fang & Li, 2008) used G-CSF, and two studies (Xu & Wang, 2010; Zeng et al., 
2013) reported neutrophil count as mean difference, so these studies were analysed separately. 
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All studies were published from 2005 to 2013. Thirty-one studies were conducted in China and one in 
Japan (Kono et al., 2013). The studies reported all participants were diagnosed as CRC based on 
pathology tests, and had adequate liver and kidney function and peripheral blood count or no 
contraindication to chemotherapy pre-study. Twenty-six studies specified life expectancy of three 
months or longer and 17 studies specified no use of chemotherapy for at least one month prior to study 
commencement (Table G3, in Appendex G).  
Oxaliplatin regimens included FOLFOX in 30 studies and XELOX in two studies (Deng & Shen, 
2010; Wang, 2013). The CHMs and chemotherapy were used concurrently. Orally administered 
CHMs were used in 24 studies (1,319 particpants) and 8 studies employed commercially available 
CHM injections (Table G3, in Appendex G).  
All studies used the WHO system or National Cancer Institute Common Toxicity Criteria (NCI-CTC) 
for grading acute and sub-acute toxicity which divides CIN into 4 grades (Miller et al., 1981; National 
Cancer Institute, 1999). Data were reported as dichotomous in 30 studies. Data reported as neutrophil 
counts (2 studies) were analysed separately using MD. When RR was less than +1 or MD was less 
than zero it favoured the test group. Only one study reported FN data (see oral administration group). 
  Meta-analysis of change in chemotherapy induced neutropenia 6.4.3
The overall results showed significantly reduced CIN in the test groups compared to the control 
groups for grade 4, grade 3, grade 3/4, grade 1/2 and all grades, with no statistical heterogeneity (I2 
=0%) (Figure 6.4; Table 6.3). Results were also reported for the following sub-groups: 
1. Injection group without G-CSF (7 studies); 
2. Oral administration group without G-CSF (21 studies); 
3. Studies that used G-CSF (2 studies); and 
4. Neutrophil count group (2 studies). 
6.4.3.1 Injection group (no G-CSF) 
Seven studies tested five different injection products, three of which were tested in two studies each 
(Table 6.5). There was no difference between groups in the single study that reported grade 4 CIN or 
in the four studies that reported grade 3. There were significant differences in grade 3/4, grade 1/2, and 
all grades, with no heterogeneity. Incidence rates for grade 3/4 CIN were 4.5% in the test groups 
versus 11.1% in the controls (Figure 6.4; Table 6.3). 
6.4.3.2 Oral administration group (no granulocyte colony-stimulating factor) 
In 21 studies, CHMs were administered orally as decoctions, capsules or tablets. In the four studies 
that reported grade 4 CIN, there was no significant difference between groups. Significant differences 
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were found for grade 3, grade 3/4, grade 1/2, and all grades with no heterogeneity. Incidence rates for 
grade 3/4 were 4.6% in the test groups versus 11.8% in the controls (Figure 6.4; Table 6.3). The single 
study that reported FN (n=89) (Kono et al., 2013) found no significant difference between groups. 
 
Figure 6.4: Forest plot of risk ratio for Chinese herbal medicine alleviation of chemotherapy 
induced neutropenia (included oral and non-oral sub-groups) 
6.4.3.3 Granulocyte colony-stimulating factor group 
One study used an injection (Fang & Li, 2008) and one used oral CHM (Deng & Shen, 2010). For the 
pooled data there was no significant difference between groups in grade 3/4 and all grades 
neutropenia. No data were available on FN (Table 6.3). 
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Total (95% CI)
Total events
Heterogeneity: Chi² = 20.15, df = 26 (P = 0.78); I² = 0%
Test for overall effect: Z = 10.20 (P < 0.00001)
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11.5%
1.8%
2.9%
3.1%
1.2%
1.7%
67.0%
3.1%
3.8%
4.5%
8.0%
9.8%
3.8%
33.0%
100.0%
IV, Fixed, 95% CI
0.34 [0.15, 0.73]
0.73 [0.44, 1.22]
0.44 [0.23, 0.86]
0.56 [0.35, 0.89]
0.52 [0.23, 1.18]
0.56 [0.30, 1.04]
0.43 [0.20, 0.96]
0.25 [0.09, 0.72]
0.54 [0.23, 1.26]
0.60 [0.27, 1.34]
0.50 [0.23, 1.08]
0.47 [0.26, 0.87]
0.45 [0.25, 0.80]
0.69 [0.49, 0.96]
0.72 [0.54, 0.96]
0.74 [0.56, 0.98]
0.42 [0.21, 0.86]
0.71 [0.41, 1.25]
0.52 [0.31, 0.90]
0.45 [0.19, 1.08]
0.37 [0.18, 0.76]
0.59 [0.53, 0.67]
0.71 [0.41, 1.21]
0.50 [0.31, 0.82]
0.57 [0.37, 0.89]
0.71 [0.51, 0.99]
0.72 [0.53, 0.98]
0.55 [0.33, 0.89]
0.65 [0.55, 0.76]
0.61 [0.56, 0.67]
Experimental Control Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control
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Table 6.3: Meta-analysis results for chemotherapy induced neutropenia (febrile neutropenia, 
grades 4, 3, 3/4, 1/2, all grades), neutrophil count 
Group 
No. studies 
(participant 
No. T/C) 
EoT (between groups) RE I2 Incidence T/C (%) 
1. Injection group (no G-CSF): 7 studies 
Gr 4 1 (65/52) 0.27 [0.01, 6.44], p = 0.42 NA T: 0% (0/65); C: 1.9% (1/52) 
Gr 3 4 (199/186) 0.62 [0.28, 1.40], p = 0.25 0 T: 4.5% (9/199); C: 7.5% (14/186) 
Gr 3/4 5 (221/207) 0.47 [0.22, 0.98], p = 0.04* 0 T: 4.5% (10/221); C: 11.1% (23/207) 
Gr 1/2 4 (199/186) 0.58 [0.44, 0.77], p = 0.0001* 0 T: 26.1% (52/199); C: 46.2% (86/186) 
All grades 6 (269/252) 0.65 [0.55, 0.76], p < 0.00001* 0 
T: 37.9% (102/269); 
C: 61.5% (155/252) 
2. Oral administration group (no G-CSF): 21 studies 
FN 1 (44/45) 0.20 [0.01, 4.14], p = 0.30 NA T: 0% (0/44); C: 4.4% (2/45) 
Gr 4 4 (116/116) 0.25 [0.05, 1.18], p = 0.08 0 T: 0% (0/116); C: 5.2% (6/116) 
Gr 3 15 (509/462) 0.37 [0.21, 0.65], p = 0.0005* 0 T: 3.1% (16/509); C: 9.5% (44/462) 
Gr 3/4 17 (583/537) 0.44 [0.29, 0.66], p = 0.0001* 0 T: 4.6% (27/583); C: 12.5% (67/537) 
Gr1/2 19 (635/585) 0.62 [0.54, 0.72], p < 0.00001* 0 
T: 25.8% (164/635); 
C: 44.1% (258/585) 
All grades 21 (686/632) 0.59 [0.53, 0.67], p < 0.00001* 0 
T: 31.5% (216/686); 
C: 57.8% (366/633) 
Total: groups 1 and 2 (no G-CSF): 28 studies 
Gr 4 5 (181/168) 0.26 [0.06, 1.03], p = 0.05 0 T: 0% (0/181); C: 4.2% (7/168) 
Gr 3 19 (708/647) 0.42 [0.27, 0.67], p = 0.0002* 0 T: 3.5% (25/708); C: 9.6% (62/647) 
Gr 3/4 22 (804/743) 0.45 [0.31, 0.65], p < 0.0001* 0 T: 4.6% (37/804); C: 11.8% (88/743) 
Gr 1/2 23 (834/771) 0.61 [0.54, 0.70], p < 0.00001* 0 
T: 25.9% (216/834); 
C: 43.3% (334/771) 
All grades 27 (955/885) 0.61 [0.56, 0.67], p < 0.00001* 0 
T: 33.3% (318/955); 
C: 58.9% (521/885) 
3. G-CSF group: 2 studies 
Grade 3/4 2 (66/63) 1.00 [0.15, 6.63], p =1.00 0 T: 3.0% (2/66); C: 3.2% (2/63) 
All grades 2 (66/63) 0.91 [0.48, 1.74], p =0.78 27 T: 36.3% (24/66); C: 38.1% (24/63) 
4. Neutrophil count: 2 studies 
Total neutrophils 
(MD) 2 (122/90) 
MD: 1.62 [0.93, 2.32], p < 
0.00001* 66 NA 
T: treatment group; C control group; EoT: end of treatment; FN: febrile neutropenia; RE: random effect; * 
significant at p< 0.05 
6.4.3.4 Neutrophil count 
In the two studies that presented data as mean neutrophil count (Xu & Wang, 2010; Zeng et al., 2013) 
there was a significant difference in favour of the test groups (MD 1.62 [0.93, 2.32] I2=66%) (Table 
6.3). 
   
187 
  Effect of number of cycles of chemotherapy on chemotherapy induced neutropenia 6.4.4
incidence 
Grade 3/4 CIN incidence was stratified by number of cycles of chemotherapy (2, 3, 4, 6, 8+) for the 
oxaliplatin control groups and the test groups (Table 6.4). In the control groups, the mean grade 3/4 
CIN incidence was higher at 2 cycles (12.30%) than at 3 cycles (6.92%), but then the incidence 
increased with increasing number cycles to 19.00% for 8 or more cycles (Figure 6.5). There were 
significant reductions in grade 3/4 CIN incidence in the test groups for two cycles (RR 0.37 [0.17, 
0.80]) and four cycles (RR 0.26 [0.10, 0.66]), with a marginal difference at 6 cycles (RR 0.36 [0.13, 
1.02], p=0.05). There were no significant differences at 3 and 8 cycles or more. It was not feasible to 
calculate accumulated oxaliplatin and 5-FU dose due to variation in data reporting 
Table 6.4: Grades 3/4 chemotherapy induced neutropenia incidence by number of cycles of 
oxaliplatin-based chemotherapy 
No. Cycles of 
chemotherapy 
No studies 
(participants) 
Control gps. 
(Mean% ±SE) 
Test gps. (Mean% 
±SE) RR [95%CI] I
2 
2 7 (380) 12.30 ± 1.88 4.14 ± 1.00 0.37 [0.17, 0.80] I2=0* 
3 4 (350) 6.92 ± 0.82 4.19 ± 1.06 0.66 [0.27, 1.64] I2=0 
4 5 (391) 11.28 ± 6.09 2.55 ± 0.75 0.26 [0.10, 0.66] I2=0* 
6 3 (219) 12.75 ± 3.82 5.13 ± 0.58 0.36 [0.13, 1.02] I2=0, p=0.05 
8+ 3 (207) 19.00 ± 8.91 10.28 ± 7.12 0.61 [0.32, 1.15] I2=0 
*significant in favour of test groups 
Meta-analysis of tumour response rate (tRR) 
To test whether the reduction of CIN was associated with reduction of the cytotoxicity of the 
chemotherapeutic agents, we pooled results of the studies that also reported tRR. Data were available 
for 6 studies in the injection group, seventeen studies in the oral group, one in the G-CSF group and 
two in the neutrophil count group. The results showed there were no significant reductions in tRR in 
the pooled data (Table 6.5) 
 Sensitivity analyses for selection of herbs for chemotherapy induced neutropenia 6.4.5
The multi-ingredient CHMs differed in name but their main ingredients were similar. The effects on 
reduction of CIN of the plant-based HM ingredients used in multiple studies are reported below at the 
level of the single HM, pair of HMs, and groups of 3 up to 10 HMs. It was not feasible to use this 
procedure for studies of injection products since these were likely to vary according to manufacturer 
and administration. 
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Figure 6.5: Grade 3/4 chemotherapy induced neutropenia incidence by number of cycles of 
oxaliplatin based chemotherapy 
t: test groups; c: control groups 
All plant-based ingredients (n=85) in the oral HMs were recorded in a spread-sheet. The number of 
ingredients per intervention averaged 10 and ranged from 1 to 23. Thirty-six HMs were used in two or 
more interventions. The RR (CIN all grades) of the group of studies that included each particular HM 
was calculated and the RRs were ranked from low to high. The significant RRs were identified (n=36), 
and groups with moderate or higher heterogeneity (I²> 30%) were excluded (n= 6) leaving 30 different 
HMs in the following analyses. Since the aim was to select HMs for further research, only significant 
RR results that were equal or lower than the total pooled RR of oral interventions (0.59 [0.53, 0.67]) 
are reported in the text. See Table 6.6 for all significant RR results. For each of the 30 HMs, the full 
botanical name is given in Table 6.6 together with the Chinese name in pinyin. Therefore, the name is 
shortened to the genus only in the text. The most frequently used plants were: Atractylodes (n=15); 
Poria (n=13); Coix (n=13); Astragalus (n=12); and Codonopsis (n=10). 
6.4.5.1 Level 1: Single herbal medicines 
Of the 30 HMs included at level 1, six were not always associated with another HM in the CHM 
interventions (Table 6.6). Of these, Poria (n=13) had the lowest RR (0.50 [0.42, 0.60], I²=0%), 
followed by Panax N (n=4) (RR 0.51 [0.36, 0.72], I²=0%), Codonopsis (n=10) (RR 0.54 [0.45, 0.65], 
I²=0%), Astragalus (n=12) (RR 0.55 [0.47, 0.65], I²=0%), Coix (n=13) (RR 0.56 [0.48, 0.66], I²=0%), 
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and Atractylodes (n=15) (RR 0.57 [0.50, 0.66], I²=0%). The remaining HMs always appeared in 
association with at least one other HM. 
Table 6.5: Tumour response rate (tRR) for studies included in chemotherapy induced 
neutropenia groups 
Group 
No. studies 
(participant 
No. T/C) 
EoT (between groups) RE I2 Incidence T/C (%) 
1. Injection group (no G-CSF): 6 studies that reported CIN data for Grade 3/4 and/or all grades 
Reported CIN Gr 3/4 4 (191/177) 1.43 [1.04, 1.96], p = 0.03* 37 T: 52.4% (100/191); C: 35.0% (62/177) 
Reported CIN all 
grades 5 (239/222) 1.38 [1.07, 1.78], p = 0.01* 27 
T: 51.9% (124/239); 
C: 36.5% (81/222) 
2. Oral administration group (no G-CSF): 17 studies 
Reported CIN Gr 3/4 16 (534/482) 1.21 [1.03, 1.42], p = 0.02* 0 T: 40.3% (215/534); C: 33.0% (159/482) 
Reported CIN all 
grades 17 (569/514) 1.20 [1.03, 1.41], p = 0.02* 0 
T: 40.6% (231/569); 
C: 33.5% (172/514) 
Total for groups 1 and 2 (no G-CSF): 23 studies 
Reported CIN Gr 3/4 20 (725/659) 1.29 [1.13, 1.48], p = 0.0002* 0 T: 43.4% (315/725); C: 33.5% (221/659) 
Reported CIN all 
grades 23 (832/759) 1.27 [1.13, 1.44], p = 0.0001* 0 
T: 44.6% (371/832); 
C:34.9% (265/759) 
3. G-CSF group: 1 study 
Reported CIN Gr 3/4 
& all grades 1 (48/45) 1.16 [0.77, 1.74], p=0.47 NA 
T: 54.2% (26/48); 
C:46.7% (21/45) 
4. Neutrophil count: 2 studies 
Did not report CIN 
grades 2 (122/90) 1.24 [0.92, 1.66], p=0.16 0 
T: 52.5% (64/122); 
C:42.2% (38/90) 
T: treatment group; C control group; EoT: end of treatment; Gr. Grade; RE: random effect. 
6.4.5.2 Level 2: Pairs of herbal medicines 
When the 30 HMs that showed significant RR results were paired with other HMs from level 1, 
thirteen pairs showed RRs that were lower than the total pool for oral HM interventions (Table 6.6).  
Table 6.6: Effects of specific herbal medicines on chemotherapy induced neutropenia (all 
grades): single herbal medicines and combinations 
Level Herbal Medicine (HM) RR 95% CI 
No. 
studies 
(part.) 
I² 
1 Angelica sinensis (Oliv.) Diels. (dang gui) 0.38 [0.22,0.64] 2 (118) 0 
1 Ligusticum chuanxiong Hort. (chuan xiong)  0.38 [0.22,0.66] 2 (114) 0 
1 Glycyrrhiza uralensis Fisch. (gan cao) 0.40 [0.27,0.60] 3 (178) 0 
1 Amomum kravanh Pierre ex. Gagnep. (bai dou kou) 0.41 [0.26,0.65] 2 (126) 0 
1 Pinellia ternata (Thunb.) Breit. (ban xia) 0.45 [0.31,0.64] 3 (186) 0 
1 Smilax glabra Roxb. (tu fu ling) 0.46 [0.27,0.80] 2 (121) 0 
1 Citrus reticulata Blanco (chen pi) 0.46 [0.29,0.72] 2 (120) 0 
1 Eclipta prostrata L. (mo han lian) 0.47 [0.29,0.75] 2 (138) 0 
1 Paeonia lactiflora alba. (bai shao) 0.47 [0.34,0.65] 4 (212) 0 
1 Sparganium stoloniferum Buch.-Hamil. (san leng) 0.47 [0.27,0.81] 2 (132) 0 
1 Spatholobus suberectus Dunn (ji xue teng) 0.48 [0.34,0.68] 3 (192) 0 
1 Actinidia arguta (Sieb. & Zucc) Planch. ex Miq. (teng li gen) 0.49 [0.29,0.84] 2 (108) 0 
1 Smilax china L. (ba qia) 0.49 [0.30,0.81] 2 (113) 0 
1 Poria cocos (Schw) Wolf (fu ling) 0.50 [0.42,0.60] 13 (780) 0 
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Level Herbal Medicine (HM) RR 95% CI 
No. 
studies 
(part.) 
I² 
1 Ligustrum lucidum Ait. (nu zhen zi) 0.51 [0.33,0.79] 2 (130) 0 
1 Curcuma zedoaria (Berg.) Rosc. or C. phaeocaulis Val. (e zhu) 0.51 [0.38,0.67] 6 (379) 0 
1 Panax notoginseng (Burk.) F.H. Chen (san qi) 0.51 [0.36,0.72] 4 (245) 0 
1 Lycium barbarum L. (gou qi zi) 0.52 [0.38,0.71] 3 (168) 0 
1 Akebia quinata (Thunb.) Decne. (ba yue zha) 0.52 [0.38,0.72] 5 (264) 0 
1 Dioscorea opposita Thunb. (shan yao) 0.52 [0.39,0.71] 4 (261) 4 
1 Curcuma wenyujin Y. H. Chen et C. Ling (yu jin) 0.53 [0.36,0.79] 2 (91) 0 
1 Vitis quinquangularis Rehd. (ye pu tao teng) 0.53 [0.38,0.73] 4 (218) 0 
1 Codonopsis pilosula (Franch.). Nannf. (dang shen) 0.54 [0.45,0.65] 10 (615) 0 
1 Astragalus membranaceus (Fisch.) Bge. (huang qi) 0.55 [0.47,0.65] 12 (682) 0 
1 Coix lacryma-jobi L. (yi ren) 0.56 [0.48,0.66] 13 (773) 0 
1 Epimedium brevicornum Maxim (yin yang huo) 0.57 [0.43,0.77] 4 (271) 0 
1 Atractylodes macrocephala Koidz. (bai zhu)  0.57 [0.50,0.66] 15 (962) 0 
1 Scutellaria barbata D. Don. (ban zhi lian) 0.61 [0.50,0.74] 6 (356) 0 
1 Hedyotis diffusa Willd. (she she cao) 0.63 [0.51,0.79] 5 (288) 0 
1 Agrimonia pilosa Ledeb. (xian he cao) 0.65 [0.48,0.88] 2 (170) 0 
2 Poria + Coix 0.46 [0.37,0.57] 9 (523) 0 
2 Poria + Atractylodes 0.47 [0.39,0.57] 11 (633) 0 
2 Paeonia + Poria 0.47 [0.34,0.65] 4 (212) 0 
2 Vitis + Atractylodes 0.50 [0.36,0.70] 4 (218) 0 
2 C. zedoaria + Atractylodes 0.51 [0.38,0.67] 6 (379) 0 
2 Akebia + Atractylodes 0.52 [0.38,0.72] 5 (264) 0 
2 Poria + Dioscorea 0.52 [0.39,0.71] 4 (261) 4 
2 Codonopsis + Atractylodes 0.54 [0.45,0.65] 10 (615) 0 
2 Coix + Atractylodes 0.56 [0.47,0.67] 10 (595) 0 
2 Astragalus + Atractylodes 0.56 [0.48,0.67] 11 (650) 0 
2 Epimedium + Coix 0.57 [0.43,0.77] 4 (271) 0 
2 Atractylodes + Hedyotis 0.63 [0.51,0.79] 5 (288) 0 
2 Agrimonia + Atractylodes 0.65 [0.48,0.88] 2 (170) 0 
3 Poria + Atractylodes + Ligusticum 0.38 [0.22,0.66] 2 (114) 0 
3 Poria + Coix + Amomum 0.41 [0.26,0.65] 2 (126) 0 
3 Poria + Coix + Pinellia 0.45 [0.31,0.64] 3 (186) 0 
3 Poria + Dioscorea + Paeonia 0.45 [0.32,0.64] 3 (172) 0 
3 Poria + Coix + Atractylodes 0.46 [0.37,0.59] 8 (465) 0 
3 Poria + Astragalus + Smilax glabra 0.46 [0.27,0.80] 2 (121) 0 
3 Poria + Atractylodes + Astragalus 0.47 [0.38,0.60] 8 (479) 0 
3 Poria + Coix + Astragalus 0.48 [0.37,0.61] 7 (415) 0 
3 Spatholobus + Poria + Atractylodes 0.48 [0.34,0.68] 3 (192) 0 
3 Poria + Atractylodes + Paeonia 0.48 [0.33,0.71] 3 (154) 0 
3 Poria + Atractylodes + Actinidia 0.49 [0.29,0.84] 2 (108) 0 
3 Poria + Atractylodes + Codonopsis 0.50 [0.40,0.62] 9 (515) 0 
3 Astragalus + Atractylodes + C. zedoarea 0.50 [0.36,0.69] 5 (315) 0 
3 Astragalus + Atractylodes + Akebia 0.51 [0.35,0.72] 4 (224) 0 
3 Coix + Atractylodes + Astragalus 0.58 [0.48,0.69] 9 (545) 0 
4 Poria + Atractylodes+ Angelica + Coix 0.38 [0.22,0.64] 2 (118) 0 
4 Poria + Atractylodes + Glycyrrhiza + Coix 0.40 [0.27,0.60] 3 (178) 0 
4 Paeonia + Dioscorea + Poria+ Atractylodes 0.45 [0.29,0.71] 2 (114) 0 
4 Astragalus + Atractylodes + Coix + Eclipta 0.47 [0.29,0.75] 2 (138) 0 
4 Astragalus + Atractylodes + Akebia + Vitis 0.48 [0.31,0.74] 3 (154) 0 
4 Codonopsis + Astragalus + Atractylodes + Poria 0.48 [0.38,0.62] 7 (411) 0 
4 C. zedoaria + Poria + Atractylodes + Codonopsis 0.49 [0.36,0.67] 5 (309) 0 
4 Poria + Codonopsis + Atractylodes + Hedyotis  0.49 [0.35,0.70] 4 (228) 0 
4 Astragalus + Coix + C. zedoaria + Atractylodes 0.51 [0.36,0.73] 4 (251) 0 
4 Codonopsis + Atractylodes + Poria + Akebia 0.52 [0.34,0.80] 3 (153) 0 
4 Paeonia + Codonopsis + Atractylodes + Poria 0.55 [0.35,0.86] 2 (104) 0 
4 Astragalus + Coix + Atractylodes + Scutellaria 0.61 [0.50,0.74] 6 (356) 0 
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Level Herbal Medicine (HM) RR 95% CI 
No. 
studies 
(part.) 
I² 
4 Astragalus + Atractylodes + Coix + Hedyotis 0.61 [0.46,0.80] 4 (248) 0 
5 Astragalus + Atractylodes + Poria + Smilax + Coix  0.46 [0.27,0.80] 2 (121) 0 
5 Codonopsis + Poria + Astragalus + C. zedoaria + Atractylodes 0.48 [0.33,0.70] 4 (245) 0 
5 Astragalus + Coix + Poria + Codonopsis + Atractylodes 0.49 [0.37,0.63] 6 (348) 0 
5 Codonopsis + Atractylodes + Poria + C. zedoaria + Vitis 0.51 [0.35,0.73] 3 (177) 0 
5 Atractylodes + Hedyotis + Akebia + Poria + Codonopsis 0.52 [0.32,0.84] 2 (100) 0 
5 Astragalus + Coix + Atractylodes + C. zedoaria + Akebia 0.52 [0.35,0.76] 3 (183) 0 
5 Lycium + Atractylodes + Coix + Astragalus + Scutellaria 0.53 [0.39,0.73] 3 (168) 0 
5 Atractylodes + Astragalus + Coix + Hedyotis + Scutellaria 0.61 [0.46,0.80] 4 (248) 
1
5 
6 Codonopsis + Astragalus + Coix + Glycyrrhiza + Atractylodes + Poria 0.43 [0.27,0.68] 2 (128) 0 
6 Astragalus + Coix + Poria + Pinellia + Spatholobus + Atractylodes 0.45 [0.28,0.72] 2 (128) 0 
6 Hedyotis + Scutellaria + Coix + Codonopsis + Astragalus + Poria 0.47 [0.32,0.69] 3 (188) 0 
6 Astragalus + Atractylodes + Poria + Codonopsis + C. zedoaria + Sparganium 0.47 [0.27,0.81] 2 (132) 0 
6 Codonopsis + Atractylodes + Astragalus + Coix + Poria + Scutellaria 0.50 [0.37,0.68] 4 (226) 0 
6 Astragalus + Atractylodes + Poria + Codonopsis + Coix + C. zedoaria 0.50 [0.33,0.75] 3 (181) 0 
6 Codonopsis + Atractylodes + Poria + C.zedoaria + Vitis + Spatholobus 0.50 [0.33,0.75] 2 (124) 0 
6 C.zedoaria + Astragalus + Atractylodes + Coix + Panax + Scutellaria 0.51 [0.35,0.74] 3 (198) 0 
6 Codonopsis + Poria + Atractylodes + Coix + Astragalus+ Epimedium 0.53 [0.37,0.83] 3 (152) 0 
7 Astragalus + Coix + Codonopsis + Poria + Atractylodes + C. wenyujin+ Epimedium 0.55 [0.37,0.83] 2 (91) 0 
8 Scutellaria + Hedyotis + Codonopsis + Atractylodes + Poria + Astragalus + Coix + Citrus 0.46 [0.29,0.72] 2 (120) 0 
8 Codonopsis + Poria + Atractylodes + Coix + Astragalus + Lycium+ Scutellaria+ Epimedium 0.53 [0.36,0.76] 2 (98) 0 
9 Scutellaria + Hedyotis + C.zedoaria + Codonopsis + Atractylodes + Astragalus + Poria + Coix + Panax  0.48 [0.30,0.78] 2 (128) 0 
9 
Ligustrum + Panax + C. zedoaria + Akebia + 
Scutellaria + Lycium + Coix + Atractylodes + 
Astragalus 
0.51 [0.33,0.79] 2 (130) 0 
10 
Akebia + C. zedoaria + Vitis + Coix + Atractylodes + 
Astragalus + Codonopsis + Poria + Smilax china + 
Epimedium 
0.49 [0.30,0.81] 2 (113) 0 
RR: risk ratio; N: number; part.: participants; CI: confidence interval; stud.: studies.  
Notes: Full botanical names are provided for level 1 with Chinese pin yin names in parentheses. Genus names 
are used for subsequent levels with abbreviated botanical name being used when clarity is required. RRs are 
listed in ascending order for each level. Lower RRs are associated with greater reductions in risk. Data with no 
significant effect or heterogeneity greater than 30% have been excluded. 
The most frequent pairs were: Poria + Atractylodes (n=11) (RR 0.47 [0.39, 0.57], I²=0%), and 
Astragalus + Atractylodes (n=11) (RR 0.56 [0.48, 0.67], I²=0%). The lowest RRs were for Poria + 
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Coix (n=9) (RR 0.46 [0.37, 0.57], I²=0%), followed by Poria + Atractylodes (n=11) (RR 0.47 [0.39, 
0.57], I²=0%). 
6.4.5.3 Level 3: Combinations of three herbal medicines 
The significant pairs from level 2 were combined with other HMs from level 1. Fifteen different 
triplets showed significant RRs that were lower than the total pool (Table 6.6). The most frequent 
combinations were: Poria + Atractylodes + Codonopsis (n=9) RR (0.50 [0.40, 0.62], I²=0%), and Coix 
+ Atractylodes + Astragalus (n=9) RR (0.58 [0.48, 0.69], I²=0%). The combination of Poria + 
Atractylodes + Ligusticum had the lowest RR (0.38 [0.22, 0.66], I²=0%) based on two studies. 
6.4.5.4 Level 4: Combinations of four herbal medicines 
The significant combinations from level 3 were combined into groups of four, using the same method. 
Thirteen combinations were significant, with RR lower or equal to the pool. Codonopsis + Astragalus 
+ Atractylodes + Poria (n=7) (RR 0.48 [0.38, 0.62], I²=0%) was the most frequent combination. The 
lowest RR was for Poria + Atractylodes + Coix + Angelica (RR 0.38 [0.22, 0.64], I²=0%) (Table 6.6). 
6.4.5.5 Level 5: Combinations of five herbal medicines 
Eight combinations of five HMs showed RRs lower than the total pool. The most common 
combination was Astragalus + Coix + Poria + Codonopsis + Atractylodes (n=6) (RR 0.49 [0.37, 0.63], 
I²=0%). The combination of Astragalus + Atractylodes + Poria + Coix + Smilax (n=2) had the lowest 
RR (0.46 [0.27, 0.80], I²=0%) (Table 6.6). 
6.4.5.6 Level 6: Combinations of six herbal medicines 
Nine combinations of six HMs showed significant RRs lower than the total pool. The most common 
combination (n= 4) was Codonopsis + Atractylodes + Astragalus + Coix + Poria + Scutellaria (RR 
0.50 [0.37, 0.68], I²=0%). The combination Codonopsis + Astragalus + Coix + Glycyrrhiza + 
Atractylodes + Poria (n= 2) had the lowest RR (0.43 [0.27, 0.68], I²=0%) (Table 6.6). 
6.4.5.7 Level 7: Combinations of seven or more herbal medicines 
There was one combination of seven, two combinations of eight and nine, and one combination of ten 
HMs that showed RRs that were significant and lower than the total pool, but all combinations were 
based on two studies only (Table 6.6). 
 Herbal medicines with consistent results at multiple levels 6.4.6
To select HMs for further research we identified those that showed reduced RRs at multiple levels. RR 
results that were significant and lower than the pool total, with heterogeneity less than 30%, were 
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evident at all eight levels for Atractylodes, Poria, Coix, Astragalus and Codonopsis when used in 
various combinations. Therefore, when these five HMs were included in CHM interventions, the data 
suggested a clinical benefit for CIN based on multiple studies. Also, the RRs for the pools of studies 
that included these HMs were lower than the total pool for the oral interventions. This was also the 
most frequent combination of five HMs. In the six studies (320 participants) that used this 
combination, the incidence of all grades CIN was 26.7% (47/176) compared to 56.4% (97/172) in the 
control groups. For 3/4 CIN, this combination showed a significant reduction (RR 0.41 [0.17, 0.96] 
I2=0, 5 studies, 295 participants) with incidences of 4.7% (7/148) in the test groups and 12.2% 
(18/147) in the control groups. 
 Potential synergistic effects of herbal medicines 6.4.7
A number of combinations of HMs showed RRs that were lower than those of the HMs singly. These 
included two pairs of HMs: Poria + Coix and Poria + Atractylodes; four triplets: Poria + Coix + 
Atractylodes, Poria + Atractylodes + Astragalus, Poria + Coix + Astragalus, and Poria + Atractylodes 
+ Codonopsis; two groups of four HMs: Codonopsis + Astragalus + Atractylodes + Poria and 
Astragalus + Coix + Poria + Codonopsis + Atractylodes; and the group of five mentioned above: 
Atractylodes + Poria + Coix + Astragalus + Codonopsis (Table 6.6). 
  Summary of the results for chemotherapy induced neutropenia 6.4.8
The 32 studies included in the meta-analysis were comparable in that they all employed oxaliplatin 
regimens in the test and control groups; all participants were diagnosed with CRC; all studies assessed 
CIN incidence using the WHO criteria; all studies assessed performance status; and all required no use 
of chemotherapy in the month prior to commencement. With regard to these aspects, the included 
studies were similar to other studies of oxaliplatin regimens for CRC. One difference was these studies 
typically used fewer cycles of chemotherapy (mostly 2 to 4) than the large international studies 
(Cassidy et al., 2008; de Gramont et al., 2000; Hind et al., 2008) which may account for the relatively 
low CIN incidence rates. Number of cycles is an important factor in CIN profile. Sugihara et al (2012) 
reported 55-88% CIN (all grades, median of 7-12 cycles) for two Asian studies of FOLFOX 4 for 
CRC. In the present analysis, the 58.9% (all grades) in the pool of 27 studies (1,840 participants) that 
did not employ prophylaxis with G-CSF was within this range (Table 6.6). In the case of grade 3/4 
CIN, Sugihara et al (2012) reported 37-52% and Park et al. (2015) reported 21.9% (median 9.7 
cycles), both of which were considerably higher than the 11.8% (88/743) in the control groups of the 
pooled result for 22 studies (743 participants). A likely reason for this difference is seventeen of the 
included studies reported CIN at 4 cycles or less of chemotherapy. For studies that employed 8 or 
more cycles, the CIN incidence for Grade 3/4 (19%) was close to the result of 21.9% CIN reported by 
Park et al. (2015). 
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When the effects of number of cycles of chemotherapy on grade 3/4 CIN incidence was stratified by 2, 
3, 4, 6, and 8+ cycles, there was a trend towards increased grade 3/4 CIN incidence as the number of 
cycles increased. In Gascon et al (2016), which included various cancers, there was an increase in 
grade 4 CIN probability with increase in cycles from one (7%) to six cycles (16%). The results of the 
present analysis support this relationship between CIN incidence and number of cycles of 
chemotherapy. Some other factors that are known to impact in CIN/FN incidence that could not be 
assessed due to data availability included stage of cancer, treatment history and gender (Aapro et al., 
2010). 
CIN incidence in the two studies that used G-CSF (Deng & Shen, 2010; Fang & Li, 2008) for two 
cycles was 38% (all grades) and 3.2% for grade 3/4 compared to the pool of studies of 2 cycles which 
reported 63.1% (all grades) and 12.9% (grade 3/4). This suggests that the G-CSF was effective in 
reducing CIN incidence and there were no further reductions with the addition of the CHMs.  
Overall, the addition of the CHMs to the oxaliplatin regimens reduced all grades CIN by 24% (95% CI 
20% to 28%) and grade 3/4 CIN by 6% (95% CI 3% to 8%). Importantly, the addition of the CHM 
interventions did not reduce tumour response rate (Table 6.6). This result was consistent with Chen et 
al. (2016). From the safety perspective, none of the studies reported serious adverse events associated 
with the addition of the CHM intervention to oxaliplatin regimens. Also, the sensitivity analyses based 
on HM ingredients did not identify any HMs or HM combinations that significantly increased the 
incidence of CIN in the test groups relative to the controls. 
  Effects of the five selected HMs in models relevant to chemotherapy induced neutropenia 6.4.9
When Atractylodes, Poria, Coix, Astragalus and Codonopsis were included in a CHM intervention, 
the incidence of CIN in the treatment groups showed greater reductions than found in the pool of 22 
studies of oral CHMs. Moreover, in the studies that used all five of these HMs orally, the incidence of 
CIN was lower in the test groups (28.0% all grades; 5.2% grade 3/4) than in the controls (58.9% all 
grades; 14.3% grade 3/4) and there was zero heterogeneity in these pools. Based on these analyses it 
appears that this group of HMs showed the best available clinical evidence for CIN reduction when 
combined with oxaliplatin regimens (without G-CSF) for CRC. There were insufficient data to assess 
the effects of any of these HMs when combined with G-CSF. 
Significant reductions in neutropenia incidence were also found for other HMs and HM combinations 
but the data were insufficient for a consistent pattern of results to be apparent. For example, Panax 
notoginseng, Ligusticum chuanxiong, Angelica sinensis and Glycyrrhiza uralensis all appeared in sub-
groups that showed the greatest reductions in CIN incidence at one level. However, these sub-groups 
always included Astragalus, Atractylodes, Codonopsis, Poria and/or Coix which makes assessment of 
their contributions more difficult. Nevertheless, it is possible that these HMs also contributed to the 
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results, so these HMs could also be considered for further research. Some have already received 
research attention. In particular, the combination of Astragalus and Angelica is frequently used for 
neutropenia in clinical practice and has been the subject of animal studies (Yang et al., 2007; Yan et 
al., 2008). Also, Astragalus, Atractylodes, Codonopsis, Poria, Angelica and Glycyrrhiza are all 
commonly used in China for the treatment of myelosuppression induced by chemotherapy for various 
cancers (Wang et al., 2014). 
To explore the question of how the five main HMs might reduce CIN incidence, PubMed and CNKI 
were searched for experimental studies in models of myelosuppression induced by cytotoxic drugs or 
irradiation, haematopoiesis, and immune-regulation. These studies are summarised briefly below. 
In murine models of myelosuppression induced by cyclophosphamide, intraperitoneal injections of 
extracts of Astragalus membranaceus injection (AMI) have been reported to promote colony-forming 
unit-fibroblast (CFU-F) formation that was associated with improved production of interleukin 6 (IL-
6) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) by bone marrow stromal cells 
(BMSC), increasing Bcl-2 protein and mRNA expression in BMSC, thus enhancing survival of BMSC 
and proliferation of CFU-F (Zhu & Zhu, 2007). Oral administration of an extract of Astragalus root 
increased counts of leucocytes and bone marrow CD34+ cells, mean number of CD20 immunopositive 
B lymphocytes, and produced significant decreases in the mean area of fat in bone marrow sections 
(Ismail et al., 2014). A study of the hematopoietic effect of Astragalus polysaccharides (APS) on 
healthy human marrow in vitro found that compared to negative control (APS 0 mg/L), APS 
significantly promoted colony-forming unit granulo-monocyte formation at 5 mg/L with or without 
presence of GM-CSF, and improved the formation of colony-forming unit erythrocytes with 
erythropoietin. At 125 mg/L, APS promoted erythroid burst-forming units only in combination with 
erythropoietin or phytohemagglutinin (Zhang & Hong, 2000). 
Studies of Shenqifuzheng injection, which is comprised of bioactive components of Astragalus and 
Codonopsis that mainly contain calycosin-7-O-β-glucoside, lobetyolin, and astragaloside IV, have 
reported increases in peripheral white blood cell and bone marrow cell counts, enhanced T cell and B 
cell proliferation responses, enhanced splenic NK1 cell activity and peritoneal macrophage 
phagocytosis, and restoration of the level of interleukin-2 (IL-2) in the serum (Wang et al., 2012; 
Wang et al., 2014). 
A CHM called Liujunzitang, which contains Codonopsis, Atractylodes, Poria and Glycyrrhiza, was 
found to increase counts of white blood cells, reticulocytes, and nucleated bone marrow cells in mice 
with leukopenia induced by cyclophosphamide (Yuan, 2008). In a similar model, the CHM 
Shenbaiyin, which mainly is composed of Astragalus and Coix, produced a similar result (Li et al., 
2006). In mice administered the microtubule inhibitor epothilone B, the co-administration of the CHM 
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Sijunzitang (SJZ), which contains Atractylodes, Poria and Glycyrrhiza, improved immunity and 
attenuated myelosuppression (Zhang, 2014). 
In irradiation induced myelosuppression in mice, SJZ was administered 7 days before irradiation, and 
continuously for 7 days after the irradiation. The SJZ showed a protective effect on peripheral blood 
counts of white cells and platelets compared to negative controls (Li et al., 2015). In mice subjected to 
irradiation, intragastric administration of the saponin astragaloside IV attenuated radiation-induced 
apoptosis of bone marrow cells, indicating a radio-protective effect (Li et al., 2011). When irradiated 
mice were injected with an extract of Astragalus root and Angelica sinensis root with weekly 
assessments for 21 days, the treatment group showed significant recovery of blood cells (platelets, 
WBC, RBC), and in the colony growth and histology of bone marrow cells harvested after 21 days, 
compared to the controls (Yang et al., 2009). A multi-HM formula that contained Codonopsis was 
reported to promote the recovery of bone marrow haematopoietic function in a myelosuppression 
model in irradiated mice (Liu et al., 2014). 
A number of studies have investigated the effects of these five herbs on immune response. In healthy 
chickens, Astragalus polysaccharides (APS) were injected for seven days and the phagocytosis rate 
and phagocytic index of neutrophil granulocytes in peripheral blood were measured for 56 days. The 
results showed both measures increased significantly in the APS group, reached the highest level at 28 
days, then slowly decreased. At 56 days, the phagocytosis rate and phagocytic index were still higher 
than the negative control for APS doses of 12.5mg/mL, 25 mg/mL and 50 mg/mL. (Li & Jin, 2014). A 
study of the effects of an aqueous extract of APS reported the extract stimulated activity of RAW 
264.7 macrophages (Zhao et al., 2011). A polysaccharide derived from Codonopsis was reported to 
reduce tumour growth and activate the immune system in mice inoculated with Hepatoma-22 (H22) 
cells (Xu et al., 2012). Codonopsis polysaccharides have also been reported to improve immunity in 
mice with immunosuppression induced by cyclophosphamide (Zhang et al., 2003; Gong et al., 2012). 
Polysaccharides from Atractylodes exhibited immune-enhancing activity in vitro in a study of splenic 
T-lymphocyte proliferation (Sun et al., 2015). A glycoprotein purified from Poria was reported to 
activate RAW 264.7 macrophages in vitro (Chang et al., 2009) and a review of the pharmacological 
properties of Poria found that its polysaccharides appear to potentiate immune response by up-
regulating immune stimulators and down-regulating immune suppressors (Rios, 2011). 
Coix has been developed into an anti-tumour drug in China called Kanglaite injection which can be 
combined with chemotherapy. Besides its inhibitory effects on tumour growth, it has been reported to 
stimulate T cell proliferation in C57BL/6 mice with Lewis lung carcinoma (Pan et al., 2012), rescue 
the levels of CD4+ T cells in tumour bearing mice, and increase the number of T cells and natural 
killer cells in the blood of hepatocellular carcinoma patients (Huang et al., 2014). 
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Although there have been studies of these five HMs or their constituents in experimental models, this 
does not mean that these HMs acted via the same mechanisms in the clinical studies. Also, it cannot be 
inferred that the HMs for which there was more experimental evidence were more effective than other 
short-listed herbs. These issues require further research. It should be noted that the sensitivity analysis 
procedure used for the selection of the above five herbs did not allow any tests between the groups of 
HMs included in Table 6.6, so relative ranking is not an index of clinical effectiveness. The purpose of 
the ranking was shortlisting candidates for further research from amongst a large list of potentially 
interesting HMs. 
 Potential synergetic effects 6.4.10
The HM combinations identified as potentially having synergistic effects in the above sensitivity 
analyses were various combinations of Codonopsis, Atractylodes, Poria, Astragalus and Coix. Of 
these, Codonopsis, Atractylodes and Poria are the main components of the multi-component CHM 
Sijunzitang (Duan et al., 2011). Sijunzitang and its modifications, which frequently include addition of 
Astragalus, have been used clinically as adjuncts to chemotherapy for various cancers in China 
(Huang et al., 2014; Zhang et al., 2013; Gan et al., 2010). Not studies that investigated potential 
synergistic effects of the components of Sijunzitang in models of neutropenia could be located but 
there have been reports in other models. In AHH-1 human lymphoblasts, the addition of aqueous 
extracts of Sijunzitang improved survival and growth following irradiation, with an effect that was 
greater than for extracts of any of the four component HMs used singly (Li et al., 2015). A study of 
normal rat small intestine epithelial IEC-6 cells, which aimed to investigate the effects of the 
individual ingredients of Sijunzitang plus Astragalus on promoting healing of small intestine epithelial 
IEC-6 cells, reported that the combination of Codonopsis plus Atractylodes and the combination of 
Atractylodes plus Astragalus, showed enhanced effects when compared to these HMs used singly 
(Zhang & Chen, 2002).  
A study of rat bone marrow stem cells investigated the effects of extracts of Astragalus and Angelica 
sinensis, singly and in combination, on proliferation and vascular endothelial growth factor (VEGF) 
expression. It reported that the Astragalus promoted stem cell proliferation and induced protein 
expression of VEGF while there was no significant effect for the Angelica extract, however, the 
combination of Astragalus plus Angelica was better than Astragalus extract alone (Shen et al., 2011). 
In a study of HMs used for neutropenia in cancer treatment in China, Astragalus and Angelica were 
the two most frequent (Wang et al., 2014). However, the frequency of Angelica was relatively low in 
the included studies, so it was not possible to determine whether it was consistently associated with 
reductions in CIN incidence.  
Overall, the evidence for potential synergistic effects of these HM combinations was scanty and the 
effects on neutropenia have received relatively little research attention. However, an in vivo study of a 
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different combination of four HMs found marked differences in tumour response, body weight and/or 
mortality in a CRC model when certain HMs were omitted from the formulation (Liu & Chang, 2012). 
Future studies could consider a similar approach to investigating the effects of specific HM 
combinations in CIN models.  
 Summary of results for chemotherapy induced neutropenia 6.4.11
These meta-analyses suggest that the addition of CHMs to oxaliplatin regimens was associated with 
reduced CIN incidence. However, there was considerable risk that bias in the conduct of the studies 
could have influenced results, so strong conclusions could not be drawn. Future clinical studies require 
adequate protocols, sufficient durations and sample sizes, and should report results for each grade of 
CIN and for neutrophil counts. 
The sensitivity analyses identified a short-list of HMs: Atractylodes, Poria, Coix, Astragalus and 
Codonopsis. Experimental studies also indicated anti-myosuppression and/or immnoregulation effects 
for these five HMs in vitro and in vivo. These herbs warrant further clinical research as additions to 
chemotherapy regimens in patients whose CIN is not sufficiently well-controlled by conventional 
therapies. 
6.5 Chapter 6 summary and conclusions 
In this chapter, the meta-analyses suggest that the combination of orally administered CHMs with 
oxaliplatin regimens (mainly FOLFOX) significantly increased tRR, and reduced the incidences of 
CINV and CIN in the treatment of CRC. 
The sensitivity analyses showed that the three shortlisted plant-based HMs Paeonia, Curcuma, and 
Sophora were each associated with consistently higher contributions to the tRR results and each of 
these HMs have shown anti-cancer effects in multiple experimental studies. 
For CINV, there were six shortlisted herbs: Atractylodes, Poria, Coix, Glycyrrhiza, Astragalus and 
Panax ginseng. These consistently showed greater reductions in all grades of CINV when used in 
combinations with other HM. In the experimental studies, these HMs have shown effects on vomiting 
and/or intestinal functioning which may account for their apparent clinical actions but animal models 
of nausea and vomiting are limited so the experimental support for their actions on CINV was less 
clear than that found for the herbs shortlisted for tRR. 
For CIN, the shortlisted HMs were Atractylodes, Poria, Coix, Astragalus and Codonopsis. For each of 
these HM, experimental studies were available that suggested that they may be protective against 
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myelosuppression or improve immune status but only Astragalus showed evidence of effects on the 
production of blood cells. 
It is important to note that the HMs selected above were not the only HMs that showed improved RR 
for tRR, CINV or CIN when they were included in a CHM intervention. Rather, they are the HMs that 
showed consistent effects in multiple studies and in multiple combinations. Another caveat on the 
interpretation of these results is that the short-listed herbs cannot be ranked in order of effectiveness 
based on the RR, since each RR was based on a different sub-group of studies. 
Based on the information in the clinical trial reports it was not possible to determine whether the short-
listed HMs were included in order to improve tRR, or reduce CINV or CIN, or for other reasons. This 
issue is made more complex since CHMs are considered to have multiple effects in traditional medical 
theory. However, all are clinically used for treating disorders relating to cancer and its treatment with 
CMT including immunosuppression, nausea, bloating, fatigue, poor appetite, and/or diarrhoea (Bensky 
et al., 2004). 
In experimental studies, these HMs has been reported to exhibit anti-cancer, inhibitory effects on 
nausea and vomiting (or its animal equivalent), regulation of gastrointestinal motility, gastro-
protective effects, attenuation of myelosuppression and/or enhancement of immune response. 
However, these experimental studies employed a diversity of cell-lines and animal models, the test 
materials ranged from whole plant extracts to isolated compounds, and there was little evidence of 
replication. In addition, the evidence from laboratory reports for the synergistic effects of these HM 
combinations in models relevant to cancer inhibition, vomiting and myelosuppression was scanty. 
Future studies could investigate the effects of fractionated extracts of these HMs and compounds 
extracted from these HMs, to systematically assess their effects and safty in anti-cancer, antiemetic, 
and anti-myelosuppression, singly and in combination, in cell and animal models. 
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Chapter 7. Colorectal Cancer Cell-line Study of Matrine from ku shen 
(Sophora flavescens root) 
7.1 Background and rationale 
In Chapter 6, the sensitivity analyses showed that the HMs Sophora (ku shen), Curcuma (e zhu) and 
Paeonia (chi shao) each produced consistently higher contributions to the tumour response rate (tRR) 
results. Laboratory studies also found that extracts of these herbs or their constituent chemical 
compounds possessed anti-cancer effects in models of CRC in vitro or in vivo. Of these three herbs, ku 
shen was selected for further study for the following reasons: 
1.  The analyses in Chapter 6 found that studies that included ku shen in oral CHMs consistently 
showed better pooled outcomes in the sensitivity analysis of single herbs and herbal 
combinations for tumour response rate. 
2.  Ku shen products, singly or in combination with other herbal extracts, are used for cancer 
treatment in China and have been approved by the Chinese State Food and Drug 
Administration (SFDA) (Sun et al., 2012). 
3. In the short list of three herbs for improved tumour response, two herbs (chi shao and e zhu) 
can be sourced from multiple species. Chi shao can be derived from the roots of Paeonia 
lactiflora and Paeonia veitchii (Nanjing University of TCM, 2015), and e zhu is from 
Curcuma wenyujin, C. phaeocaulis Val., or C. kwangsiensis (Nanjing University of TCM, 
2015). Whereas, ku shen is only derived from the root of Sophora flavescens Ait (Nanjing 
University of TCM, 2015), therefore we can be confident that the ku shen mentioned in the 
different clinical trials always referred to the same species. 
Phytopharmacological research has found that crude extracts of S. flavescens and its chemical 
compounds exhibited in vitro and in vivo pharmacological activity including: antitumour activity, anti-
inflammatory activity, anti-nociceptive activity, anti-anaphylaxis and anti-asthma activity, anti-
microbial activity (anti-bacterial, anti-viral, insecticidal, and anti-fungal), effects on the cardiovascular 
system (anti-arrhythmic, anti-myocardial fibrosis, effects on myocardial contractility, vascular 
relaxing and anti-myocardial hypoxic activity), immune-regulatory activity, neuroprotective effects, 
and anti-hyperlipidemic effects (He et al., 2015). 
  Chemical compounds in Sophora flavescens 7.1.1
To date, more than 200 chemical compounds have been identified from S. flavescens, including 47 
alkaloids, 124 flavonoids, 9 triterpene glycosides (He et al., 2015), 1 quinone, 47 essential oils, 8 
dimethylchromones, 15 amino acids, and 20 fatty acids (Li and Wang, 2014). 
The alkaloids and flavonoids are the major bioactive substances derived from this plant and have 
received the most research attention (He et al., 2015). S. flavescens alkaloids are mainly quinolizidine-
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type alkaloids, with a small portion of dipiperidine-type alkaloids. The quinolizidine alkaloids can be 
divided into 4 subtypes: matrine-type, cytosine-type, anagyrine/sparteine-type, and lupinine-type. The 
matrine-type is the majority and includes matrine, oxymatrine, sophoridine, isomatrine, sophocarpine, 
sophoramine, and sophoranol (Miao et al., 2001). S. flavescens flavonoids are classified into: 14 
flavonols, 41 flavanones 13 flavanonols, 27 isoflavones, 3 isoflavanones, 2 homoisoflavones, 7 
chalcones, 2 biflavonoids, and 14 pterocarpans. The majority of these flavonoids are isoprenylated or 
lavandulylated flavonoids (He et al., 2015; Li and Wang, 2014). 
The alkaloids form a major portion of the bioactive compounds contained in S. flavescens. Of the main 
alkaloids, the matrine content of extracts of S. flavescens roots has been reported to be 0.32% per 
fraction weight, followed by 0.13% sophocarpine, 0.12% oxymatrine (matrine N-oxide) and 0.073% 
oxysophocarpine (sophocarpine N-oxide) (Chen X, 2004). Oxymatrine is metabolised to the more 
absorbable matrine by intestinal bacteria in the gastrointestinal tract and liver (Wang et al., 2005). 
  Pharmacokinetics of S. flavescens and its principal compounds 7.1.2
Pharmacokinetics describes the movement of a drug into, through and out of the body. The 
pharmacokinetics S. flavescens alkaloids have been studied in animals and the human body using 
various mass spectrometric methods. 
One study followed a single oral dose of 300 mg oxymatrine (OMT) capsules in six beagle dogs, and 
the authors quantified oxymatrine (OMT) and its metabolite matrine (MT) in the dog plasma using a 
liquid-liquid extraction procedure and then used liquid chromatography-electrospray ionization mass 
spectrometric (LC-ESI-MS) analysis. The results showed that both OMT (about 223 ng/mL) and MT 
(about 19 ng/mL) were detected at 0.25 h after administration. The time to reach the maximum plasma 
concentrations (Tmax) following oral administration was 1.3h for OMT and 2.9 h for MT. The 
elimination half-life (t1/2) and the mean residence times of the metabolite MT were longer than those 
of OMT. The AUC0 –t value (AUC = area under the concentration time curve) for the metabolite MT 
following oral administration of OMT capsules (7.07 mg h/l) was about 1.2 times as large as that of 
OMT (5.86 mg h/l). These results suggested that most of the MT was from the reduction of OMT and 
the active MT seemed to play a major role in the pharmacological actions of the orally administered 
OMT. 
Using LC-MS/MS to analyse beagle dog plasma, another study investigated the differences in 
pharmacokinetic parameters between OMT and MT after oral administration of the pure compounds, 
and of S. flavescens granules (KFG), which contained equivalent amounts of OMT and MT, to 
determine the possible influence of other constituents of S. flavescens on the pharmacokinetic 
behaviors of OMT and MT. The results indicated that the absorption of OMT and MT after oral 
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administration of KFG was significantly better than after the oral administration of the pure 
compounds separately (Wang et al., 2007). 
The high-performance liquid chromatography tandem mass spectrometric (HPLC-MS) method has 
been used for the simultaneous determination of matrine (MT), oxymatrine (OMT) and 
oxysophocarpine (OSP) in rat plasma after oral administration of S. flavescens extract. OMT and OSP 
were more rapidly absorbed and eliminated from plasma compared to MT. The values of clearance 
were 4.388 L/h for OSP and 4.198 L/h for OMT, which were much higher than for MT (0.024 L/h). 
The results suggest that MT plays an important role in the pharmacological actions of orally 
administered S. flavescens extract (Zhang et al., 2008). 
In an open-label, randomised, 3×3 crossover human study, of the oral administration of a single dose 
of matrine (100, 200 and 400mg), the LC/MS/MS method with a lower limit of quantification of 5 
ng/mL was used to determine the pharmacokinetic parameters of matrine in human plasma. The 
pharmacokinetic results for matrine indicated that the increase in mean concentration Cmax (range 603-
2383 ng/mL) and the mean AUC 0−t (from 6203 to 20078 ng h/mL) were correlated with the dose 
increase. The Tmax and the T1/2 had no apparent change as the dose ascended. Therefore, the authors 
concluded that matrine had linear pharmacokinetic trends in healthy Chinese volunteers (Zhang et al., 
2009). 
A liquid chromatography tandem mass spectrometry (LC–MS/MS) method was developed for the 
simultaneous determination of OMT and its metabolite MT in human plasma in a pharmacokinetic 
study involving intravenous (i.v.) administration of OMT. The result showed that about one fifth of 
OMT was reduced to MT following i.v. administration of OMT [(AUC0–∞) MT/(AUC0–∞) OMT = 
19.9±5.4%)] (Wu et al., 2006). 
Overall, S. flavescens alkaloids including MT, OXM, and OSP, appear in plasma after oral 
administration of pure alkaloids or of S. flavescens extract or of an S. flavescens formula, in animal 
and/or human studies. Orally administered OXM can be reduced to the more absorbable MT by 
intestinal bacteria in the gastrointestinal tract and liver. The absorption of S. flavescens alkaloids after 
oral administration was better in a crude S. flavescens extract or a S. flavescens formula compared to 
the pure compounds suggesting that other compounds in the herb may affect the absorption. OMT and 
OSP were more rapidly absorbed and eliminated in plasma compared to MT. MT plays an important 
role in the pharmacological action of orally administered S. flavescens extract. These studies suggest it 
is likely that matrine is a major contributor to the therapeutic effects and pharmacological actions of 
orally administered S. flavescens root. 
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  Effects of matrine in cancer 7.1.3
Matrine has been reported to inhibit proliferation of various cancer cells (Li et al., 2015; Ma et al., 
2015; Yang et al., 2015; Li et al., 2016; Zhou et al., 2016); induce cell cycle arrest and differentiation 
(Liu et al., 2014; Ou & Chen et al., 2014; Xu et al., 2015); accelerate apoptosis (Hu et al., 2015; Yang 
& Yao, 2015; Zhou et al., 2015); as well as prevent toxicity from chemotherapy or radiotherapy (Rong 
et al., 2015; Zhou et al., 2015; Wan et al., 2009; Ge et al., 2016). Moreover, products containing 
matrine and oxymatrine have been approved for use in cancer therapy in China (Sun et al., 2012). 
Therefore, matrine was selected as the test compound in the three experiments reported in this chapter. 
  Aims of the experimental studies 7.1.4
The experimental studies aimed to test the effects of matrine in CRC cell lines in vitro. The 
experiments involved three arms: negative control groups (vehicle), matrine groups, and positive 
control oxaliplatin (OXA) group. The experiments were as follows: 
Experiment 1: effects of matrine on proliferation in four CRC cell lines; 
Experiment 2: effects of matrine on cell morphology; and 
Experiment 3: effects of matrine on cell cycle progress and apoptosis. 
7.2 Methods and materials used in the experiments 
See Chapter 3 for more detailed descriptions of the methods used in the assays. 
  Test compounds 7.2.1
The two test compounds were:  
1. Matrine (PubChem CID 91466); chemical formula C15H24N2O; molecular 248.37 g/mol 
(Figure 6.1). Purchased from Yuanye Bio-Technology Co., Ltd (Shanghai, China). Purity was 
˃97% confirmed by high-performance liquid chromatography (HPLC); and 
2. Oxaliplatin (PubChem CID 9887053); chemical formula C8H14N2O4Pt; molecular weight 
397.294 g/mol (Figure 6.2). Purchased from Yuanye Bio-Technology Co.  
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Figure 7.1: Matrine molecular structure 
Retrieved from PubChem. https://pubchem-ncbi-nlm-nih-gov.ezproxy.lib.rmit.edu.au/compound/91466 
 
Figure 7.2: Oxaliplatin molecular structure 
Retrieved from PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/9887053#section=Top 
  Cell lines 7.2.2
The four human CRC cell lines were: 1. LS 174T (CL-188™, ATCC); 2. Caco-2 (HTB-37™, ATCC); 
3. SW1116 (CCL-233™, ATCC); and 4. RKO (CRL-2577™, ATCC). These were obtained from the 
Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences 
(Shanghai, China), where they were tested and authenticated. The procedures included cross-species 
checks, DNA authentication and quarantine. 
The LS174T cell line was derived from a Duke's type B adenocarcinoma of the colon that was able to 
produce high levels of carcinoembryonic antigen (CEA). A morphological study of this cell-line 
revealed abundant microvilli and intracytoplasmic mucin vacuoles (Tom et al., 1976). The LS174T 
cell line positively expresses oncogenes c-myc, N-myc, H-ras, N-ras, Myb, and fos, and also expresses 
p53 mRNA (Trainer et al., 1988). 
   
205 
RKO is a poorly differentiated colon carcinoma cell line (Brattain et al., 1984) that expresses p53 + 
(wild type) (Smith et al., 1995) and urokinase receptor (u-PAR) (Boyd et al., 1988). 
CaCo 2 expresses enterocytic differentiation upon confluency, so it can be a model for the study of the 
factors involved in the regulation of the differentiation of enterocytes (Jumarie et al., 1991). The cells 
express retinoic acid binding protein I and retinol binding protein II (Levin MS, 1993); heat stable 
enterotoxin (Sta, E. coli) (Cohen MB, et al.1993); and epidermal growth factor (EGF) (Basson MD, et 
al.1994). 
The SW1116 cell line is positive for expression of c-myc, K-ras, H-ras, myb, sis and fos oncogenes 
(Trainer et al., 1988). The cells also express tumour specific nuclear matrix proteins CC-4, CC-5 and 
CC-6 that scaffold nuclear shape, organise chromatin, and probably are important regulatory proteins 
as well (Keesee SK, et al.,1994). 
  Equipment 7.2.3
• Inverted microscope (Citadel 2000, Thermo Fisher Scientific Inc., USA). 
• Benchtop Centrifuges (Thermo Fisher Scientific Inc., USA). 
• Biosafety cabinet (ESCO, Esco Airstream®A2, Esco Technologies, Inc., USA). 
• CO2 Incubator (Thermo Fisher Scientific Inc., USA). 
• Magnetic stirrer (Shanghai Lei magnetic Co Lit, China). 
• Flow cytometry (Novo Express™ACEA Biosciences®, Inc., San Diego, California, USA). 
• Micropipettor (Eppendorf, Germany). 
• Microplate reader (Sunrise™ TECAN, Switzerland). 
• Hemacytometer and Electronic balance (Shanghai Precision Instrument & Meter Co., Ltd, 
China). 
 Reagents 7.2.4
• Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s Medium (DMEM), 0.25% (w/v) 
trypsin-EDTA and Phosphate Buffer Saline (PBS) (Gibco Invitrogen Life Technologies, 
Carlsbad, CA, USA).  
• Propidium iodide (PI) (Sigma-Aldrich St. Louis, MO, U.S.A.). 
• Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories Science and Technology, Inc., 
Kumamoto, Japan). 
• The Annexin V‑FITC Apoptosis Detection kit and DNA content Quantitation Assay for cell 
cycle analysis (KeyGENBioTECH, Nanjing, China). 
• RNase A (50 µg/mL) (KeyGENBioTECH, Nanjing, China). 
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  Preparation of reagents 7.2.5
1. Culture medium: Fetal bovine serum (FBS) 50 mL was added into Dulbecco’s modified 
Eagle’s Medium (DMEM)-high glucose 500 mL, and asepsis was checked for 48 hrs, then stored 
at 4 deg.C. (expired in one month). 
2. Oxaliplatin (100 mg) was dissolved in 5% glucose and saline. The final volume of stock 
solution was 25.2 mL, and the concentration of stock solution was 4 mg/mL (10 mM). The stock 
was aliquoted into 500μL sterile EP tubes, and was stored at 4 deg.C in a dark environment. The 
stock was diluted in medium to requested concentrations prior to each experiment. 
3. Matrine (500 mg) was dissolved in 0.9% saline. The final volume of the stock solution was 100 
mL, and the concentration of the stock solution was 5 mg/mL (20 mM). The stock solution was 
aliquoted into 1.5 mL sterile EP tubes, and was stored at -20 deg.C in a dark environment. The 
stock was diluted in medium to requested concentrations prior to each experiment.  
4. Phosphate buffered saline (PBS): the following substances were weighed: KCl, 0.20 g; 
KH2PO4, 0.20 g; NaCl, 8.00 g; Na2HPO4•12H2O, 2.08 g. The substances were put into a flask and 
stirred using the magnetic stirrer while gradually added into tri-distilled water until completely 
dissolved. The final volume of the stock solution was 1000 mL. The stock was aliquoted into 500 
mL bottles, autoclaved, and stored at 4 deg.C in a dark environment.  
 Experimental methods and procedures 7.2.6
The procedures for each of the experiments were detailed in Chapter 3, including methods for cell line 
culture, maintenance of cell lines, detaching cell lines and sub-culturing, cell viability assays, 
observation of cellular morphological changes, cell cycle analysis, and apoptosis analysis. 
7.3 Results of the experiments 
The results of each of the four experiments are summarised below. 
 Effects of matrine on proliferation 7.3.1
To investigate the effects of matrine and OXA on the proliferation of four CRC cell lines, the viability 
of cells was measured using the CCK-8 assay. The exposure of the four CRC cell lines to matrine at 
concentrations of 1, 2, 4, 8, 10mM (100μl/well) for 24, 48 and 72h caused significant growth 
inhibition in a dose- and time-dependent manner (Figure 7.3a; Table 7.1). The IC50 values of matrine 
on LS 174T, Caco-2 and SW1116, RKO cells were 2.78 mM, 3.92 mM, 1.18 mM and 1.86 mM 
respectively after 48h treatment.  
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As the positive control, treatment with OXA at concentrations of 10, 20, 40, 80, 100μM (100μl/well) 
for 24, 48 and 72h, also inhibited the CRC cells in a dose- and time-dependent manner. After 48h 
treatment, the IC50 values of OXA on LS 174T, Caco-2, SW1116 and RKO cells were 29.83 μM, 
10.15 μM, 28.59 μM and 11.67 μM respectively (Figure 7.3b; Table 7.1). 
 
Figure 7.3: The proliferative inhibition effect of matrine and oxaliplatin on LS 174T, Caco-2, 
SW1116 and RKO cells 
a Matrine and b OXA inhibited the growth of CRC cell lines LS 174T, Caco-2, SW1116 and RKO in a dose- and 
time-dependent manner. Cell viability curves were plotted as viable cell percentage versus control group based 
on the CCK-8 assay. Data are expressed as mean ± SD of three independent experiments 
Table 7.1: Colorectal cancer cell-line viability (%) under treatment with matrine (MT) and 
oxaliplatin (OXA) for 24, 48, and 72 hours 
Cell-
line 
LS174T SW1116 RKO Caco-2 
End-
point 
24h 48h 72h 24h 48h 72h 24h 48h 72h 24h 48h 72h 
MT 
doses 
(mM) 
CRC cell-line viability: mean± Standard deviation (%) 
1 97.49
±5.36 
62.65
±2.80 
57.53
±2.42 
73.73
±4.26 
52.34
±6.62 
25.14
±2.80 
94.59
±4.64 
66.70
±5.3 
49.58
±4.37 
87.47
±2.23 
91.15
±2.06 
84.79
±5.40 
2 97.52
±4.40 
56.89
±1.91 
54.24
±2.31 
71.67
±7.05 
44.02
±2.80 
20.11±
1.89 
87.35
±1.54 
61.52
±5.38 
26.87
±3.60 
84.61
±7.96 
77.04
±2.60 
71.30
±1.30 
4 95.12
±6.76 
50.26
±1.08 
43.67
±3.21 
61.74
±5.69 
37.51
±5.97 
18.79
±2.65 
71.84
±3.81 
15.48
±1.97 
5.02±
2.73 
81.18
±8.77 
53.25
±2.53 
41.24
±1.93 
8 69.53
±6.31 
46.13
±3.27 
25.29
±0.84 
59.05
±7.85 
31.65
±2.57 
14.92
±2.02 
40.62
±5.46 
5.30±
0.85 
1.46±
0.2 
36.49
±4.11 
27.62
±1.25 
11.11±
0.15 
10 30.15
±2.30 
17.02
±0.74 
4.45±
0.11 
47.78
±4.15 
24.45
±2.82 
14.80
±1.44 
33.80
±5.64 
5.35±
3.31 
1.09±
0.11 
22.52
±3.07 
11.44±
1.26 
4.53±
0.39 
OXA
doses 
(µM) 
CRC cell-line viability: mean± Standard deviation (%) 
10 90.29
±3.15 
73.03
±1.90 
43.09
±6.09 
84.49
±7.70 
65.61
±2.98 
40.89
±4.05 
75.14
±3.51 
52.72
±1.32 
13.30
±0.63 
78.10
±5.26 
51.72
±3.68 
36.86
±0.55 
20 72.91
±2.16 
58.74
±5.02 
33.51
±3.50 
78.18
±6.27 
59.31
±3.21 
33.56
±3.72 
71.29
±5.50 
34.07
±2.39 
10.26
±0.88 
55.78
±5.16 
39.57
±5.01 
34.24
±1.88 
40 63±4.
02 
51.98
±5.01 
25.75
±2.63 
76.50
±5.53 
39.46
±2.04 
19.13
±1.91 
49.40
±1.45 
7.84±
1.13 
2.40±
0.48 
41.89
±1.93 
20.03
±0.22 
17.21
±1.35 
80 45.03
±2.14 
29.67
±4.99 
21.82
±2.46 
75.28
±7.28 
26.25
±1.94 
14.59
±2.22 
14.65
±1.37 
1.79±
0.68 
0.81±
0.18 
40.99
±2.22 
15.67
±0.45 
14.04
±2.52 
100 41.05
±3.89 
16.95
±1.62 
18.57
±2.41 
57.06
±4.29 
22.20
±2.15 
12.23
±2.02 
8.58±
1.40 
1.25±
0.46 
0.49±
0.29 
40.75
±1.72 
17.24
±0.29 
9.94±
1.26 
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 Effects of matrine on cell morphology 7.3.2
Morphological features of apoptosis were observed using the Inverted microscope in the four CRC cell 
lines after treatment with matrine and OXA.  
Compared to negative control, cell densities in each of the four cell-lines were decreased in the 
matrine low dose treatment groups and further decreased in the matrine high dose treatment groups. In 
each cell line, growth reduction was most evident in the OXA controls. Cells in the matrine and OXA 
treated groups showed morphological changes consistent with apoptosis including blebbing (bulge or 
protrusion of the cellular membrane), cell shrinkage, nuclear condensation and fragmentation (Figure 
7.4). 
 
Figure 7.4: Effects of matrine and oxaliplatin on morphology of LS 174T, Caco-2, SW1116 and 
RKO cells 
Morphological changes in colorectal cancer cell lines LS 174T, Caco-2, SW1116 and RKO cells treated with 
matrine (low-dose and high-dose) and OXA for 48h. (Magnification, ×100. Scale bars, 100μM) 
 Effects of matrine on cell cycle arrest 7.3.3
The effects of matrine on cell cycle progress in the four CRC cell lines were detected by FCM. As 
shown in Figure 7.5, matrine increased the population of cells in the G0/G1 phase, and decreased the 
population of cells in S phase, in all four cell lines. This tendency was more apparent in the high-dose 
group, which showed statistically significant differences in all cell lines, indicating that matrine 
induced cell cycle arrest at the G0/G1 phase. OXA increased the population of cells in the G0/G1 
phase in SW1116 and RKO cells, but the population of cells in S phase was increased in LS 174T and 
Caco-2 cells. 
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Figure 7.5: Effects of matrine and oxaliplatin on cell cycle distribution in LS 174T, Caco-2, 
SW1116 and RKO cells 
The proportion of cells in the G1 phase increased in a dose-dependent manner after treatment with matrine (low-
dose and high-dose) for 24h. The percentage of cells in the S phase decreased compared to the negative control. 
Data are expressed as mean ± SD. Representative profiles are from one of three independent experiments.  
*P ˂ 0.05, **P ˂ 0.01, or ***P ˂ 0.001 versus vehicle control 
 Effects of matrine on apoptosis 7.3.4
The effects of matrine on apoptosis in the four CRC cell lines were detected by FCM. The Annexin-V-
FITC/PI double staining assay shows the percentage of live, dead and apoptotic cells in the scatter 
plots and representative histograms in Figure 7.6. Matrine induced apoptosis in cells after 24 h 
treatment. Significant increases in apoptosis rates were evident for matrine 0.5 mM to 1.0 mM in 
Caco-2 and SW1116, and for matrine 2.0 mM to 4.0 mM in LS 174T cells. In RKO cells, significant 
increases in apoptosis rates were evident for matrine only at 1.0 mM. In each cell line, the higher the 
matrine dose, the higher the apoptosis rate. OXA also induced apoptosis in each cell line in same 
manner. 
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Figure 7.6: Matrine and oxaliplatin induced apoptosis in LS 174T, Caco-2, SW1116 and RKO 
cells 
Both matrine (low-dose and high-dose) and OXA induced apoptosis in LS 174T, Caco-2, SW1116 and RKO 
cells. The apoptosis rates were higher in the higher dose matrine groups. Data are expressed as mean ± SD. 
Representative profiles are from one of three independent experiments.  
*P ˂ 0.05, **P ˂ 0.01, or ***P ˂ 0.001 versus vehicle control 
7.4 Discussion of the cell-line experiments 
Cell proliferation is tightly regulated by pro-proliferation and anti-proliferation molecules in normal 
cells in order to maintain homeostasis in the number of cells in a tissue. In cancer, the balance is 
disrupted. Cancer cells proliferate uncontrollably due to alterations in growth ligands, their receptors, 
and intracellular signal molecules (Fouad and Aanei, 2017). The goal of chemotherapy is to restrict the 
reproductive potential of cancer cells via various mechanisms including apoptosis, necrosis, mitotic 
catastrophe, autophagy, cell cycle arrest or senescence (Deloch et al., 2016). However, undesirable 
side effects including hair loss, nausea, vomiting, anaemia, fatigue, dyspepsia, loss of appetite, 
immunodeficiency and weight change may damage the quality of life of patients and increase the rates 
of morbidity and mortality (Nichols and Bae, 2012). Consequently, there is a need for drugs that 
reduce the proliferation of cancer cells without producing severe adverse effects. 
In this study, the cell viability assays (CCK-8) showed that matrine inhibited proliferation dose- and 
time- dependently in the CRC cell lines LS 174T, Caco-2, RKO, and SW1116 (Figure 7.3a, b). These 
findings were consistent with previous investigations of matrine in other CRC cell-lines, such as HT-
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29 (Chang et al., 2013; Huang et al., 2007; Peng et al., 2005; Ren et al., 2014), SW1116 (Zhu et al., 
2009), SW620 (Li et al., 2015; Liang et al., 2008; Wang et al., 2008), SW480 (Xiao 2013, Zhou 2009, 
Wang 2008, Zou 2016), LoVo (Zhang et al., 2014), and DLD1 (Ren et al., 2014). The IC50 results 
showed the SW1116 cell-line was the most sensitive to matrine, followed by RKO, Caco-2 and 
LS174T cells. 
The cell cycle is a cascade event that consists of five different phases: G0, G1, S, G2, and M phase. 
Cells in the G0 phase are not in the process of proliferation. The cell cycle initiates in response to 
mitogenic growth factors stimulating the G1 phase. In this phase, the cell increases supplies of its 
nutrients, and increases in size. DNA synthesis commences in the S phase, all DNA are replicated and 
chromosomes double by the end of this phase. In the G2 phase, proteins are synthesised rapidly and 
there is continuous growth of the cell in readiness for mitosis in the M phase. In the M phase, the cell 
completes the process of dividing the chromosomes into two identical sets, followed by dividing cell 
components including nuclei, cytoplasm, organelles and cell membrane into two identical daughter 
cells (cytokinesis). Initiation of the G1 phase is dependent on tightly-controlled mitogenic growth 
signalling (Strachan et al., 2015). FCM was used to measure the DNA content of cells at different 
phases. The results showed matrine induced cell cycle arrest at the G1 phase in all four cell-lines 
(Figure 7.5). This result was consistent with studies of matrine in other CRC cell-lines including HT-
29 cells (Chang et al., 2013; Huang et al., 2007), SW620 cells (Wang et al., 2008), and LoVo cells 
(Zhang et al., 2014).  
Apoptosis induction is an important mechanism of anti-cancer drugs. The Annexin V-FITC/PI double 
staining assay showed that matrine induced apoptosis in all four CRC cell-lines (Figure 7.6), and the 
morphological study found that all four cell lines showed apoptotic changes after treatment with 
matrine and OXA (Figure 7.4). This suggests that the anti-cancer effects of matrine, at the 
concentrations tested, were via apoptosis rather than necrosis or other process of cell death.  
7.5 Conclusions from the experimental studies 
These studies demonstrated that the dose-dependent, anti-proliferative effects of matrine involved cell 
cycle arrest at the G1 phase and pro-apoptotic effects in all four CRC cell-lines, each of which has 
different biological and histological characteristics due to specific oncogenes and mutant genes. 
Based on these findings, further experiments could test the validity of the anti-cancer effects of 
matrine in animal models of CRC. In addition, western blot could be conducted to explore feasible 
molecular mechanisms of the actions of matrine and docking simulations could be undertaken to 
identify potential protein-ligand structural interactions. The next chapter will discuss the mechanisms 
of action of S. flavescens and its constituent compounds on cell cycle arrest and apoptosis based on 
current in vitro and in vivo studies.  
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Chapter 8. The Molecular Mechanisms of Action of Sophora flavescens 
and Its Constituent Compounds 
8.1 Chapter 8 introduction 
The experiments in Chapter 7 have demonstrated that one of the major components of Sophora 
flavescens (ku shen) showed pro-apoptotic effects in multiple CRC cell lines. In this chapter, the 
possible mechanisms for the actions of matrine and other compounds isolated from S. flavescens are 
discussed to identify future directions for research. 
8.2 Identification of experimental studies 
PubMed and CNKI were searched (to December 2016) to locate experimental studies of S. flavescens, 
its extracts and its principal compounds (e.g. matrine and oxymatrine) in CRC cell lines or animal 
models of CRC. The literature search identified 26 experimental studies that tested a S. flavescens 
extract, total S. flavescens alkaloids, total S. flavescens flavonoids and 20 different S. flavescens 
compounds. These studies investigated 37 different protein targets and involved 11 different CRC cell 
lines as well as in vivo models. Most of the chemical compounds were classified as alkaloids or 
flavonoids and most studies investigated the following four quinolizidine type alkaloids (Chen et al., 
2004): 
• matrine (15 studies); 
• oxymatrine (7 studies); 
• sophoridine (4 studies); 
• sophocarpine (3 studies). 
Sixteen flavonoids were studied. Of these, sophoraflavanone G was the most commonly investigated 
(3 studies) followed by kurarinone (two studies). The other flavonoids were all investigated in one 
study (Ryu et al., 1997; Table 7.1). The flavonoids can be sub-classed into flavanone-type, isoflavone-
type, flavanonol-type, chalcone-type, and pterocarpan-type (He et al., 2015; Table 7.1). 
Table 8.1 lists each of the compounds that were investigated in these studies identified from the 
literature. For each compound the chemical formula, molecular weight and PubChem CID are given. 
A PubChem CID is given to each unique chemical structure. It is possible for the same compound to 
have different CIDs since there are different tautomeric forms of the same compound that are recorded 
from various depositors. Tautomers are structural isomers. For instance, the name ‘kurarinone’ has 
two CIDs: 5318882 and 11982640, since kurarinone has two structural isomers structurally.  
   
213 
Table 8.1: Sophora flavescens compounds in colorectal cancer studies in vitro and in vivo 
Compound Chemical 
Formula 
Molecular 
weight 
g/mol 
PubChem CID Chemical 
class 
*Study N 
Matrine C15H24N2O 248.37  91466 Quinolizidine  1, 2, 4, 5, 7, 10, 
11, 13, 18, 19, 22, 
23, 24, 25, 26. 
Oxymatrine C15H24N2O2 264.369  114850 Quinolizidine 5, 7, 8, 9, 12, 20, 
25. 
Sophoridine C15H24N2O 246.354  165549 Quinolizidine 5, 6, 17, 24. 
Sophocarpine C15H22N2O 246.354  115269 Quinolizidine 5, 23, 24. 
Sophoraflavanone 
G 
C25H28O6 
 
424.48622  9910234 
 
Flavanone 3, 14, 15. 
Kurarinone C26H30O6 438.52  5318882/ 
11982640 
Flavanone 14,15. 
2′-methoxy-
kurarinone 
C27H32O6 452.547  11982641 Flavanone 15. 
Kurarinol C26H32O7 456.52808  44563198 Flavanone 14. 
Norkurarinol C25H30O7 442.51 12146484 Flavanone 14 
Kushenol B C30H36O6 492.612  5318891/ 
102004745 
Flavanone 14 
Kushenol E C25H28O6 424.493  9979767 Flavanone 14 
Formononetin C16H12O4 268.268  5280378 Isoflavone 14 
Kosamol A C30H38O8 526.626  102506430 Flavanonol 14 
Kushenol H C26H30O7 454.52 21721872 Flavanonol 14 
Kushenol K C26H32O8 472.534  44428630 Flavanonol 14 
Kushenol L C25H28O7 440.492  21721878 Flavanonol 14 
Kushenol M C30H36O7 508.611  180948 Flavanonol 14 
Kushenol N C26H30O7 454.519  102004822/ 
10253436/ 
381851 
Flavanonol 14 
Kuraridin C26H30O6 438.52  9954815 Chalcone 14 
Trifolirhizin C22H22O10 446.408  442827 Pterocarpan 14 
*Study N (1st author (year)): 1. Chang C (2013); 2. Huang J (2007); 3. Kim B (2013); 4. Li N (2015); 5. Liang L (2008); 6. 
Liang L (2012); 7. Liu L (2008); 8. Lu L (2007); 9. Lu L (2008); 10. Ou X (2014a); 11. Peng Y (2005); 12. Peng Y (2012); 
13. Ren H (2014); 14. Ryu S (1997); 15. Sun M (2007); 16. Sun M (2008); 17. Wang Q (2010); 18. Wang X (2008); 19. 
Wang X (2008a); 20. Xiang Y (2015); 21. Xiao Z (2013); 22. Zhang S (2014); 23. Zhang Y (2008a); 24. Zheng Y (2014); 25. 
Zhou X (2009); 26. Zou L (2016). 
Table 8.2 lists 37 proteins that were reported to have been regulated by these compounds. Due to 
diversity in the names used, these were standardised to UniProt nomenclature 
(http://www.uniprot.org/) with the UniProt gene name being adopted as the abbreviation. The tumour-
related bio-process was based on the description in UniProt ‘GO - Biological process’. The proteins in 
Table 8.2 have been associated with the regulation of cell proliferation, cell cycle progression, cell 
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migration, inflammation and angiogenesis. Each of these proteins is discussed in the following 
sections. 
Table 8.2: Proteins regulated by Sophora flavescens compounds in colorectal cancer studies in 
vitro and in vivo 
Target 
(name used 
in study) 
Uniprot 
entry 
Uniprot 
gene name 
Uniprot protein 
name 
Tumour-related bio-
process *Study N 
Akt P31749 AKT1 
RAC-alpha 
serine/threonine-
protein kinase 
Regulation of proliferation, 
cell survival, growth and 
angiogenesis 
22 
Bad Q92934 BAD 
Bcl2-associated 
agonist of cell 
death 
BH3 domain only Bcl-2 
protein, sensitizer, pro-
apoptosis 
22 
Bax Q07812 BAX Apoptosis regulator BAX 
Multi-domain Bcl-2 
proteins, pro-apoptosis 
1, 22 
Bcl-2 P10415 Bcl-2 Apoptosis regulator Bcl-2 
Multi-domain Bcl-2 
protein, anti-apoptosis 
1, 12, 18, 22 
caspase-3 P42574 CASP3 Caspase-3 Caspase executor, pro-apoptosis. 
1, 6, 18 
caspase-7 P55210 CASP7 Caspase-7 Caspase executor, pro-apoptosis. 
6, 16 
caspase-9 P55211 CASP9 Caspase-9 
Caspase activator, pro-
apoptosis. 
1, 6, 18, 22 
CyclinD1 P24385 CCND1 G1/S-specific cyclin-D1 
Pro-cell cycle regulator 9, 19, 22 
Cyclin E1 P24864 CCNE1 G1/S-specific cyclin-E1 
Pro-cell cycle regulator 8 
CDK2 P24941 CDK2 Cyclin-dependent kinase 2 
Signal transducer, pro-cell 
cycle regulator 
8 
CDK4 P11802 CDK4 Cyclin-dependent kinase 4 
Signal transducer, pro-cell 
cycle regulator 
9, 12, 20 
Cyto C P99999 CYCS Cytochrome c Caspase activator, pro-apoptosis.  
1 
E2F1 Q01094 E2F1 Transcription factor E2F1 
Transcription activator, 
regulation of G1/S 
transition of mitotic cell 
cycle 
9 
GSK-3b P49841 GSK3B Glycogen synthase kinase-3 beta 
Glucose homeostasis 
regulator, intracellular 
signal transduction 
22 
IKKβ O14920 IKBKB 
Inhibitor of 
nuclear factor 
kappa-B kinase 
subunit beta 
Signal transducer, Inhibitor 
of nuclear factor kappa-B 
kinase 
18 
IL-6 P05231 IL6 Interleukin-6 Cytokine, pro-inflammation 12, 23 
MEK1/2 Q02750 MAP2K1 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 1 
Signal transducer of the 
MAPK/ERK cascade 
26 
c-myc P01106 MYC Myc proto-oncogene protein 
Transcription factor, 
positive regulation of cell 
proliferation. 
12 
MMP2 P08253 MMP2 72 kDa type IV collagenase 
Ubiquitinous 
metalloproteinase, 
extracellular matrix 
disassembly, pro-
13 
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Target 
(name used 
in study) 
Uniprot 
entry 
Uniprot 
gene name 
Uniprot protein 
name 
Tumour-related bio-
process *Study N 
metastasis. 
MMP9 P14780 MMP9 
Matrix 
metalloproteinase-
9 
Extracellular matrix 
disassembly, pro-
metastasis. 
13 
NF-κB1 P19838 NFKB1 
Nuclear factor NF-
kappa-B p105 
subunit 
Transcription factor, 
regulation of inflammation, 
differentiation, cell growth, 
tumourigenesis and 
apoptosis. 
18 
OCLN Q16625 OCLN Occludin 
Bicellular tight junction 
assembly, tumour 
metastasis inhibitor 
12 
P21 P38936 CDKN1A Cyclin-dependent kinase inhibitor 2A 
Inhibitors in cell cycle 
progression. 
8, 22 
P27 P46527 CDKN1B Cyclin-dependent kinase inhibitor 1 
Inhibitors in cell cycle 
progression 
8, 22 
P16 P42771 CDKN2A Cyclin-dependent kinase inhibitor 1B 
Inhibitors in cell cycle 
progression 
20 
P38 Q16539 MAPK14 Mitogen-activated protein kinase 14 
MAP kinase signal 
transduction,  
13 
PARP P09874 PARP1 Poly [ADP-ribose] polymerase 1 
DNA repair gene, negative 
regulation of apoptosis 
6 
PSMD9 O00233 PSMD9 
26S proteasome 
non-ATPase 
regulatory subunit 
9 
Transcription co-activator 
12 
p65 Q04206 RELA Transcription factor p65 
Regulation of 
inflammation, 
differentiation, cell growth, 
tumourigenesis and 
apoptosis. 
18 
RhoA P61586 RHOA Transforming protein RhoA 
Regulation of cell 
migration and adhesion 
assembly and disassembly 
4 
Skp2 Q13309 SKP2 
S-phase kinase-
associated protein 
2 
Pro-cell cycle progression 
9 
STAT3 P40763 STAT3 
Signal transducer 
and activator of 
transcription 3 
Regulation of 
inflammation, cell cycle 
progression, apoptosis and 
angiogenesis. 
3 
hTERT O14746 TERT 
Telomerase 
reverse 
transcriptase 
Apoptosis suppressor, 
negative regulation of 
cellular senescence 
11, 22 
TNF-α P01375 TNF Tumour necrosis factor 
Cytokine, regulation of 
inflammation and 
proliferation. 
12, 23 
p53 P04637 TP53 Cellular tumour antigen p53 
Tumour suppressor, 
induces growth arrest or 
apoptosis 
9, 12, 17, 18 
TUBA1A Q71U36 TUBA1A Tubulin alpha-1A chain 
Regulation of G2/M 
transition of mitotic cell 
12 
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Target 
(name used 
in study) 
Uniprot 
entry 
Uniprot 
gene name 
Uniprot protein 
name 
Tumour-related bio-
process *Study N 
cycle, cell division 
VEGF P15692 VEGFA 
Vascular 
endothelial growth 
factor A 
Pro-angiogensis  
17 
*Study N (1st author (year)): 1. Chang C (2013); 2. Huang J (2007); 3. Kim B (2013); 4. Li N (2015); 5. Liang L (2008); 6. 
Liang L (2012); 7. Liu L (2008); 8. Lu L (2007); 9. Lu L (2008); 10. Ou X (2014); 11. Peng Y (2005); 12. Peng Y (2012); 13. 
Ren H (2014); 14. Ryu S (1997); 15. Sun M (2007); 16. Sun M (2008); 17. Wang Q (2010); 18. Wang X (2008); 19. Wang X 
(2008a); 20. Xiang Y (2015); 21.Xiao Z (2013); 22. Zhang S (2014); 23. Zhang Y (2008); 24. Zheng Y (2014); 25. Zhou X 
(2009); 26. Zou L (2016). 
8.3 Effects of S. flavescens compounds on proliferation in colorectal cancer cells 
The S. flavescens compounds and extracts were examined in vitro and in vivo at different doses and for 
different treatment durations. The cell inhibitory rates (IR) and apoptosis rates (compared to negative 
control) are shown in Table 8.3. Of the six cell-lines, the most commonly tested was HT-29. The 
results showed inhibition of proliferation in time- and dose-dependent manners. In Chapter 7, matrine 
inhibited the growth of the CRC cell lines LS 174T, Caco-2, SW1116 and RKO in a dose- and time-
dependent manner. This result was consistent with other studies. 
In SW620 cells, various alkaloids inhibited proliferation in dose-dependent manners. The inhibition 
rates, from lowest to highest, were: S. flavescens total alkaloids (10.2%), oxymatrine (18.8%), 
sophorcarpine (21.4%), matrine (32.5%) and sophoridine (58.8%) (Liang et al., 2008). Xiang (2015) 
reported that oxymatrine (8-32 µmol/L) reduced survival of SW620 cells dose- and time-dependently 
(Xiang, et al., 2015). 
Cell morphology studies of HT-29, SW480 and SW620 cells showed they had at least partially 
undergone apoptotic changes, and compared to negative controls these changes were significant in 
both a dose-dependent and a time-dependent manner (Huang et al., 2007; Liang et al., 2008; Wang et 
al., 2008; Zou et al., 2016). In Chapter 7, the morphological changes of apoptosis were observed for 
matrine, which is consistent with previous studies. 
The half inhibitory concentration (IC50) expresses the effectiveness of a drug in inhibiting 
proliferation. A smaller value of IC50 indicates more effectiveness. The results for IC50 in HT-29 and 
HC116 indicated oxymatrine was more effective than matrine (Liu et al, 2008) (Table 8.4). In SW620 
cells, the IC50 values, from largest to smallest were: oxymatrine (4.57 ± 0.47 mM), sophorcarpine 
(4.43 ± 0.48 mM), matrine (4.28 ± 0.18 mM) and sophoridine (3.82 ± 0.43 mM). Sophoridine 
appeared to be the most effective in inhibiting proliferation among these alkaloids (Zheng, 2014). This 
ranking was the same as for apoptotic rate in Liang (2008) (see Table 8.1).  
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Table 8.3: Inhibitory rate (IR) and apoptosis rate (AR) in colorectal cancer cells for S. flavescens 
compounds 
Cell-line Compound IR%, (dose, treatment time) AR %,(dose, treatment 
time) 
Reference 
HT-29 Matrine 17.88 ± 3.51, 45.96 ± 3.95, 59.35 ± 3.36 
(4, 8 or 16 mg/mL, 24hs); 42.48 ± 2.78, 
58.20 ± 4.33, 68.29 ± 4.79 (4, 8 or 16 
mg/mL, 36hs) 
16.53, 34.11, 54.83 ( for 4, 8 or 
16 mg/mL, 24hs) 
Chang C et 
al., 2013 
HT-29 Matrine 86. 69 ± 2. 38 (0.5mg/mL, 48hs) 1.12 ± 0.45, 2.08 ± 0.76, 2.22 ± 
0.64, 2.98 ± 0.03, 27.46 ± 4.39 
(0.0625, 0.125, 0.25, 0.5, 1.0 
mg/mL, 48hs) 
Huang J et 
al., 2007 
HT-29 Matrine 33.7, 59.0, 66.7, 69.0 (3, 6, 8, 10μg /L, 
24 hs) 
15 .31, 17.99, 26.58 (5 μg 
/L,24,48,72hs) 
Peng Y et 
al., 2005 
HT-29 Matrine Reported in figure. IR increased on dose 
dependent. (0.0-2.0mg/mL, 24h) 
nr Ren H et al., 
2014 
HT-29 Kushen 
ethanol extract 
52.0 (2.5 mg/mL, 24 hs) nr Xiao Z et al., 
2013 
SW620 Matrine 25.13 ± 1.14, 28.77 ± 1.08 42.06 ± 1.37 
(0.5, 1.0, 1.5 mg/mL, 24hs); 42.46 ± 
1.43, 51. 84 ± 1. 58, 71.28 ± 1.65 (0.5, 
1.0, 1.5 mg/mL, 48hs) 
9.44 ±2.32, 15. 87 ± 1. 63, 
24.33 ± 1.45 (0.5, 1.0, 1.5 
mg/mL,48hs) 
Li N, 2015 
SW620 Matrine 32.5 (1.0mg/mL, 24hs) 5.5 ± 1.0, 12.8 ± 3.0, 33.5 ± 3.3, 
46.2 ± 2.5 (1.25mg/mL, 0, 12, 
24, 48hs) 
Liang L et 
al., 2008 
SW620 Oxymatrine 18.8 (1.0mg/mL, 24hs) nr Liang L et 
al., 2008 
SW620 Sophocarpine 21.4 (1.0mg/mL, 24hs) nr Liang L et 
al., 2008 
SW620 Sophoridine 58.8 (1.0mg/mL, 24hs) 5.0 ± 1.0, 14.7 ± 3.0, 37.1 ± 4.0, 
56.0 ± 4.5 (1.0mg/mL, 0, 12, 
24, 48hs) 
Liang L et 
al., 2008 
SW620 Total alkaloids 10.2 (1.0mg/mL, 24hs) nr Liang L et 
al., 2008 
SW620 Oxymatrine ⃰CVR: 42.32 ± 3.37, 32.52 ± 2.29, 27.17 
± 1.24 (8, 16, 32µmol/L, 24hs); 32.21 ± 
2.36, 20.23 ± 1.83, 16.18 ± 1.19 (8, 16, 
32µmol/L, 48hs); 5-FU: 48.32 ± 4.68, 
40.21 ± 2.39 (4mg/L, 24, 48hs). 
nr Xiang Y, 
2015 
SW620 Matrine 38.38 ± 11.72, 37.89±8.58, 59.60 ± 
8.80(0.5, 1.0, 1.5 mg/mL, 24 hs); 24.11 
± 5.34, 45.57 ± 16.44, 56.11 ± 10.33 
(0.5, 1.0, 1.5 mg/mL, 48hs) 
nr Wang X, 
2008a 
SW480 Sophoridine 55.69 ± 1.77 (1.0 mg/mL, 48hs) 38.7 ± 3.4 (0.8 mg/mL, 48 hs) Liang L et 
al., 2012 
SW480 Matrine 36.08 ± 6.88, 53.86 ± 5.43, 68.44 ± 5.90 
(0.5, 1.0, 1.5 mg/mL, 24 hs); 45.77 ± 
7.20, 67.68 ± 3.58, 89.46 ± 10.50 (0.5, 
1.0, 1.5 mg/mL, 48hs) 
3.77 ± 0.47, 22.73 ± 1.78 (0.5 
mg/mL, 24, 48 hs) 
Wang X, 
2008 
SW480 (K-
Ras 
mutation) 
Matrine 0.71 ± 0.01, 1.27 ± 0.01, 1.47 ± 0.02 
(0.125 mg/mL, 24, 48, 72hs) 
3.38 ± 0.10, 4.06 ± 0.10, 4.40 ± 
0.13, 7.54 ± 0.12, 10.78 ± 0.45 
(0.125, 0.25, 0.5, 1 mg/mL, 24 
hs 
Zou L et al., 
2016 
SW1116 Matrine Reported in figure on dose and time 
dependent. (0.0-2.0mg/mL, 24, 48, 72, 
96h) 
nr Zhou X et 
al., 2009 
LOVO Oxymatrine 17.74 ± 7.54, 27.51 ± 8.79, 34.90 ± 
5.11(1.0 mg/mL, 6, 24, 48hs); 34.42 ± 
9.65, 54.36 ± 6.97, 67.64 ± 7.87 
(2.0mg/mL, 6, 24, 48hs) 
4.07 ± 1.77, 6.08 ± 1.59, 7.40 ± 
1.38 (0.1 mg/mL, 6, 24, 48hs); 
4.27 ± 1.66, 8. 27 ± 2. 77,9.80 ± 
1.32 (0.2 mg/mL, 6, 24, 48hs) 
Peng Y et 
al., 2011 
LOVO Matrine Reported in figure. IR increased on dose 
and time dependent (0.0-2.0mg/mL, 24, 
48, 72h) 
8.6, 16.7, and 24.4 %, (0.4, 0.8, 
1.6mg/mL. 48 hs) 
Zhang S et 
al., 2014 
DLD1 Matrine Reported in figure. IR increased on dose 
dependent (0.0-2.0mg/mL, 24h) 
nr Ren H et al., 
2014 
CVR: cell viability rate; IR: inhibition rate; AR: apoptosis rate; nr: no report 
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Zhou (2009) reported that the IC50 of matrine was 1.13 mg/mL (48h) in SW1116 cells. However, in 
this project, the IC50 of matrine was 1.18 mM (=0.293 mg/mL, 48h) (see Chapter 7). The reason for 
this difference in the IC50 value on SW1116 cells between the two studies was unclear. There are 
several factors that could affect to the result, such as human error, accuracy of equipment, purification 
of the test drug, and variation in the cell-line or contamination of the test cells. 
In CaCo-2 cells, kurarinone had the smallest IC50 value compared to ku shen flavonoids and 
sophoraflavanone G. (Sun et al., 2007). In a study of 15 flavanoids in HCT15 CRC cells, kushenol B 
had the lowest IC50 value (3.0 ± 0.2 µg/mL, 48 hs) and was closest to the positive control cisplatin (2.2 
± 0.4 µg/mL, 48 hs) (Ryu et al., 2013) (Table 8.4). 
Table 8.4: IC50 in colorectal cancer cell-lines of S. flavescens compounds 
Compound Cell-line (IC50 unit, hs) Reference 
 CaCo-2  
Kurarinone 13 µg/mL, 48hs Sun M et al., 2007 
Sophoraflavanone G 16 µg/mL, 48hs Sun M et al., 2007 
2’-methoxy-kurarinone 27 µg/mL, 48hs. Sun M et al., 2007 
Kushen flavonoids (KS-Fs)  29 µg/mL, 48hs Sun M et al., 2007 
 DLD1  
Matrine 1.569 mg/mL, 24hs Ren H et al., 2014 
 HCT15 (ED50 µg/mL,48hs)  
Kushenol B 3.0 ± 0.2 Ryu S et al., 2013 
Kushenol E 4.6 ± 0.3 Ryu S et al., 2013 
Kuraridin 5.0 ± 0.1 Ryu S et al., 2013 
Kushenol M 5.1 ± 0.3 Ryu S et al., 2013 
Sophoroflavanone G 5.7 ± 0.3 Ryu S et al., 2013 
Kosamol A 6.5 ± 0.2 Ryu S et al., 2013 
Kushenol L 8.4 ± 0.3 Ryu S et al., 2013 
Kurarinone 8.6 ± 0.3 Ryu S et al., 2013 
Kushenol N 14.5 ± 0.1 Ryu S et al., 2013 
Norkurarinol 16.5 ± 0.3 Ryu S et al., 2013 
Trifolirhizin 21.0 ± 0.4 Ryu S et al., 2013 
Kurarinol 28.7 ± 0.4 Ryu S et al., 2013 
Kushenol H >50 Ryu S et al., 2013 
Kushenol K >50 Ryu S et al., 2013 
Formononetin >50 Ryu S et al., 2013 
̽Cisplatin (pos. control) 2.2 ± 0.4 Ryu S et al., 2013 
 HCT116  
Oxymatrine  11.61 ± 4.06 μg/mL, 48hs, Liu L et al., 2008 
Matrine 158.62 ± 19.02 μg/mL, 48hs, Liu L et al., 2008 
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Compound Cell-line (IC50 unit, hs) Reference 
 HCT116 p53⁺/⁺  
Matrine 3.25 ± 0.16 mM, 72hs Ou X, 2014 
 HT29  
Matrine 1.569 mg/mL, 24hs Ren H et al., 2014 
Oxymatrine 17.89 ± 3.04 μg/mL, 48hs Liu L et al., 2008 
Matrine 28.11 ± 1.02 μg/mL,48hs Liu L et al., 2008 
Kushen flavonoids (KS-Fs) 21.95 μg/mL, 48hs Sun M et al., 2008 
 LoVo  
Matrine 2.62 mg/mL, 24hs Wang X, 2008 
Matrine 0.738 mg/mL, 48hs Zhang S et al., 2014 
 SW480  
Sophoridine 0.78045 mg/mL (median), 48hs Liang L et al., 2012 
Matrine 0.81 mg/mL, 24hs Wang X, 2008 
 SW480 (K-Ras mutation)  
Matrine 0.66, 0.59, 0.45 mg/mL, 24, 48, 72hs Zou L et al., 2016 
 SW620  
Matrine 1.01 mg/mL, 24hs Wang X, 2008a 
Sophoridine 3.818 ± 0.425 mM, 48hs Zheng Y et al. 2014 
Matrine 4.284 ± 0.181 mM, 48hs Zheng Y et al., 2014 
Sophocarpine 4.431 ± 0.484 mM, 48hs Zheng Y et al. 2014 
Oxymatrine 4.571 ± 0.467 mM, 48hs Zheng Y et al. 2014 
Kushen flavonoids (KS-Fs) 18.26 μg/mL, 48hs Sun M et al., 2008 
 SW1116  
Matrine 1.74, 1.13, 0.89, 0.65 mg/mL, 24, 48, 
72, 96hs 
Zhou X et al., 2009 
IC50: The half maximal inhibitory concentration; ED50: value of compound against each cancer cell line, defined 
as the concentration that caused 50% inhibition of cell proliferation in vitro. 
Xenograft tumour studies of HT-29 and SW480 cells in mice further supported the anti-cancer effects 
of matrine and sophoridine. The tumour growth inhibition rates were significantly higher in these cells 
than the negative controls (Table 8.5). The anti-tumour effect of the high-dose sophoridine was not 
inferior to the 5-FU positive control (Liang et al., 2012). 
Overall, S. flavescens alkaloids and flavonoids inhibited cell proliferation in a variety of CRC cell-
lines. Among the alkaloids, sophoridine appeared more effective. Sophoridine and matrine also 
demonstrated inhibition of tumour growth in vivo. Of the S. flavescens flavonoids, a number have 
shown anti-tumour effects but direct comparison between specific flavonoids and alkaloids in the 
same CRC cell lines were not available. However, it is notable that one study in other cancer cell-line 
studies, found the flavonoids to be more effective than the alkaloids (Sun 2007). Future in vitro and in 
vivo studies could focus on selecting the most effective compounds, or combinations of alkaloids and 
   
220 
flavonoids. Such studies should include anti-proliferative assays, toxicity assessment, and 
pharmacokinetics. 
Table 8.5: Tumour growth inhibition in colorectal cancer studies in vivo for S flavescens 
compounds 
Xenograft 
tumour Compound 
Tumour growth inhibitory 
rate %(IR), (dose, treatment 
time) 
Others 
 
Reference 
HT29 matrine 
Proximally 50% reduction of 
volume and weight of tumour 
(intragastric administration 
(60 mg/kg/day, for 21 days) 
No. of lung metastatic sites 
decreased 42.47% 
Ren et al., 
2014 
SW480 sophoridine 
62.4 ± 4.3 (25 mg/kg/day, 5 
days/wk, ip. 4weeks) 
IR compared to 69.0 ± 
2.3% for 5-FU (30 mg/kg, 
3 days/week) p>0.05 
Liang et al., 
2012 
SW480 
(p53mutant) 
sophoridine 
34.07 (16.9 mg/kg/day, ip, 28 
days.) 
na 
Wang et al., 
2010 
SW480-EGFP matrine 
59.52 (80 mg/kg/day, ip, 4 
weeks) 
ID50 of matrine to mice 
was 157.13 mg/kg, 95% 
(88.08, 280.31) 
Wang, 2008 
Ip: intraperitoneal injection; ID50: the infective dose that will cause 50% of exposed individuals to become ill. 
 Outline of the cell cycle  8.3.1
The cell cycle is a cascade event that consists of four different phases: Gap1 (G0), Synthesis (S), Gap 
2 (G2), and Mitosis (M) phases. Cells in the Gap 0 (G0) phase are not in the process of proliferation. 
The cell cycle initiates in response to mitogenic growth factors stimulating the G1 phase. In this phase, 
the cell increases supplies of its nutrients, and increases in size. DNA synthesis commences in the S 
phase, all DNA are replicated and chromosomes double by the end of this phase. In the G2 phase, 
proteins are synthesised rapidly and there is continuous growth of the cell in readiness for mitosis in 
the M phase. In the M phase, the cell completes the process of dividing the chromosomes into two 
identical sets, followed by dividing cell components including nuclei, cytoplasm, organelles and cell 
membrane into two identical daughter cells (cytokinesis) (Strachan, 2015). 
The progression of the cell cycle in each phase is positively regulated by the combination of cyclin 
dependent kinases (CDKs) and their subunits – cyclins, as complexes of cyclins/CDKs. CDKs are 
present throughout the cell cycle, whereas cyclins are synthesised and degraded in response to cellular 
signals at various cell cycle phases. The newly synthesised cyclin binds to the CDK and activates it. 
The activated cyclin/CDK complexes phosphorylate target proteins positively or negatively in each 
phase in order to progress the cell cycle sequentially (Diehl J, 2002). Mutant cyclin D can result in cell 
cycle changing from mitogenic dependent progression to enter into mitogenic independent progression 
(Sherr and Roberts, 1999). The development of inhibitors of CDKs attracts researchers interested in 
the development of novel anti-cancer drugs. 
   
221 
8.3.1.1 Cell cycle checkpoints 
Cell cycle checkpoints allow cells to monitor and regulate cell cycle progression. There are three 
important checkpoints in the cell cycle: 
• G1/S checkpoint: where the cell checks its preparation to fully replicate its DNA; 
• G2/M checkpoint: where the cell checks the cell contents (e.g. cytoplasm and 
phospholipids) to ensure there is sufficient for two daughter cells, and determines when 
to replicate; 
• metaphase (mitotic) checkpoint: where the cell checks the chromosomes are ready before 
anaphase begins. 
During DNA replication and chromosome division, any deficiency could activate a checkpoint that 
could slow cell cycle progress or induce cell cycle arrest to allow the cell to repair the deficiency by 
modulating CDK activities. If the damage is irreversible, cell apoptosis will occur (Malumbres and 
Barbacid, 2009). Cancer cells with dysfunctional checkpoint control are more sensitive to additional 
genotoxic or microtubular damage. Therefore, components of cell cycle checkpoints are potential 
targets for new anti-cancer drugs (Shapiro and Harper, 1999). 
8.3.1.2 G1 phase 
In a cell in the resting G0 phase, cell cycle is initiated by mitogenic growth factors through 
extracellular signalling pathways (such as the MAPK signalling pathway). Progression of the cell 
cycle from the G0 phase into the G1 phase is dependent on mitogenic growth factors up until the late 
G1 phase which is the G1/S checkpoint, also referred to as the restriction point. Beyond this point, the 
cell cycle does not require mitogenic growth factors in order to progress (Zetterberg et al., 1995; Diehl 
J, 2002). In cancer, due to mutation and dysregulation of genes or signalling pathways, cell cycle 
initiates independently of mitogenic growth factors and the proliferation becomes uncontrollable 
(Fouad & Aanei, 2017). 
8.3.1.3 Cyclin D/CDK4/6 complex and cyclin E/CDK2 complex 
In humans, cyclin D has three homologues: cyclin D1, cyclin D2 and cyclin D3. In the G1 phase, 
stimulation of mitogenic growth factors triggers cyclin D production and assembly with CDK 4/6 to 
form the activated cyclin D/CDK4 complex, which then moves to the nucleus (Diehl J, 2002.). The 
p27 and p21 members of the CDK interacting protein/kinase inhibitory protein (cip/kip) family act as 
assembly factors by binding to cyclin D and CDK4 in the cytoplasm and promoting movement of the 
cyclin D complex to the nucleus (Coqueret et al., 2002). 
The assembly and nuclear localisation of the cyclin D/CDK4 complex phosphorylates retinoblastoma 
protein (Rb). This inactivates Rb as a repressor of E2F1, which initiates the subsequent activation of 
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genes that promote cell cycle progression (Tannoch et al., 2000). The released E2F1 activates the 
cyclin E/CDK2 complex. The activation of cyclin E/CDK2 complex can inactivate cip/kip proteins 
and Rbs through phosphorylation and promote a positive feedback loop guarding the cell cycle’s 
progression from the G1 phase to the S phase. This is the restriction point in the G1/S phase. 
Withdrawal of mitogens before the restriction point will result in the release of the cip/kip proteins that 
are retained by the cyclin D/CDK4 complex. The cip/kip proteins inhibit cyclin D/CDK4 and cyclin 
E/CDK2 complexes and induce cell cycle arrest during the G1 phase. Cyclin D acts as a link between 
the mitogen-dependent and mitogen-independent stages of the G1 phase and is not involved in the rest 
of the cell cycle. The initiation of phosphorylation of Rb by cyclin D in the G1 phase is maintained by 
cyclin E in the transition from the G1 phase to the S phase, and by cyclin A and cyclin B in later 
stages of the cell cycle until the cell exits mitosis. After mitosis, retinoblastoma protein returns to a 
hypophosphorylated state in readiness for the next G1 phase (Sherr & Roberts, 1999; Diehl, 2002). 
Overexpression of cyclin D1 and cyclin E is associated with early adenoma development and later 
carcinoma genetic progression in CRC (Hur et al., 2000). 
8.3.1.4 CDK inhibitor families 
Progression from the G1 phase to the S phase is negatively regulated by two CDK inhibitor families: 
the inhibitor of kinase 4/alternative reading frame (INK4/ARF) family and the cip/kip family. These 
inhibitor families are known as tumour suppressors because they can inhibit cell cycle progression. 
The inhibitors of kinase 4 (p16INK4A, p15INKB, p18INK4C and p19INK4D) only bind to CDK4/6 
and inhibit catalytic activity in the early G1 phase. The cip/kip family (p21, p27 and p57) can bind to 
both cyclins and CDKs, and inhibits the catalytic activity of cyclin D and E in the G1/S phases (Sherr 
& Roberts, 1999). Also, p21 and p27 are required in the cyclin D/CDK4 complex assembly and 
nuclear localisation under mitogenic stimuli in the early G1 phase (LaBaer et al., 1997; Coqueret et al., 
2002). 
8.3.1.5 Roles of Skp2, GSK-3β, c-Myc, p53 in G1 phase 
S-phase kinase-associated protein 2 (Skp2) is a member of the F-box protein family. The Skp2/SCF 
complex (including Skp1, Cullin-1, F-box protein Skp2 and Rbx1) can inhibit cip/kip by ubiquitin-
mediated degradation, which activates cyclin E/CDK2 and leads to G1/S transition (Ungermannova et 
al., 2005; Wang et al., 2005). Overexpression of Skp2 has been found in several cancers. Skp2 is a 
substrate of Akt, which regulates Skp2 activities in terms of mediating cell cycle progression, cell 
migration and tumourigenesis. Thus, Skp2 may be an ideal target in future cancer therapy (Chan et al., 
2010). 
The role of cyclin D as a G0/G1 initiator is also negatively regulated by glycogen synthase kinase-3B 
(GSK-3β). Phosphorylation of cyclin D by GSK-3β induces export of cyclin D from the nucleus and 
subsequent ubiquitin-dependent degradation, thereby halting the G1 phase (Sherr & Roberts, 1999). 
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Inhibition of GSK-3β activity through the Ras/PI3K/Akt pathway results in cyclin D1 nuclear 
localization and stabilization (Diehl, 2002). In addition, activation of GSK-3β can inhibit Skp2 
expression, increasing nuclear import of p27Kip1 which binds to CDK2 and inhibits its activity (Wang 
et al., 2008). 
The MYC family includes three nuclear phosphoproteins: c-MYC, N-MYC and L-MYC. The 
oncogenic transcription factor c-Myc participates in cell proliferation, transformation and death. 
Growth factors and mitogenic signals regulate c-Myc expression via the MAPK/ERK pathway. 
Deregulation and overexpression of c-Myc have been frequently found in both inflammatory bowel 
disease and CRC (Sipos et al., 2016). The transcription factor c-MYC promotes G1/S progression by 
directly targeting MYU (c-Myc upregulated IncRNA, LOC100128881, NCBI: NR_036480.1), which 
interacts with the RNA binding protein hnRNP-K to stabilise CDK6 expression and binds with cyclin 
D to form cyclinD/CDK complexes, thereby activating G1 progression (Kawasaki et al., 2016). 
Molecular agents that target c-Myc or other genes acting in the c-Myc pathway are of interest as future 
CRC treatments (The Cancer Genome Atlas Network, 2013). DNA damage can activate p53 which 
binds to p21 (WAF1), thereby activating p21 to inhibit cyclin D and induce cell cycle G1 arrest (Li et 
al., 2015). 
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Figure 8.1: Major proteins involved in the G1 phase of the cell cycle and the actions of S. 
flavescens compounds 
Proteins: GSK-3β - Glycogen synthase kinase-3 beta; C-Myc - Myc proto-oncogene protein; p16 - Cyclin-
dependent kinase inhibitor 1B; E2F1 - Transcription factor E2F1; Rb – Retinoblastoma; p53 - Cellular tumour 
antigen p53; p21 - Cyclin-dependent kinase inhibitor 2A; p27 - Cyclin-dependent kinase inhibitor 1; Skp2 - S-
phase kinase-associated protein 2. 
S. flavescens compounds: MT – matrine; OXY- oxymatrine. ‘˫’ : down-regulation; ‘←’: up-regulation 
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8.3.1.6 Effects of matrine and oxymatrine on cell cycle arrest at G1 
Matrine dose-dependently induced cell cycle arrest at the G1 phase in HT-29 (Chang et al. 2013; 
Huang et al., 2007), SW480, SW620 (Wang X, 2008) and LoVo cell lines (Zhang et al., 2014). 
Oxymatrine dose-dependently induced cell cycle arrest at the G1 phase in SW1116 (Lu and Ran, 
2007; Lu et al., 2008), SW620 (Xiang et al., 2015) and LoVo (Peng et al., 2012) cell lines. 
In SW1116 cells, oxymatrine down-regulated the expression of cyclin D1, CDK4, cyclin E, E2F1 and 
Skp2 at the mRNA and protein levels. Oxymatrine up-regulated expression of p53, p21 and p27 at the 
mRNA and protein levels, whereas CDK2 expression was only down-regulated at the mRNA level. 
These effects were both time dependent and dose dependent (Lu and Ran, 2007; Lu et al., 2008). 
SW620 cells treated with oxymatrine showed significant up-regulation of p16 and down-regulation of 
cyclin D and CDK4 (Xiang et al., 2015). 
In LoVo cells, oxymatrine suppressed the mRNA expression of CDK4 and c-Myc at a dose of 0.5 g/L 
at 48 and 96 hours. However, at a dose of 0.25 g/L at 48 hours, oxymatrine only suppressed the c-Myc 
mRNA expression and had no significant effect on CDK4. It is possible that c-Myc is more sensitive 
to low-dose oxymatrine in LoVo cells (Peng et al., 2012). Matrine dose-dependently suppressed 
protein expression of cyclin D1, up-regulated p27 and p21, and increased phosphorylated GSK-3b 
(activation) in LoVo cells (Zhang et al., 2014). The actions of matrine and oxymatrine on protein 
targets in G1 phase are shown in Figure 8.1. 
In summary, oxymatrine and matrine both induced cell cycle arrest at the G1 phase in multiple CRC 
cell lines. The mechanism of the induction of cell cycle arrest was suppression of cyclin/CDKs (cyclin 
D1, CDK4, cyclin E and CDK2) and the promotion of expression of the CDK inhibitors p16, p21 and 
p27. These compounds also regulate cyclin/CDKs via associated transcription factors and signalling 
proteins including p53, E2F1, GSK-3B, Skp2 and c-Myc. Therefore, matrine and oxymatrine may be 
ideal candidates for the development of new anti-cancer drugs that target either CDK2/4 and the 
components of cell cycle entry or the G1/S checkpoints such as Skp2, E2F1, p16, p21 and p27. 
 Outline of apoptosis  8.3.2
Apoptosis is one type of programmed cell death. The balance between pro-apoptotic and anti-
apoptotic molecules maintains the homeostasis of an organism. Physically, apoptosis eliminates cells 
that are damaged or non-functioning, and prevents the accumulation of genetically mutant cells. In 
cancer, malfunctions of apoptotic mechanisms that favour anti-apoptosis lead to oncogenesis and the 
development of resistance to antitumour drugs. Morphological changes during apoptosis include 
cytoplasmic filament aggregation, chromatin condensation, DNA fragmentation, plasma membrane 
blebbing and packing of cytosolic ingredients that result in formation of the apoptotic body. After 
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apoptosis, the cell is phagocytised by neighbouring cells. Two classical signalling pathways are 
involved in apoptotic processes: the intrinsic pathway and the extrinsic pathway. Two families of 
proteins are important in the regulation of apoptosis: the caspase family and the Bcl-2 family (Kiraz et 
al., 2016). 
8.3.2.1 Intrinsic pathway 
The intrinsic pathway is independent of death ligand or receptor signalling. Cells undergo apoptosis in 
response to intracellular signalling, which positively or negatively mediates mitochondria-dependent 
apoptosis events. The positive stimuli (e.g. radiation, toxins, hypoxia, hyperthermia and viral 
infections) induce apoptosis by directly activating pro-apoptotic factors; the negative stimuli (e.g. 
deprivation of growth factors, hormones and different cytokines) induce apoptosis by suppressing anti-
apoptotic factors. All of these stimuli eventually cause mitochondrial outer membrane 
permeabilisation (MOMP) and release a set of pro-apoptotic proteins including: cytochrome C, 
apoptosis-inducing factor (AIF), endonuclease G, Smac/DIABLO (second mitochondria-derived 
activator of caspase/direct IAP-binding protein with low PI); and the serine protease Omi/HtrA2. The 
released cytochrome C binds to apoptosis protease activating factor-1 (Apaf-1) and forms the 
apoptosome complex that leads to activation of caspase-9, which in turn activates caspase 3 and 
executes cell apoptosis (Kiraz et al., 2016; Plati et al., 2011). The mitochondrial-initiated events 
(mitochondrial outer membrane permeabilisation and cytochrome C release) are crucial to the intrinsic 
pathway and are mainly mediated by the Bcl-2 family (Elmore, 2007). 
8.3.2.2 Extrinsic pathway 
The extrinsic pathway is initiated by extracellular ligands (e.g. TNF and Fas-L) binding to the 
extracellular death domain of the transmembrane death receptor (TNFR1, Fas and TRAIL). This 
results in the transmembrane death receptors binding with the intracellular death domains that interact 
with death domain-containing adaptor proteins (FADD [FAS-associated via death domain] and TNFR-
associated death domain [TRADD]). These adaptor proteins have a death effector domain (DED) that 
interacts with pro-caspase 8 (which also contains a death effector domain) to form the death-inducing 
signalling complex (DISC). The death-inducing signalling complex mediates caspase-8 activation, 
which in turn activates caspases -3, -6 and -7, and leads to cell death (Goldar et al., 2015). Caspase-8 
is crucial to the extrinsic pathway. The active caspase-8 also activates BID by truncating BID to form 
tBID, which translocates to the mitochondria resulting in mitochondria-dependent apoptosis (the 
intrinsic pathway) (Plati et al., 2011). 
8.3.2.3 Caspase family 
The caspase family consists of cysteine aspartic-specific proteases with a N-terminal peptide or pro-
domain and two subunits (Cohen G, 1997). The caspase family members are important in the 
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mediation of apoptotic process. The 14 caspase family members found in mammals are classed into 
three sub-groups: initiator caspases (caspase-2, -8, -9 and -10), effector caspases (caspase-3, -6, -7 and 
-14) and cytokine activators (caspase-1, -4, -5, -11, -12 and -13). Caspases are involved in cell death, 
proliferation, differentiation and inflammation.  
In response to apoptotic signals, initiator caspases (caspase-8 or -9) are activated and then activate 
effector caspases (caspase-3, -6, -7). The activated caspase-3 cleaves the poly (ADP-ribose) 
polymerase (PARP) protein that promotes DNA repair and leads to the execution of apoptosis. 
Initiator caspases can be self-activated, whereas effector caspases are activated by initiator caspases 
through internal cleavage. Caspase-3 is important for the cleavage of PARP and the DNA 
fragmentation that are hallmarks of the apoptotic process. Caspase-3 can be activated in both the 
intrinsic and extrinsic pathways (Kiraz et al., 2016). 
8.3.2.4 Bcl-2 family 
The Bcl-2 family includes three sub-families: BH3-domain-only proteins (BID, BIM, BAD, PUMA 
and BIK) that act as sensors of pro-apoptosis signals, pro-apoptosis multi-domain proteins (BAX, 
BAK and BOK) and anti-apoptosis multi-domain proteins (Bcl-2, Bcl-XL, MCL1, Bcl-W, Bcl-B and 
A1). The BH3-domain-only proteins are activated under stress stimuli. The activated BH3-only family 
members directly activate pro-apoptosis multi-domain proteins (e.g. BAX) and neutralise anti-
apoptosis multi-domain proteins (e.g. Bcl-2 and Bcl-XL), which results in mitochondria-dependent 
apoptosis (Plati et al., 2011). The balance of pro- and anti-apoptotic Bcl-2 proteins determines the 
death or survival of cells. The ratio of Bcl-2 to Bax is an indicator of cell susceptibility to apoptosis, 
with a decreasing ratio indicating an increase in apoptosis (Khodapasand et al., 2015). 
8.3.2.5 Effects S. flavescens compounds on the intrinsic (mitochondrial) pathway 
In HT-29 cells treated with matrine, apoptosis was induced in a dose-dependent manner. There was 
up-regulation of cleaved caspase-3 and -9, increased cytochrome C translocation to the cytosol, 
increased Bax expression and decreased expression of Bcl-2, which resulted in a decreased ratio of 
Bcl-2 to Bax (Chang et al., 2013). 
Matrine induced apoptosis in LoVo cells, reduced phosphorylation of Akt (the upstream factor), 
reduced the ratio of Bcl-2 to Bax and increased phosphorylation of Bad (Zhang et al., 2014). 
Sophoridine induced apoptosis in SW480 cells up to 67.5±5.9%. Sophoridine time-dependently up-
regulated cleaved caspase-3, -7 and -9. The initiator, caspase-9, was cleaved as early as 12 hours after 
treatment. Cleaved PARP was also up-regulated (Liang et al., 2012). 
Among the experimental studies of S. flavescens and its compounds, there were no direct tests of the 
extrinsic pathway. Some studies measured TNF, but these were in relation to inflammation rather than 
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apoptosis (Zhang et al., 2008). The actions of matrine and sophoridine on protein targets in the 
intrinsic (mitochondrial) pathway are illustrated in Figure 8.2. 
Caspase 3Cytochrome C
Stimuli (positive 
& negative)
Cell membrane
Bcl-2
Bax
Apaf-1
Caspase 9
Mitochondrion 
(MOMP)
MT
MT
PARP
SPD
APOPTOSIS
Bad
BIM
 
Figure 8.2: Major proteins involved in the intrinsic (mitochondrial) pathway and the actions of 
S. flavescens compounds 
Proteins: BIM - Bcl-2-like protein 11; Bax - Apoptosis regulator BAX; Bcl-2 - Apoptosis regulator Bcl-2; Bad - 
Bcl2-associated agonist of cell death; Apaf-1 - Apoptotic protease-activating factor 1; PARP - Poly [ADP-
ribose] polymerase 1; MOMP - mitochondrial outer membrane permeabilization. 
S. flavescens compounds: MT – matrine; SPD – Sophoridine. ‘˫’ : down-regulation; ‘←’: up-regulation. 
8.4 Intracellular signalling pathways 
Intracellular signalling pathways transmit biological signals from the cell surface to the nucleus. The 
process of signal transmission responds to extracellular stimuli and involves sequential reactions from 
the cell surface to a variety of intracellular targets that result in changes in gene expression (Cooper, 
2000). The anti-cancer effects of S. flavescens compounds appear to involve regulation of key 
components in the following cellular signalling pathways. 
 MAPK/ERK pathways 8.4.1
The mitogen-activated protein kinase (MAPK) signalling pathways are sub-divided into four distinct 
pathways: extracellular signal-related kinases (ERK1/2), Jun amino terminal kinases (JNK), p38-
MAPK and ERK5 (Sun et al., 2015). The MAPK signalling pathways receive extracellular stimuli in 
response to a broad range of cellular activities including proliferation, differentiation, migration, 
senescence and apoptosis (MacCorkle & Tan, 2005). The Ras family of GTPases (H-Ras, K-Ras and 
N-Ras) are involved in signal transduction upstream of the MAPK pathways (Meloche & Pouyssegur, 
2007), while Ras oncogenes are involved in many cancers (Fernández-Medarde & Santos, 2011). 
The MAPK/ERK pathway is a classical MAPK pathway that is also known as the Ras-Raf-MEK-ERK 
pathway. MEK refers to the dual-specificity protein kinases MAP2K1/MeK1 and MAP2K2/MeK2. 
MEK and ERK both play key roles in the MAPK/ERK signalling pathway. Upstream growth factor 
receptors such as receptor tyrosine kinases (RTK) activate Ras/Raf1 and then further activate 
MEK/ERK, leading to sequential activation and further transduction of the signal within the 
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MEK/ERK cascade (Cook et al., 2017). Each of the proteins Raf1, MEk1/2 and ERk1/2 is required for 
cell proliferation and survival (Liu et al., 2004). In tumours, activated MEK/ERK promotes cell 
survival by activating pro-survival BcL-2 proteins (BcL-2, BcL-XL and MCL1) and repressing pro-
apoptotic proteins (BAD, BIM, BMF and PUMA) (Cook et al., 2017). Mutant Ras is found in about 
40% of CRC, and can lead to independent activation of the downstream MEK/ERK and PI3K/AKT 
pathway without the presence of growth factors (De Roock et al., 2010). 
8.4.1.1 Effects of S. flavescens compounds on the MAPK/ERK pathways 
SW480 cells, which have a K-Ras gene mutation, were treated with matrine (0.125, 0.25 and 0.5, 1.0 
mg/mL) for 24 hours. The results showed that matrine significantly inhibited the proliferation and 
migration of the SW480 cells and promoted apoptosis through the down-regulation of MEK1/2 protein 
expression in the MAPK/ERK pathway (Zou et al., 2016). 
 PI3K/AKT pathway 8.4.2
AKTs are serine/threonine-protein kinases, including AKT1, AKT2, and AKT3. Under the stimuli of 
growth factors, phosphatidylinositide (PI) 3-kinase (PI3K) is activated by receptor tyrosine kinases 
(RTKs)/Ras. PI3K phosphorylates PIP2, which then converts to PIP3. The activated PIP3 binds to 
AKT and transports it to the inner face of the plasma membrane where AKT is phosphorylated by 
phosphatidylinositide (3,4,5) P3-dependent protein kinase-1 (PDK1). Activated AKT phosphorylates 
downstream target proteins that promote survival and proliferation (Arcaro & Guerreiro, 2007; 
Cooper, 2000). This pathway is also called the Ras /PI3K/Akt pathway, since Ras is an upstream 
activator. 
In CRC, AKT mediates proliferation and metastasis via the PI3K/AKT pathway (Hu et al., 2017; Li et 
al., 2017; Sun et al., 2017). High expression (68.3%) of active AKT has been reported in CRC (Zhang 
et al., 2012), while suppression of AKT pathway activity prolongs non-metastatic CRC patient 
survival (Zhou et al., 2017). 
8.4.2.1 Effects of S. flavescens compounds on the PI3K/AKT pathway 
In LoVo cells, matrine (0.4 and 0.8 mg/mL, 48h) induced apoptosis and suppressed expression of 
phosphorylated AKT. Matrine also regulated molecules downstream of the P13/AKT signalling 
pathway including GSK-3, BAD, p21, p27 and cyclin D1, which affect cell proliferation and apoptosis 
(Zhang et al., 2014). 
 Cross-talk in MEK/ERK and PI3K/Akt pathways 8.4.3
The MEK/ERK and PI3K/Akt intracellular signalling pathways are both downstream of Ras. In 
cancer, these pathways can be activated by genetic alterations in upstream signalling components as 
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well as by mutations in the components of these two pathways. Cross-talk, feedback loops and point 
convergence are evident in these two pathways. Over-activity of these pathways is associated with 
chemotherapeutic drug resistance and the proliferation of cancer. Dual targeting of these two pathways 
may lead to optimal outcomes in cancer treatment (Mendoza et al., 2011; Ramjaun and Downward, 
2007; Saini et al., 2013). 
Inhibitors targeting MEK, PI3K and AKT have been used in cancer treatment. For instance, 
Selumetinib (AZd6244 and Arry-142886) is a MEK inhibitor that has been used in Phase I, II trials for 
melanoma, liver cancer, pancreatic cancer, CRC, lung cancer and breast cancer. Perifosine (Krx-0401) 
targets AKT, MEK 1/2, ERK 1/2 and JNK, and has also been used in Phase I, II trials for multiple 
myeloma, leukemias, non-small cell lung cancer and advanced solid tumours (Chappell et al., 2011). 
 p38 MAPK pathway 8.4.4
The p38 protein is a stress-activated MAPK that responds to cell stress and cytokines. In mammals, 
p38 is activated via the Rac/MEKK3/MKK3 signalling pathway in response to various stimuli. The 
biological effects of p38 MAPK depend on the stimuli and the type of cell (Bradham & McClay, 
2006). 
In CRC, activation of p38 MAPK has been shown to be associated with CRC cell proliferation, 
migration and invasion (Huang et al., 2017). Inhibition of expression of p38 is associated with 
decreased expression of matrix metalloproteinases (MMPs) that play important roles in the 
degradation of the extracellular matrix that is a critical barrier in tumour migration and invasion (Wei 
et al., 2013). In CRC patients, high expression of MMPs were associated with lower DFS and lower 
histological grade (i.e. higher-grade tumours), and was more common in carcinomas of the descending 
colon and rectum (Buhmeida et al., 2009). High MMP expression was associated with more invasive 
tumours and with death (Araújo et al., 2015; Salem et al., 2016).  
8.4.4.1 Effects of S. flavescens compounds on the p38 MAPK pathway 
Figure 8.3 illustrates the actions of S. flavescens compounds in intracellular signalling pathways. 
Matrine inhibited p38 activation by reducing the phosphorylation level of p38 in HT29 CRC cells in a 
dose-dependent manner. The inhibition of p38 activation was associated with suppression of MMP-2 
and MMP-9 activity and the CRC cells’ migration and invasion. Synergistic reduction of invasion was 
found when matrine was combined with SB203580 (a p38 inhibitor) in vitro.  
In an HT29 tumour xenograft mouse, a lung metastatic model was established whereby matrine was 
found to inhibit the growth and metastasis of HT29 CRC tumours. Matrine inhibited the migration and 
invasion of the tumours by supressing the p38 signalling pathway (Ren et al., 2014). 
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Figure 8.3: Major proteins involved in intracellular signalling pathways and the actions of S. 
flavescens compounds 
Proteins: RTK - Receptor tyrosine kinases; CR: cytokine receptor; PI3K - Phosphoinositide 3-kinase; AKT: 
RAC-alpha serine/threonine-protein kinase; Ras - Ras GTPases; Raf - RAF proto-oncogene serine/threonine-
protein kinase; MEK - Dual specificity mitogen-activated protein kinase kinase 1; ERK - Extracellular signal-
related kinases; GEF - Guanine nucleotide-exchange factor; RhoA - Transforming protein RhoA; ROCK - Rho-
associated protein kinase; Rac - Rac GTPase; MEKK3 - Mitogen-activated protein kinase kinase kinase 3; 
MKK3 - Dual specificity mitogen-activated protein kinase kinase 3; p38 - Mitogen-activated protein kinase 14; 
Jak - Janus kinase; STAT3 - Signal transducer and activator of transcription 3. 
S. flavescens compounds: MT – matrine; SG - Sophoroflavanone G. ‘˫’ : down-regulation; ‘←’: up-regulation. 
 JAK/STAT3 pathway 8.4.5
STAT3 is a member of the signal transducer and activator of transcription (STAT) protein family, in 
which there are seven members in mammals (Darnell, 1997). The JAK/STAT pathway is initially 
activated by cytokines or interferons binding to membrane receptor-associated Janus kinases (JAK), a 
non-receptor tyrosine kinase. The activated JAK then recruits and phosphorylates STATs resulting in 
the translocation of STATs to the nucleus where they mediate transcription of target genes. The 
JAK/STAT pathway mediates cell proliferation, differentiation, survival and inflammation (Leonard & 
O'Shea, 1998). The JAK/STAT3 pathway is crucial to CRC development (including cell growth, 
survival, invasion, and migration) via mediation of the gene expression of Bcl-2 (up-regulation); p16, 
p21 and p27 (down-regulation); E-cadherin, VEGF and MMPs (up-regulation) (Xiong et al., 2008). 
Down-regulating JAK/STAT3 signalling can induce CRC apoptosis through mediation of the intrinsic 
(mitochondrial) pathway (Du et al., 2012). STAT3 is also essential in RhoA/Rho-associated kinase 
(ROK) -mediated cell proliferation and cell migration (Debidda et al., 2005). 
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8.4.5.1 Effects of S. flavescens compounds on the JAK/STAT3 pathway 
Sophoraflavanone G is a flavanone-type of kushen flavonoid. In CRC HCT-116 cells treated with 
Sophoraflavanone G (20 µm) for 9 hours in vitro, there was a significant reduction in the expression of 
phosphorylated STAT3 (p-STAT3). In the same study, the authors reported that in other cancer cell 
lines, sophoraflavonone G inhibited the activity of many proteins in STAT3 upstream signalling 
pathways, including down regulation of p-JAK1/JAK2/JAK3, p-TYK, p-Src, p-Lyn, p-Akt, p-
ERK1/2, and p-NF-κB in MDA-MB-468 breast cancer cells, HDLM-2 Hodgkin’s lymphoma cells and 
L540 lung cancer cells at the same dosage and time frame.Unfortunately, CRC cell lines were not 
included in these experiments. Nevertheless, the results suggested that sophoraflavonone G inhibits 
cancer cell proliferation and induces apoptosis by inhibiting activity of the JAK/STAT3 signalling 
pathway. Further studies in CRC cell lines are needed to test these potential effects (Kim et al., 2013). 
 RhoA/ROCK pathway 8.4.6
RhoA is a member of the Rho GTPases, which is a sub-group of the Ras superfamily. Of the 22 
members of the Rho family, Rho (A, B and C), Rac (1, 2 and 3) and Cdc42 have received intensive 
study. Rho GTPases are able to regulate the transcription factors SRF, NF-κB, and STATs in 
tumourigenesis. The activation of RhoA is mediated by guanine nucleotide-exchange factors. RhoA is 
associated with cell-cell adhesion disruption and increased migration and metastasis in CRC. Mutant 
APC, Ras and p53 are highly prevalent in CRC and mediate the cellular events of tumourigenesis, 
migration and invasion by activating the Rho/ROCK pathway. Rho GTPases and their regulators have 
been considered promising therapeutic targets in the development of new anti-cancer drugs (Leve & 
Morgado-Diaz, 2012). 
8.4.6.1 Effects of S. flavescens compounds on the RhoA/ROCK pathway 
SW620 cells were treated with matrine which induced dose-dependent apoptosis. The RT-PCR assay 
showed that the mRNA of RhoA was dose-dependently down-regulated. The increased apoptotic rate 
was correlated with decreased expression of mRNA of RhoA (r= −0.86, p<0.05), which suggested that 
the down-regulation of mRNA of RhoA is associated with the induction of apoptosis in CRC cells (Li 
& Zhang, 2015). The actions of matrine and sophoroflavanone G on key components of intracellular 
signalling pathways are shown in Figure 8.3. 
 Transcription factor p53  8.4.7
The p53 protein is a tetrameric transcription factor that mediates many cellular functions including 
DNA damage detection and repair, cell cycle arrest, and inducing apoptosis and senescence in the 
presence of cellular stress such as DNA damage, hypoxia or oncogene activation (Li et al., 2015; 
Fischer M, 2017). Activated p53 binds to p21 (WAF1) to induce cell cycle G1 arrest; p53 is also able 
to induce G2/M arrest by down-regulating CDK1, which is essential for the initiation of mitosis (Li et 
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al., 2015). The transcription-dependent apoptotic pathway of p53-induced apoptosis activates pro-
apoptosis proteins such as PUMA, BID, BAX, TRAILR2, CD95 and Apaf1 in both the intrinsic and 
extrinsic apoptosis pathways. In addition, p53 can translocate directly to the mitochondria and bind to 
Bcl-XL and Bcl-2 to form the inhibitory complex that results in cytochrome C release (Kiraz et al., 
2016). In cancers, the expression of mutant forms of p53 leads to failure of its tumour suppression 
functions. In CRC, about 50% of patients have p53 gene mutations, and over-expression of mutant p53 
in CRC is associated with a poor survival rate (Lacopetta B, 2003). 
8.4.7.1 Effects of oxymatrine and sophoridine on p53 
In a SW480 xenograft tumour model in mice, high expression of p53 in tumour tissues suggests that 
p53 was the mutant type from the SW480 xenograft, which typically shows elevated mutant p53. 
Wild-type p53 is hard to detect due to its short life (5 minutes). SW480 tumour-bearing nude mice 
were treated with sophoridine for 28 days, which significantly down-regulated the expression of p53 at 
the protein and mRNA levels in the tumour tissues compared with a negative control group. The 
tumour cells also showed the morphological changes of apoptosis (Wang et al., 2010). 
In LoVo cells, oxymatrine (2 mg/mL) induced apoptosis and time-dependently down-regulated p53 
protein expression (Peng et al., 2011). Lu (2008) reported that when SW1116 cells were treated with 
oxymatrine (2, 3 and 4 mg/mL) for 24 and 48 hours, the cell cycle was arrested at the G0/G1 phase, 
whereas p53 at both the protein and mRNA level was time- and dose-dependently up-regulated (Lu et 
al., 2008). 
These contradictory results may be due to alteration of the p53 gene in the CRC cell lines. We would 
expect that down-regulation of mutant p53 to be pro-apoptotic, whereas up-regulation of wild-type 
p53 should promote tumour suppression. In the above two studies, the type of p53 was unclear. To 
investigate the effect of p53 on pro-apoptosis or anti-apoptosis, a future study could compare the effect 
of the test substance on apoptosis in cells with and without p53 use the method of gene modification to 
knockdown p53 in the CRC cells. 
 NF-κB signalling 8.4.8
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a protein complex 
comprising five components: NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA (p65), c-Rel and RelB. 
The protein mediates the transcription of DNA, cytokine synthesis and cell survival or death. Two 
pathways activate NF-κB: the canonical pathway and the non-canonical pathway (Dutta et al., 2006). 
In the canonical pathway, extracellular signalling activates the inhibitor of NF-κB kinase β (IKKβ) 
leading to the phosphorylation and degradation of the inhibitor of NF-κB (IκB) that releases the NF-
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κB dimer p50/RelA (comprising components 1 and 3 above). Then, p50/RelA translocates to the 
nucleus where it binds to DNA and results in alteration of cell functions (Li et al., 1999). 
In the non-canonical pathway, upstream kinases, such as NF-κB-inducing kinase, (NIK) activate the 
inhibitor of NF-κB kinase α (IKKα) leading to the processing of the NF-κB2 precurs or p100/RelB (a 
dimer of components 2 and 5 above) into a mature p52/RelB subunit that translocates to the nucleus 
and binds with DNA (Senftleben et al., 2001, Oeckinghaus et al., 2011). 
NF-κB is commonly associated with immune cell function and pro-inflammation, but it can also 
inhibit programmed cell death to maintain the physiological development and homeostasis of the 
immuno, hepatic and nervous systems. In human tumours, NF-κB derived from tumour cells or 
infiltrating inflammatory cells is an important factor contributing to tumourgenesis and 
chemoresistance by promoting the expression of anti-apoptotic genes (Dutta et al., 2006). 
NF-κB can regulate some genes in different manners under different circumstances. As well as 
inhibiting programmed cell death, NF-κB can also induce programmed cell death in response to 
certain stimuli in certain cells. Under the conditions of ultraviolet light, expression of the Her2/Neu 
oncogene, treatment with the chemotherapeutic drug doxorubicin, hypoxia/re-oxygenation or 
hydrogen peroxide stimulation, NF-κB can be activated via an IKK-independent atypical pathway. In 
this case, phosphorylation and degradation of IκB could occur via the casein kinase II (CK2) or in a 
tyrosine kinase-dependent manner. This can change the function of NF-κB to tumour suppression and 
programmed cell death induction (Perkins & Gilmore, 2006). 
In CRC, over-expression of NF-κB was found in 70.2% of human CRCs, and was positively correlated 
with histological grading, depth of invasion, TNM staging and lymph node metastasis of CRC (Zheng 
et al., 2015). The over-expression of NF-κB may be also associated with the chemo-resistance in CRC 
therapy (Hassanzadeh, 2011). 
8.4.8.1 Effect of matrine on NF-κB  
In SW480 cells, matrine (0.5 mg/mL) time-dependently induced apoptosis at 8, 24, 48 and 72 hours. 
The RT-PCR assay showed significantly increased mRNA time-dependent expression of caspase-3 
and NF-κB1, and time-dependently decreased mRNA expression of Bcl-2. The mRNA expression of 
p53 and IKKα were not changed. The Western blot assay showed that matrine activated caspase-3, 
caspase-7 and caspase-9, and time-dependently supressed Bcl-2 expression. Phosphorylated p65 and 
IKKβ proteins increased time dependently, but phosphorylated IKKα was not expressed. These results 
suggest that matrine activates NF-κB1/p65 via the canonical pathway, and therefore, matrine may 
activate the p65/Bcl-2/caspases/apoptosis pathway (Wang, 2008). 
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The experiment suggested that matrine can induce CRC cell apoptosis while increasing NF-κB 
expression. Whether NF-κB expression in CRC cells plays a pro-apoptotic role or an anti-apoptotic 
role needs further investigation. Methods using the NF-κB suppressive agent pyrrolidine 
dithiocarbamate or using genetic modification to silence NF-κB as a control may be able to clarify the 
matter. 
 VEGF and angiogenesis 8.4.9
Angiogenesis is the growth of new blood vessels from the existing vasculature. This biological process 
is tightly regulated by angiogenesis inducers and inhibitors to maintain a dynamic balance (Wang et 
al., 2017). VEGF and VEGF receptors (VEGFRs) are central regulators of this biological process. The 
VEGF family includes VEGF (or VEGF-A), placenta growth factor (PLGF), VEGF-B, VEGF-C and 
VEGF-D. The VEGF ligands bind with three endothelial transmembrane tyrosine kinase receptors: 
VEGFR-1, VEGFR-2 and VEGFR-3 (Tammela et al., 2005). VEGF expression is up-regulated in 
response to molecular signals from hypoxia-inducible factor 1a (HIF-1a), proliferator-activated 
receptor gamma coactivator 1a (PGC-1a), growth factors, inflammatory cytokines, oncogenes and 
hormones. The activation of angiogenesis is primarily via VEGFR-2. The binding of VEGF-A, VEGF-
C and VEGF-D to VEGFR-2 activates the downstream phospholipase Cγ/protein kinase C pathway, 
which in turn activates the c-Raf-MEK-MAP-kinase pathway or the phosphorinositide 3-kinase 
(PI3K)-AKT pathway and this leads to proliferation and migration of endothelial cells. In addition, 
VEGF-induced phospholipase C γ/protein kinase pathway activation can activate another downstream 
pathway involving protein kinase D-dependent phosphorylation and nuclear export of histone 
deacetylase 7. All three pathways lead to proliferation and migration of endothelial cells (Lohela et al., 
2009). 
Overexpression of VEGF has been found in most human cancers (Ferrara N, 2004) and has been 
reported in 61.7% of CRC cases (Zhang et al., 2012). In the tumour hypoxic microenvironment, the 
overexpression of HIF-1a can increase expression of VEGF via the Wnt/β-catenin/TCF3 (T cell factor 
3)/LEF1 (lymphocyte enhancement factor 1)/VEGF pathway in CRC cell lines (Sui et al., 2017). 
Monoclonal antibodies targeting VEGF (e.g. bevacizumab) or its receptor VEGFR (e.g. aflibercept) in 
combination with FOLFOX or FOLFIRI are now standard treatments in stage IV CRC patients (Fakih, 
2015). 
8.4.9.1 Effect of sophoridine on VEGF 
In a SW480 xenograft tumour model, VEGF and p53 were highly expressed in tumour tissues. The 
tumour-bearing nude mice were treated with sophoridine (16.9 mg/kg, 0.2 mL/head, ip, once a day for 
28 days), which significantly down-regulated the expression of VEGF and p53 at the protein and 
mRNA levels in the tumour tissues compared with a negative control group. The tumour cells also 
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showed the morphological changes of apoptosis. This suggested that inhibition of the tumour growth 
was associated with the suppression of VEGF and p53 (Wang et al., 2010). 
 Telomerase activity and hTERT 8.4.10
Telomeres are terminal capping structures in chromosomes that stabilise and protect the chromosome 
from degradation, recombination and fusion with other chromosomes. Telomerase is a 
ribonucleoprotein that adds TTAGGG repeats to telomeres to compensate for the shortening of 
telomeres from normal cell division. Telomerase is normally inactive in somatic cells. Human 
telomerase reverse transcriptase (hTERT) is the catalytic subunit of the telomerase complex. The 
expression of hTERT is positively correlated with telomerase activity in tumour cells (Pinol-Felis et 
al., 2017). In CRC, the dysfunctional overactivity of telomeres promotes chromosomal instability in 
genes such as APC and MSH2 that play key roles in the early steps of CRC carcinogenesis. The 
activation of telomerase maintains the length of telomeres and this allows cancer cells to proliferate 
indefinitely. Thus, the activation of telomerase and expression of hTERT is correlated with CRC 
formation and tumour progression (Bertorelle et al., 2014). 
8.4.10.1 Effect of matrine on telomerase activity and hTERT 
In HT-29 cells, matrine induced apoptosis and suppressed telomerase activity (Peng et al., 2005). In 
SW1116 cells, matrine treatment for 48 hours, showed a dose-dependent reduction in telomerase 
activity and down-regulation of expression of the mRNA hTERT (Zhu et al., 2009). Thus, matrine-
induced CRC cell apoptosis was associated with inhibition of telomerase activity by inhibiting the 
expression of mRNA hTERT. 
 Microtubules, OCLN and TUBA1A 8.4.11
Microtubules are the backbone of the cytoskeleton in cells. The proteins alpha-tubulin and beta-tubulin 
form heterodimers that constitute the building blocks of microtubules. Tubulin alpha-1A chain 
(TUBA1A) is a tubulin, for which the microtubules’ dynamic equilibrium is the fundamental basis for 
many biological processes such as cellular motility, cytoplasmic transport and cell division. Disabling 
the dynamic equilibrium of microtubules may cause chromosome instability (Cirillo et al., 2017). 
Tubulins have been targets of anti-cancer drugs (such as paclitaxel and docetaxel) for decades. Tubulin 
inhibitors increase microtubule stabilisation and prevent the dynamic equilibrium of microtubules. 
These drugs impair the metaphase–anaphase process of mitosis in cell division and lead to cellular 
death via apoptosis or mitotic catastrophe. Tubulin inhibitors also can indirectly inhibit angiogenesis 
and enhance immunotherapeutic effects by increasing the immunogenicity of cancer cells (Hardin et 
al., 2017). 
Occludin (OCLN) is a transmembrane tight junction protein that induces cell-cell adhesion when 
expressed in cells (Furuse et al., 1993). The metastatic progression of cancer is characterised by matrix 
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degradation, tight junction reductions and vessel formation (Angiolini et al., 2017). The tight junction 
is an important paracellular permeability barrier that cancer cells must break through during metastatic 
progression (Martin et al., 2010). 
8.4.11.1 Effect of Oxymatrine on OCLN and TUBA1A 
In a LoVo cell-line, oxymatrine (2 mg/mL, 24 h) induced apoptosis. The RT-PCR assay showed that 
oxymatrine suppressed mRNA expression of TUBA1A and Bcl-2, and promoted the mRNA 
expression of OCLN. The Western blot assay showed that oxymatrine promoted the protein expression 
of OCLN and supressed the protein expression of Bcl-2 (Peng, 2011). These results suggest that 
oxymatrine induced apoptosis in the LoVo cells by suppressing Bcl-2 and TUBA1A, and promoted 
the expression of OCLN. Further studies are needed to determine any association between increased 
OCLN expression and reduced cell migration and invasion in animal models. 
8.5 Outline of tumour-related inflammation 
About 15% of cancers are related to infections or chronic inflammation (Kuper et al., 2000). Several 
sources of evidence have connected inflammation and cancer, as follows: 
• Many chronic inflammatory diseases increase the risk of cancer. 
• These cancers develop at sites of chronic inflammation. 
• Cells involved in the chronic inflammatory process are present at sites of cancers. 
• Many inflammatory factors are found in cancers, and suppressing these inflammatory factors 
can inhibit cancer development. 
• Long-term use of non-steroidal anti-inflammatory medicines is associated with a reduction in 
mortality in some cancers. 
• Inflammatory bowel diseases (IBD) have been identified as one of the factors in the 
pathogenesis of CRC (Balkwill F, 2006). 
In the inflammatory microenvironment, cells are under oxidative and nitrosative stress. Excessive 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) accumulate in cells and these 
subsequently cause DNA damage and can induce mutations in cancer-related genes. The mutant genes 
result in inactivation of tumour suppressor genes (such as p53) and activation of oncogenes (such as 
K-Ras). These pathological changes initiate malignant transformations of the cells. After the initiation 
of cancer, infiltrating inflammatory cells and tumour cells can produce proinflammatory cytokines 
such as IL-6, IL-1β, NF-κB and TNF-α, which are important for the survival, proliferation, invasion 
and metastasis of cancer cells (Zhang et al., 2017). 
It has been proposed that TNFα/NF-κB/IL-6/STAT3 axis cellular signalling plays an important role in 
the progression of inflammation-related cancer (Aggarwal et al., 2006). Targeting these inflammation-
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related molecules and pathways are a useful strategy for the prevention and treatment of cancer (Zhang 
et al., 2017). 
 Tumour necrosis factor (TNF) α 8.5.1
Tumour necrosis factor (TNF) α is a hormone-like peptide that is mainly produced by activated 
macrophages and monocytes in response to various bioactive process such as inflammation, cellular 
proliferation, apoptosis and morphogenesis. Two types of receptors, TNFR1 and TNFR2, have been 
identified. TNFR1 is found in most cell types, but TNFR2 is only expressed by immune cells, 
endothelial cell and nerve cells (Aggarwal et al., 2012). TNFα binding to TNFR1 or TNFR2 leads to 
promotion of inflammation, cell survival or induction of apoptosis. TNFα binds to TNF receptors 
(TNFR) on the cell surface and initiates signal transduction. The three main signalling pathways 
activated are: 
1. NF-kB signalling through the recruitment of receptor-interacting serine/threonine-protein 
kinase (RIP) that enables activation of IKK and leads to the phosphorylation of IκBα and 
the subsequent activation of NF-kB. 
2. MAP/ERK kinase kinase 1 (MEKK1) and MAPK kinase 7 (MKK7), which in turn activate 
c-Jun N-terminal kinase (JNK) and activator protein 1. 
3. death signalling, via TNFR-associated death domain (TRADD) recruiting FAS-associated 
via death domain (FADD), which in turn activates caspase 8 dependent apoptosis pathways 
(Aggarwal et al., 2012). 
The activation of p38 MAPK through the sequential activation of TNFR1/TRADD/RIP/MAPK kinase 
3 (MKK3) is a less well-known pathway that leads to pro-inflammatory effects and cell survival. The 
activation of TNFR2 can recruit TNFR-associated factor 2 (TRAF2), and cause the same cascades in 
the TRAF2-dependant pathways (Aggarwal, 2003). 
TNFα was initially identified as a tumour suppressor when there is a high-dose and local application. 
But TNFα can be produced chronically in small amounts in the cancer micro-environment and plays a 
role in promoting cancer proliferation (Balkwill, 2002, 2009). TNFα also promotes cachexia by 
inhibiting lipoprotein lipase (Beutler et al., 1985). CRC patients who show high expression of TNF-α 
have worse prognosis (in terms of cancer cell differentiation, TNM stage, distant metastasis, and 
disease-free survival) than patients who show low expression of TNF-α (Li et al., 2016). 
 Interleukin (IL)-6 8.5.2
Interleukin (IL)-6 is mainly secreted by monocytes and macrophages in the acute inflammatory phase 
but is also secreted by T cells in the chronic inflammatory phase. In the normal homeostatic condition, 
the serum level of IL-6 is low. Under inflammatory conditions, the serum level of IL-6 can rise 
quickly. The activity of IL-6 is involved in acute and chronic inflammatory diseases and infections, 
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including inflammatory bowel diseases, arthritis and inflammation-associated carcinogenesis (Naugler 
& Karin, 2008). The IL-6 receptor (IL-6R) is composed of an IL-6 binding α chain (IL-6Rα) and a 
homodimer of the signal-transducing glycoprotein 130 (gp130). IL-6 binds to its receptor to form an 
active complex that activates downstream signalling pathways. There are two IL-6 signalling 
pathways: the classical signalling pathway and the trans-signalling pathway. 
In the classical signalling pathway, IL-6 binds to IL-6Rα at the cell surface and, via gp130, transduces 
the signal to downstream targets. Only cells that express IL-6Rα at the cell surface, such as 
hepatocytes and some immune cells, respond to this pathway. In the trans-signalling pathway, cells 
that do not have IL-6Rα at the cell surface can recruit soluble IL-6Rα (sIL-6Rα) that is found in the 
serum and can bind to IL-6 and interact with gp130 at the cell surface to transduce intracellular 
signalling. These two signalling pathways can activate downstream pathways such as JAK/STAT, 
ERK/MAPK and PI3K/AKT (Waldner et al., 2014). 
IL-6 trans-signalling and IL-6/STAT3 signalling are associated with the link between bowel 
inflammatory diseases and CRC development in vitro and in vivo (Becker et al., 2005; Grivennikov et 
al., 2009; Bollrath et al., 2009). Tocilizumab, an anti-IL-6R antibody has been developed and used in a 
pilot study of patients with active Crohn’s disease. The result showed the antibody had an effect on the 
clinical response rate – a decrease of at least 70 points on the Crohn’s Disease Activity Index (CDAI), 
– and was well tolerated. But there has been no report of the use of tocilizumab for cancer treatment 
(Waldner et al., 2014). Siltuximab, another anti-IL-6 antibody, has been used in phase I and phase II 
studies. The results showed that siltuximab was well tolerated, but there was no clinical effect on solid 
tumours including CRC (Angevin et al., 2014). 
 Effects of S flavescens compounds on inflammation in vitro and in vivo 8.5.3
In a cachexia model in BALB/c mice induced by inoculation of colon 26 carcinoma cells for 12 days, 
matrine (50 mg/kg) or sophorcarpine (50 mg/kg) were administered i.p. daily for 5 days. Investigators 
found the mice that were administrated matrine or sophorcarpine showed significantly reduced 
cachexia symptoms: loss of body weight, loss of epididymal fat weight, loss of gastrocnemius muscle 
weight and lower dry carcass weight. In both the matrine and sophorcarpine groups, the mice 
improved food intake compared with a negative control group in which tumour-bearing mice were 
only administered 0.2 mL saline i.p. daily for 5 days. Matrine and sophorcarpine significantly reduced 
TNF-α and IL-6 levels in the serum of the tumour-bearing mice compared with the negative controls. 
However, this dose of matrine and sophorcarpine did not reduce tumour weight in the mice (Zhang et 
al., 2008). In the same study, RAW 264.7 mouse macrophage cells and primary macrophages were 
collected from the peritoneal cavities of mice and cultured with lipopolysaccharide (LPS) for 6 hours 
in the presence or absence of matrine, sophorcarpine, oxymatrine, sophoramine and sophoridine (0.5 
mg/mL). The results showed that the production of TNF-α and IL-6 induced by LPS and the mRNA 
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expression of TNF-α and IL-6 were all significantly reduced in the presence of these kushen alkaloids. 
A parallel MTT assay showed that, at this dosage, these kushen alkaloids did not significantly inhibit 
proliferation of RAW 264.7 cells and primary macrophages (Zhang et al., 2008). Thus, matrine and 
sophorcarpine were able to suppress the expression of TNF-α and IL-6 in the serum of tumour-bearing 
mice and in macrophage cells in vitro. 
Overall, TNFα/NF-kB/IL-6/STAT3 axis cellular signalling has been linked to the development of 
tumourigenesis, including proliferation, invasion and metastasis, angiogenesis, and chemo-resistance 
(Aggarwal, 2006). S. flavescens compounds such as matrine and sophorcarpine appear to have anti-
inflammatory effects by regulating these cytokinases as well as mediating by a number of key genes in 
several cellular signalling pathways such as AKT, MEK, p38, and STAT3. Therefore, these S. 
flavescens compounds may be good candidates as anti-inflammatory and chemopreventive agents in 
the future. 
8.6 Chapter 8 summary and conclusions 
S. flavescens extracts and its compounds have shown anti-cancer effects in models of CRC in vitro and 
in vivo. The anti-cancer effects included inhibition of cell proliferation, suppression of xenograft 
tumour growth by causing cell cycle arrest at the G1 phase and inducing apoptosis via the intrinsic 
pathway. 
S. flavescens extracts and its compounds showed:  
• down-regulation of MEK1/2, AKT, RhoA, p38, STAT3, telomerase, cyclin D/CDK4, 
cyclin E/CDK2, E2F1, Skp2, c-Myc and Bcl-2, and over-expression of p53 
• up-regulation of BAX, caspase-3, -7, -9, cytochrome C translocation to the cytosol, 
Cleaved PARP, p21, p27, p16, GSK-3B. 
Among these protein targets, MEK1/2, AKT, RhoA, p38, and STAT3 are key proteins in the following 
intracellular signalling pathways: 
• MEK/ERK and PI3K/AKT 
• JAK/STAT3 
• p38/MAPK 
• RhoA/ROCK. 
The inhibition of VEGF, TUBA1A and MMP-2/-9, and the promotion of OCLN, by S. flavescens 
compounds suggest that the anti-cancer effects of S. flavescens are also associated with anti-
angiogenesis and anti-metastasis. Matrine and sophorcarpine attenuated tumour-related cachexia in 
vivo. This effect was associated with their anti-inflammatory effects by down-regulating the 
cytokinases TNFα and IL-6 in the tumour microenvironment.  
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In conclusion, S. flavescens and its compounds have demonstrated multiple actions in CRC 
management including a range of anti-cancer actions, possible chemopreventive actions and 
improving quality of life. S. flavescens and its compounds show potential as candidate natural products 
for future clinical and experiment research in CRC. 
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Chapter 9. General Discussion and Directions for Future Research 
9.1 Summary of the project 
The primary objectives of this research project were to: 
• Evaluate the efficacy and safety of HMs in the clinical management of CRC; 
• Identify potentially effective HMs and combinations of HMs that warrant further 
experimental and clinical research; 
• Investigate the actions and mechanisms of action of promising HMs in experimental models 
of CRC; and  
• Determine directions for future experimental and/or clinical research. 
In order to achieve these objectives, this project involved the following sequence of stages: 
• Systematic reviews of randomised controlled trials (RCTs) of HMs for the management of 
CRC (Chapters 4 and 5) 
• Sensitivity analyses to identify individual HMs that showed promise for further research 
(Chapter 6) 
• Experimental studies on a bioactive compound found in the promising herb S. flavescens 
(Chapter 7) 
• Analyses of the possible mechanisms of action of S. flavescens and its constituent 
compounds (Chapter 8) 
• Proposals for future research (Chapter 9) 
The following were the specific research questions targeted in this study: 
1. Can HM interventions, used either singly or in combination with conventional therapies, 
elevate tumour response rate and/or prolong the survival of CRC patients? (answered in 
Chapters 4 and 5) 
2. Can HM interventions alleviate the adverse events associated with conventional anti-cancer 
treatments for CRC? (answered in Chapters 4 and 5)  
3. Can HM interventions improve the quality of life of CRC patients? (answered in Chapters 4 
and 5) 
4. How safe are HM interventions for CRC? (answered in Chapters 4 and 5) 
5. Which herbs and herbal combinations appear effective for CRC treatment and/or alleviation of 
adverse events associated with conventional CRC treatments? (answered in Chapter 6) 
6. What are the effects of specific herb-derived compounds in CRC cell lines? (answered in 
Chapter 7) 
7. What are the likely mechanisms of action of potentially effective HMs and their constituent 
compounds? (answered in Chapter 8) 
8. What questions could be addressed in future studies and how would a future study be 
implemented? (answered in Chapter 9) 
The main components of each of the above stages and the main results are summarised below. 
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9.2 Systematic reviews and meta-analysis of randomised controlled trials 
Comprehensive searches were conducted of English language and Chinese language biomedical 
databases, and systematic reviews of randomised controlled trials (RCTs) of HMs were performed 
using the Cochrane collaboration method (see Chapters 4 and 5, and published paper). Meta-analyses 
of outcome measure data were conducted to determine whether any HMs showed evidence of potential 
effects in the management of CRC, including the management of adverse events associated with 
chemotherapy. 
The results of the meta-analyses identified a range of potential beneficial effects on tumour response, 
survival, quality of life, immunity, and the alleviation of adverse events (AEs) induced by 
chemotherapy. Most of the evidence was for systemic CHMs combined with systemic chemotherapy 
for which data from 75 RCTs of were available (Chapter 4). A sub-group analysis of CHMs combined 
with FOFOX4 for ACRC that included 14 RCTs (Chapter 5) found results which reflected the 
outcomes of the broader meta-analyses. 
The meta-analyses found significant improvements in tumour response rate in the groups of 
participants who received CHM combined with chemotherapy, without important statistical 
heterogeneity. Most of the data were for oxaliplatin-based chemotherapies in current use. 
However, the results for survival outcomes were less clear, were based on considerably fewer studies 
and tended to greater heterogeneity. Nevertheless, there was an improvement in one-year survival in 
the palliative setting for ACRC, without heterogeneity, based on 9 RCTs (Research question 1). 
With regard to alleviation of adverse events associated with conventional anti-cancer treatments, most 
data were for chemotherapy-related adverse events. In the groups that combined systemic CHM with 
chemotherapy, there were reductions in nausea and vomiting (35 studies), diarrhoea (22 studies), 
neutropenia (38 studies), thrombocytopenia (18 studies), neurotoxicity (26 studies) and other 
outcomes for which less data were available. For the oxaliplatin-based chemotherapies, the meta-
analysis results showed significant reductions without important heterogeneity for each of the above 
outcomes (Research question 2). 
For quality of life, most data were for KPS which found significant improvements in KPS in the CHM 
plus chemotherapy groups, but there was substantial heterogeneity in this result (Research question 3). 
The meta-analyses did not locate any serious safety concerns associated with combining CHMs with 
chemotherapy regimens. Conversely, the incidences of impairment in liver function and kidney 
function tended to be lower in the CHM plus chemotherapy groups (Research question 4). 
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9.3 Sensitivity analyses to identify individual HMs for further research  
Based on the results of the meta-analyses, a short list of outcomes was selected and further sensitivity 
analyses of the outcome data from the RCTs. The outcomes selected were: tumour response rate (tRR) 
since this is directly related to the anti-cancer effects of herbs; chemotherapy-induced nausea and 
vomiting (CINV) since this is a common clinical issue that has a major impact on quality of life; and 
chemotherapy-induced neutropenia (CIN) since this is a serious adverse event that can lead to 
reduction or cessation of adjuvant and palliative chemotherapy. For each outcome, the intervention 
groups comprised oxaliplatin-based chemotherapies combined with orally administered CHMs. There 
was no important heterogeneity in the total meta-analysis for any of these three outcomes. 
The approach to sensitivity analysis was novel and developed in order to provide a rational basis for 
shortlisting herbs for further research. The rationale was that, if a particular herb was effective (or 
ineffective) in improving the particular outcome, this would be reflected in the pooled result of all the 
studies that employed this herb as a component of a multi-herb CHM intervention. Also, the reliability 
of a particular herbs' effect on the outcome could be estimated based on its showing a consistent effect 
when used in combination with a variety of other herbs in multiple studies. Since this approach 
required, low statistical heterogeneity in the meta-analysis pool combined with a sufficiently large data 
set to enable multi-level sensitivity analysis, it could only be applied to a limited number of outcome 
measures and to herbs that were frequently used as ingredients in the CHM interventions. 
The sensitivity analyses for tRR identified Sophora (ku shen), Paeonia (chi shao), and Curcuma (e 
zhu) as the herbs that were most consistently associated with tRRs that were elevated above that for 
the total meta-analysis pool, without heterogeneity (Research question 5). In addition, each of these 
plants and/or their constituent phytochemicals has been reported to have demonstrated anti-tumour 
properties in multiple experiment models of cancer. 
For CINV, the following six herbs were similarly shortlisted: Atractylodes (bai zhu), Poria (fu ling), 
Coix (yi yi ren), Glycyrrhiza (gan cao), Astragalus (huang qi) and Panax ginseng (ren shen) (Research 
question 5). There was some experimental evidence for each of these herbs for effects relevant to 
gastro-intestinal dysfunctions but the relevance to CINV was less compelling compared to that for 
tRR. 
The sensitivity analyses for CIN, identified Atractylodes (bai zhu), Poria (fu ling), Coix (yi yi ren), 
Astragalus (huang qi) and Codonopsis (dang shen) as the herbs which showed the most consistent 
evidence for reduction in CIN incidence when they were ingredients in the CHM interventions 
(Research question 5). Experimental studies suggested that each of these herbs may be protective 
against myelosuppression or improve immune status but only Astragalus showed evidence of effects 
on the production of blood cells. 
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The procedures used in these sensitivity analyses provided a rational method for shortlisting individual 
herbs used in multi-ingredient formulations for further research. A large proportion of clinical trials of 
CHM use such formulas and this leads to questions regarding the meaningfulness of the meta-analyses 
of pooled results of multi-ingredient formulas that contiain some but not all ingredents in common. It 
was notable that each of the herbs identified in the short-listing process showed evidence of bioactivity 
relevant to the outcome. 
However, the approach could only provide a relative ranking of the herbs and could not provide 
comparisons between herbs, so the meaningfulness of differences in ranking was difficult to 
determine. Also, the procedure could only be undertaken for the most frequently used herbs so less 
frequently used herbs were excluded from the short lists. 
9.4 Experimental studies on a bioactive compound found in S. flavescens 
Of the outcomes investigated in the sensitivity analyses, tRR was selected as most relevant for further 
research. Of the three short-listed herbs Sophora (ku shen) was selected as the most promising. This 
herb is exclusively derived from the plant Sophora flavescens which contains a number of bioactive 
compounds. Based on a review of previous studies of the compounds contained in S. flavescens, the 
alkaloid matrine, which is a major constituent, was selected for the experimental studies. 
A series of four experiments were conducted to assess the effects of matrine in four different human 
CRC cell-lines. The results indicated that matrine inhibited proliferation in these cells cell-lines in a 
dose-dependent manner. The morphological appearance of cells under microscopy indicated that cell 
death was likely to be due to apoptosis rather than necrosis. This observation was confirmed by further 
experiments using flow cytometry (FCM) that showed that the proportions of apoptotic cells increased 
with concentration of matrine. Moreover, cell cycle analysis showed that matrine increased the 
population of cells in the G0/G1 phase. Oxaliplatin, which was used as positive control in these 
experiments, showed a similar pattern of effects in these experiments although oxaliplatin is 
considerably more toxic than matrine, so the dosage was lower than for matrine. 
Overall, the experiments indicated that matrine, one of the principal compounds in Sophora inhibited 
the growth of these human cancer cells. This may, at least partially explain the effect of this herb on 
tRR (Research question 6). These experiments showed similar results to previous experiments but in 
multiple and additional cell lines. They formed a basis for ongoing studies in collaboration with the 
team led by Prof. Mo of Sun Yat Sen University in China. Further studies of the anti-cancer effects 
matrine and its molecular mechanisms are currently underway. 
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9.5 Possible mechanisms of action of S. flavescens and its constituent compounds  
In addition to matrine, the alkaloids oxymatrine, sophorcarpine and sophoridine, and the flavonoids 
kurarinone, sophoraflavanone G and kushenol B have all shown antiproliferative effects in CRC cell 
lines. 
A considerable number of studies have investigated the effects of matrine and/or other compounds 
from S. flavescens on proteins involved in the regulation of cell cycle. Analysis of these studies 
suggested that they may induce apoptosis via actions on the following four main signalling pathways: 
• MEK/ERK and PI3K/AKT, 
• JAK/STAT3, 
• p38/MAPK, and 
• RhoA/ROCK. 
In addition, the anticancer effects of S. flavescens may be via other mechanisms including actions on: 
• Transcription factor p53 
• NF-κB signalling 
• VEGF and angiogenesis 
• Telomerase activity and hTERT 
• Microtubules, OCLN and TUBA1A. 
Moreover, a number of S. flavescens compounds can exert anti-inflammatory effects via down-
regulation of TNFα and IL-6 in the tumour microenvironment (Research question 7). 
9.6 Limitations of the current project 
Several limitations to the studies included in this project are acknowledged. 
The systematic review findings (Chapters 4 and 5) that HMs, notably CHMs, improved the outcomes 
of CRC treatment, alone or in combination with chemotherapy, cannot be considered as high level 
evidence due to the generally poor reporting of methodological aspects of RCT design in the original 
published reports. In addition, the majority of studies were not placebo controlled and this lack of 
blinding is likely to have included the outcomes. Consequently, the risk of bias in the studies was 
often high. These issues have been discussed in more detail in Chapters 4 and 5 and in the published 
papers (Chen et al. 2014; 2016a; 2016b; 2016c; 2017).  
The main approach taken in the meta-analyses to mitigating the effect of bias was to group studies 
according to the similarity in their design, the type of participants, and the type of chemotherapy. For 
the more objective outcomes such as tRR and survival, this approach had the effect of reducing 
heterogeneity in the results. Since multiple studies conducted by different researchers showed similar 
results for these outcomes and the studies reflected the integrative methods used in hospitals, the 
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likelihood of the overall direction of effect found in the meta-analyses being solely due to bias seem 
low, although there was certainly a risk that the magnitude of the effect was inflated. In addition, there 
was asymmetry in the funnel plots for a number of meta-analysis pools suggesting that there may have 
selective reporting of outcomes and/or studies with negative results were not published. This issue was 
addressed, at least partially, by sensitivity analyses that removed outliers. These analyses generally 
showed that the outliers had inflated the effect sizes but had not changes the overall direction of the 
results. 
The method of sensitivity analysis used to identify shortlisted HMs (Chapter 6) needed relatively large 
numbers of RCTs in the pooling to allow multiple levels of analyses in order to show a consistent 
effect of any particular HM. For example, in selecting the HM shortlist for tRR, Coptis (huang lian) 
and Sanguisorba (di yu) appeared the most promising at level 1 based on their individual tRRs but 
these HMs were infrequent overall, and were consequently eliminated at later levels of the analysis. 
Hence, this approach represented a compromise between apparent effect on tRR in the first analysis 
and consistent effects on tRR in multiple analyses. It remains to be seen whether the addition of the 
dimension of consistency improved selection. Unfortunately, no objective measure of this was possible 
since the procedure was based on ranking and no direct comparisons between herbs were possible. 
Even with sufficient data this method cannot assess the relative effectiveness of HMs quantitatively, 
since the pooled results are from multi-ingredient formulas rather than directly from individual HMs. 
Also, it was unlikely that small differences in ranking were meaningful since there was no objective 
way of determining how much change in tRR was important. Literature searches for experimental 
studies tended to validate the short-listed herbs as worthy of further research, but literature searches 
were not conducted for the herbs that had been eliminated so it is likely that some of these were also 
suitable candidates. It should be noted that this project aimed to reduce the short-listed herbs to a 
single herb to enable a more focussed experimental study, but a broader study could consider a much 
larger short-list of herbs for screening in assays. In such cases, the above limitations would be less 
significant. 
Future studies could assess this approach to herb selection based on pooled clinical trial data to 
determine its discrimminatory power. It could be combined into other approaches such as systems 
pharmacology (Luo et al., 2014), systems biology (Margineanu, 2012), or virtual molecular docking 
(Kirkpatrick, 2004). 
In the experimental studies (Chapter 7), only one the compounds found in S. flavescens was tested. 
Constituent components found in the other short-listed HMs are also potential candidates in CRC 
management: paeonol and paeoniflorin from the roots of Paeonia lactiflora and P. veitchii; and beta-
elemene and curcumin from the rhizomes Curcuma wenyujin and C. kwangsiensis have all shown anti-
proliferation effects in CRC cell studies (see Chapter 6). 
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This compound matrine was only studied in cell-lines, so it remains unclear whether matrine would 
have similar effects in an animal model, let alone in humans with CRC. Therefore, the findings of 
these experiments can only be considered as preliminary. In addition, other S. flavescens compounds 
could be tested singly and in combination in the same cell-lines to determine which are more or less 
promising for further research into their effects on apoptosis. In addition, future experiments should 
assess the effects of these compounds on specific proteins and genes involved in the signalling 
pathways involved in cell cycle regulation. 
The analyses of the pathways potentially involved in the actions of matrine and other compounds 
found in S. flavescens (Chapter 8) were based on data provided by published experimental studies. 
These studies mainly reported on the up-regulation or down-regulation of the expression of particular 
proteins in response to the compound. Therefore, it was not possible to determine whether the 
compound had a direct effect on the particular protein or whether the effect was indirect. Also, within 
each pathway only a small number of the proteins have been included in the available studies, so the 
effects of these compounds on the majority of the proteins remains unknown. Consequently, the study 
of effects of S. flavescens on the signalling pathways in Chapter 8 could only summarise the current 
state of the published evidence and it is likely that as more studies are conducted these proposals will 
require modification.  
Overall, this project presents the best evidence available at the time, with the caveat that the quality of 
the evidence was variable and there were substantial gaps in the available evidence. Hence, it is 
possible that the findings of these studies will change as further studies become available. 
9.7 Implications for clinical practice 
The meta-analyses conducted in this study suggest that orally administered CHMs combined with 
oxaliplatin-based chemotherapies reduced the incidence of chemotherapy-induced nausea and 
vomiting and chemotherapy-induced neutropenia. In these analyses, the sample sizes were relatively 
large and there was no evidence that the addition of the CHMs to the chemotherapy adversely affected 
the tumour response rate. To the contrary, meta-analyses that focussed on tumour response found that 
the addition of certain CHMs appeared to improve tumour response when combined with oxaliplatin-
based chemotherapies in CRC and when combined with FOLFOX4 in advanced CRC.  
Of the individual plants included in the CHMs, when the roots of Sophora flavescens (ku shen) were 
included in a CHM formula and combined with oxaliplatin-based chemotherapy, tumour response rate 
appeared to be increased. Of the constituent chemicals found in this plant, the alkaloid matrine has 
been reported to show anti-proliferative activity. Moreover, the in-vitro experiments in CRC cell lines 
suggested that matrine induced apoptosis. This, at least partially, provides a plausible mechanism for 
the results of the clinical studies.  
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From the clinical perspective of the integrated management of CRC, these results suggest that 
clinicians could consider patient requests to combine CHMs with oxaliplatin-based chemotherapies 
since the addition of the CHM does not appear to reduce the efficacy of the chemotherapy and may 
even confer additional benefits.  
For practitioners of CHM, this research provides some evidence-based guidance on the ingredients of 
herbal formulae for the integrative management of the above adverse events associated with 
oxaliplatin-based chemotherapy for CRC. 
9.8 Proposals for future experimental research 
Matrine is perhaps the most studied of compounds found in S. flavescens, but its mechanisms of action 
in cancer still require further research. Although it appears to be clear that it exerts a pro-apoptotic 
effect on CRC cells, it remains unclear whether this is via direct actions on specific proteins or 
whether it exerts up-stream actions which lead to changes in cell cycle. Since it may be impractical to 
conduct assays on a large number of proteins within four main signalling pathways identified in 
Chapter 8, an alternative approach would be to conduct computer-based virtual molecular docking 
studies (Kirkpatrick, 2004) on multiple proteins to determine likely ligand-receptor interactions 
followed by specific ligand binding assays. As mentioned earlier, other compounds found in S. 
flavescens require further testing both singly and in combinations, so virtual molecular docking may 
be an efficient approach to selecting short lists of compounds and target proteins for use in future 
assays. Promising pathways related to proliferation and tumour growth in CRC include: WNT 
signalling, MAPK signalling, TGF-β signalling, and p53 signalling (The Cancer Genome Atlas 
Network, 2012). Future studies could investigate the effects of Sophora alkaloids and flavonoids on 
the protein components of these pathways. 
In addition to cell-line experiments, testing in in vivo models is required. Such models include 
xenografts of CRC cell lines in nude mice and more recent orthotopic models in which the tumour is 
located in the mouse colon. Such models enable more realistic estimations of dose-response effects as 
well as measures of protein and gene expression (Mittal, 2015). 
Besides its effects on cell cycle, the analysis in Chapter 8 suggest that matrine and other compounds 
may affect cancer progression via effects on mutant p53, down regulation of angiogenesis via VEGF 
signalling and/or tight junction proteins. In addition, the possible roles of matrine and other 
compounds in regulating the inflammatory microenvironment suggest it may be able to play a role in 
the prevention of cancer or its recurrence. 
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Another avenue for further research is to follow-up the results of the meta-analyses and sensitivity 
analyses for neutropenia and to investigate the possible mechanisms of action of certain HMs and their 
constituent compounds on the hemopoietic system. 
9.9 Conclusions 
This series of studies suggests that in randomised controlled clinical trials of CRC a number of herbal 
medicines have shown beneficial effects on tumour response when combined with conventional 
chemotherapies. In addition, the addition of certain herbal medicines to chemotherapies, notably 
oxaliplatin-based chemotherapies, have shown reductions in chemotherapy-related adverse events 
including nausea and vomiting and neutropenia. For each of these outcomes, there are supportive 
experimental studies which have demonstrated relevant bioactivities in cell and animal models for 
specific compounds contained in the herbs used frequently in the clinical trials. Furthermore, a series 
of experiments of the alkaloid matrine (derived from S. flavescens) showed that it produced apoptotic 
effects in CRC cell lines which may at least partially explain the effects of the herb ku shen on tumour 
response rate in the clinical trials. Moreover, by investigating the research evidence on matrine and 
other compounds derived from S. flavescens, the likely mechanisms of action of this herb as an anti-
cancer agent were elucidated and directions for future experimental research were identified. 
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Appendix A. TNM Staging System 
Table A. Comparison between TNM Staging System and the 6th and 7th Editions of the 
AJCC Cancer Staging Manual 
TNM stage AJCC-6 AJCC-7 
I 
T1N0M0 T1N0M0 
T2N0M0 T2N0M0 
IIA  T3N0M0  T3N0M0 
IIB T4N0M0  T4aN0M0 
IIC NA  T4bN0M0* 
IIIA 
T1N1M0  T1N1/1cM0 
T2N1M0  T2N1/1cM0 
NA  T1N2aM0ᶧ 
IIIB  
T3N1M0  T3N1M0 
T4N1M0  T4bN1M0 
NA  T1N2bM0ᶧ 
NA T2N2a-bM0ᶧ 
NA  T3N2aM0ᶧ 
IIIC  
T1N2M0  T4aN2aM0 
T2N2M0  T3N2bM0 
T3N2M0  T4aN2bM0 
T4N2M0 T4bN2M0 
NA  T4bN1M0* 
IVA Any T any N M1 Any T any N M1a 
IVB NA  Any T any N M1b* 
AJCC, American Joint Committee on Cancer; AJCC-6, AJCC Cancer Staging Manual, 6th edition; AJCC-7, AJCC Cancer 
Staging Manual, 7th edition; NA, not applicable. T4a: Tumor invades the surface of the visceral peritoneum; T4b: Tumor 
directly invades or is histologically adherent to other organs or structures; N1a: metastasis in 1 regional node; N1b: 
metastasis in 2–3 nodes; N1c: T1-2 lesions that lack regional lymph node metastasis but exhibit tumor deposit(s); N2a: 
metastasis in 4–6 nodes; N2b: metastasis in 7 or more nodes; M1a: single metastatic site; M1b: multiple metastatic sites (Gao 
et al., 2013). *staging upgrades; ᶧstaging downgrades (Hari et al., 2013). 
Appendix B: Search Strategies 
Searches were conducted of the major international biomedical databases: PubMed, Cochrane 
CENTRAL, CINAHL, ScienceDirect and PsycINFO; and the major Chinese language databases: 
China Academic Journals (CNKI) and Chinese Sci &Tech Journals (CQVIP).  
Search terms were divided into three groups:  
1). Disorder: colorectal cancer and related terms;  
2). Intervention: Chinese medicine, herbal medicine and related terms;  
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3). Study type: controlled trial, randomised and related terms.  
Individual terms were linked by the Boolean operator “OR”. Then, the three groups of terms were 
combined using the “AND” operator to limit the retrieved articles to those that were related to clinical 
trials, colorectal cancer and HM. 
No limits were imposed. Publication dates were from the inceptions of the respective databases to 
the present. The search strategies for each of the electronic databases are detailed below. 
B1. PubMed search strategy 
The PubMed website was accessed through the RMIT library. The ‘advanced search’ interface 
was selected with no limits on fields. The search proceeded as below: 
A. Search to identify RCTs: This part follows the Cochrane Handbook (Higgins and Green, 
2006), appendix 5b.3. 
#1. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled 
trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh]) 
NOT (animals [mh] NOT humans [mh]) 
#2. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled 
trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] 
OR mhclinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* 
[tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR 
placebo* [tw] OR random* [tw] OR research design [mh:noexp]) NOT (animals [mh] NOT humans 
[mh]) 
#3. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled 
trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] 
OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] 
OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* 
[tw] OR random* [tw] OR research design [mh:noexp] OR follow-up studies [mh] OR prospective 
studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT 
humans [mh]) 
B. Search to identify studied disease. 
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#4. "colorectal neoplasms"[MeSH Terms] OR ("colorectal"[All Fields] AND "neoplasms"[All 
Fields]) OR "colorectal neoplasms"[All Fields] OR ("colorectal"[All Fields] AND "carcinoma"[All 
Fields]) OR "colorectal carcinoma"[All Fields] OR ("colorectal"[All Fields] AND "cancer"[All 
Fields]) OR "colorectal cancer"[All Fields] 
#5. "colonic neoplasms"[MeSH Terms] OR ("colonic"[All Fields] AND "neoplasms"[All Fields]) 
OR "colonic neoplasms"[All Fields] OR ("colonic"[All Fields] AND "carcinoma"[All Fields]) OR 
"colonic carcinoma"[All Fields] OR ("colonic"[All Fields] AND "cancer"[All Fields]) OR "colonic 
cancer"[All Fields] 
#6. "rectal neoplasms"[MeSH Terms] OR ("rectal"[All Fields] AND "neoplasms"[All Fields]) OR 
"rectal neoplasms"[All Fields] OR ("rectal"[All Fields] AND "carcinoma"[All Fields]) OR "rectal 
carcinoma"[All Fields] OR ("rectal"[All Fields] AND "cancer"[All Fields]) OR "rectal cancer"[All 
Fields] 
#7. "intestinal neoplasms"[MeSH Terms] OR ("intestinal"[All Fields] AND "neoplasms"[All 
Fields]) OR "intestinal neoplasms"[All Fields] OR ("bowel"[All Fields] AND "cancer"[All Fields]) 
OR "bowel cancer"[All Fields] 
#8. ("intestine, large"[MeSH Terms] OR ("intestine"[All Fields] AND "large"[All Fields]) OR 
"large intestine"[All Fields] OR ("large"[All Fields] AND "intestinal"[All Fields]) OR "large 
intestinal"[All Fields]) AND ("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR 
"cancer"[All Fields]) 
#9. "sigmoid neoplasms"[MeSH Terms] OR ("sigmoid"[All Fields] AND "neoplasms"[All 
Fields]) OR "sigmoid neoplasms"[All Fields] OR ("sigmoid"[All Fields] AND "cancer"[All Fields]) 
OR "sigmoid cancer"[All Fields] 
C. Search to identify evaluated intervention (i.e. herbal medicine): 
#10. "medicine, east asian traditional"[MeSH Terms] OR ("medicine"[All Fields] AND "east"[All 
Fields] AND "asian"[All Fields] AND "traditional"[All Fields]) OR "east asian traditional 
medicine"[All Fields] OR ("medicine"[All Fields] AND "east"[All Fields] AND "asian"[All Fields] 
AND "traditional"[All Fields]) OR "medicine, east asian traditional"[All Fields] 
#11. "herbal medicine"[MeSH Terms] OR ("herbal"[All Fields] AND "medicine"[All Fields]) OR 
"herbal medicine"[All Fields] 
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#12. "medicine, chinese traditional"[MeSH Terms] OR ("medicine"[All Fields] AND 
"chinese"[All Fields] AND "traditional"[All Fields]) OR "chinese traditional medicine"[All Fields] 
OR ("traditional"[All Fields] AND "chinese"[All Fields] AND "medicine"[All Fields]) OR "traditional 
chinese medicine"[All Fields] 
#13. "complementary therapies"[MeSH Terms] OR ("complementary"[All Fields] AND 
"therapies"[All Fields]) OR "complementary therapies"[All Fields] OR ("complementary"[All Fields] 
AND "medicine"[All Fields]) OR "complementary medicine"[All Fields] 
#14. ("Medicine, East Asian Traditional "[MeSH Terms] OR ("East Asian"[All Fields] AND 
"continental"[All Fields] AND "ancestry"[All Fields] AND "group"[All Fields]) OR "asian continental 
ancestry group"[All Fields] OR "chinese"[All Fields]) AND ("herbal medicine"[MeSH Terms] OR 
("herbal"[All Fields] AND "medicine"[All Fields]) OR "herbal medicine"[All Fields]) 
D. combination of the above three searches 
#15. #3 AND (#4or #5 or #6 or #7 or #8 or #9) AND (#10 or #11 or # 12 or #13 or #14) 
The resultant citations were downloaded to an Endnote file. 
B2. CENTRAL search strategy 
The Cochrane Library website was accessed through RMIT library. The Cochrane Central 
Register of Controlled Trials (Trials; CENTRAL) database was selected. The advanced search model 
was used. The search strategy was as follows: 
A. The search strategy to identify colorectal cancer was based on that used in the review by Wu et 
al (2005) as follows: 
#1. COLONIC-NEOPLASMS*: ME 
#2. RECTAL-NEOPLASMS*: ME 
#3. (#1 or #2) 
#4. ((((COLORECT* near CANCER) or NEOPLASM*) OR CARCINOM*) OR ADENOM*) 
#5. ((((COLO* near CANCER) or NEOPLASM*) OR CARCINOM*) OR ADENOM*) 
#6. ((((RECT* near CANCER) or NEOPLASM*) OR CARCINOM*) OR ADENOM*) 
#7. ((#4 or #5) or #6) 
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#8. (#3 or #7) 
B. Search strategy to identify herbal medicine: 
#9. Chinese traditional medicine*: ME 
#10. (herb* or drug*) 
#11. ((herb* or medic*) near tradition*) 
#12. (#10 or #11) 
#13. (#9 or #12) 
C. Combination of the above two searches 
#14. (#8 and #13) with a restriction to clinical trials. 
The resultant citations were downloaded to an Endnote file. 
B3. ScienceDirect search strategy 
The ScienceDirect (Elsevier) website was accessed through RMIT library. The advanced search 
interface was selected with ‘Explore all sources’. The search strategy was as follows: 
#1. Chinese herbal medicine or herbal drug or traditional medicine 
#2. plant medicine or phytotherapy 
#3. #1 or # 2 
#4. random* or controlled trials or clinical trials 
#5. blind* or placebo* 
#6. #4 or #5 
#7. colorectal cancer or colorectal tumour or colorectal carcinoma 
#8. large bowel cancer 
#9. rectal cancer or rectal tumour or rectal carcinoma 
#10. colon cancer or colon tumour or colon carcinoma 
#11. #7 or #8 or #9 or #10 
   
321 
#12. #3 and #6 and #11 
The resultant citations were downloaded to an Endnote file. 
B4. CINAHL search strategy 
CINAHL with the Full Text (EBSCO host) interface was accessed through RMIT library. The 
advanced search model with Boolean/Phrase modes was selected. No limits were placed on results. 
Searches included both Mesh terms (MH) and text terms (TX). The search strategy was as below: 
#1. colorectal neoplasms. MH 
#2. colonic cancer or rectal cancer or colorectal cancer or large bowel cancer. TX 
#3. #1 or #2 
#4. medicine, herbal MH or medicine, chinese traditional MH or functional food MH 
#5. chinese herbal medicine or herbal drug or traditional medicine. TX 
#6. #4 or #5 
#7. clinical trial MH 
#8. randomised controlled trial or blinding or placebo. TX 
#9. #7 or #8 
#10. #3 and #6 and #9 
The resultant citations were downloaded to an Endnote file. 
B5. PsycINFO (ProQuest) search strategy 
The PsycINFO database via ProQuest interface was accessed through RMIT library, and 
‘advanced search’ was selected. No limit was placed on the settings. The following the search strategy 
as used: 
#1. colorectal cancer or colorectal neoplasms or colorectal tumour or colonic cancer or colonic 
neoplasms or colonic tumour or rectal cancer or rectal neoplasms or rectal tumour 
#2. Chinese herbal medicine or traditional medicine or herbal drug or plant medicine or 
phytotherapy or complementary medicine or complementary therapy 
#3. random* or randomised trial or randomised controlled trial or blind* or single blind or double 
blind or placebo* 
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#4. #1 and #2 and #3 
The resultant citations were downloaded to an Endnote file. 
B6. CNKI search strategy 
CNKI was accessed via Google at www.CNKI.net and a log-in was used. Advanced search was 
selected. No limit was placed on the settings. The following is an English translation of the search 
strategy that was used: 
#1. Search terms: (((( (key word=Chinese-English explode (colon cancer) or key word= Chinese-
English explode(rectal cancer))) or (key word=Chinese-English explode(large bowel cancer) or key 
word=Chinese-English explode( colorectal cancer))) and (key word=Chinese-English explode 
(integrated medicine) or key word=Chinese-English explode (Chinese medicine))) or (key 
word=Chinese-English explode(Chinese herbal medicine) and key word=Chinese-English 
explode(clinical trials))) (precisely match). 
#2. Search model: multi-sources search. 
The resultant citations were downloaded to an Endnote file, and see below for the Chinese terms: 
检 索条件：(((( (关键词=中英文扩展(结肠癌) 或者 关键词=中英文扩展(直肠癌))) 或者 
(关键词=中英文扩展(大肠癌) 或者 关键词=中英文扩展(结直肠肿瘤))) 并且 (关键词=中英文
扩展(中西医结合) 或者 关键词=中英文扩展(中医))) 或者 (关键词=中英文扩展(中药) 并且 关
键词=中英文扩展(临床研究))) (精确匹配) 
检索方式：跨库检索; 检索到:878条记录 数据库：中国学术期刊网络出版总库,中国重要
会议论文全文数据库,中国专利数据库,国家标准全文数据库,中国行业标准全文数据库,国外标准
数据库,国家科技成果数据库,德国SPRINGER公司期刊数据库,TAYLOR期刊数据库,Earthscan期
刊数据库; 
B7. CQVIP search strategy 
CQVIP was accessed via Google at www.CQVIP.com and a log-in was used. Advanced search 
was selected. No limit was placed on the settings. The following is an English translation of the search 
strategy that was used: 
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(Keyword C = large bowel cancer + rectalcancer + colon cancer)* (Keyword C = Chinese 
medicine + integrated medicine + kampo medicine + Chinese herbal medicine) - (Keyword C = animal 
study) 
The resultant citations were downloaded to an Endnote file, and see below for the Chinese terms: 
(Keyword_C=大肠癌+直肠癌+结肠癌)*(Keyword_C=中医+中西医结合+汉方医+中药)-
(Keyword_C=动物实验) 
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Appendix C. Outcome Measurements 
C1. WHO definitions of objective response in solid tumours (Miller et al., 1981) 
Measurable disease:  
• Complete response (CR) - The disappearance of all known disease, determined by two 
observations not less than four weeks apart. 
• Partial response (PR) - 50% or more decrease in total tumour load of the lesions that 
have been measured to determine the effect of therapy by two observations not less 
than four weeks apart. Bidimensional: single lesion, greater than or equal to 50% 
decrease in tumour area (multiplication of longest diameter by the greatest 
perpendicular diameter); multiple lesions, a 50% decrease in the sum of the products 
of the perpendicular diameters of the multiple lesions. Unidimensional: greater than or 
equal to 50% decrease in linear tumour measurement. In addition there can be no 
appearance of new lesions or progression of any lesion. 
• No change (NC) - A 50% decrease in total tumour size cannot be established nor has a 
25% increase in the size of one or more measurable lesions been demonstrated. 
• Progressive disease (PD) - 25% or more increase in the size of one or more 
measurable lesions or the appearance of new lesions. 
C2. RECIST guideline (version 1.1) for solid tumours (Eisenhauer et al., 2009) 
Response criteria 
This section provides the definitions of the criteria used to determine objective tumour 
response for target lesions. 
• Complete Response (CR): Disappearance of all target lesions. Any pathological lymph 
nodes (whether target or non-target) must have reduction in short axis to <10 mm. 
• Partial Response (PR): At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters. 
• Progressive Disease (PD): At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one 
or more new lesions is also considered progression). 
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 
study 
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Table C1. WHO recommendations for grading of acute and subacute toxicity (Miller et 
al., 1981) 
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From: Miller et al., 1981 
Table C2. Karnofsky Performance Status Scale (KPS) (Yates et al., 1980) 
 
From: Yates et al., 1980
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Appendix D. Risk of Bias Assessment  
Table D. Risk of bias domains and judgment criteria  
Bias Authors' judgement criteria 
Random sequence generation 
(selection bias) 
Low risk: used computer generated random numbers, or random 
number table, or coin tossing or similar.  
Unclear risk: insufficient information or not reported. 
High risk: used other inadequate methods e.g. date of birth, date of 
admission, number of record. 
Allocation concealment 
(selection bias) 
Low risk: central allocation, sequentially numbered, opaque, sealed 
envelopes. 
Unclear risk: insufficient information or not reported. 
High risk: open random allocation or similar. 
Blinding of participants and 
personnel (performance bias) 
Low risk: blinding or no blinding, but the outcome is unlikely 
influenced by lack of blinding. 
Unclear risk: insufficient information or not reported. 
High risk: no blinding and the outcome could be influenced by lack of 
blinding. 
Incomplete outcome data 
(attrition bias) 
Low risk: no missing outcome data or missing data is addressed 
properly. 
Unclear risk: insufficient information or not reported. 
High risk: missing data and is not addressed properly. 
Selective reporting (reporting 
bias) 
Low risk: study protocol is available or outcomes are reported in non-
selected way. 
Unclear risk: insufficient information or not reported. 
High risk: selectively reported outcomes or incompletely reported. 
Other bias Low risk: baseline data is balanced and appears to be free of other 
potential bias. 
Unclear risk: insufficient information or not reported. 
High risk: imbalanced baseline or other potential bias. 
Adapted from: Higgins and Green, 2011 
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Appendix E. Characteristics of Studies Included in Chapter 4 and Risk of Bias summary 
Table E1. Characteristics of Group 1 studies: herbal medicine (HM) vs. chemotherapy or no treatment or placebo (11 studies) 
First author (year); 
Sample size T/C; 
Trial duration. 
Gender (M) T/C; 
Age (mean) T/C. 
Stage T/C; 
KPS (mean) T/C. 
Test treatment: 
HM, dosage & administration 
Control treatment: 
Dosage & administration 
Outcome measures; HM adverse 
events 
Gu C (2009); 
24/23; 
01/2006 to 01/2009. 
14/12; 
55.12 ± 13.18/55.16 
± 10.63. 
Dukes A: 13,  
B: 25, C: 9 (all); 
NS. 
Surgery + Xuebijing injection, 
100 mL Xuebijing injection 
diluted with 250 mL 0.9% Nacl 
injection fluid ID, twice per day, 
day1-5 post surgery. 
Surgery + no specified 
treatment. 
T-cell subset: CD4+, CD8+, ratio of 
CD4+/CD8+; 
NS. 
Hou A (2009); 
15/15; 
01/2005 to 12/2006. 
14/13; 
40-59: 9/7 
60-79: 16/18. 
TNM IIIb: 11/9, 
IV:14/16; 
≥50 (all). 
Fuzhengxiaoai decoction-I, one 
decoction daily, for 4 wks. 
Best supportive care. For 4 
wks. 
tRR, mOS, AEs, KPS, TCM 
symptoms; Mild vomiting. 
Li H (2000); 
16/17; 
5/1997 to 12/1998. 
9/10; 
54.65/51.23. 
Dukes B, C (all); 
NS. 
Chang'ai Kangfu decoction 
(CAKF), one decoction daily, for 
3 months. 
5- FU 500mg/ m2 + MMC 
2mg/m2, ID, per course, 
total for 5-FU 5g, MMC 
20mg. 
T-cell subset: CD3+, CD4+, 
CD4+/CD8+; NK cells; 
NS.  
Schink M (2007); 
11/11; 
08/2002 to 09/2004. 
7/5; 
72 ± 8.2/69 ± 10.4; 
 
Dukes B: 6/7, 
C:1/3, D: 4/1; 
76 ± 20.2/80 ± 
15.5. 
Surgery+ Iscador® M special 
injection, 1 mL ‘Iscador® M 
special 5 mg’ in 250 mL saline ID 
during the operation. 
Surgery + no specified 
treatment. 
NK (nature killer) cell activity, 
HLA-DR (human leucocyte antigen-
DR); 
NO. 
Shen H (2003); 
51/50; 
01/1997 to 06/1998. 
29/32; 
52.6/54.2. 
Dukes B: 27/26, C: 
24/24; 
NS. 
Surgery + Changbi'an capsule,4 
capsules/day, for 3 months. 
Surgery + no specified 
treatment. 
3-year OS; 
NO. 
Torisu M (1990); 
56/55; 
Over 13 years. 
NS; 
59.3/58.4. 
Dukes C: 56/55; 
NS. 
Surgery + PSK (YunZhi powder 
Coriolus vesiocolor spores), 
3g daily for 2 months after 
surgery; then 2g daily for 24 
months; 1g daily thereafter.  
Surgery + placebo (identical 
powder). 
3g daily for 2 months after 
surgery; then 2g daily for 24 
months; 1g daily thereafter. 
mTTP; mOS; 
Immune assay;  
Pigmentation of nail, cough when 
taking the PSK, mild diarroea, 
constipation. 
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First author (year); 
Sample size T/C; 
Trial duration. 
Gender (M) T/C; 
Age (mean) T/C. 
Stage T/C; 
KPS (mean) T/C. 
Test treatment: 
HM, dosage & administration 
Control treatment: 
Dosage & administration 
Outcome measures; HM adverse 
events 
Wang H (2000); 
34/42; 
07/1995 to 07/1999 
20/23; 
55/51. 
TNM III:19/17, 
IV: 15/25; 
NS. 
Mutmihui Glycoside Pill; 6 pills 
(1.8g) each time, 3 times/day, for 
4 mths. 
5-FU/LV: LV200mg/m2/day, 
dayl-5, ID, 5-FU 
500mg/m2/day, dayl-5, ID. 
Once mth, for 4 mths. 
tRR, CEA, KPS, 1-, 2-, 3-yrs OS; NS. 
Xion S (2003); 
60/60; 
NS. 
39/36; 
57.2/54.5. 
 
TNM III: 39/37, 
IV: 21/23; 
≥50 (all). 
Changfukang capsule, 
10g/time, tid, for 12 wks. 
5-FU/LV: 5-FU: 
10mg/kg/day, CF 
2mg/kg/day, ID, 5 days/wks, 
3wks/cycle, for cycles. 
tRR, KPS, TCM symptoms, CEA; 
Mild nausea, diarrhoea. 
Yang Y (2005); 
55/55; 
03/1998 to 03/2000. 
34/33; 
37-68/35-71. 
TNM III: 38/36, 
IV: 17/19; 
≥50 (all). 
Changfukang capsule, 
4 capsules/time, tid, for 12 wks. 
5-FU 0.75g / day, ID, 5 days 
/ wks, 3 wks / cycle, for 3 
cycles. 
tRR, KPS, TCM symptoms, T-cell 
subset, CEA; 
NS. 
Yang Y (2007); 
23/21; 
08/2005 to 10/2006. 
14/14; 
55.24 ± 29.38/52.4 ± 
26.72. 
TNM II:15/13, 
III: 8/8; 
≥70. 
(After surgery + chemotherapy) 
Quxie Capsule, 2 capsules bid, 
for 6 months. 
(After surgery + 
chemotherapy) placebo (not 
specified). 
TTP, KPS, AEs, T-cell subset; 
Mild diarrhoea. 
Zhang B (2008); 
30/30; 
NS. 
38 (all); 
57 (all). 
TNM IV (Liver 
metastasis, all); 
≥70. 
Javanica oil emulsion, 100 
mL/m2 TACE, repeated every 4-6 
wks, average 2.5 times.  
OX, 5-FU, HCPT, PDD, 
combination of selected 2-3 
drugs TACE, repeated every 
4-6 wks, average 2.5 times. 
KPS, TACE AEs; 
NS. 
T: treatment group; C: control group; M: male; N: number; NS: not stated; ID: intravenous drip; tRR: tumour response rate; OS: overall survival; mOS: median OS; TTP: time to progress; AEs: adverse 
events; RCT: randomized control trial; KPS: Karnofsky performance scoring; wks: weeks; TACE: transcatheter arterial chemoembolisation; OX: oxaliplatin; HCPT: Hydroxycamptothecine; 5-FU: 5- 
Fluorouracil; LV: leucovorin; MMC: Mitomycin; PDD: Cisplatin; Tid: three times a day; Bid: twice a day; TCM: traditional Chinese medicine; CEA: carcinoembryonic antigen. 
   
330 
 
Table E2. Characteristics of group 2 studies: herbal medicine plus chemotherapy vs. chemotherapy (79 studies) 
First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
Cao B (2011); 
01/2005-
12/2007. 
60/60; 32/33; 
55.2 ± 13.3/58.8 
± 13.7 
IV (all); 
ECOG: 0-1. 
Yiqizhuyu decoction (YZD); one 
decoction per day orally 
administered; up to 48 weeks. 
FOLFOX4; up to 24 cycles (all). tRR, mOS, TTP, AEs 
(neurotoxicity, 
gastrointestinal events, 
and hematologic events); 
NO. 
Cao C (2005); 
NS. 
33/29;20/19; 
52/49 (med) 
IV (all); NS. Shengmai injection; 40 mL, ID, day 
1–7; NS. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 750 mg /m², ID, day1-5, cycle/21 
days; cycle NS. 
tRR, mOS, 1-year OS, 
AEs (gastrointestinal 
events, and hematologic 
events); NS. 
Cazacu M 
(2003); 
1997–2000. 
29/21; NS; NS. Dukes C: 
18/16, Dukes 
D: 11/5; NS. 
Isorel (MistletoeViscum albu) 
5mg/kg, ID, 3 days/week; for whole 
postoperative period. 
5-FU+ LV (either the Mayo or de Gramont protocol); 
6 cycles (all). 
mOS, AEs 
(gastrointestinal events, 
and hematologic events); 
NS. 
Chen X 
(2005); 
2002-2004. 
47/46; 31/32; 
54/53 (med) 
II: 11/12, III: 
21/20, 
IV:15/14; KPS 
≥60 
Composite salviae dripping pill; 
25mg/pill, 10 pills/day; for 3 cycles 
or more. 
FOLFOX: Ox. 130 mg/m² 2hours ID, LV 200mg/m², 
2 hours ID, 5-FU 500mg, bolus, then 3000mg/m² ID 
for 48 hours. 3weeks /cycle; for 3 cycles (all). 
tRR, KPS, BW, AEs 
(neutropenia, 
neurotoxicity, stomatitis), 
IR (CD4+/CD8+); NS. 
Deng D 
(2010); 
05/2009-
01/2010. 
18/18; 9/9; 
54.17±10.04/53.
56±11.10. 
IV(all); KPS 
≥60. 
Yiqixiaoji decoction; one decoction 
per day orally administered; for up 
to 6 weeks. 
XELOX: Ox. 130 mg/m², 2hours ID, day 1; Xel. 850 
mg/ m², bid, for 14 days; 21 days/cycle; for 2 cycles. 
KPS, AEs (neutropenia, 
thrombocytopenia, 
anaemia), CEA; NS. 
Ding X 
(2010); 
9/2007-
8/2008. 
30/30; 18/20; 
64.5/63 (med) 
ACRC; KPS 
≥70 
Co-Kushen injection; 20 mL, ID, 
day 1-7, 14 day/cycle; for 8 cycles. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, LV 200 
mg /m², ID, day 1-2, 5-FU 400 mg /m², bolus, 600 
mg /m², ID, 22 hours, day1-2; 8/8 cycles. 
mOS, TTP, AEs 
(neutropenia, nausea and 
vomiting, neurotoxicity, 
IR (CD3+, CD4+, 
CD4+/CD8+, NK cells); 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
NS. 
Dong J 
(2011); 
01/04/2008-
01/03/2010. 
20/20; 14/13; 
54/51(mean). 
II: 12/15, III: 
8/5; KPS ≥60. 
Yiqijianpi decoction; one decoction 
per day orally administered; for up 
to 6 weeks. 
Xel. 1250 mg/ m²/day, for 14 days; 21 days/cycle; for 
2 cycles (all). 
KPS, AEs 
(myelosupression, 
gastrointestinal reactions, 
liver and kidney 
impairment), IR (CD3, 
CD4/CD8, NKcells); NS 
Fang M 
(2008); 
05/2002-
06/2007. 
48/45; 30/28; 
59.5 ± 11.3/56.4 
± 10.3 
IV (all); KPS 
≥70. 
Javanica oil emulsion injection; 30 
mL, ID, day 1-14 / cycles; for two 
cycles 
FOLFOX4; 2 cycles (all). tRR, KPS, AEs 
(alopecia, neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver 
impairment, stomatitis), 
CEA; NS. 
Guo Z (1999); 
1991-1996. 
38/31; 22/17; 
51.4 ± 6.4/50.8 
± 5.4. 
B: 8/8, C: 
15/11, D: 
15/12 (dukes); 
≥60. 
Fuzheng Yiai decoction, one 
decoction per day; for 16 weeks. 
MeF(V): 5-FU + MeCCNu + Vincristine: 5-FU 500 
mg, ID, day 1-5, MeCCNu 200 mg, oral, day1, 
Vincristine 1mg, ID, day1; 4 cycles. 
1-, 3-, 5-year OS, KPS, 
AEs (alopecia, 
leukopenia, 
thrombocytopenia, liver 
impairment), CEA, IR 
(CD3+, CD4+/CD8+, 
NKcells); NS. 
Hu A (2006); 
01/2001-
12/2005. 
 
28/22; 18/14; 
49.3 ± 4.5/48.5 
± 4.3 
IV (all); KPS 
≥50. 
Treatment with 4 different CHM 
decoctions according to syndrome 
differentiation; one decoction per 
day; for more than 30 days. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-2, 5-FU 2400 mg /m², ID, 46 hours, 
cycle/21 days; for 2 cycles (all). 
tRR, KPS, AEs 
(neutropenia, anaemia, 
nausea and vomiting, 
diarrhoea, neurotoxicity, 
liver impairment); NS. 
Huang Z 
(2002); 
30/30; 22/20; 
46/47(mean). 
Dukes B: 5/11, 
C: 13/9, D: 
Pinxiao capsule; 8 capsules, tid; for 
12 weeks. 
5-FU+LV+ MeCCNu; 5-FU 500 mg/ m², ID, day 1-5, 
LV 100 mg, ID, day1-5, MeCCNu 150 mg /m², day 1, 
tRR, KPS, AEs (alopecia 
n, neutropenia, nausea 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
06/1997-
08/2001. 
15/10; KPS 
≥60. 
4 weeks/cycle; for 2 cycles.  and vomiting, diarrhoea); 
NS. 
Huang Z 
(2005); 
10/2000-
11/2002. 
31/30; 21/21; 
51/52 (mean). 
Dukes B: 5/9, 
C: 12/11, D: 
14/10; KPS 
≥60. 
Jianpixiaoji formula, one decoction 
per day orally administered; for up 
to 12 weeks. 
5-FU + LV + MeCCNu: 5-FU 500mg/ m², ID, day 1-
5, LV 100 mg, ID, day1-5, MeCCNu 150 mg /m², day 
1, 4 weeks/cycle; for 2 cycles. 
tRR, KPS, AEs (alopecia 
n, neutropenia, nausea 
and vomiting, diarrohea); 
NS. 
Huang Z 
(2008); 
05/2004-
12/2007. 
31/30; 20/22; 
51/52.2(mean). 
Dukes B: 4/8, 
C: 12/12, D: 
15/10; KPS 
≥50. 
Bazhen decoction, one decoction 
per day orally administered; for up 
to 16 weeks 
5-FU + LV + MeCCNu: 5-FU 500 mg/ m², ID, day 1-
5, LV 200 mg, ID, day1-5, MeCCNu 150 mg /m², day 
1, 1 wk/cycle, 4 cycles/course; for 1 course. (all) 
tRR, KPS, AEs (alopecia 
n, neutropenia, nausea 
and vomiting, diarrhoea); 
NS. 
Jian X (2005); 
06/1997-
06/2001. 
28/29; 31 (all); 
55.64 (mean, 
all). 
Dukes B: 37, 
C: 17, D: 3 
(all); KPS 
≥60. 
Treatment according to syndrome 
differentiation using 
Shenlingbaizhu formula, 
Shiquandabu wan, Fuzhilizhong 
tang, Sishen wan, Dabuyin wan, 
and Zhibaibawei wan. one 
decoction per day orally 
administered; for 9 wks 
5-FU + LV (no details); 3 wks/cycle; for 3 cycles (all) 1-,2-, 3-year OS, QoL 
(1990 Chinese version), 
AEs (no classified);  
NS. 
Jiang G 
(2013); 
01/2010-
06/2012. 
32/31; 18/18; 
53. 2 ± 12. 4/53. 
1 ± 12.8. 
ACRC; NS. Unnamed multi-CHM formula; one 
decoction per day; for 8 weeks. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-2, 5-FU 400 mg bolus, day 1-2, 2400-3600 
mg /m², ID for 48 hours, 14 days/cycle; for 4 cycles 
(all). 
tRR, QoL (FACT-C); 
NS. 
Kono T 
(2013); 
01/05/2009 
-31/03/2010. 
27/23; NS; 
67/61 (mean). 
NS;ECOG 0–
1 
TJ-107 Goshajinkigan; or placebo 
was administered orally, tid, before 
each meal (7.5 g/day); for 26 weeks 
FOLFOX4, or mFOLFOX6; Ox.85 mg/m², ID, day 1, 
LV 200 mg /m², ID, 5-FU 400 mg bolus, follow 2400 
mg /m², ID for 46 hours, 14 days/cycle; for 8 cycles 
or more (all). 
tRR, AEs (neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
constipation, 
neurotoxicity, liver 
impairment, stomatitis); 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
NO. 
Lao G (2012); 
12/2008-
12/2010. 
30/30; 21/23; 
35.1 ± 20.2/36.7 
± 20.1. 
II: 5/7, III: 
15/14, 
IV:10/9; KPS 
≥60 
Jianpijiedu decoction; one 
decoction per day, 21 days /cycle; 
for two cycles. 
FOLFOX; Ox.130 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1, 5-FU 500 mg bolus day 1, 2400 mg /m², 
ID, 48 hours, day 1-2, 21 days /cycle; 2 cycles (all) . 
tRR, TTP, AEs 
(neutropenia, 
thrombocytopenia, 
nausea and vomiting, 
neurotoxicity); NS. 
Li H (2000); 
05/1997-
12/1998. 
15/17; 8/10; 
56.31/51.23. 
II&III: 15/17 
(all); NS. 
Chang’ai Kangfu decoction; one 
decoction per day; for 12 weeks. 
5-FU + MMC; 5-FU 500 mg/ m2, ID, 1-2/week, 
5g/cycle; MMC 2mg/ m2, ID, 1-2/week, 20mg/cycle; 
NS. 
IR (CD3+, CD4+/CD8+, 
NK); NS. 
Li H (2007); 
10/2002-
02/2006. 
 
65/52; 43/36; 
58/59 (med). 
III: 27/19, IV: 
38/33; KPS 
≥60 
Aidi injection; 60 mL, ID, day 1-
10, 14days/cycle; for 11weeks. 
FOLFOX4; 5.5/5.5 cycles (mean). tRR, med. OS, 1-year 
OS, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
constipation, 
neurotoxicity, liver and 
kidney impairments, 
stomatitis); NS. 
Li Y (1999); 
1991-1995. 
60/36; 38/23; 
54.2/53.4(mean) 
III: 16/9, IV: 
44/27; NS. 
HM decoction 100 mL enama, once 
day; for 8 weeks. 
5-FU 1000mg + Dexamethasone 5 mg (intrperitoneal 
infusion) & MMC 6-8 mg (ID), once week, 5 
cycles/course; for 2 courses. 
tRR, 1- , 2-, 3-year OS. 
Li Y (2007); 
01/2005-
04/2006. 
20/18; 22 (all); 
72.2 (med, all) 
III: 15, IV: 23 
(all); KPS ≥60 
Wenshenjianpi decoction; one 
decoction per day; for median 10-
12 weeks 
FOLOFOX4; 6/5.5 cycles (med.). tRR, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver 
impairment); NS. 
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Liang Q 
(2009); 
10/2005-
10/2007. 
76/76; 50/51; 
53/52 (med) 
III: 45/46, IV: 
31/30; KPS 
≥60 
Shenqifuzheng injection; 250 
mL/day, ID, 3 weeks/cycle; for 2 
cycles 
FOLFOX: Ox. 130 mg/m² 2 hours, ID, day 1, LV 200 
mg/m², 2 hours, ID, day1, 5-FU 500 mg, bolus, day1, 
then 3000 mg/m², ID, for 48 hours. 3weeks /cycle; 
for 2 cycles (all). 
tRR, med OS, KPS, BW, 
AEs (neutropenia), IR 
(CD4+/CD8+); NS. 
Lim M 
(2012); 
NS. 
24/23; 17/14; 
56.89 ± 14.77/ 
55.37 ± 16.01 
III: 15/16, IV: 
9/7; KPS ≥70 
Pianzaihuang capsule; two 
capsules, bid; 14 days/cycle; 8-10 
cycles. 
FOLFOX4; 8-10/8-10 cycles (all). tRR, KPS, AEs 
(neutropenia, nausea and 
vomiting, neurotoxicity, 
liver impairment, 
stomatitis); NS. 
Liu H (2009); 
01/2004-
12/2007. 
36/34; 16/18; 
50.2 (mean) 
ACRC (all); 
KPS ≥60 
Kang’aifangyi pian; one decoction 
per day, 21 days / cycle; for 3 
cycles. 
FOLFOX; Ox.130 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 300 mg /m², ID, day 1-5, 21 
days/cycle; 3 cycles (all).  
tRR, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver and 
kidney impairments, 
stomatitis), IR 
(CD4+/CD8+, NKcells); 
NS. 
Liu H (2013); 
01/2008-
01/2009. 
30/30; 12/13; 
53.83 ± 8.52/ 
53.63 ± 8.14. 
II: 7/5, III: 
23/25; NS. 
CHM formula; one decoction 
administered orally per day, for 30 
days; CHM enema formulae 100-
150 mL, enema, once every second 
day; for 14 times. 
5-FU + LV; 5-FU 600mg/ m², ID, day 1-5, LV 
200mg/m², ID, day1-5; for 4 cycles (all). 
KPS, AEs (nausea and 
vomiting, stomatitis), IR 
(CD4+, CD8+, 
CD4+/CD8+, NK cells); 
NS. 
Liu J (2000); 
1989-1996. 
96/58; 74/44; 
46/44 (mean). 
II: 12/7, III: 
36/23, IV: 
48/28; NS. 
Pi-shen feng decoction 
administered orally per day; for 6 
weeks. 
5-FU (750mg) + MMC (6mg) + ADM (50mg, week 1 
and week 4), ID, once week, 4 weeks/cycle; NS.  
AEs (neutropenia, 
thrombocytopenia, 
nausea and vomiting, 
diarrhoea), 1-, 3-, 5-year 
OS; NS. 
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Liu J (2005b); 
2002-2003. 
52/26; 24/12; 
63.11 ± 
11.89/62.78 ± 
11.04 
IV (all); KPS 
≥50. 
Jianpihuoxue formula; one 
decoction per day, 30 days/ cycle; 
for 3 cycles. 
FOLFOX; Ox.150 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 500 mg /m², ID, day 1-5, 30 days/ 
cycle; 3 cycles (all). 
tRR, IR (CD3+, CD4+, 
CD8+, CD4+/CD8+, 
NKcells); NS. 
Liu J (2005a); 
2002-2003. 
43/21; 23/10; 
61.52 ± 10.12 
/60.11 ± 9.78 
IV (all); KPS 
≥50. 
Jianpihuoxue formula; one 
decoction per day, 30 days/ cycle; 3 
cycles. 
FOLFOX; Ox.150 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 500 mg /m², ID, day 1-5, 30 days/ 
cycle; 3 cycles (all). 
tRR, AEs (alopecia 
neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver and 
kidney impairments); 
NS. 
Liu W (2011); 
05/2003-
05/2010. 
16/16; 11/10; 
51/52 (mean). 
IV (all); 
KPS 40-60. 
Yierkang capsule: 4-6 capsules, bid; 
5-25 months. 
FOLFOX; Ox.130 mg/m², ID, day 1, LV 100 mg /m², 
ID, day 1-5, 5-FU 400 mg /m², ID, day 1-5, 21 days/ 
cycle; 6 cycles (all). 
Med. OS, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
nausea and vomiting, 
diarrhoea, neurotoxicity); 
NS. 
Lu Q (2010); 
05/2007-
12/2007. 
20/20; 13/11; 
51.00 ± 
11.84/54.15 + 
12.83 
III: 14/13; IV: 
6/7; KPS≥60. 
Fuzheng kang'ai formula; one 
decoction per day; for 6 weeks. 
FOLFOX; Ox.200 mg/m², ID, day 1, LV 300 mg/m², 
ID, day 1-5, 5-FU 120 mg/m², ID, day 1-5, 21 days/ 
cycle; 2 cycles (all). 
KPS, IR (CD3+, CD4+, 
CD8+, CD4+/CD8+, NK 
cells); NS. 
Ma J (2005); 
02/1999-
02/2003. 
28/25; 15/13; 
58.1/57.5 
(mean) 
II: 7/4,  
III: 21/21; 
KPS ≥60. 
Jianpi xiaoliu decoction; one 
decoction per day, 90 days/ cycle; 2 
cycles. 
FOLFOX; Ox.130 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 375 mg /m², ID, day 1-5, 21 days / 
cycle; 6/6 cycles (all). 
1-, 2-, 3-year OS, KPS, 
AEs (neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, 
stomatitis); NS. 
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Ma M (2010); 
06/2006-
06/2009. 
20/20; NS; 
median 61 (all). 
Dukes A: 8, B: 
10, C: 15, D: 7 
(all); NS. 
Aidi injection; 40 mL, ID, per day, 
21days/cycle; for 2 cycles. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 400 mg /m², ID, day 1-5, 21 days / 
cycle; for 2 cycles (all). 
KPS, CD4+/CD25+ 
Treg; NS. 
Mao X 
(2005); 
03/2002-
03/2004. 
46/33; 48 (all); 
45 (mean, all). 
NS; KPS≥60. Decoction of Costus (aucklandia) 
and Amomum with Six Noble 
Ingredients, once day; Shen ma 
injection 50 mL/day, ID; for 4 
weeks. 
LV 200 mg /m², ID, day 1-5, 5-FU 600 mg /m², ID, 
day 1-5; for 4 weeks 
KPS, BW, AEs (nausea 
and vomiting, 
myelosupression, liver 
impairment); 
NS. 
Meng Z 
(2003); 
NS. 
20/19; 24 (all); 
56.7 ± 13.6 (all) 
Dukes D (all); 
KPS ≥70. 
Sijunzhi decoction; one decoction 
per day; for 4 weeks. 
TACE; 5-FU 1000mg, Cisplatin 60 mg, Pirarubicin 
60-80 mg; 2.7 time procedure /per patient (mean) 
tRR, mOS,1-, 2-, 3-year 
OS, QoL (EORTC QLQ-
C30 V3.0); NS. 
Pan M (2003); 
1994-1997. 
43/40; 28/24; 
47.5/47 (mean). 
I: 6/5, II: 
22/20, III: 
15/15; NS. 
Yiqitiaofu Decoction; one 
decoction per day; for 6 weeks. 
LV+5-FU; LV 100 mg, ID, day1-5, 5-FU 500 mg, ID, 
day1-5, 21days/cycle; for 2 cycles. 
1-, 3-, 5-yr OS, 5-year 
DFS, KPS; NS. 
Qian Y 
(2009); 
01/2004-
04/2008. 
40/30; 48 (all); 
54 (mean, all). 
Dukes B: 21, 
C: 49 (all); 
KPS ≥70. 
Jianpi CHM; one decoction per 
day; for 616 days (mean) 
FOLFOX: Ox.100 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1, 5-FU 400 mg /m² bolus, and 2400 mg, ID 
46 hours, day 1, 14 days / cycle; for 6 cycles (all). 
DFS, KPS;  
NS. 
Qin Y (2011); 
01/2001-
08/2007. 
36/37; NS; NS.  ACRC; NS Fuzhengguban decoction; one 
decoction per day, 21 days/ cycle, 2 
cycles. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-2, 5-FU 2400 mg /m², ID, for 48 hours, 21 
days/ cycle, 2 cycles (all). 
tRR, mOS,1-,2-, 3-year 
OS, KPS, AEs (%), IR 
(CD4/CD8, NK cells); 
NS. 
Qiu Z (2011); 
01/2005-
08/2009. 
22/21;14/13; 
56.9/52.7 (med) 
IV (all); KPS 
≥60. 
 
Kang’ai injection; 40 mL, ID, day 
1–10, 14 days/cycle; for four cycles 
FOLFOX4; for 4 cycles (all). tRR, KPS, AEs 
(neutropenia, nausea and 
vomiting); NS.  
Song W 
(2012); 
10/2008-
07/2010 
20/20; 12/13; 
56.4 ± 9.1 /48.3 
± 8.2 
ACRC; KPS 
≥70. 
Xiaoliuhuajichang fang II; one 
decoction per day, 21 days/cycle; 2 
cycles. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 200mg /m², 
ID, day 1-2, 5-FU 2400 mg /m², ID, for 48 hours, 21 
days/ cycle; 2 cycles (all). 
tRR, KPS, AEs 
(neutropenia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver 
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impairment); IR (CD3+, 
CD4+, CD8+, NK cells); 
NS. 
Tang X 
(2009); 
04/2002-
12/2007. 
30/30; 16/14; 
46.1/45.5 
(mean) 
NS; KPS ≥60. Yiqijianpi CHM; one decoction per 
day; for 8 weeks. 
FOLFOX4; for 4 cycles (all). Thrombocytopenia; NS. 
Tao C (2013); 
02/2008-
02/2010. 
74/74; 51/50; 
60.1 ± 7.9 /60.4 
± 8.9. 
ACRC; KPS 
65.6 ± 
12.3/66.7 ± 
14.5 
Co-kushen injection; 15 mL per 
day, ID, started 14 days before 
chemotherapy, 5 weeks/cycle; for 1 
cycle. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 200 mg/m², 
ID, 2 hours, day 1-5, 5-FU 500 mg/m² ,ID, 8-10 
hours, day1-5, 3 weeks/cycle; for 1 cycle (all). 
tRR, AEs (neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, neurotoxicity, 
stomatitis); NS. 
Wan H 
(2013); 
01/2008-
12/2011. 
30/30; 
35(all);51.7 
(mean, all). 
III: 40(all), IV: 
20(all); KPS 
≥60. 
Kushen injection 40 mL, ID, and 
Huangqi injection 20 mL, ID, per-
day, 10 days/cycle; for 6 cycles. 
FOLFOX; Ox.100 mg/m², ID, day1,  LV 200 
mg/m², ID,  5-FU 15-20 mg/kg, ID, day 1-5, 21 
days/ cycle; for 6 cycles (all). 
tRR, 2-year OS, KPS; 
NS. 
Wang C 
(1999); 
01/1992-
12/1997. 
46/40; 35/23; 
49/53 (mean). 
I: 4/5, II: 
18/14, III: 
13/12, IV: 
11/9; NS. 
HMs decoction 70 mL enema; for 7 
days before operation. 
5-FU 20mg/kg enema; for 7 days before operation. IR (CD3+, CD4+, CD8+, 
NK cells), 1-, 3-, 5-year 
OS; NS 
Wang D 
(2012); 
01/2006-
05/2011. 
49/49; 58(all); 
54.5 (mean, all). 
ACRC; KPS 
≥60. 
Unnamed multi-TM formula; one 
decoction per day; duration NS. 
FOLFOX; Ox.120 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 300 mg /m², ID, day 1-5, 21 days/ 
cycle; cycle NS.  
tRR, KPS; NS. 
Wang H 
(2000); 
07/1995-
071999. 
56/42; 
34/23;53/51 
(mean) 
III: 25/17, IV: 
31/25; NS. 
Mutmihui GlycosidePil; 1.8 g each 
time, tid; for 4 months. 
LV+5-FU; CF 200 mg/m2/day, dayl-5, ID, 5-FU 500 
mg/m2/day, dayl-5, ID. Once month; for 4 months. 
tRR, CEA, KPS, 1-, 2-, 
3-year OS; NS. 
Wang H 34/34; 20/22; IV: 34/34; Yiqiguoxiebuchang decoction; one FOLFOX: Ox.85 mg/m², ID, day 1, LV 200 mg/m², tRR, AEs (alopecia, 
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(2008); 
06/2001-
12/2006. 
52.58 ± 
8.12/51.11 ± 
7.72 
KPS ≥50. decoction per day; for 3 months.  ID, day 1-2, 5-FU 500 mg bolus day 1, 5-FU 2500 
mg/m², ID, for 48 hours, 21 days/ cycle; 4 cycles 
(all). 
neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver and 
kidney impairments); 
NS. 
Wang J 
(2011); 
03/2007-
02/2O11. 
30/30; 18/21; 
52.3 ± 6.2/ 56.7 
± 7.8. 
ACRC; KPS 
≥60. 
Yichangning decoction; one 
decoction per day; for 2 months. 
FOLFOX4; 21 days /cycle; for two cycles (all). tRR, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver 
impairment, stomatitis); 
NS. 
Wang Y 
(2012); 
03/2007-
03/2010. 
38/36; 26/25; 
52 (mean all). 
ACRC; KPS 
≥70. 
Aidi injection; 80 mL, ID, per day, 
10 days/cycle; for 4 cycles 
FOLFOX4; for 4 cycles (all). tRR, KPS, AEs 
(neutropenia, 
gastrointestinal reactions, 
neurotoxicity); NS. 
Wang Y 
(2013); 
08/2008-
08/2012. 
32/30; 20/19; 
NS. 
ACRC; KPS 
≥70. 
Xiaoaiping injection; 60 mL, ID, 
per day, 14 days/cycle; for two 
cycles. 
XELOX; no details; for two cycles (all). tRR, KPS, AEs 
(neutropenia, 
gastrointestinal reactions, 
neurotoxicity); NS. 
Wang Z 
(2007); 
09/2003-
07/2005. 
34/33; 47 (all); 
55 (mean all). 
ACRC; KPS 
≥60. 
Delisheng injection; 40-60 mL, ID 
per day, 15 days/cycle; for 3 cycles. 
FOLFOX; Ox. 130 mg/m², 2 hours ID, day 1 ,LV 200 
mg/m², 2 hours ID, day1-5,5-FU 500 mg/m², ID 
day1-5, 3 weeks/cycle; for 3 cycles (all). 
mOS, tRR, AEs 
(myelosupression, 
gastrointestinal events);  
NS. 
Wu G (2010); 
10/2004-
33/25; 23/17; 
55.4 ±13.6 /52.8 
I: 5/3, II:10/8, 
III: 15/11, IV: 
Fupiyiwei decoction; one 
decoction per day; for 24 weeks. 
FOLFOX4; 12/12 cycles (all). tRR, KPS, AEs 
(neutropenia, 
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05/2008. ± 15.2. 3/3; KPS ≥60.  thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity), IR 
(CD3+, CD4+, CD8+, 
NK cells); NS. 
Wu Y (2009); 
2007-2009. 
35/35; 42 (all); 
53.6 (mean, all) 
Dukes B: 19, 
C: 43, D: 8 
(all); KPS ≥60 
Fuzhenghuayujiedu formula; one 
decoction per day; for 12 weeks. 
HCPT: 10 mg, ID, day1-5, 4 weeks/cycle; for 3 
cycles. 
tRR, 1-year OS, AEs;  
NS. 
Xiao Y 
(2008); 
01/2004-
05/2006. 
27/24; 15/13; 
50/45 (mean). 
Dukes A: 8/5, 
B: 11/10, C: 8 
/9; KPS ≥60 
Huangqidangshenmogu decoction; 
one decoction per day; for 8 weeks. 
5-FU + LV + Cisplatin; Cisplatin. 30 mg/m², ID, day 
1-3, LV 150 mg/m², ID, day1-5, 5-FU 500 mg/m², ID 
day1-5, 4 weeks/cycle; for 2 cycles(all). 
tRR, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia); NS. 
Xiao Z 
(1998); 1989-
1997. 
50/25; 28/13; 
58/56 (mean). 
II: 10/6, III: 
34/14, IV: 8/5; 
NS. 
Fuyue decoction 15 mL tid, 3 
months/cycle; for 3 cycles in first 
year, for 2 cycles in second years, 
for one cycles in third years. 
5-FU 500 mg + MMC 4 mg, ID, twice wk, 10 
wks/cycle; for 3 cycles in first year, for 2 cycles in 
second years, for one cycles in third years. 
AEs (nausea and 
vomiting), 5-year OS;  
NS. 
Xu Y (2006); 
07/2001-
06/2004. 
32/20; 21/12; 
53/51 (med) 
IV: 32/20; 
KPS ≥60. 
Fuzhenghuayujiedusanjie formula; 
one decoction per day; for 6 
months. 
FLOFLX; Ox.100 mg/m², ID, day 1, 8, 5-FU 500 mg 
bolus, 250 mg /m², ID, day 1-15, or plus HCPT 10 
mg/ m², ID, day 1-5, 30 days/ cycle; for 6 cycles(all). 
tRR, 1-year OS, KPS;  
NS. 
Xu Y (2010); 
08/2004-
11/2008. 
61/60; 38/37; 
53/52 (mean) 
ACRC; KPS 
≥70. 
Jiangniling formula; one decoction 
per day, 14 days/cycle; for 8-10 
cycles 
FOLFOX4; 11.1/7.8 (mean) cycles. tRR, TTP, KPS, AEs 
(anaemia, nausea and 
vomiting, diarrhoea); 
NS. 
Yang C 
(2007); 
NS. 
50/50; 29/27; 
51.36 ± 10.58 
/53.48 ± 9.35. 
ACRC; KPS 
≥60. 
Jianpikangfu pill; 6g, tid; for 4 
weeks. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 100mg /m², 
ID, day 1-5, 5-FU 425 mg /m², ID day 1-5; for 4 
weeks (all). 
tRR, KPS, AEs 
(neutropenia), CEA; NS. 
Yang Y 
(2008); 
18/19; 10/8; 
63.05 ± 
IV (all); KPS: 
64.71 ± 
Quxie capsule; 5 mg/kg, bid; for 12 
weeks. 
FOLFOX (no details) OS, TTP, KPS;  
mild diarrhoea. 
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HM AEs. 
03/2003-
11/2003. 
11.17/62.35 ± 
11.42 
6.24/64.44 ± 
5.11 
Yang Y 
(2008a); 
01/2007-
11/2007. 
30/30; 16/19; 
51.07 ± 10.44 
/51.33 ± 10.95. 
ACRC; KPS 
≥60. 
Kang'ainjection; 50 mL, ID, day1-
20, 30 days/cycle; for 2 cycles. 
FOLFOX4; for 4 cycles (all). tRR, QoL (zhang yan 
questionnaire), BW, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, stomatitis, 
liver impairment); NS. 
Yang Z 
(2005); 
2002-2004. 
30/30; 18/20; 
29-70 /28-69 
III (all); KPS: 
82.21 ± 
8.68/83.53 ± 
8.56 
Xuesaitong injection, 500 mg, ID; 
Huangqi injection, 60 mL, ID; 
Shenmai injection, 50 mL, ID & 
HM decoction, one decoction per 
day, day1-5, 21 days/cycle; for 2 
cycles. 
FOLFOX; Ox.200 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-5, 5-FU 500 mg /m², ID day 1-5; 2/2 
cycles. 
KPS, AEs (nausea and 
vomiting, diarrhoea), NK 
cells;  
NS. 
Yin X (2011); 
04/2009-
01/2012. 
32/32; 17/16; 
62.00 ± 5.23 
/61.70 ± 6.23 
ACRC; NS. Jianpi formula; one decoction per-
day, 21 days/cycle; for 2 cycles. 
XELOX; Ox.130 mg/m², ID, day 1, Xel 250 mg/ m², 
day 1-14, bid, 21 days/cycle; 2 cycles (all). 
tRR, KPS, IR (CD3+, 
CD4+, CD8+, NK cells); 
NS. 
You J (2010); 
01/2007-
11/2009. 
30/30; 14/13; 
Range: 30-
75/31-74. 
III: 8/9, IV: 
22/21; KPS 
≥50. 
WD-3 decoction; 50 mL, tid, 4 
weeks/cycle; for 4 cycles. 
FOLFOX; Ox.125 mg/m², ID, day 1, LV 100 mg /m², 
ID, day 1-5, 5-FU 500 mg /m², ID day 1-5, 4 
weeks/cycle; for 4 cycles (all). 
tRR, KPS, IR (CD3+, 
CD4+, CD4+/CD8+);  
NS. 
Zeng B 
(2008); 
02/2000-
02/2003. 
25/25; 16/17; 
58.3 ± 12.4/56.2 
± l1.5. 
III (all); KPS 
≥70. 
Kangeifangyi tablet; 10 tablets, tid; 
for 12 weeks. 
FOLFOX4; for 6 cycles. 1-, 2-,3-yr OS, IR 
(CD3+, CD4+, CD8+, 
CD4+/CD8+, NK cells), 
CEA; NS. 
Zeng C 
(2013);  
04/2009-
30/30; 39/19; 
54.3 ± 6.3/53.2 
± 6.6 
III: 20/12, IV: 
41/18; KPS 
≥60. 
Fuzhengxiaoji decoction; one 
decoction per day, 14 days/cycle; 
for 4-6 cycles. 
FOLFOX; Ox.85 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-2, 5-FU 360-500 mg /m² bolus, 600 mg 
/m², ID, for 22 hours, day 1-2, 14 days/cycle; for 4-6 
tRR, KPS, AEs 
(neutropenia, anaemia), 
IR (CD4+, CD8+, 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
01/2012.  cycles (all) CD4+/CD8+); NS. 
Zeng D 
(2009); 
02/2007-
12/2008. 
35/32; 25/21; 
50<: 4/5, 51-69: 
28/25, >70: 3/2. 
IV (all); 
KPS≥70. 
Ginsenoside Rg3 capsules; 2 
capsules, bid; for 8 weeks. 
FOLFOX4; for 4 cycles (all). tRR, KPS, BW, AEs 
(neutropenia, 
neurotoxicity), IR 
(CD3+, CD4+, CD8+, 
CD4+/CD8+, NK cells); 
NS. 
Zeng J 
(2008); 
NS. 
30/30; 19/18; 
48/60 (med). 
ACRC; KPS 
≥60. 
Multi-TM formula; one decoction 
per day; for 4weeks. 
FOLFOX4; 2/2 cycles (all). tRR, KPS, AEs 
(neutropenia, 
neurotoxicity); NS. 
Zeng J 
(2010); 
01/2004-
01/2008. 
54/50; 40/38; 54 
± 2.4/51 ± 2.3. 
II: 30/28, III: 
24/28; NS. 
Xiaoliu decoction; one decoction 
per day; for 8 weeks. 
IHPC; 5-FU 1500mg + Cisplatin 80 mg, once per 
week; for 3 weeks. 
1-, 3-yr OS, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
nausea and vomiting, 
diarrhoea, neurotoxicity), 
IR (CD4+/CD8+, NK 
cells); NS. 
Zhang H 
(2008); 
03/2003-
11/2006. 
31/29; 28/23; 
52.35/53.40 
(mean) 
Advance; KPS 
≥60. 
3 CHM decoctions based on 
syndrome differentiation; one 
decoction per day; Started on one 
week before chemotherapy till one 
week after chemotherapy 
completed.  
FOLFOX4; 4/4 cycles (all). tRR, KPS, AEs 
(myelosuppressio, 
nausea and vomiting); 
NS. 
Zhang J 
(2004); 
05/2000-
01/2004. 
53/50; 65 (all); 
31-75. 
Dukes B: 23, 
C: 80 (all). 
Aidi injection; 50 mL, ID, day 1-
10; for 6 cycles. 
LV+5-FU+HCPT; LV 200 mg /m², ID, day 1-5, 5-FU 
500 mg /m², ID, day 1-5, HCPT 6 mg /m², ID, day1-
7, 21day/cycle; for 6 cycles.  
1-, 2-, 3-yr OS, KPS, 
AEs (neutropenia, 
nausea and vomiting, 
liver impairment); NO. 
Zhang Q 
(2006); 
38/30; 35 (all); 
54.8 (mean, all). 
ACRC; KPS: 
76.5 ± 
Yiqihuoxue formula; one decoction 
per day, 21 days/cycle; for 3 cycles. 
FOLFOX; Ox.125 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-2, 5-FU 500 mg /m² bolus, day 1-2, 2000 
tRR, 1 yr OS, KPS, AEs 
(neutropenia, 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
04/2002-
07/2004. 
5.8/73.5 ± 6.0 mg /m² ID for 72 hours, 21 days/cycle; for 3 cycles 
(all). 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity), IR 
(CD4+/CD8+, NK cells); 
NS. 
Zhang Q 
(2010); 
02/2005-
10/2007. 
60/60; 35/33; 
56.2 (mean, all) 
ACRC; KPS 
≥60. 
Gubenxiaoliu capsule; 4 capsules, 
bid; for 8 weeks.  
FOLFOX4; 4/4 cycles (all). tRR, 1-year OS, KPS, 
AEs (neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, 
neurotoxicity), IR 
(CD4+/CD8+, NK cells); 
NS. 
Zhang S 
(2007); 
10/2005-
09/2006. 
50/46; 35/31; 
56.14 ± 
7.75/53.83 ± 
9.83. 
NS; NS. Yiqijianpijiedu CHM; one 
decoction per day; for 16 days. 
FOLFOX4; one cycle. QoL (EORTC QLQ-C30, 
Self-reported Anxiety 
Scales (SAS) and 
Depression Scales 
(SDS); NS. 
Zhang W 
(2013); 
10/2007-
08/2009. 
32/32; 
15/16;56.8 ± 
10.1/46.4 ± 9.2 
Dukes B: 
23/22, C: 
9/10; KPS: 
≥60. 
Xiaoliuhuaji decoction I; one 
decoction per day; for 20 weeks. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 200 mg /m², 
ID, day 1-2, 5-FU 2400 mg /m², ID day 1, for 48 
hours, 21 days /cycle; for 6 cycles (all). 
DFS, KPS, AEs 
(neutropenia, nausea and 
vomiting, diarrhoea, 
neurotoxicity, liver 
impairment), IR (CD3+, 
CD4+, CD8+, NK cells); 
NS. 
Zhang Y 
(2010); 
01/2005-
12/2008. 
21/20; NS; NS;  ACRC; KPS: 
≥60. 
Jianpijiedu decoction; one 
decoction per day; for 4weeks. 
FOLFOX 4; 2/2 cycles (all). tRR, med OS,1-year OS, 
TTP, KPS, BW, AEs 
(alopecia, neutropenia, 
thrombocytopenia, 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
anaemia, nausea and 
vomiting, neurotoxicity, 
liver impairment); NS. 
Zhang Y 
(2010a); 
07/2008-
03/2009. 
20/20; 12/11; 
48.5 ± 12.8/ 
47.6 ± 11.9). 
NS; NS. Shenqi fuzheng injection; 250 mL, 
ID, day1-5; duration NS. 
FOLFOX; Ox.135 mg/m², ID, day 1, LV 150 mg /m², 
ID, day 1-5, 5-FU 500 mg /m², ID day 1-5, duration 
NS. 
KPS, AEs 
(myelosuppression, 
gastrointestinal events, 
liver and kidney 
impairment), 
CD4+/CD8+; NS. 
Zheng X 
(2005); 
NS. 
75/67; 56/60; 
NS. 
Dukes A: 
10/12, B: 
28/25, C: 
37/30; KPS: 
≥60. 
Co-Kushen injection; 50 mL, ID, 
day 1-5; for 4 weeks. 
CF+5-FU+HCPT; LV 200 mg /m², ID, day 1-5, 5-FU 
500 mg /m², ID, day 1-5, HCPT 8 mg /m², day1-5, 
ID, 5-day/cycle; for 4 cycles. 
KPS, AEs (neutropenia, 
liver impairment); NS.  
Zheng Y 
(2011); 
01/2009-
01/2011. 
32/30; 20/18; 
62.9 ± 7.86/63.1 
± 7.12. 
ACRC; KPS: 
≥70. 
Shenqi san (powder); 5g, tid; for 24 
weeks. 
5-FU+LV; LV 200 mg /m², ID, day 1-5, 5-FU 500 mg 
/m², ID, day 1-5, 30 days/cycle; for 6 cycles. 
KPS, AEs (neutropenia, 
thrombocytopenia, 
anaemia, nausea and 
vomiting, diarrhoea, liver 
and kidney impairment), 
CEA; NS.  
Zhou J 
(2011); 
08/2007-08/ 
2009 
34/34; 22/20; 
51.2/52.5 
II: 14/13, III: 
16/11, IV: 6/5; 
KPS: ≥60. 
Fuzhengjianpi decoction; one 
decoction per day; for 8 weeks. 
FOLFOX; Ox.130 mg/m², ID, day 1, LV 100 mg /m², 
ID, day 1-5, 5-FU 500 mg /m², ID, day 1-5, 28 
days/cycle; for 2 cycles (all) 
tRR, KPS, AEs 
(neutropenia, 
thrombocytopenia, 
anaemia, gastrointestinal 
reactions), IR (CD3+, 
CD4+, CD8+, 
CD4+/CD8+, NK cells); 
NS. 
Zou B (2007); 32/27; 29/22; ACRC; KPS: Gubenkang'ai decoction; one FOLFOX; Ox.135 mg/m², ID, day 1, LV 200 mg /m², tRR, KPS, AEs 
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First author 
(year); 
Trial 
duration. 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
TNM (T/C); 
KPS or 
ECOG  
HM Intervention; dosage; 
duration 
Oxaliplatin (Ox.) regimen; dose, cycles(T/C) Outcomes; 
HM AEs. 
03/2000-
11/2005. 
53/54.3 (mean)  ≥60. decoction per day; for 6 weeks. ID, day 1-2, 5-FU 2400 mg /m², ID, for 48 hours, day 
1, 21 days/cycle; for 2 cycles (all) 
(myelosuppression, 
nausea and vomiting); 
NS.  
T: treatment group; C: control group; M: male; HM: herbal medicine; N: number; NS: not stated; ID: intravenous drip; tRR: Tumour Response Rate; OS: overall survival; TTP: time to progress; DFS: 
disease free survival; AEs: adverse events; BW: body weight; IR: immune regulation; TNM: cancer staging system. ‘T’ for tumour, denotes the extent of invasion of the intestinal wall, ‘N’ for lymphatic 
node, the amount of lymphatic node involvement, and ‘M’ for the metastasis; QoL: quality of live; KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group Performance 
Status; EORTC QLQ-C30: European Organisation for Research Treatment Of Cancer; HM: herbal medicine; 5-FU: 5-Fluorouracil; LV: Leucovorin; Ox: Oxaliplatin; Xel: Capecitabine; ADM: 
Adrimycin; HCPT: Hydroxycamptothecine; MeCCNu: Semustine; MMC: Mitomycin; FOLFOX: OXA. + 5-FU + LV; FOLFOX4: 2-hour infusion of LV (200 mg/ m²/d), followed by a 5FU bolus (400 
mg/ m²/d) and a 22-hour infusion (600 mg/ m²/d) for 2 consecutive days every 2 weeks, oxaliplatin 85 mg/m² as a 2-hour infusion on day 1,repeated every 14 days; XELOX: Oax. + Capecitabine; TACE: 
Transcatheter Arterial Chemoembolization; IHPC: intraperitoneal hyperthermic perfusion chemotherapy; ACRC: advanced colorectal cancer; bid: twice per day; tid: three times per day; qd: once per day; 
med: median. 
Table E3: Risk of bias summary: review authors' judgements about each risk of bias item for each of the 88 included studies 
Study: First 
author (year) 
RSG (selection 
bias) 
AC (selection 
bias) 
BPP (perform. 
bias) 
BOA-subj. 
(detection bias) 
BOA-obj. 
(detection bias) 
IOD (attrition 
bias) 
SR (reporting 
bias) 
Other bias 
(funding) 
Cao B 2011 L L L L L L L U 
Cao C 2005 U U H H L L L U 
Cazacu M 2003 U U H L L L L H 
Chen X 2005 U U H H L L L U 
Deng D 2010 U U L H L L L U 
Ding X 2010 L U H H L L L U 
Dong J 2011 L U H H L L L L 
Fang M 2008 L U H H L L L U 
Gu C 2009 U U H L L L L U 
Guo Z 1999 U U H H L H L U 
Hou A 2009 L U H H L H L U 
Hu A 2006 U U H H L L L U 
Huang Z 2002 U U H H L L L U 
Huang Z 2005 L U H H L L L U 
Huang Z 2008 L U H H L L L U 
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Study: First 
author (year) 
RSG (selection 
bias) 
AC (selection 
bias) 
BPP (perform. 
bias) 
BOA-subj. 
(detection bias) 
BOA-obj. 
(detection bias) 
IOD (attrition 
bias) 
SR (reporting 
bias) 
Other bias 
(funding) 
Jian X 2005 U U H H L L L U 
Jiang G 2013 U U H H L L L U 
Kono T 2013 L L L L L L L U 
Lao G 2012 L U H H L L L U 
Li H 2000 U U H L L L L U 
Li H 2007 U U H H L L L U 
Li Y 2007 L U H H L L H U 
Liang Q 2009 L U H H L L L U 
Lim M 2012 U U H H L L L L 
Liu H 2009 L U H H L L L L 
Liu H 2013 L U  H H L L L U 
Liu J 2000 U U H H L L L U 
Liu J 2005 L  U H H L L L U 
Liu J 2005a  L U H H L L L U 
Liu W 2011 U U H H L L L L 
Lu Q 2010 U U H H L L L U 
Ma J 2005 U U H H L L L U 
Ma M 2010 U U H L L L L U 
Mao X 2005 U U H H L L L U 
Meng Z 2003 U U H H L L L U 
Pan M 2003 U U H H L H L U 
Qian Y 2009 U U H H L L L U 
Qin Y 2011 U U H H L H H U 
Qiu Z 2011 U U H H L L L U 
Schink M 2007 U U H L L L L U 
Shen H 2003 U U H H L L L L 
Song W 2012 L U H H L L L U 
Tang X 2009 U U H L L L L U 
Tao C 2013 U U H H L L L U 
Torisu M 1990 U U L L L L L U 
Wan H 2013 U U H H L L L U 
Wang C 1999 U UI H H L L L U 
Wang D 2012 U U H H L L L U 
Wang H 2000 H U H H L L H U 
Wang H 2008 U U H H L L L U 
Wang J 2011 L U H H L L L U 
Wang Y 2012 U U H H L L L U 
Wang Y 2013 U U H H L L L U 
Wang Z 2007 U U H H L L L U 
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Study: First 
author (year) 
RSG (selection 
bias) 
AC (selection 
bias) 
BPP (perform. 
bias) 
BOA-subj. 
(detection bias) 
BOA-obj. 
(detection bias) 
IOD (attrition 
bias) 
SR (reporting 
bias) 
Other bias 
(funding) 
Wu G 2010 L U H H L L L L 
Wu Y 2009  U U H H L L L U 
Xiao Y 2008 U U H H L L L L 
Xiao ZQ 1998 U U H H L L L U 
Xion S 2003 U U H H L L L U 
Xu Y 2006 U U H H L H L U 
Xu Y 2010 U U H H L L L U 
Yang Y 2008a U U H H L L L L 
Yang C 2007 U U H H L L L L 
Yang Y 2005 L U H H L L L U 
Yang Y 2008 L U H H L L L U 
Yang Z 2005 U U H H L L L U 
Yin X 2011 L U H H L L L L 
You J 2010 U U H H L L L L 
Zeng B 2008  U U H L L L L U 
Zeng C 2013 U U H H L L L U 
Zeng D 2009 U U H H L L L L 
Zeng J 2008 U U H H L L L U 
Zeng J 2010 U U H H L L L L 
Zhang B 2008 U U H H L L L U 
Zhang H 2008  U U H H L L L U 
Zhang J 2004 U U H H L L L U 
Zhang Q 2006 L U H H L L L U 
Zhang Q 2010 L U H H L L L L 
Zhang S 2007 U U H H L L L U 
Zhang W 2013 L U H L L L L U 
Zhang Yan 2010 L U H H L H L L 
Zhang Yong 2010 U U H H L H L U 
Zheng X 2005 U U H H L L L U 
Zhang Y 2011 L U H H L L L U 
Zhou J 2012 U U H H L L L U 
Zou B 2007 U U H H L L L U 
 
RSG: random sequence generation; AC: allocation concealment; BPP: blinding participants and personnel; BOA-subj.: blinding outcome assessment-subjective outcome; BOA-obj.: blinding outcome 
assessment-objective outcome; IOD: incomplete outcome data; SR: selective reporting; L: low risk of bias; H: high risk of bias; U: unclear risk of bias 
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Appendix F. Characteristics of Studies Included in Chapter 5 
Table F1. Characteristics of the fourteen studies included in the meta-analysis of FOLFOX4 for ACRC 
First author 
(year); 
Sample size 
T/C; 
Duration. 
Gender 
(M) T/C; 
Age T/C; 
KPS all. 
Previously 
untreated 
T/C; 
Previously 
treated T/C; 
Metastatic 
sites T/C. 
HM: name (manufacturer), ingredients (pinyin, scientific name, part); dosage & administration; 
FOLFOX4: cycles (T/C).  
Outcome 
measures 
Cao B (2011); 
60/60; 
01/2005 to 
12/2007. 
32/33; 
55.2±13.3/
58.8±13.7; 
ECOG 0: 
36/37, I: 
24/23. 
60/60; 
1:26/29, 2: 
19/20, 3: 10/8, 
≥4: 5/3. 
Yiqi Zhuyu Decoction (Ren shen, Panax ginseng C.A. Mey. Root; Sophora flavescens Ait.root; Huang qi, 
Astragalus membranaceus (Fisch.) Bge. Root; Dang shen, Codonopsis pilosula (Franch.) Nannf. root; Bai 
zhu, Atractylodes macrocephala Koidz. root; Ban zhi lian, Scutellaria barbata D. Don.; Bai hua she she cao, 
Hedyotis diffusa Willd. herb; Yu jin, Curcuma wenyujin Y. H. Chen et C. Ling. rhizome; E zhu, Curcumae 
phaeocaulis Val. rhizome; Bai shao, Paeonia lactiflora Pall. root; San leng, Sparganiumstoloniferum Buch. 
Hamil. root; Chuanxiong, Ligusticum chuanxiong Hort. root; Dang gui, Angelica sinensis (Oliv.) Diels. root.); 
5 mL/kg oral administration, 2 weeks/cycle, for 48 weeks; FOLFOX 4: 24/24. 
tRR; PFS; mOS; 
AEs(neurotoxicity, 
gastrointestinal 
events, 
hematological 
events). 
 
Ding X 
(2010); 
30/30; 
09/2007 to 
08/2008. 
18/20; 
64.5/63; 
≥ 70. 
NS; 
NS; 
NS. 
Compound Kushen Injection (Zhendong Jinjing Pharmaceutical Co.): Ku shen, Sophora flavescens Ait.root; 
Bai tu ling, Heterosmilax yunnanensis Gagnep. root; 20 mL, ID, day 1-7, for 8 cycles; 
FOLFOX 4: 8/8. 
Median OS; 
Median TTP; AEs 
(leukopenia, 
nausea, vomiting, 
neurotoxicity); T-
cell subsets (CD3+, 
CD4+, CD8+), NK 
cells. 
Fang M 
(2008); 
48/45; 
05/2002 to 
06/2007. 
30/28; 
59.5±11.3/
56.4±10.3; 
≥ 70.  
 
NS; 
NS; 
NS. 
 
Javanica oil Emulsion Injection (Shenyang Pharmaceutical University Pharmaceutical Co.): Yan dan zi, 
Brucea javanica (L.) Merr. seed; 30 mL diluted with saline, 250 mL ID, day 1-14, for 2 cycles; 
FOLFOX 4: 2/2. 
tRR; 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
nausea, vomiting, 
diarrhoea, 
stomatitis, 
neurotoxicity, 
alopecia); 
KPS. 
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First author 
(year); 
Sample size 
T/C; 
Duration. 
Gender 
(M) T/C; 
Age T/C; 
KPS all. 
Previously 
untreated 
T/C; 
Previously 
treated T/C; 
Metastatic 
sites T/C. 
HM: name (manufacturer), ingredients (pinyin, scientific name, part); dosage & administration; 
FOLFOX4: cycles (T/C).  
Outcome 
measures 
Li HJ (2007); 
65/52; 
10/2002 to 
02/2006. 
 
43/36; 
58/59 
(median); 
70(median
). 
 
31/20; 
34/32; 
NS. 
 
Aidi Injection (Guizhou Yibai Pharmaceutical Co): Ren shen, Panax ginseng C.A. Mey.root; Huang qi, 
Astragalus membranaceus (Fisch.) Bge. Root; Ci wu jia, Acanthopanax Senticosus (Ruper.et Maxim.) Harms. 
root; Ban mao, Mylabris phalerata Pallas; 60 mL (0.3g crude drug/mL) diluted with 250 mL 5% glucose 
injection fluid ID, day 1-10, 14 days/cycle, for 11 weeks;  
FOLFOX 4:5.5/5.5 (mean) 
tRR; 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
nausea, vomiting, 
diarrhoea, 
constipation, 
stomatitis, 
liver/kidney 
impairment, 
neurotoxicity, 
alopecia); Median 
OS; One year OS;  
KPS. 
Li YJ (2007); 
20/18; 
01/2005 to 
04/2006. 
 
22 (all); 
72.7 
(median, 
all); 
≥ 60. 
 
28(all); 
10(all); 
NS. 
 
Wenshenjianpi decoction (NS): Rou cong rong, Cistanche deserticola Y. C. Ma. herb; Yin yang huo, 
Epimedium grandiflorum Mot. leaf; Gou ji, Lycium barbarum L. fruit; Dang shen, Codonopsis pilosula 
(Franch.) Nannf. root; Huang qi, Astragalus membranaceus (Fisch.) Bge. root; Bai zhu, Atractylodes 
macrocephala Koidz. root; Fu ling, Poria cocos (Schw) Wolf sclerotium; Yi yi ren, Coix lacryma-jobi L. seed; 
Yu jin, Curcuma wenyujin Y. H. Chen et C. Ling. rhizome; Shan zha, Crataegus pinnatifida Bge. fruit; Mai ya, 
Hordeum vulgare L. germinating seed; Ban zhi lian, Scutellaria barbata D. Don. herb; modified. 
One decoction per day orally administered concurrently with chemotherapy for median 10-12 weeks;  
FOLOFOX 4: 6/5.5 cycles (median) 
tRR; 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
liver impairment, 
nausea, vomiting, 
diarrhoea 
neurotoxicity); 
KPS. 
Qiu ZC 
(2011); 
22/21*; 
01/2005 to 
08/2009. 
14/13; 
56.9/52.7 
(median); 
≥ 60. 
 
22/21; 
NO; 
NS. 
Kang'ai Injection (Jilin Changbaishan Pharmaceutical Co): Ku shen, Sophora flavescens Ait.root; Ren shen, 
Panax ginsengC.A. Mey.root; Huang qi, Astragalus membranaceus (Fisch.) Bge. root; 40 mL of Kang’ai 
injection diluted with 250 mL 5% glucose injection fluid ID, day 1-10, 14 days/cycle, for 4 cycles;  
FOLFOX 4: 4/4 cycles. 
tRR; 
Chemotherapy AEs 
(leukopenia, 
nausea & 
vomiting); KPS. 
Wu GL  23/17; NS; Fupiyiwei decoction (NS): Shi hu, Dendrobium loddigesii Rolfe. stem; Cang zhu, Atractylodes lancea tRR; 
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First author 
(year); 
Sample size 
T/C; 
Duration. 
Gender 
(M) T/C; 
Age T/C; 
KPS all. 
Previously 
untreated 
T/C; 
Previously 
treated T/C; 
Metastatic 
sites T/C. 
HM: name (manufacturer), ingredients (pinyin, scientific name, part); dosage & administration; 
FOLFOX4: cycles (T/C).  
Outcome 
measures 
(2010); 
33/25; 
10/2004 to 
05/2008. 
55.4 
±13.6/52.8 
±15.2 
(mean); 
≥ 60. 
 
NS; 
NS. 
(Thumb.) DC. root; Yi yi ren, Coix lacryma-jobi L. seed; Ban xia Pinellia ternata (Thunb.) Breit. tuber; Shan 
yao, Dioscorea opposita Thunb. rhizome; Fu ling, Poria cocos (Schw) Wolf. sclerotium; Dou kou, Alpinia 
katsumadai Hayata. seed; Jiao gu lan, Gynostemma pentaphyllum (Thunb.) Mak. herb; Bai shao, Paeonia 
lactiflora Pall. root; Huo xiang, Pogostemon cablin (Blanco) Benth. herb; One decoction per day oral-
administered concurrently with chemotherapy for 24 weeks;  
FOLFOX 4:12/12 cycles 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
nausea, vomiting, 
diarrhoea 
neurotoxicity); 
KPS; T-cell subsets 
(CD3+, CD4+, 
CD8+), NK cells. 
Xu YX  
(2010); 
61/60; 
08/2004 to 
11/2008. 
38/37; 
53/52 
(mean); 
≥ 70. 
 
NS; 
NS; 
NS. 
 
Jiangniling decoction (NS): Dang shen, Codonopsis pilosula (Franch.) Nannf. root; Bai zhu, Atractylodes 
macrocephala Koidz. root; Fu ling, Poria cocos (Schw) Wolf. sclerotium; Bai dou kou, Amomum 
cardamomumL. seed, Ban xia, Pinellia ternata (Thunb.) Breit. tuber; Sha ren, Amomum villosum Lour. Seed; 
Xiang fu, Cyperus rotundus L. rhizome; Chen pi, Citrus reticulata Blanco. peel; Zhu ru, Phyllostachyl nigra 
(Lodd.). shaving; Sheng jiang, Zingiber officinale Rosc. rhizome; Yi yi ren, Coix lacryma-jobi L. seed; One 
decoction per day orally administered concurrently with chemotherapy for 22 weeks;  
FOLFOX 4: 11.1/7.8 cycles (mean). 
tRR; 
Chemotherapy AEs 
(nausea, vomiting, 
diarrhoea, anaemia, 
leukopenia, 
thrombocytopenia); 
TTP; KPS.  
Yang YF 
(2008); 
30/30; 
01/2007 to 
11/2007. 
16/19; 
51.07±10.4
4/51.33 
±10.95 
(mean); 
40.73±3.49
/ 
40.90±2.44 
9/7; 
21/23; 
NS. 
Kang'ai Injection (Jilin Changbaishan Pharmaceutical Co): Ku shen, Sophora flavescens Ait. root; Ren shen, 
Panax ginseng C.A. Mey. root; Huang qi, Astragalus membranaceus (Fisch.) Bge. root; 50 mL of Kang’ai 
injection diluted with 250 mL 5% glucose injection fluid ID per day, day 1-20, 30 days/course, for 2 courses; 
FOLFOX 4: 4/4 cycles. 
tRR; 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
liver impairment, 
nausea, vomiting, 
diarrhoea, 
neurotoxicity);  
QoL, BW. 
Zeng DX 
(2009); 
35/32; 
02/2007 to 
12/2008. 
16/19; 
50-70 
(range);  
≥ 70. 
 
67(all); 
NO; 
Liver: 15/19, 
Lung: 8/7, 
Others: 9/9. 
Ginsenoside Rg3 capsules (Jilin Yatai Pharmaceutical Co): 2 capsules/day, administered concurrently with 
chemotherapy for 8 weeks. 
FOLFOX 4: 4X4 cycles 
tRR;  
Chemotherapy AEs 
(leukopenia, 
nausea, vomiting, 
diarrhoea, 
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First author 
(year); 
Sample size 
T/C; 
Duration. 
Gender 
(M) T/C; 
Age T/C; 
KPS all. 
Previously 
untreated 
T/C; 
Previously 
treated T/C; 
Metastatic 
sites T/C. 
HM: name (manufacturer), ingredients (pinyin, scientific name, part); dosage & administration; 
FOLFOX4: cycles (T/C).  
Outcome 
measures 
neurotoxicity); 
T cell subsets 
(CD3+, CD4+, 
CD8+, 
CD4+/CD8+). 
Zeng JQ 
(2008); 
30/30; 
NS. 
19/18; 
48/60 
(median);  
≥ 60. 
 
NO; 
30/30; 
Liver: 14/7, 
Lung: 6/8, 
Others: 15/12. 
Basic HM formula (NS): Huang qi, Astragalus membranaceus (Fisch.) Bge. root; Bai zhu Atractylodes 
macrocephala Koidz. root; Yi yi ren, Coix lacryma-jobi L. seed; Ban zhi lian, Scutellaria barbata D. Don. 
herb; Ku shen, Sophora flavescens Ait. root; Mu xiang, Aucklandia lappa Decne. root; Bai hua she she cao, 
Hedyotis diffusa Willd. herb; modified; One decoction per day orally administered concurrently with 
chemotherapy for 4 weeks. 
FOLFOX 4: 2/2 cycles. 
tRR;  
Chemotherapy AEs 
(leukopenia, 
gastrointestinal 
reaction, 
neurotoxicity);  
KPS. 
Zhang HT 
(2008); 31/29; 
03/2003 to 
11/2006. 
 
 
28/23; 
52.35/53.4 
(mean); 
≥ 60. 
 
NS; 
NS; 
NS. 
3 HM decoctions based on CM ‘Zheng’ differentiation (NS):  
1. Damp heat tenesmus decoction: Ku shen, Sophora flavescens Ait. root; Zhong jie feng, Sarcandra glabra 
(Thunb.) Nakai. herb; Yi yi ren, Coix lacryma-jobi L. seed; Huai hua, Sophora japonica L. flower-bud; Di yu, 
Sanguisorba officinalis L. root; Bai jiang cao, Patrina villosa Juss. herb; Jin yin hua, Lonicera japonica 
Thunb. flower; Mu mian hua, Bombax malabarica (DC.) Merr. flower; Bai hua she she cao, Hedyotis diffusa 
Willd. herb; Yin chen, Artemisia capillaris Thunb. herb; Hou po, Magnolia officinalis Rehd. et Wils. bark; 
Huang lian, Coptis chinensis Franch. root. 
2. Toxic stasis in colon decoction: Ku shen, Sophora flavescens Ait. root; Zhong jie feng, Sarcandra glabra 
(Thunb.) herb; Huai hua, Sophora japonica L. flower-bud; Di yu, Sanguisorba officinalis L. root; Bai jiang 
cao, Patrina villosa Juss. herb; Jin yin hua, Lonicera japonica Thunb. flower; Bai hua she she cao, Hedyotis 
diffusa Willd. herb; Yan dan zi, Brucea javanica (L.) Merr. seed; Da ji, Cirsium japonicum DC. herb; Qi ye yi 
zhi hua, Paris polyphylla Smith. root; Chi shao, Paeonia veitchii Lynch. root; E zhu, Curcumae phaeocaulis 
Val. rhizome;  
3. Spleen and kidney deficiencydecoction: Dang shen, Codonopsis pilosula (Franch.) Nannf. root; Fu ling, 
Poria cocos (Schw) Wolf. sclerotium; Huang qi, Astragalus membranaceus (Fisch.) Bge. root; Ku shen, 
Sophora flavescens Ait. root; Zhong jie feng, Sarcandra glabra (Thunb.) Nakai. herb; Yi yi ren, Coix lacryma-
jobi L. seed; Sha ren, Amomum villosum Lour. seed, Lian zi, Nelumbo nucifera Gaertn. Seed; Bai zhu, 
Atractylodes macrocephala Koidz. root; He zi, Terminalia chebula Retz. seed; He shou wu, Polygonum 
multiflorum Thunb. root; Bai shao, Paeonia lactiflora Pall. root; One decoction per day orally administered 
concurrently with chemotherapy. Started one week before chemotherapy till one week after chemotherapy 
tRR; 
Chemotherapy AEs 
(gastrointestinal 
reaction, 
myelotoxicity); 
KPS. 
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First author 
(year); 
Sample size 
T/C; 
Duration. 
Gender 
(M) T/C; 
Age T/C; 
KPS all. 
Previously 
untreated 
T/C; 
Previously 
treated T/C; 
Metastatic 
sites T/C. 
HM: name (manufacturer), ingredients (pinyin, scientific name, part); dosage & administration; 
FOLFOX4: cycles (T/C).  
Outcome 
measures 
completed.  
FOLFOX 4: 4/4 cycles. 
Zhang Q 
(2010); 
60/60; 
02/2005 to 
10/2007. 
35/33; 
56.2 (mean 
all); 
≥ 60. 
 
32/34; 
28/26; 
Liver: 32/36, 
Lung: 16/19, 
Others: 51/39. 
Guben Xiaoliu Capsule (Beijing Chinese Medicine Hospital, affiliated with Beijing Medical University): 
Dong chong xia cao, Cordyceps sinensis (berk.) Sacc. ascocarp and dead larva; Ling zhi, Ganoderma lucidum 
(Leyss.ex Fr.) karst. sporocarp; Yin yang huo, Epimedium grandiflorum Mot.leaf; Zhe bei mu, Fritillaria 
thunbergii Miq. bulb; Xi yang shen, Panax quinquefolium L. root; Yi yi ren, Coix lacryma-jobi L. seed; Shui 
zhi, Hirudo nipponica Whitman. whole leech; Quan xie, Buthus martensii Karsch. whole insect; Long kui, 
Solanum nigrum L. herb; 4 capsules each time, twice a day, orally administered concurrently with 
chemotherapy for 8 wks. 
FOLFOX 4: 4/4 cycles. 
tRR; 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
nausea & vomiting, 
diarrhoea, 
neurotoxicity); 
KPS; T cell subsets 
CD4+/CD8+, NK 
cells. 
Zhang Y 
(2010); 
21/20; 
01/2005 to 
12/2008. 
NS; 
NS; 
≥ 60. 
 
NS; 
NS; 
NS. 
Jianpi Jiedu decoction (NS): Huang qi, Astragalus membranaceus (Fisch.) Bge.root; Bai zhu, Atractylodes 
macrocephala Koidz. root; Ba yue zha, Akebia quinata (Thunb.) Decne. fruit; Shi jian chuan, Salvia chinensis 
Benth. herb; Ye pu tao teng, Vitis quinquangularisRehder. vine and leaf; One decoction per day orally 
administered concurrently with chemotherapy, for 4 weeks. 
FOLFOX 4: 2/2 cycles 
tRR; 
Chemotherapy AEs 
(leukopenia, 
anaemia, 
thrombocytopenia, 
liver impairment, 
nausea & vomiting, 
neurotoxicity); 
TTP; One year OS; 
Median OS; KPS; 
BW. 
T: treatment group, C: control group, M: male, N: number, NS: not stated, ID: intravenous drip, H: high risk; L: low risk; U: unclear risk; FOLFOX regimen: 5-FU, Leucovorin, 
Oxaliplatin. ID: intravenous drip; tRR: Tumour Response Rate; BW: Body Weight; QoL: Quality of Life; TTP: Time to Progression; OS: Overall Survival; mOS: median Overall 
Survival; mPFS: median Progressive Free Survival; KPS: Karnofsky Performance Status; CM: Chinese medicine; HM: herbal medicine.  
* note error in method section which states 20 in control, whereas elsewhere the number is 21. 
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Appendix G. Characteristics of Studies Included in Chapter 6 
Table G1.Characteristics of randomised controlled trials of Chinese herbal medicines 
combined with oxaliplatin-based regimens for colorectal cancer with tumour response 
rate incidence as an outcome 
First 
author 
(year) 
Sample size T/C; 
Gender (M) 
T/C;Age T/C 
TNM 
(T/C); 
KPS/ 
ECOG 
CHM Intervention; 
dosage & duration 
Oxaliplatin (Ox.) regimen; dose, 
cycles (T/C) 
Cao B 
(2013) 
60/60; 32/33; 55.2 
± 13.3/58.8 ± 
13.7 
IV (all); 
ECOG 0-
1. 
Yiqizhuyu decoction 
(YZD); one decoction per 
day orally administered for 
up to 48 wks. 
FOLFOX4: Ox.85 mg/m², 2 hours 
ID, day 1, LV 200 mg /m², ID, day 1-
2, 5-FU 400 mg /m², bolus, 600 mg 
/m², ID, 22 hours, day1-2, cycle/14 
days, up to 24 cycles (all). 
Cao C 
(2005) 
33/29; 20/19; 
52/49 (med) 
IV (all); 
NS. 
Shengmai injection; 40 
mL, ID, day 1–7, NS. 
FOLFOX: Ox.130 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-5, 5-FU 
750 mg /m², ID, day1-5, cycle/21 
days, cycle NS. 
Chen X 
(2005) 
47/46; 31/32; 
54/53 (med) 
II: 11/12, 
III: 
21/20, 
IV: 
15/14; 
KPS ≥60 
Composite salviae dripping 
pill; 25mg/pill, 10pills/day, 
tid, for 3 cycles or more. 
FOLFOX: Ox. 130 mg/m² 2hours ID, 
LV 200 mg/m², 2 hours ID, 5-FU 500 
mg, bolus, then 3000 mg/m² ID for 
48 hours. 3wks /cycle, for 3cycles 
(all). 
Fang M 
(2008) 
48/45; 30/28; 59.5 
± 11.3/56.4 ± 10.3 
IV (all); 
KPS 
≥70. 
Javanica oil emulsion 
injection; 30 mL, ID, day 
1-14 / cycles, for two 
cycles 
 FOLFOX4: 2 cycles (all). 
Hu A 
(2006) 
28/22; 18/14; 49.3 
± 4.5/48.5 ± 4.3 
IV (all); 
KPS 
≥50. 
Treatment with 4 different 
CHM decoctions according 
to syndrome 
differentiation; one 
decoction per day, for more 
than 30 days. 
FOLFOX: Ox.130 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-2, 5-FU 
2400 mg /m², ID, 46 hours, cycle/21 
days, 2 cycles (all). 
Jiang G 
(2013) 
32/31; 18/18; 53. 
2 ± 12. 4/53. 1 ± 
12.8 
ACRC; 
NS. 
Unnamed multi-CHM 
formula; one decoction per 
day, for 8 weeks. 
FOLFOX: Ox.135 mg/m², ID, day 1, 
LV 200mg /m², ID, day 1-2, 5-FU 
400 mg bolus, day 1-2, 2400-3600 
mg /m², ID for 48 hours, 14 
days/cycle, for 4 cycles (all). 
Kono T 
(2013) 
27/23; NS; 67/61 
(mean) 
NS; 
ECOG 
0–1 
TJ-107 Goshajinkigan; or 
placebo was administered 
orally, tid, before each meal 
(7.5 g/day) for 26 weeks 
FOLFOX4, or mFOLFOX6: Ox.85 
mg/m², ID, day 1, LV 200 mg /m², 
ID, 5-FU 400 mg bolus, follow 2400 
mg /m², ID for 46 hours, 14 
days/cycle, for 8 cycles or more (all). 
Lao G 
(2012) 
30/30; 21/23; 35.1 
± 20.2/36.7 ± 
20.1. 
II:5/7, 
III: 
15/14, 
IV:10/9; 
KPS ≥60 
Jianpijiedu decoction; one 
decoction per day, 21 days 
/cycle, for two cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1, 5-FU 500 
mg bolus day 1, 2400 mg /m², ID, 48 
hours, day 1-2, 21 days /cycle, 2 
cycles (all) . 
Li H 
(2007) 
65/52; 43/36; 
58/59 (med) 
III: 
27/19, 
IV: 
38/33; 
KPS ≥60 
Aidi injection; 60 mL, ID, 
day 1-10, 14days/cycle, for 
11weeks. 
FOLFOX4: 5.5/5.5 cycles (mean). 
Li Y 
(2007) 
20/18; 22 (all); 
72.2 (med, all) 
III: 15, 
IV: 23 
(all); 
KPS ≥60 
Wenshenjianpi decoction; 
one decoction per day, for 
median 10-12 weeks 
FOLOFOX4: 6/5.5 cycles (med). 
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First 
author 
(year) 
Sample size T/C; 
Gender (M) 
T/C;Age T/C 
TNM 
(T/C); 
KPS/ 
ECOG 
CHM Intervention; 
dosage & duration 
Oxaliplatin (Ox.) regimen; dose, 
cycles (T/C) 
Liang Q 
(2009) 
76/76; 50/51; 
53/52 (med) 
III: 
45/46, 
IV: 
31/30; 
KPS ≥60 
Shenqifuzheng injection; 
250 mL/day, ID, 3wks 
/cycle, for 2cycles 
FOLFOX: Ox. 130 mg/m² 2hours, 
ID, day 1, LV 200 mg/m², 2 hours, 
ID, day1, 5-FU 500 mg, bolus, day1, 
then 3000 mg/m², ID, for 48 hours. 
3wks /cycle, for 2cycles (all). 
Lim M 
(2012) 
24/23; 17/14; 
56.89 ± 
14.77/55.37 ± 
16.01 
III: 
15/16, 
IV: 9/7; 
KPS ≥70 
Pianzaihuang capsule; two 
capsules, bid; 14 
days/cycle, 8-10 cycles. 
FOLFOX4; 8-10/8-10 cycles. 
Liu H 
(2009) 
36/34; 16/18; 50.2 
(mean) 
ACRC 
(all); 
KPS ≥60 
Kang’aifangyi pian; one 
decoction per day, 21 
days/cycle, for 3 cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-5, 5-FU 
300 mg /m², ID, day 1-5, 21 days / 
cycle, 3 cycles (all).  
Liu 
J(2005b) 
52/26; 24/12; 
63.11 ± 
11.89/62.78 ± 
11.04 
IV (all); 
KPS 
≥50. 
Jianpihuoxue formulae; 
one decoction per day, 30 
days/ cycle, 3 cycles. 
FOLFOX; Ox.150 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-5, 5-FU 
500 mg /m², ID, day 1-5, 30 days/ 
cycle, 3 cycles (all). 
Liu J 
(2005a) 
43/21; 23/10; 
61.52 ±10.12 
/60.11 ±9.78 
IV (all); 
KPS 
≥50. 
Jianpihuoxue formulae; 
one decoction per day, 30 
days/ cycle, 3 cycles. 
FOLFOX; Ox.150 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-5, 5-FU 
500 mg /m², ID, day 1-5, 30 days/ 
cycle, 3 cycles (all). 
Qin Y 
(2011) 
36/37; NS; NS.  ACRC; 
NS 
Fuzhengguban decoction; 
one decoction per day, 21 
days/ cycle, 2 cycles. 
FOLFOX: Ox.135 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-2, 5-FU 
2400 mg /m², ID, for 48 hours, 21 
days/ cycle, 2 cycles (all). 
Qiu Z 
(2011) 
22/21;14/13; 
56.9/52.7(med) 
IV (all); 
KPS 
≥60. 
 
Kang’ai injection; 40 mL, 
ID, day 1–10, 14 
days/cycle, for four cycles 
FOLFOX4, for 4 cycles (all). 
Song W 
(2012)  
20/20; 12/13; 56.4 
± 9.1 /48.3 ± 8.2 
ACRC; 
KPS 
≥70. 
Xiaoliuhuajichangfang II; 
one decoction per day, 21 
days/ cycle, 2 cycles. 
FOLFOX: Ox.135 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-2, 5-FU 
2400 mg /m², ID, for 48 hours, 21 
days/ cycle, 2 cycles (all). 
Tao C 
(2013) 
74/74;51/50;60.1 
+ 7.9 /60.4 + 8.9. 
ACRC; 
KPS 65.6 
+ 
12.3/66.7 
+ 14.5 
Co-kushen injection; 15 
mL per day, ID, started 14 
days before chemotherapy, 
5wks/cycle, for 1 cycle. 
FOLFOX: Ox.135 mg/m², ID, day 1, 
LV 200 mg/m², ID, 2 hours, day 1-5, 
5-FU 500 mg/m² ,ID, 8-10 hours, 
day1-5, 3wks/cycle, for 1 cycle (all). 
Wan H 
(2013) 
30/30;35(all); 
51.7 (mean, all) 
III: 40 
(all) IV: 
20 (all); 
KPS 
≥60. 
Kushen injection 40 mL, 
ID, and Huangqi injection 
20 mL, ID, perday, 10 
days/cycle, for 6 cycles. 
FOLFOX: Ox.100 mg/m², ID, day1,  
LV 200 mg/m², ID,  5-FU 15-20 
mg/kg, ID, day 1-5, 21 days/ cycle, 
for 6 cycles (all). 
Wang D 
(2012) 
49/49; 58(all); 
54.5 (mean, all). 
ACRC; 
KPS 
≥60. 
Unnamed multi-TM 
formula; one decoction per 
day, duration NS. 
FOLFOX: Ox.120 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-5, 5-FU 
300 mg /m², ID, day 1-5, 21 days/ 
cycle, cycle NS.  
Wang H 
(2008) 
34/34; 20/22; 
52.58 ± 
8.12/51.11 ± 7.72 
IV: 
34/34; 
KPS 
≥50. 
Yiqiguoxiebuchang 
decoction; one decoction 
per day, for 3 mths.  
FOLFOX: Ox.85 mg/m², ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 
500 mg bolus day 1, 5-FU 2500 
mg/m², ID, for 48 hours, 21 days/ 
cycle, 4 cycles (all). 
Wang J 
(2011) 
30/30; 18/21; 52.3 
± 6.2/ 56.7 ± 7.8. 
ACRC; 
KPS 
≥60. 
Yichangning decoction; 
one decoction per day, for 2 
months. 
FOLFOX4, 21 days /cycle, for two 
cycles (all). 
Wang Y 
(2012) 
38/36; 26/25; 52 
(mean, all). 
ACRC; 
KPS 
≥70. 
Aidi injection; 80 mL, ID, 
per day, 10days/cycle, for 4 
cycles 
FOLFOX4, for 4 cycles (all). 
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First 
author 
(year) 
Sample size T/C; 
Gender (M) 
T/C;Age T/C 
TNM 
(T/C); 
KPS/ 
ECOG 
CHM Intervention; 
dosage & duration 
Oxaliplatin (Ox.) regimen; dose, 
cycles (T/C) 
Wang Y 
(2013) 
32/30; 20/19; NS. ACRC; 
KPS 
≥70. 
Xiaoaiping injection; 60 
mL, ID, per day, 14 days/ 
cycle, for two cycles. 
XELOX: no details, for two 
cycles(all) 
Wang Z 
(2007) 
34/33; 47 (all); 55 
(mean all). 
ACRC; 
KPS 
≥60. 
Delisheng injection; 40-60 
mL, ID per day, 15 
days/cycle, for 3 cycles. 
FOLFOX: Ox. 130 mg/m², 2hours 
ID, day 1 ,LV 200 mg/m², 2 hours 
ID, day1-5,5-FU 500 mg/m², ID 
day1-5, 3wks/cycle, for 3cycles (all). 
Wu 
G(2010) 
33/25; 23/17; 55.4 
± 13.6 /52.8 ± 
15.2. 
I: 5/3, II: 
10/8, III: 
15/11, 
IV: 3/3; 
KPS 
≥60. 
Fupiyiwei decoction; one 
decoction per day, for 24 
weeks; 
 
FOLFOX4:12/12 cycles. 
Xu Y 
(2006) 
32/20; 21/12; 
53/51 (med) 
IV: 
32/20; 
KPS 
≥60. 
Fuzhenghuayujiedusanjie 
formula; one decoction per 
day, for 6 mths. 
FLOFLX: Ox.100 mg/m², ID, day 1, 
8, 5-FU 500 mg bolus, 250 mg /m², 
ID, day 1-15, or plus HCPT 10 mg/ 
m², ID, day 1-5, 30 days/ cycle, for 6 
cycles (all). 
Xu Y 
(2010) 
 
61/60; 38/37; 
53/52 (mean) 
ACRC; 
KPS 
≥70. 
Jiangniling formula; one 
decoction per day, 14 
days/cycle, for 8-10 cycles 
FOLFOX 4: 11.1/7.8 (mean) cycles. 
Yang C 
(2007) 
50/50; 29/27; 
51.36 ± 10.58 
/53.48 ± 9.35. 
ACRC; 
KPS 
≥60. 
Jianpikangfu pill; 6g, tid, 
for 4 wks. 
FOLFOX: Ox.135 mg/m², ID, day 1, 
LV 100 mg /m², ID, day 1-5, 5-FU 
425 mg /m², ID day 1-5, for 4 weeks 
(all). 
Yang Y 
(2008a) 
30/30;16/19;51.07 
± 10.44 /51.33 ± 
10.95. 
ACRC; 
KPS 
≥60. 
Kang'ai injection; 50 mL, 
ID, day1-20, 30days/cycle, 
for 2 cycles. 
FOLFOX4, for 4 cycles (all). 
Yin 
X(2011) 
32/32; 17/16; 62. 
00 ± 5. 23 /61.70 
± 6. 23 
ACRC; 
NS. 
Jianpi formula; one 
decoction per day, 21 
days/cycle, for 2 cycles. 
XELOX: Ox.130 mg/m², ID, day 1, 
Xel250 mg/ m², day 1-14, bid, 21 
days/cycle, 2 cycles (all). 
You J 
(2010) 
30/30; 14/13; 
Range: 30-75/31-
74 
III: 8/9, 
IV: 
22/21; 
KPS 
≥50. 
WD-3 decoction; 50 mL, 
tid, 4 weeks/cycle, for 4 
cycles. 
FOLFOX: Ox.125 mg/m², ID, day 1, 
LV 100 mg /m², ID, day 1-5, 5-FU 
500 mg /m², ID day 1-5, 4 
weeks/cycle, for 4 cycles (all). 
Zeng C 
(2013) 
30/30; 39/19; 54. 
3 ±6. 3/53. 2 ± 6. 
6 
III: 20/12 
IV: 
41/18; 
KPS 
≥60. 
 
Fuzhengxiaoji decoction; 
one decoction per day, 14 
days/cycle, for 4-6 cycles. 
FOLFOX: Ox.85 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-2, 5-FU 
360-500 mg /m² bolus, 600 mg /m², 
ID, for 22 hours, day 1-2, 14 
days/cycle, for 4-6 cycles (all) 
Zeng D 
(2009) 
35/32; 25/21; 
50<: 4/5, 51-69: 
28/25, >70: 3/2. 
IV (all); 
KPS 
≥70. 
Ginsenoside Rg3 capsules: 
2 capsules, bid, for 8 wks. 
FOLFOX4, for 4 cycles (all). 
Zeng J 
(2008) 
30/30; 19/18; 
48/60 (med). 
ACRC; 
KPS 
≥60. 
Multi-CHM formulae; one 
decoction per day, for 
4wks. 
FOLFOX4: 2/2 cycles. 
Zhang H 
(2008) 
 
31/29; 28/23; 
52.35/53.4 (mean) 
ACRC; 
KPS 
≥60. 
3 CHM decoctions based 
on symptom 
differentiation; one 
decoction per day. Started 
one week before 
chemotherapy till one week 
after chemotherapy 
completed.  
FOLFOX4: 4/4 cycles. 
Zhang Q 
(2006) 
38/30; 35 (all); 
54.8 (mean, all). 
ACRC; 
KPS:76.5 
Yiqihuoxue formulae; one 
decoction per day, 21 
FOLFOX: Ox.125 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-2, 5-FU 
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First 
author 
(year) 
Sample size T/C; 
Gender (M) 
T/C;Age T/C 
TNM 
(T/C); 
KPS/ 
ECOG 
CHM Intervention; 
dosage & duration 
Oxaliplatin (Ox.) regimen; dose, 
cycles (T/C) 
± 
5.8/73.5 
± 6.0 
days/cycle, for 3 cycles. 500 mg /m² bolus, day 1-2, 2000 mg 
/m² ID for 72 hours, 21 days/cycle, 
for 3 cycles (all). 
Zhang Q 
(2010) 
60/60; 35/33; 56.2 
(mean, all) 
ACRC; 
KPS: 
≥60. 
Gubenxiaoliu capsule; 4 
capsules, bid, for 8 wks.  
FOLFOX4, 4/4 cycles. 
Zhang Y 
(2010) 
21/20; NS; NS;  ACRC; 
KPS: 
≥60. 
Jianpijiedu decoction; 
onedecoction per day, for 
4weeks. 
 
FOLFOX 4: 2/2 cycles 
Zhou J 
(2011) 
34/34; 22/20; 
51.2/52.5. 
II: 14/13, 
III: 
16/11, 
IV: 6/5; 
KPS: 
≥60. 
Fuzhengjianpi decoction; 
one decoction per day, for 8 
wks. 
FOLFOX: Ox.130 mg/m², ID, day 1, 
LV 100 mg /m², ID, day 1-5, 5-FU 
500 mg /m², ID, day 1-5, 28 
days/cycle, for 2 cycles (all) 
Zou B 
(2007) 
32/27; 29/22; 
53/54.3 (mean)  
ACRC; 
KPS: 
≥60. 
Gubenkang'ai decoction; 
one decoction per day, for 6 
wks. 
FOLFOX: Ox.135 mg/m², ID, day 1, 
LV 200 mg /m², ID, day 1-2, 5-FU 
2400 mg /m², ID, for 48 hours, day 1, 
21 days/cycle, for 2 cycles (all) 
T: treatment group, C: control group, M: male, N: number, NS: not stated, ID: intravenous drip, tRR: Tumour Response 
Rate; TNM: cancer staging system. ‘T’ for tumour, denotes the extent of invasion of the intestinal wall, ‘N’ for lymphatic 
node, the amount of lymphatic node involvement, and ‘M’ for the metastasis. KPS: Karnofsky Performance Status; ECOG: 
Eastern Cooperative Oncology Group Performance Status; CHM: Chinese herbal medicine. 5-FU: 5-Fluorouracil; LV: 
Leucovorin; Ox.: Oxaliplatin; Xel: Capecitabine; HCPT: Hydroxycamptothecine; FOLFOX: Ox. + 5-FU + LV; XELOX: Ox. 
+ Capecitabine; ACRC: advanced colorectal cancer; bid: twice per day; tid: three times per day; qd: once per day; wk: week; 
mth: month; med: median. 
Table G2. Characteristics of randomised controlled trials of Chinese herbal medicine 
combined with oxaliplatin-based regimens for colorectal cancer with chemotherapy 
induced nausea and vomiting incidence as an outcome 
First 
author 
(year) 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
CHM Intervention; dosage & 
duration 
Oxaliplatin regimen; dose, cycles (T/C); 
anti-emetic drug. 
Ding X 
(2010). 
30/30; 18/20; 
64.5/63 (med.) 
Co-Kushen injection; 20 mL, ID, 
day 1-7, 14 day/cycle, for 8 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 8/8 cycles. 
Fang M 
(2008) 
48/45; 30/28; 
59.5 ± 
11.3/56.4 ± 
10.3 
Javanica oil emulsion injection; 
30 mL, ID, day 1-14 / cycles, for 
two cycles 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 2 cycles (all); anti-emetic drug used 
(unknown) 
Hu A 
(2006). 
28/22; 18/14; 
49.3 ± 4.5/48.5 
± 4.3 
Treatment with 4 different CHM 
decoctions according to symptom 
differentiation; one decoction per 
day, for more than 30 days. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 200 
mg /m², ID, day 1-2, 5-FU 2400 mg/m², ID, 
46 hours, cycle/21 days, 2/2 cycles; 
Granisetron, Metoclopramide. 
Kono T 
(2013). 
27/23; NS; 
67/61 (mean) 
TJ-107 Goshajinkigan aqueous 
extract; or placebo was 
administered orally, tid, before 
each meal (7.5 g/day) for 26 wks 
FOLFOX4: or mFOLFOX6: Ox.85 mg/m², 
ID, day 1, LV 200 mg/m², ID, 5-FU 400 mg 
bolus, follow 2400 mg /m², ID for 46 hours, 
14 days/cycle, 8/8 cycles or more. 
Lao G 
(2012). 
30/30; 21/23; 
35.1 ± 
Jianpijiedu decoction; one 
decoction per day, 21 days /cycle, 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1, 5-FU 500 mg bolus day 1, 
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First 
author 
(year) 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
CHM Intervention; dosage & 
duration 
Oxaliplatin regimen; dose, cycles (T/C); 
anti-emetic drug. 
20.2/36.7 ± 
20.1. 
for two cycles. 2400 mg/m², ID, 48 hours, day 1-2, 21 days 
/cycle, 2/2 cycles; 5-HT3 receptor antagonist 
and dexamethasone. 
Li H 
(2007). 
65/52; 43/36; 
58/59 (med) 
Aidi injection; 60 mL, ID, day 1-
10, 14 days/cycle, for 11 weeks. 
FOLFOX 4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 5.5/5.5 cycles (mean); Granisetron. 
Li Y 
(2007). 
20/18; 22 (all); 
72.2 (med, all) 
Wenshenjianpi decoction; one 
decoction per day, for med 10-12 
weeks. 
FOLFOX 4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 6/5.5 cycles (med). 
Lim M 
(2012). 
24/23; 17/14; 
56.89 ± 
14.77/55.37 ± 
16.01 
Pianzaihuang capsule; two 
capsules, bid; 14 days/cycle, 8-10 
cycles. 
FOLFOX4:Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 8-10/8-10 cycles. 
Liu H 
(2009). 
36/34; 16/18; 
50.2 (mean) 
Kang’aifangyipian; one decoction 
per day, 21 days/cycle, for 3 
cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-5, 5-FU 300 mg/m², ID, day 
1-5, 21 days / cycle, 3/3 cycles.  
Liu J 
(2005). 
43/21; 23/10; 
61.52 ± 10.12 
/60.11 ± 9.78 
Jianpihuoxueformulae; one 
decoction per day, 30 days/ cycle, 
3 cycles. 
FOLFOX: Ox.150 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-5, 5-FU 500 mg/m², ID, day 
1-5, 30 days/ cycle, 3/3 cycles; Ondansetron 
hydrochloride. 
Liu W 
(2011). 
16/16; 11/10; 
51/52 (mean) 
Yi erkang capsule; 4-6 capsules, 
bid, for 5-25 months. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 100 
mg/m², ID, day 1-5, 5-FU 400 mg/m², ID, day 
1-5, 21 days / cycle, 6 /6 cycles; Ondansetron. 
Ma J 
(2005). 
28/25; 15/13; 
58.1/57.5 
(mean) 
Jianpixiaoliu decoction; one 
decoction per day, 90 days/ cycle, 
2 cycles. 
FOLFOX: Ox.130 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-5, 5-FU 375 mg/m², ID, day 
1-5, 21 days / cycle, 6/6 cycles. 
Qiu Z 
(2011). 
22/21; 14/13; 
56.9/52.7 
(med) 
Kang’ai injection; 40 mL, ID, day 
1–10, 14 days/ cycle, for 4 cycles. 
FOLFOX4:Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 4/4 cycles. 
Song W 
(2012). 
20/20; 12/13; 
56.4 ± 9.1 /48.3 
± 8.2 
Xiaoliuhuajichangfang II; one 
decoction per day, 21 days/ cycle, 
2 cycles. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 2400  mg/m², ID, 
for 48 hours, 21 days/ cycle, 2 /2 cycles; 
Ramosetron, Metoclopramide.  
Tao C 
(2013). 
74/74; 51/50; 
60.1 ± 7.9 /60.4 
± 8.9. 
Co-kushen injection; 15 mL per 
day, ID, started 14 days before 
chemotherapy, 5 weeks/cycle, for 
1 cycle. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 200 
mg/m², ID, 2 hours, day 1-5, 5-FU 500 
mg/m² , ID, 8-10 hours, day1-5, 3wks/cycle, 
1/1 cycle. 
Wang 
H 
(2008). 
34/34; 20/22; 
52.58 ± 
8.12/51.11 ± 
7.72 
Yiqiguoxiebuchang decoction; 
one decoction per day, for 3 
months.  
FOLFOX: Ox.85 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 500 mg bolus day 
1, 5-FU 2500 mg/m², ID, for 48 hours, 21 
days/ cycle, 4/4 cycles; Ondansetron 
hydrochloride.  
Wang J 
(2011). 
30/30; 18/21; 
52.3 ± 6.2/ 56.7 
± 7.8. 
Yichangning decoction; one 
decoction per day, for 2 months. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 21 days /cycle, 2/2 cycles; Ondansetron.  
Wu G 
(2010). 
33/25; 23/17; 
55.4 ± 13.6 
/52.8 ± 15.2. 
Fupiyiwei decoction; one 
decoction per day, for 24 weeks. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 12/12 cycles; Ondansetron hydrochloride 
Xu Y 
(2010) 
61/60; 38/37; 
53/52 (mean) 
Jiangniling formula; one 
decoction per day, 14 days/cycle, 
for 8-10 cycles 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 11.1/7.8 (mean) cycles; Granisetron. 
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First 
author 
(year) 
Sample size 
T/C; Gender 
(M) T/C; Age 
T/C 
CHM Intervention; dosage & 
duration 
Oxaliplatin regimen; dose, cycles (T/C); 
anti-emetic drug. 
Yang Y 
(2008). 
30/30; 16/19; 
51.07 ± 10.44 
/51.33 ± 10.95. 
Kang'ai injection; 50 mL, ID, 
day1-20, 30days/cycle, for 2 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 4/4 cycles; Granisetron. 
Yang Z 
(2005) 
30/30; 18/20; 
29-70 /28-69 
Xuesaitong injection, 500 mg, ID; 
Huangqi injection, 60 mL, ID; 
Shenmai injection, 50 mL, ID 
&CHM decoction, one decoction 
per day, day1-5, 21 days/cycle, for 
2 cycles. 
FOLFOX: Ox.200 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-5, 5-FU 500 mg/m², ID day 
1-5, 2/2 cycles. 
Zhang 
H 
(2008) 
31/29; 28/23; 
52.35/53.4 
(mean) 
3 CHM decoctions based on 
syndrome differentiation; one 
decoction per day. Started one 
week before chemotherapy till one 
week after chemotherapy 
completed.  
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600mg/m², ID, 22 hours, day1-
2, 4/4 cycles; Ondansetron hydrochloride. 
Zhang 
Q 
(2006). 
38/30; 35 (all); 
54.8 (mean all). 
Yiqihuoxue formulae; one 
decoction per day, 21 days/ cycle, 
for 3 cycles. 
FOLFOX: Ox.125 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 500 mg/m² bolus, 
day 1-2, 2000 mg/m² ID for 72 hours, 21 
days/cycle, 3/3 cycles; Ondansetron 
hydrochloride 
Zhang 
Q 
(2010). 
60/60; 35/33; 
56.2 (mean all);  
Gubenxiaoliu capsule; 4 capsules, 
bid, for 8 wks.  
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400mg/m², 
bolus, 600 mg/m², ID, 22 hours, day1-2, 4/4 
cycles; Ondansetron hydrochloride. 
Zhang 
W 
(2013). 
32/32; 15/16; 
56.8 ± 
10.1/46.4 ± 9.2. 
Xiaoliuhuaji Decoction I; one 
decoction per day, for 5 mths.  
FOLFOX: Ox.135 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 2400 mg/m² , ID 
for 48 hours, 21 days/cycle, 6/6 cycles; 
Ramosetron.  
Zhang 
Y 
(2010). 
21/20; NS; NS;  Jianpijiedu decoction; one 
decoction per day, for 4 wks. 
FOLFOX4: Ox.85 mg/m², 2 hours ID, day 1, 
LV 200 mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 22 hours, day1-
2, 2/2 cycles. 
Zou B 
(2007) 
32/27; 29/22; 
53/54.3 (mean)  
Gubenkang'ai decoction; one 
decoction per day, for 6 wks. 
FOLFOX: Ox.135 mg/m², ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 2400 mg/m², ID, 
for 48 hours, day 1, 21 days/ cycle, for 2 
cycles(all); Granisetron, Metoclopramide. 
RN: reference number (superscript); T: treatment group; C: control group; M: male; N: number; NS: not stated; ID: 
intravenous drip; CHM: Chinese herbal medicine; CINV: chemotherapy induced nausea and vomiting; 5-FU: 5-Fluorouracil; 
LV: Leucovorin; Ox.: Oxaliplatin; FOLFOX: Ox. + 5-FU + LV; bid: twice per day; tid: three times per day; qd: once per day; 
wk: week; mth: month; med: median. 
Table G3. Characteristics of randomised controlled trials of Chinese herbal medicines 
combined with oxaliplatin-based regimens for colorectal cancer with chemotherapy 
induced neutropenia incidence as an outcome 
First 
author 
(year). 
Sample size 
T/C; Gender 
(M) T/C; 
Age T/C 
TNM 
(T/C); 
KPS/ 
ECOG  
TM Intervention; 
dosage & duration 
Oxaliplatin regimen; dose, 
cycles (T/C) 
Outcome: 
CIN gr.: 
T/C 
Deng D 
(2010) 
18/18; 9/9; 
54.17 ± 
10.04/53.56 ± 
11.10. 
IV (all); 
KPS ≥60. 
Yiqixiaoji decoction; 
one decoction per day, 
for up to 6 wks. 
XELOX: Ox. 130 mg/m², 
2hours ID, day 1; Xel. 850 
mg/m², bid, for 14 days; 21 
days/cycle, for 2 cycles; G-
CSF used. 
I: 2/4; II: 
1/1; 
III: 0/1; IV: 
0/0. 
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First 
author 
(year). 
Sample size 
T/C; Gender 
(M) T/C; 
Age T/C 
TNM 
(T/C); 
KPS/ 
ECOG  
TM Intervention; 
dosage & duration 
Oxaliplatin regimen; dose, 
cycles (T/C) 
Outcome: 
CIN gr.: 
T/C 
Ding X 
(2010) 
30/30; 18/20; 
64.5/63 
(med) 
ACRC 
(all); KPS 
≥70 
Co-Kushen injection; 
20 mL, ID, day 1-7, 14 
day/cycle, for 8 cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 8/8 cycles. 
I: 9/10; II: 
3/6; 
III: 0/1; IV: 
0/0. 
Fang M 
(2008)  
48/45; 30/28; 
59.5 ± 
11.3/56.4 ± 
10.3 
IV (all); 
KPS ≥70. 
Javanica oil emulsion 
injection; 30 mL, ID, 
day 1-14 / cycles, for 
two cycles 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2. 2/2 cycles; 
G-CSF used. 
I/II: 19/17; 
III/IV: 2/1. 
Hu A 
(2006) 
28/22; 18/14; 
49.3 ± 
4.5/48.5 ± 4.3 
IV (all); 
KPS ≥50. 
Treatment with 4 
different TM 
decoctions according 
to syndrome 
differentiation; one 
decoction per day, for 
more than 30 days. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-2, 5-FU 2400 mg/m², ID, 46 
hours, cycle/21 days, 2/2 
cycles. 
I: 4/7; II: 
2/6; 
III: 0/1; IV: 
0/0. 
Kono T 
(2013) 
44/45; 23/25; 
67/61 (med) 
NS; ECOG 
0–1 
TJ-107 Goshajinkigan 
aqueous extracts; or 
placebo was 
administered orally, 
tid, before each meal 
(7.5 g/day) for 26 
weeks 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2 or 
mFOLFOX6: Ox.85 mg/m², 
ID, day 1, LV 200 mg/m², ID, 
5-FU 400 mg bolus, follow 
2400 mg/m², ID for 46 hours, 
14 days/cycle, 8/8 cycles or 
more. 
All gr.: 
15/21; 
≥III: 10/15. 
Lao G 
(2012) 
30/30; 21/23; 
35.1 ± 
20.2/36.7 ± 
20.1. 
II:5/7, III: 
15/14, IV: 
10/9; KPS 
≥60 
Jianpijiedu decoction; 
one decoction per day, 
21 days /cycle, for two 
cycles. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1, 5-FU 500 mg bolus day 1, 
2400 mg/m², ID, 48 hours, 
day 1-2, 21 days /cycle, 2/2 
cycles. 
I: 4/9; II: 
3/5; 
III: 1/4; IV: 
0/0. 
Li H 
(2007) 
65/52; 43/36; 
58/59 (med) 
III: 27/19, 
IV: 38/33; 
KPS ≥60 
Aidi injection; 60 mL, 
ID, day 1-10, 14 
days/cycle, for 11 
weeks. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 5.5/5.5 
cycles (mean). 
I: 9/14; II: 
5/7; 
III: 3/5; IV: 
0/1. 
Li Y 
(2007) 
20/18; 22 
(all); 72.2 
(med, all) 
III: 15, IV: 
23 (all); 
KPS ≥60 
Wenshenjianpi 
decoction; one 
decoction per day, for 
10-12 weeks. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 6/5.5 cycles 
(med). 
I: 5/10; II: 
4/4; 
III: 1/1; IV: 
0/0. 
Lim M 
(2012) 
24/23; 17/14; 
56.89 ± 
14.77/55.37 ± 
16.01 
III: 15/16, 
IV: 9/7; 
KPS 84.78 
± 
14.66/83.42 
± 13.09 
Pianzaihuang capsule; 
two capsules, bid; 14 
days/cycle, 8-10 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 8-10/8-10 
cycles. 
I: 5/7; II: 
1/4; 
III: 0/1; IV: 
0/0. 
Liu H 
(2009) 
36/34; 16/18; 
50.2 (med, 
all) 
ACRC 
(all); KPS 
≥60 
Kang’ai fangyi pian; 
one decoction per day, 
21 days / cycle, for 3 
cycles. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-5, 5-FU 300 mg/m², ID, day 
1-5, 21 days / cycle, 3/3 
cycles.  
I: 7/9; II: 
2/5; 
III: 1/1; IV: 
0/0. 
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Liu J 
(2005) 
43/21; 23/10; 
61.52 ± 10.12 
/60.11 ± 9.78 
IV (all); 
KPS ≥50. 
Jianpihuoxue 
formulae; one 
decoction per day, 30 
days/cycle, 3 cycles. 
FOLFOX: Ox.150 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-5, 5-FU 500 mg/m², ID, day 
1-5, 30 days/ cycle, 3/3 
cycles. 
I: 5/5; II: 
2/3; 
III: 1/1; IV: 
0/0. 
Liu W 
(2011) 
16/16; 11/10; 
51/52 (mean) 
IV (all); 
KPS 40-60 
(range). 
Yierkang capsule; 4-6 
capsules, bid, for 5-25 
months. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 100 mg/m², ID, day 
1-5, 5-FU 400 mg/m², ID, day 
1-5, 21 days / cycle, 6 /6 
cycles. 
All gr.: 
3/12. 
Ma J 
(2005) 
28/25; 15/13; 
58.1/57.5 
(mean) 
II:7/4,  
III: 21/21; 
KPS ≥60. 
Jianpi Xiaoliu 
decoction; one 
decoction per day, 90 
days / cycle, 2 cycles. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-5, 5-FU 375 mg/m², ID, day 
1-5, 21 days / cycle, 6/6 
cycles. 
I: 4/8; II: 
2/2; 
III: 0/0; IV: 
0/0. 
Qiu Z 
(2011) 
22/21; 14/13; 
56.9/52.7 
(med) 
IV (all); 
KPS ≥60. 
Kang’ai injection; 40 
mL, ID, day 1–10, 14 
days/cycle, for 4 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 21 days 
/cycle, 4/4 cycles. 
III/IV: 1/8. 
Song 
W 
(2012) 
20/20; 12/13; 
56.4 ± 9.1 
/48.3 ± 8.2 
ACRC 
(all); KPS 
≥70. 
Xiaoliuhuajichangfang 
II; one decoction per 
day, 21 days/cycle, 2 
cycles. 
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-2, 5-FU 2400 mg/m², ID, 
for 48 hours, 21 days/ cycle, 2 
/2 cycles. 
I: 2/4; II: 
3/3; 
III: 1/2; IV: 
0/1. 
Tao C 
(2013) 
74/74; 51/50; 
60.1 ± 7.9 
/60.4 ± 8.9. 
ACRC 
(all); KPS 
65.6 ± 
12.3/66.7 ± 
14.5 
Co-kushen injection; 
15 mL per day, ID, 
started 14 days before 
chemotherapy, 5 
wks/cycle, for 3 
cycles. 
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 200 mg/m², ID, 2 
hours, day 1-5, 5-FU 500 
mg/m² , ID, 8-10 hours, day1-
5, 3 wks/cycle, 3/3 cycle. 
I: 10/14; II: 
5/16; 
III: 5/5; IV: 
0/0. 
Wang 
H 
(2008) 
34/34; 20/22; 
52.58 ± 
8.12/51.11 ± 
7.72 
IV: 34/34; 
KPS ≥50. 
Yiqiguoxiebuchang 
decoction; one 
decoction per day, for 
3 months.  
FOLFOX: Ox.85 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-2, 5-FU 500 mg bolus day 
1, 5-FU 2500 mg/m², ID, for 
48 hours, 21 days/ cycle, 4/4 
cycles. 
I: 4/8; II: 
2/5; 
III: 1/2; IV: 
0/0. 
Wang J 
(2011) 
30/30; 18/21; 
52.3 ± 6.2/ 
56.7 ± 7.8. 
ACRC 
(all); KPS 
≥60. 
Yichangning 
decoction; one 
decoction per day, for 
2 months. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 21 days 
/cycle, 2/2 cycles. 
I/II: 8/14; 
III/IV: 1/5. 
Wang 
Y 
(2012) 
38/36; 26/25; 
52 (med, all). 
ACRC 
(all); KPS 
≥70. 
Aidi injection; 80 mL, 
ID, per day, 10 
days/cycle, for 4 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 4/4 cycles. 
All gr.: 
21/28. 
Wang 
Y 
(2013) 
32/30; 20/19; 
NS. 
ACRC 
(all); KPS 
≥70. 
Xiaoaiping injection; 
60 mL, ID, per day, 14 
days /cycle, for two 
cycles. 
XELOX: no details, 2/2 
cycles. 
All gr.: 
20/26. 
 
Wu G 
(2010) 
33/25; 23/17; 
55.4 ±13.6 
/52.8 ±15.2. 
I: 5/3, II: 
10/8, III: 
15/11, IV: 
3/3; KPS 
≥60. 
Fupiyiwei decoction; 
one decoction per day, 
for 24 wks. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 12/12 
I: 7/8; II: 
2/6; 
III: 1/3; IV: 
0/0. 
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Xu Y 
(2010) 
61/60; 38/37; 
53/52 (mean, 
all) 
ACRC 
(all); 
≥70 
Jiangniling formula; 
one decoction per day, 
14 days/cycle, for 8-10 
cycles. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg /m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 11.1/7.8 
(mean) cycles. 
5.03 ± 
2.14/3.03 ± 
1.27 
(mean) 
Yang C 
(2007) 
50/50; 29/27; 
51.36 ± 10.58 
/53.48 ± 9.35. 
ACRC 
(all); KPS 
≥60. 
Jianpikangfu pill; 6g, 
tid, for 4 weeks. 
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 100 mg/m², ID, day 
1-5, 5-FU 425 mg/m², ID day 
1-5, 4/4 wks. 
I: 18/18; II: 
6/14; 
III: 0/3; IV: 
0/0. 
Yang Y 
(2008) 
30/30; 16/19; 
51.07 ± 10.44 
/51.33 ± 
10.95. 
ACRC 
(all); KPS 
≥60. 
Kang'ai injection; 50 
mL, ID, day 1-20, 30 
days/cycle, for 2 
cycles. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 4/4 cycles. 
I: 9/11;II: 
2/8; 
III: 1/3; IV: 
0/0. 
Zeng C 
(2013) 
61/30; 
39/19; 54. 3 
± 6. 3/53. 2 ± 
6. 6 
III: 20/12 
IV: 41/18; 
KPS ≥60. 
Fuzhengxiaoji 
decoction; one 
decoction per day, 14 
days /cycle, for 4 
cycles. 
FOLFOX: Ox.85 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-2, 5-FU 360-500 mg/m² 
bolus, 600 mg/m², ID, for 22 
hours, day 1-2, 14 days/cycle, 
4/4 cycles. 
4.56 ± 
1.33/3.27 ± 
1.08 
(mean) 
Zeng D 
(2009) 
35/32; 25/21; 
50<: 4/5, 51-
69: 
28/25, >70:3/
2. 
IV (all); 
KPS ≥70. 
Ginsenoside Rg3 
capsules: 2 capsules, 
bid, for 8 wks. 
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 21 days 
/cycle, 4/4 cycles. 
All gr.: 
22/28. 
Zeng J 
(2008) 
30/30; 19/18; 
48/60 (med). 
ACRC 
(all); KPS 
≥60. 
Multi-TM formulae; 
one decoction per day, 
for 4wks. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 2/2 cycles. 
I: 12/16; II: 
7/8; 
III: 1/2; IV: 
0/1. 
Zhang 
Q 
(2006) 
38/30; 
35(all); 54.8 
(mean, all). 
ACRC 
(all); 
KPS:76.5 ± 
5.8/73.5 ± 
6.0 
Yiqihuoxue formula; 
one decoction per day, 
21 days/ cycle, for 3 
cycles. 
FOLFOX: Ox.125 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-2, 5-FU 500 mg/m² bolus, 
day 1-2, 2000 mg/m² ID for 
72 hours, 21 days/cycle, 3/3 
cycles. 
I: 5/9;II: 
2/4; 
III: 1/1; IV: 
0/0. 
Zhang 
Q 
(2010) 
60/60; 35/33; 
56.2 (mean, 
all);  
ACRC 
(all); KPS 
≥60. 
Gubenxiaoliu capsule; 
4 capsules, bid, for 8 
wks.  
FOLFOX4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 4/4 cycles. 
I: 10/7; II: 
3/8; 
III: 2/6; IV: 
0/0. 
Zhang 
W 
(2013) 
32/32; 15/16; 
56.8 ± 
10.1/46.4 ± 
9.2. 
II: 23/22; 
III: 9/10; 
KPS ≥70. 
Xiaoliuhuaji decoction 
I; one decoction per 
day, for 5 mths.  
FOLFOX: Ox.135 mg/m², ID, 
day 1, LV 200 mg/m², ID, day 
1-2, 5-FU 2400 mg/m² , ID 
for 48 hours, 21 days/cycle, 
6/6 cycles. 
I: 6/8;II: 
4/7; 
III: 1/4; IV: 
0/2. 
Zhang 
Y 
(2010) 
21/20; NS; 
NS;  
ACRC 
(all); 
KPS≥60. 
Jianpijiedu decoction; 
one decoction per day, 
for 4 wks. 
FOLFOX 4: Ox.85 mg/m², 2 
hours ID, day 1, LV 200 
mg/m², ID, day 1-2, 5-FU 400 
mg/m², bolus, 600 mg/m², ID, 
22 hours, day1-2, 2/2 cycles. 
I/II: 4/8; 
III/IV: 1/3. 
 
Zhou J 
(2011) 
34/34; 22/20; 
51.2/52.5. 
II: 14/13, 
III: 16/11, 
IV: 6/5; 
KPS ≥60. 
Fuzhengjianpi 
decoction; one 
decoction per day, for 
8 wks. 
FOLFOX: Ox.130 mg/m², ID, 
day 1, LV 100 mg/m², ID, day 
1-5, 5-FU 500 mg/m², ID, day 
1-5, 28 days/cycle, 2/2 cycles. 
I: 1/6;II: 
3/7; 
III: 3/4; IV: 
0/2. 
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T: treatment group; C: control group; M: male; N: number; CIN: chemotherapy induced neutropenia; gr.: WHO 
recommendations for grading of acute and subacute toxicity grade; NS: not stated; ID: intravenous drip; TNM: cancer staging 
system. ‘T’ for tumour, denotes the extent of invasion of the intestinal wall, ‘N’ for lymphatic node, the amount of lymphatic 
node involvement, and ‘M’ for metastasis; KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology 
Group Performance Status; CHM: Chinese herbal medicine; 5-FU: 5-Fluorouracil; LV: Leucovorin; Ox.: Oxaliplatin; Xel: 
Capecitabine; FOLFOX: Ox. + 5-FU + LV; XELOX: Ox. + Capecitabine; ACRC: advanced colorectal cancer; bid: twice per 
day; tid: three times per day; qd: once per day; wk: week; mth: month; med.: median. 
 
